Compounds with novel substituted glutarimidyl-isoindolinone skeleton, and uses thereof

Abstract

The present invention relates to a compound of formula (I), a compound of formula (I'), or a salt, an enantiomer, a stereoisomer, a solvate or a polymorph thereof, and the use thereof. The present invention further relates to a pharmaceutical composition containing the compound of formula (I), the compound of formula (I'), or the salt, the enantiomer, the stereoisomer, the solvate or the polymorph thereof as an active ingredient, and the use thereof. The designed and synthesized compound can effectively prevent or treat diseases or disorders associated with the cereblon protein.

Description

Compounds with novel substituted glutarimidoisoindolinone skeleton and their applications Technical Field

[0001] The present disclosure relates to compounds of formula (I), compounds of formula (I') or salts, enantiomers, stereoisomers, solvates or polymorphs thereof and uses thereof, in particular, uses thereof for preventing or treating diseases or disorders associated with cereblon protein. Background Art

[0002] Phthalimide immunomodulatory drugs (IMiDs), such as thalidomide and lenalidomide, are highly effective in treating hematologic malignancies and autoimmune diseases. However, it wasn't until 2010 that their direct binding protein, the E3 ubiquitin ligase cereblon (CRBN), was identified. Subsequently, it was demonstrated that upon binding to CRBN, these drugs act as molecular glues to recruit substrate proteins (such as the transcription factors IKZF1 / 3), enabling protein-protein interactions between CRBN and substrate proteins and subsequently ubiquitination of these substrate proteins. Polyubiquitinated substrate proteins are then recognized and degraded by the proteasome, resulting in pharmacological effects including anti-tumor and immunomodulatory effects. Molecular glue protein degraders directly target and degrade target proteins, offering potential advantages such as targeting undruggable targets. Furthermore, molecular glue degraders typically have a small molecular weight and good drugability, making their development extremely challenging. Based on the CRBN E3 ubiquitin ligase and molecular glue degradation mechanism, a series of compounds have been developed, including the marketed pomalidomide, as well as Bristol-Myers Squibb (BMS)'s CC-122, CC-220, CC-90009, CC-99282, and CC-92480, BMS-986470, which are currently undergoing clinical trials, Novartis's DKY709, C4 Therapeutics' CFT7455, and Monte Rosa's MRT-6160. The degradation substrates of these molecular glues have also expanded from the initially discovered transcription factors IKZF1 / 3 to casein kinase 1α (CK1α), zinc finger protein 91 (ZFP91), WIZ, transcription factor IKZF2, translation factor GSPT1, and the immune disease target Vav1. The degradation of these protein substrates enables the molecular glue to exert its pharmacological activities, including immunomodulatory, anti-inflammatory, and anti-tumor effects. The structural novelty of the molecular glue candidate compounds that have been designed and developed so far is very limited, so the design and development of molecular glue compounds with novel and diversified skeletons has become a research hotspot in this field.

[0003] Therefore, there is an urgent need for a series of novel CRBN E3 ubiquitin ligase ligand scaffolds and their application in the development of effective molecular glue degraders for the treatment and / or prevention of diseases or conditions mediated by or associated with degraded proteins. Summary of the Invention

[0004] In view of the above, the object of the present disclosure is to provide protein degradation compounds having a novel substituted glutarimidyl isoindolinone skeleton, their preparation methods, uses, and methods of using them.

[0005] To achieve the above-mentioned and other related purposes, in one aspect, the present disclosure provides a compound of formula (I) or its salt, stereoisomer (including enantiomer, diastereomer), isotopically enriched analog, solvate or polymorph: wherein Z represents C(O), CH2 or CD2; R a1 、R a2 、R a3 and R a4 Each independently represents hydrogen, deuterium, halogen, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy or halogenated C 1-6 Alkoxy; (R a5 ) m represents that the isoindoline ring connected thereto is optionally replaced by m R a5 Replace, each R a5 are the same or different and each independently represent deuterium, halogen, hydroxyl, mercapto, nitro, amino, cyano, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkenyl or C 2-6 Alkynyl; m represents an integer of 0, 1, 2 or 3; R represents: wherein Ring A1 represents a heterocyclic group containing at least 2 nitrogen atoms, (Rd1) n1 Indicates that ring A1 is optionally replaced by n1 R d Group substitution, each R d Each independently represents deuterium, halogen, hydroxyl, mercapto, nitro, amino, cyano, oxo, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy or C 1-6 Alkoxy, and n1 represents an integer of 0-20; and R1 represents N(R w ), where R w Represents hydrogen or C1-3 alkyl, and R2 represents a bond, or R2 represents CH2 or C(O); or R1 represents a bond, and R2 represents N(R w ), where R w Represents hydrogen or C 1-3 Alkyl, or R2 represents N(R w )C(O)*, where R w Represents hydrogen or C 1-3 Alkyl, or R2 represents -N=CH-*; or R represents: where R X represents NH, -N=CH-* or N(R w )C(O)*, where R w Represents hydrogen or C 1-3 Alkyl; or R represents: wherein Ring A2 represents a heterocyclic group containing one nitrogen atom, (R d4 ) n4 represents ring A2 optionally replaced by n4 R d4 Group substitution, each R d4 Each independently represents deuterium, halogen, hydroxyl, mercapto, nitro, amino, cyano, oxo, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy or C 1-6 alkoxy, and n4 represents an integer from 0 to 20; and wherein R y1 express The symbol ** indicates the point of attachment to ring A2; and R2 represents N(R w )C(O)*, where R w Represents hydrogen or C 1-3 The symbol * in the above formula indicates that R c The connection point of R c Indicates CR c1 R c2 , where R c1 and R c2 Each independently represents H, deuterium, halogen, an optionally substituted linear or branched alkyl group, an optionally substituted cycloalkyl group, an optionally substituted heterocyclyl group, an optionally substituted aryl group or an optionally substituted heteroaryl group, or R c represents a bond; Ring B represents a cycloalkylene group, a heterocyclylene group, an arylene group or a heteroarylene group, m1 represents an integer of 0 or 1, (R d2 ) n2 Indicates that ring B is optionally replaced by n2 R d2 Group substitution, each R d2 Each independently represents deuterium, C 1-6 Alkyl, deuterated C1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, oxo, C 2-6 Alkynyl or C 2-6 alkenyl, and n2 represents an integer of 0-20; and ring C represents a heterocyclic group, a cycloalkyl group, an aryl group or a heteroaryl group, (R d3 ) n3 represents ring C optionally replaced by n3 R d3 Group substitution, each R d3 Each independently represents deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, oxo, C 2-6 Alkynyl or C 2-6 alkenyl, and n3 represents an integer from 0 to 20; Provided that the following compounds are excluded: 3-(5-((4-diphenylmethylpiperazin-1-yl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-((4′-chloro-[1,1′-biphenyl]-2-yl)methyl)piperazin-1-yl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-((4′-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-yl)methyl)piperazin-1-yl)amino)-1-oxoisoindolin-2-yl) piperidine-2,6-dione; and 3-(5-((4-(4′-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-carbonyl)piperazin-1-yl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione.

[0006] In another aspect, the present disclosure provides a compound of formula (I') or a salt, stereoisomer (including enantiomers, diastereomers), isotopically enriched analog, solvate or polymorph thereof: wherein Z represents C(O), CH2 or CD2; R a1 、R a2 、R a3 and R a4 Each independently represents hydrogen, deuterium, halogen, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy or halogenated C1-6 Alkoxy; (R a5 ) m represents that the isoindoline ring connected thereto is optionally replaced by m R a5 Replace, each R a5 are the same or different and each independently represent deuterium, halogen, hydroxyl, mercapto, nitro, amino, cyano, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl or heterocyclic group, the heterocyclic group is optionally substituted by one or more independently selected from halogen, C 1-6 substituted by a substituent consisting of an alkyl group and a tert-butyloxycarbonyl group; m represents an integer of 0, 1, 2 or 3; Ring A1 represents a 4- to 30-membered heterocyclic group containing at least 2 nitrogen atoms, (R d1 ) n1 Indicates that ring A1 is optionally replaced by n1 R d1 Group substitution, each R d1 Each independently represents deuterium, halogen, hydroxyl, mercapto, nitro, amino, cyano, oxo, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy or C 1-6 Alkoxy, and n1 represents an integer of 0-20; and R1 represents N(R w ), where R w represents hydrogen or C optionally substituted by one or more substituents independently selected from the group consisting of optionally substituted aryl and optionally substituted heteroaryl 1-3 alkyl, and R2 represents a bond; or R1 represents a bond, and R2 represents N(R w ), where R w Represents hydrogen or C 1-3 alkyl; and R e Indicates a key, or R e Represents C(O)O, or R e Represents the following structure: R e1 represents C(O), CH2 or halogenated CH2; Ring D represents an arylene group, (R e2 ) m2 represents a ring D optionally replaced by m2 R e2 Group substitution, each R e2 Each independently represents deuterium, C 1-6 Alkyl, deuterated C 1-6Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, oxo, C 2-6 Alkynyl or C 2-6 alkenyl, and m2 represents an integer of 0-20; and ring E represents a nitrogen-containing heterocyclic group, m4 represents an integer of 0 or 1, (R e3 ) m3 represents a ring E optionally surrounded by m3 R e3 Group substitution, each R e3 Each independently represents deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, oxo, C 2-6 Alkynyl or C 2-6 alkenyl, and m3 represents an integer of 0-20; the symbol # indicates that R f The connection point of R f Indicates C 1-10 Alkyl, the C 1-10 The alkyl group is optionally substituted with one or more substituents independently selected from the group consisting of halogen, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclyl, optionally substituted cycloalkyl, and NR3R4, wherein R3 and R4 each independently represent H, C 1-3 alkyl or optionally substituted cycloalkyl; provided that the following compounds are not included: 3-(5-((4-diphenylmethylpiperazin-1-yl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-((4′-chloro-[1,1′-biphenyl]-2-yl)methyl)piperazin-1-yl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; and 3-(5-((4-((4′-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-yl)methyl)piperazin-1-yl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione.

[0007] In another aspect, the present disclosure provides a pharmaceutical composition comprising: the compound of formula (I) or its pharmaceutically acceptable salt, stereoisomer (including enantiomer, diastereomer), solvate, isotopically enriched analog or polymorph, and at least one pharmaceutically acceptable carrier; or the compound of formula (I') or its pharmaceutically acceptable salt, stereoisomer (including enantiomer, diastereomer), solvate, isotopically enriched analog or polymorph, and at least one pharmaceutically acceptable carrier.

[0008] In another aspect, the present disclosure further provides a drug box or a test kit comprising: a compound of formula (I) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising the same; or a compound of formula (I') or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising the same.

[0009] In another aspect, the present disclosure provides the compound of formula (I) or the compound of formula (I'), or a pharmaceutically acceptable salt, enantiomer, diastereomer, solvate or polymorph thereof, for use as a medicament.

[0010] In another aspect, the present disclosure provides the compound of formula (I) or formula (I'), or a pharmaceutically acceptable salt, stereoisomer (including enantiomers, diastereomers), solvate, isotopically enriched analog or polymorph thereof, or the pharmaceutical composition of the present disclosure, for use in treating or preventing a disease or condition associated with cereblon protein.

[0011] In another aspect, the present disclosure further provides the use of the compound of formula (I) or formula (I') or its pharmaceutically acceptable salts, stereoisomers (including enantiomers, diastereomers), solvates, isotopically enriched analogs or polymorphs, or the pharmaceutical composition of the present disclosure, for preparing a medicament for treating or preventing diseases or disorders associated with cereblon protein.

[0012] In another aspect, the present disclosure also provides a method for treating or preventing a disease or condition associated with cereblon protein in a subject, comprising administering to the subject a therapeutically effective amount of the compound of formula (I) or (I'), or a pharmaceutically acceptable salt, stereoisomer (including enantiomers, diastereomers), solvate, isotopically enriched analog or polymorph thereof, or the pharmaceutical composition.

[0013] In another aspect, the present disclosure also provides a method for preparing a compound of formula (I), comprising using a compound of formula (M1) and a compound of formula (M2) as starting materials to prepare a compound of formula (I): where R a1 、Ra2 、R a3 、R a4 、(R a5 ) m , Z, R, Ring B, Ring C, (R d2 ) n2 、(R d3 ) n3 , and m1 are as defined in the compounds of formula (I) and its various sub-embodiments disclosed herein; and R w3 Indicates CHO, COOH or where R c2 As defined in the compounds of formula (I) and its various sub-embodiments disclosed herein, and group LE represents Cl, Br, I, OM s ,OT s , or ON s ; Among them (1)-R w1 -R w2 express And R represents or (2)-R w1 -R w2 express And R represents or (3)-R w1 -R w2 represents -NH-NH2, and R represents -NH-NH-; or (4) -R w1 -R w2 express And R represents where R w 、Ring A1、(R d1 ) n1 , Ring A2 and (R d4 ) n4 As defined in the compounds of formula (I) and its various sub-embodiments disclosed herein; wherein when R w3 When it represents CHO, R c3 and R c4 Indicates H; or when R w3 When it represents COOH, R c3 and R c4 together to form a carbonyl group; or when R w3 express When R c3 Represents H, and R c4 It is R c2 Detailed Description of the Invention

[0014] The following detailed description is provided as an exemplary embodiment to help those skilled in the art understand and implement the present disclosure. However, it should be understood that such description is not intended to limit the scope of the present disclosure. Without departing from the spirit and scope of the present disclosure, the specific embodiments described in the present disclosure may be subjected to various modifications and changes, and these changes and improvements fall within the scope of the present disclosure. I. Compounds Formula (I) Compound

[0015] The present disclosure provides a compound of formula (I) or its salt (including pharmaceutically acceptable salt), stereoisomer (including enantiomer, diastereomer), solvate, isotopically enriched analog or polymorph: Among them, Z, R a1 、R a2 、R a3 、R a4 、(R a5 ) m , R, R c , Ring B, (R d2 ) n2 , Ring C, (R d3 ) n3 and m1 are as defined above for the compounds of formula (I) and embodiments thereof.

[0016] The compounds of formula (I) or their salts (including pharmaceutically acceptable salts), stereoisomers (including enantiomers), solvates, isotopically enriched analogs, or polymorphs provided herein have binding affinity for CRBN, facilitate recruitment of substrate proteins, and can act as molecular glues to bind to CRBN E3 ubiquitin ligases. The compounds of formula (I) or their salts (including pharmaceutically acceptable salts), stereoisomers (including enantiomers), solvates, isotopically enriched analogs, or polymorphs disclosed herein can also degrade substrate proteins (e.g., IKZF1 / 2 / 3 / 4 proteins, WEE1 proteins, CK1α proteins, GSPT1 proteins, ZFP91 proteins, etc.). Therefore, the compounds of formula (I) disclosed herein, or their salts (including pharmaceutically acceptable salts), stereoisomers (including enantiomers), solvates, isotopically enriched analogs, or polymorphs, can effectively prevent or treat diseases or conditions associated with cereblon protein (e.g., tumors or cancer), or have excellent pharmacokinetic properties and can be used as therapeutic drugs for tumor patients.

[0017] In some embodiments of the present disclosure, R a1 、R a2 、R a3 and R a4 are the same or different and each independently represents H, deuterium (ie, D), halogen (such as fluorine, chlorine, bromine or iodine), C 1-6 Alkyl (e.g. C1-3 Alkyl, such as methyl, ethyl, or propyl), halo C 1-6 Alkyl (e.g. halo-C 1-4 alkyl, such as trifluoromethyl), deuterated C 1-6 Alkyl, C 1-6 Alkoxy (e.g. C 1-4 Alkoxy, such as methoxy), deuterated C 1-6 Alkoxy or halogenated C 1-6 Alkoxy (e.g., halo-C 1-4 In some sub-embodiments of the present disclosure, R a1 、R a2 、R a3 and R a4 Each independently represents H.

[0018] In some embodiments of the present disclosure, Z represents C(O), CH2, or CD2.

[0019] In some embodiments of the present disclosure, Z represents C(O).

[0020] In some embodiments of the present disclosure, Z represents CH2.

[0021] In some embodiments of the present disclosure, Z represents CD2.

[0022] In some embodiments of the present disclosure, (R a5 ) m represents that the isoindoline ring of formula (I) attached thereto is optionally substituted by m R a5 Replace, each R a5 The same or different and each independently represents deuterium, halogen (such as fluorine, chlorine, bromine or iodine), hydroxyl, mercapto, nitro, amino, cyano, C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halo-C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C1-6 Alkoxy (e.g. C 1-4 alkoxy, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy (e.g., halo-C 1-4 Alkoxy, for example F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-), C 2-6 Alkenyl (e.g. vinyl) or C 2-6 Alkynyl (e.g., ethynyl), and m represents an integer of 0, 1, 2, or 3. In some sub-embodiments of the present disclosure, m represents an integer of 0, 1, or 2. In some sub-embodiments of the present disclosure, each R a5 The same or different and each independently represents deuterium, halogen (such as fluorine, chlorine, bromine or iodine), hydroxyl, mercapto, nitro, amino, cyano, C 1-4 Alkyl (e.g. C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl or tert-butyl), halogenated C 1-4 Alkyl (e.g. halo-C 1-3 Alkyl groups, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), C 1-4 Alkoxy (e.g. C 1-3 Alkoxy, for example methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy) or halogenated C 1-4 Alkoxy (e.g., halo-C 1-3 Alkoxy groups, such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-).

[0023] In the embodiments of the present disclosure, the number of substituents is in principle not subject to any restrictions or automatically limited by the size of the building block.

[0024] In some embodiments of the present disclosure, R represents wherein Ring A1 represents a heterocyclic group containing at least 2 nitrogen atoms, (R d1 ) n1Indicates that ring A1 is optionally substituted by n1 Rd1 groups, each R d1 Each independently represents deuterium, halogen, hydroxyl, mercapto, nitro, amino, cyano, oxo, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy or C 1-6 Alkoxy, and n1 represents an integer of 0-20; and R1 represents N(R w ), where R w Represents hydrogen or C 1-3 alkyl, and R2 represents a bond, or R2 represents CH2 or C(O); or R1 represents a bond, and R2 represents N(R w ), where R w Represents hydrogen or C 1-3 Alkyl, or R2 represents N(R w )C(O)*, where R w Represents hydrogen or C 1-3 Alkyl, or R2 represents -N=CH-*; and the symbol * indicates that R c connection point.

[0025] In some embodiments of the present disclosure, R1 represents N(R w ), where R w Represents hydrogen or C 1-3 alkyl, and R2 represents a bond.

[0026] In some embodiments of the present disclosure, R1 represents N(R w ), where R w Represents hydrogen or C 1-3 alkyl, and R2 represents CH2 or C(O).

[0027] In some embodiments of the present disclosure, R1 represents a bond, and R2 represents N(R w ), where R w Represents hydrogen or C 1-3 alkyl.

[0028] In some embodiments of the present disclosure, R1 represents a bond, and R2 represents N(R w )C(O)*, where R w Represents hydrogen or C 1-3 Alkyl. The symbol * indicates that the c connection point.

[0029] In some embodiments of the present disclosure, R1 represents a bond, and R2 represents -N=CH-*. The symbol * indicates that c connection point.

[0030] In some embodiments of the present disclosure, R1 represents N(R w ), where R w Represents hydrogen or C 1-3 alkyl, and R2 represents CH2 or C(O).

[0031] In some embodiments of the present disclosure, R represents where R X represents NH, -N=CH-* or N(R w )C(O)*, where R w Represents hydrogen or C 1-3 Alkyl, and the symbol * indicates that R c connection point.

[0032] In some embodiments of the present disclosure, R represents wherein Ring A2 represents a heterocyclic group containing one nitrogen atom, (R d4 ) n4 represents ring A2 optionally replaced by n4 R d4 Group substitution, each R d4 Each independently represents deuterium, halogen, hydroxyl, mercapto, nitro, amino, cyano, oxo, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy or C 1-6 alkoxy, and n4 represents an integer from 0 to 20; and wherein R y1 express The symbol ** indicates the point of attachment to Ring A2; and R y2 N(R w ) or N(R w )C(O)*, where R w Represents hydrogen or C 1-3 and the symbol * indicates an alkyl group with R c connection point.

[0033] In some embodiments of the present disclosure, R y1 Indicates S, and R y2 N(R w ) or N(R w )C(O)*, where R w Represents hydrogen or C 1-3 Alkyl. The symbol * indicates that the c connection point.

[0034] In some embodiments of the present disclosure, R y1 represents -S-CH2-, and R y2 N(R w ) or N(Rw )C(O)*, where R w Represents hydrogen or C 1-3 Alkyl. The symbol * indicates that the c connection point.

[0035] In some embodiments of the present disclosure, R y1 represents -S-CH2-CH2-, and R y2 N(R w ) or N(R w )C(O)*, where R w Represents hydrogen or C 1-3 Alkyl. The symbol * indicates that the c connection point.

[0036] In some embodiments of the present disclosure, R represents one of the following formulae: Among them, each R w Each independently represents hydrogen or C 1-3 Alkyl; each ring A1 independently represents a heterocyclylene group containing at least 2 nitrogen atoms (including 4- to 30-membered heterocyclylene groups, 4- to 20-membered heterocyclylene groups, and 4- to 15-membered heterocyclylene groups), (R d1 ) n1 Indicates that ring A1 is optionally replaced by n1 R d1 Group substitution, each R d1 Each independently represents deuterium, halogen, hydroxyl, mercapto, nitro, amino, cyano, oxo, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy or C 1-6 alkoxy, and n1 represents an integer of 0-20 (e.g., an integer of 0-10); Ring A2 represents a heterocyclylene group containing one nitrogen atom (including a 4- to 30-membered heterocyclylene group, a 4- to 20-membered heterocyclylene group, and a 4- to 15-membered heterocyclylene group), (R d4 ) n4 represents ring A2 optionally replaced by n4 R d4 Group substitution, each R d4 Each independently represents deuterium, halogen, hydroxyl, mercapto, nitro, amino, cyano, oxo, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy or C 1-6 Alkoxy, and n4 represents an integer of 0-20 (eg, an integer of 0-10); and the symbol * indicates that R c connection point.

[0037] In some embodiments of the present disclosure, each ring A1 herein independently represents a heterocyclylene group containing at least 2 nitrogen atoms, such as a 4- to 30-membered heterocyclylene group, a 4- to 20-membered heterocyclylene group, or a 4- to 15-membered heterocyclylene group. Ring A1 is optionally substituted by n1 R d1 Group substitution, each R d1 are independently deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano, oxo, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy or C 1-6 alkoxy, and n1 represents an integer of 0-20 (eg, an integer of 0-10).

[0038] In some embodiments of the present disclosure, each ring A1 independently represents a 4- to 30-membered heterocyclylene group (including a 4- to 25-membered heterocyclylene group, a 4- to 20-membered heterocyclylene group, a 4- to 15-membered heterocyclylene group, and a 5- to 20-membered heterocyclylene group) containing at least 2 nitrogen atoms. d1 Group substitution, each R d1 are each independently deuterium, halogen (such as fluorine, chlorine, bromine or iodine), hydroxyl, mercapto, nitro, amino, cyano, oxo, C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), halogenated C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl groups, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), C 1-6 Alkoxy (e.g. C 1-4 Alkoxy, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), or halo-C 1-6 Alkoxy (e.g., halo-C 1-4alkoxy, for example F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-), and n1 represents an integer of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20.

[0039] In some embodiments of the present disclosure, each ring A1 independently represents a 1,3-diazetidinylidene, an imidazolidinylidene, a pyrazolidinylidene, a piperazinylidene, a diazacycloheptylidene, a diazaoctyllidene, a diazabicyclo[3.1.1]heptanylidene, a diazabicyclo[2.2.1]heptanylidene, a diazabicyclo[3.2.1]octanylidene, a diazabicyclo[2.2.2]octanylidene, a 2,6-diazaspiro[3.3]heptanylidene, a 2,7-diazaspiro[3.5]nonanylidene, a 2,8-diazaspiro[4.5]decanylidene, a 3,9-diazaspiro[5.5]undecanylidene or an octahydropyrrolo[3,4-c]pyrroleylidene, which is optionally replaced by n1 R d1 Group substitution, each R d1 are each independently deuterium, halogen (such as fluorine, chlorine, bromine or iodine), hydroxyl, mercapto, nitro, amino, cyano, oxo, C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl groups, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), C 1-6 Alkoxy (e.g. C 1-4 Alkoxy, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), or halo-C 1-6 Alkoxy (e.g., halo-C 1-4alkoxy, for example F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-), and n1 represents an integer of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20.

[0040] In some embodiments of the present disclosure, each ring A2 herein independently represents a heterocyclylene group containing 1 nitrogen atom, such as a 4- to 30-membered heterocyclylene group, a 4- to 20-membered heterocyclylene group, or a 4- to 15-membered heterocyclylene group. Ring A2 is optionally substituted by n4 R d4 Group substitution, each R d4 are independently deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano, oxo, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy or C 1-6 alkoxy, and n4 represents an integer of 0-20 (eg, an integer of 0-10).

[0041] In some embodiments of the present disclosure, each ring A2 independently represents a 4- to 30-membered heterocyclylene group (including a 4- to 25-membered heterocyclylene group, a 4- to 20-membered heterocyclylene group, a 4- to 15-membered heterocyclylene group, and a 5- to 20-membered heterocyclylene group) containing 1 nitrogen atom. Ring A2 is optionally substituted by n4 R d4 Group substitution, each R d4 are each independently deuterium, halogen (such as fluorine, chlorine, bromine or iodine), hydroxyl, mercapto, nitro, amino, cyano, oxo, C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), halogenated C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl groups, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), C1-6 Alkoxy (e.g. C 1-4 Alkoxy, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), or halo-C 1-6 Alkoxy (e.g., halo-C 1-4 alkoxy, for example F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-), and n4 represents an integer of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20.

[0042] In some embodiments of the present disclosure, each ring A2 independently represents an azetidinyl, pyrrolidinyl, piperidinyl, dihydroxypiperidinyl, difluoropiperidinyl, azepanyl, octanyl, monoazabridged ring subunit (e.g., 6 to 20-membered monoazabridged ring subunit, such as 6-azabicyclo[3.1.1]heptane subunit, 3-azabicyclo[3.2.1]octanyl subunit and quinuclidinyl subunit) or monoazaspirosubunit (e.g., 5 to 20-membered monoazaspirosubunit, such as 3-azaspiro[5.5]undecane subunit and 7-azaspiro[3.5]nonane subunit), which is optionally replaced by n4 R d4 Group substitution, each R d4 are each independently deuterium, halogen (such as fluorine, chlorine, bromine or iodine), hydroxyl, mercapto, nitro, amino, cyano, oxo, C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), halogenated C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl groups, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), C 1-6 Alkoxy (e.g. C 1-4Alkoxy, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), or halo-C 1-6 Alkoxy (e.g., halo-C 1-4 Alkoxy groups, such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-), and n 4 represents an integer of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20.

[0043] In some embodiments of the present disclosure, R w Represents hydrogen or C 1-3 alkyl.

[0044] In some embodiments of the present disclosure, R w Represents hydrogen.

[0045] In some embodiments of the present disclosure, R w Indicates C 1-3 Alkyl, such as methyl, ethyl, propyl, isopropyl; wherein the above groups are optionally selected from deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, oxo, C 2-6 Alkynyl or C 2-6 The substituents of the alkenyl group are substituted.

[0046] In some embodiments of the present disclosure, examples of R include, but are not limited to: The symbol * indicates that c connection point.

[0047] In some embodiments of the present disclosure, R c Indicates CR c1 R c2 , where R c1 and R c2 Each independently represents H, deuterium, halogen (such as fluorine, chlorine, bromine or iodine), optionally substituted straight-chain or branched alkyl (such as optionally substituted straight-chain or branched C 1-10 alkyl), optionally substituted cycloalkyl (e.g., optionally substituted C 3-30cycloalkyl), optionally substituted heterocyclyl (eg, optionally substituted 4- to 30-membered heterocyclyl), optionally substituted aryl (eg, optionally substituted C 5-30 aryl) or an optionally substituted heteroaryl (e.g., an optionally substituted 5- to 30-membered heteroaryl).

[0048] In some embodiments of the present disclosure, R c Indicates a bond. When R c When a bond is represented, ring B is directly connected to R.

[0049] In some embodiments of the present disclosure, R c Indicates CR c1 R c2 , where R c1 and R c2 Each independently represents H, deuterium, halogen (such as fluorine, chlorine, bromine or iodine), an optionally substituted linear or branched C 1-10 Alkyl (e.g., optionally substituted linear or branched C 1-6 Alkyl or optionally substituted linear or branched C 1-3 alkyl), optionally substituted C 3-30 Cycloalkyl (eg, optionally substituted C 3-20 Cycloalkyl, or optionally substituted C 3-15 cycloalkyl), optionally substituted C 5-30 Aryl (eg, optionally substituted C 5-20 Aryl, or optionally substituted C 5-15 aryl), an optionally substituted 4- to 30-membered heterocyclyl (e.g., an optionally substituted 4- to 20-membered heterocyclyl, or an optionally substituted 4- to 15-membered heterocyclyl), or an optionally substituted 5- to 30-membered heteroaryl (e.g., an optionally substituted 5- to 20-membered heteroaryl, or an optionally substituted 5- to 15-membered heteroaryl). In some embodiments, the straight chain or branched C 1-10 Examples of alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, tert-pentyl, hexyl, heptyl, and octyl. In some embodiments, the linear or branched C 1-10 The alkyl group may be optionally substituted by one or more (e.g., 1-20, 1-15, 1-10, 1-6, 1-4, 1-3, 2-6, or 1) groups independently selected from deuterium, halogen, amino, hydroxyl, mercapto, cyano, nitro, oxo, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkynyl or C 2-6In some embodiments, C 3-30 Examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, cyclooctyl, decahydronaphthyl, octahydropentalenyl, octahydro-1H-indenyl, spirocycloalkyl (e.g., C5-C 15 Spirocyclyl, C5-C 20 Spirocyclyl or C5-C 25 spirocyclic groups, such as spiro[3.3]heptanyl, spiro[2.5]octanyl, spiro[3.5]nonanyl, spiro[3.5]nonenyl, spiro[4.4]nonanyl, spiro[4.5]decanyl, spiro[4.5]decenyl, and spiro[5.5]undecyl), p-menthanyl, m-menthanyl, or bridged cycloalkyl groups (e.g., C6-C 15 Bridged ring group, C6-C 20 Bridged ring group or C6-C 25 bridged ring group, such as adamantyl, noradamantyl, bornyl, norbornyl, bicyclo[2.2.1]heptanyl, 2-oxobicyclo[2.2.1]heptanyl, or bicyclo[2.2.1]heptenyl). In some embodiments, C 3-30 The cycloalkyl group may be optionally substituted by one or more (e.g., 1-20, 1-15, 1-10, 1-6, 1-4, 1-3, 2-6, or 1) groups independently selected from deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkenyl and C 2-6In some embodiments, examples of 4 to 30 membered heterocyclic groups include, but are not limited to, azetidinyl, oxetanyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, tetrahydrofuranyl, tetrahydropyranyl, dihydropyranyl, pyranyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, oxazolidinyl, thiazolidinyl, piperidinyl, piperazinyl, tetrahydropyridinyl, dihydroxypiperidinyl, difluoropiperidinyl, morpholinyl, thiomorpholinyl, azepanyl, azocanyl, dioxane, azepanyl, azocanyl, diazepanyl (e.g., 1,4-diazacycloheptane, 4,5-diazacycloheptane, and 1,3-diazacycloheptane), diazacycloheptane, bridged heterocyclic groups (e.g., 6 to 20 membered bridged heterocyclic groups, such as 6-azabicyclo[3.1.1]heptanyl, ]octanyl, 3,8-diazabicyclo[3.2.1]octanyl, 3,8-diazabicyclo[3.2.1]octanyl, 2,5-diazabicyclo[2.2.2]octanyl and quinuclidine), and azaspirocyclyl (e.g., a 5- to 20-membered azaspirocyclyl, such as 2,6-diazaspiro[3.3]heptanyl, 2,7-diazaspiro[3.5]nonanyl, 2,8-diazaspiro[4.5]decanyl, 3,9-diazaspiro[5.5]undecyl, 3-azaspiro[5.5]undecyl and 7-azaspiro[3.5]nonanyl), or octahydropyrrolo[3,4-c]pyrrolyl. In some embodiments, the 4- to 30-membered heterocyclyl is optionally substituted by one or more (e.g., 1-20, 1-15, 1-10, 1-6, 1-4, 1-3, 2-6, or 1) independently selected from deuterium, halogen, hydroxyl, thiol, amino, cyano, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkenyl and C 2-6 In some embodiments, C 5-30 Examples of aryl groups include, but are not limited to, phenyl or naphthyl. 5-30 The aryl group may be optionally substituted by one or more (e.g., 1-20, 1-15, 1-10, 1-6, 1-4, 1-3, 2-6, or 1) groups independently selected from deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C2-6 Alkenyl and C 2-6 In some embodiments, examples of 5- to 30-membered heteroaryl groups include, but are not limited to, furyl, oxazolyl, isoxazolyl, oxadiazolyl, thienyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, triazinyl, indolyl, isoindolyl, indolyl, benzofuranyl, chromanyl, isobenzofuranyl, benzothienyl, indazolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl , benzisothiazolyl, benzotriazolyl, benzo[2,1,3]oxadiazolyl, benzo[2,1,3]thiadiazolyl, benzo[1,2,3]thiadiazolyl, 2-oxo-2,3-dihydro-1H-benzo[d]imidazolyl, benzo[b][1,4]oxazinyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, quinolyl, isoquinolyl, 1,2,3,4-tetrahydroquinolyl, naphthyridinyl, cinnolinyl, quinazolinyl, quinoxalinyl, 1,2,3,4- Tetrahydroquinoxalinyl, phthalazinyl, 5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazinyl, 4,5,6,7-tetrahydrothieno[3,2-c]pyridinyl, 5-oxo-6,7-dihydrothieno[3,2-d]pyrimidinyl, thieno[2,3-d]pyrimidinyl, thieno[3,2-d]pyrimidinyl, isoxazolo[4,5-c]pyridinyl, isoxazolo[4,5-c]pyrimidinyl, isoxazolo[4,5-d]pyrimidinyl, pyrazole pyrimidinyl, 1H-pyrrolo[3,2-b]pyridinyl, 1H-pyrrolo[2,3-b]pyridinyl, 1H-pyrrolo[2,1-b]thiazolyl, 1H-imidazo[2,1-b]thiazolyl, 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidinyl, or 6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidinyl. In some embodiments, the 5- to 30-membered heteroaryl groups are optionally replaced by one or more (e.g., 1-20, 1-15, 1-10, 1-6, 1-4, 1-3, 2-6, or 1) groups independently selected from deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkenyl and C 2-6 The substituents of the alkynyl group are substituted.

[0050] In some embodiments of the present disclosure, m1 represents an integer of 1, Ring B represents a 4- to 30-membered heterocyclylene group (e.g., a 4- to 20-membered heterocyclylene group, or a 4- to 15-membered heterocyclylene group), C 3-30 Cycloalkylene (e.g. C 3-20 Cycloalkylene, or C 3-15 Cycloalkylene), C 5-30 Arylene (e.g. C 5-20 Arylene, or C 5-15 arylene) or 5 to 30 membered heteroarylene (e.g. 5 to 20 membered heteroarylene, or 5 to 15 membered heteroarylene). Ring B is optionally substituted by n2 R d2 Group substitution, each R d2 Each independently represents deuterium, C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl groups, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), C 1-6 Alkoxy (e.g. C 1-4 alkoxy, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), halo-C 1-6 Alkoxy (e.g., halo-C 1-4 alkoxy, such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-), halogen (such as fluorine, chlorine, bromine or iodine), amino, hydroxy, mercapto, cyano, oxo, C 2-6 Alkynyl (e.g., ethynyl) or C 2-6 alkenyl (e.g., vinyl), n2 represents an integer of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20.

[0051] In some embodiments, Ring B represents a 4- to 30-membered heterocyclylene, examples of which include, but are not limited to, 4- to 20-membered, 4- to 15-membered, 4- to 12-membered, 4- to 11-membered, 4- to 10-membered, 4- to 9-membered, 4- to 8-membered, 4- to 7-membered, 4- to 6-membered, 5- to 15-membered, and 5- to 9-membered heterocyclylene, such as azetidinylene, oxetanylene, pyrrolidinylene, imidazolidinylene, pyrazolidinylene, tetrahydrofuranylene, dihydropyranylene, tetrahydropyranylene, tetrahydrothiophenylene, tetrahydrothiopyranylene, oxazolidinylene, thiazolidinylene, piperidinylene, piperazinylene, morpholinylene, thiomorpholinylene, dioxanylene, azepanylene, azepanylene, diazepanylene (e.g., 1,4-diazepanylene, 4,5-diazepanylene, 1,3-diazepanylene), diazepanylene, heterocyclooctanyl, subbridged heterocyclic groups (e.g., 6- to 20-membered subbridged heterocyclic groups, such as 6-azabicyclo[3.1.1]heptanyl, 2,5-diazabicyclo[2.2.1]heptanyl, 3,6-diazabicyclo[3.1.1]heptanyl, 3-azabicyclo[3.2.1]octanyl, 3,8-diazabicyclo[3.2.1]octanyl, 2,5-diazabicyclo[2.2.2]octanyl and subbridged heterocyclic groups) The heterocyclyl group is optionally substituted with 0-20 (e.g., 1-20, 1-15, 1-10, 1-6, 1-4, 1-3, 2-6 or 1) each independently selected from deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, oxo, C 2-6 Alkynyl or C 2-6 The substituents of the alkenyl group are substituted.

[0052] In some embodiments, Ring B represents C 3-30 Cycloalkylene, examples of which include but are not limited to C 3-20 Cycloalkylene, C 3-15 Cycloalkylene and C 3-11Cycloalkylene, for example, cyclopropylene, cyclobutylene, cyclopentylene, cyclopentenylene, cyclohexylene, cyclohexenylene, cycloheptylene, cyclooctylene, decahydronaphthylene, octahydropentalenylene, octahydro-1H-indenylene, 2,3-dihydro-1H-indenylene, spirocyclylene (for example, C5-C 20 Spirocycloalkylene and C 5-15 spirocyclylene, such as spiro[3.3]heptanylene, spiro[2.5]octanylene, spiro[3.5]nonanylene, spiro[3.5]nonenylene, spiro[4.4]nonanylene, spiro[4.5]decanylene, spiro[4.5]decenylene, spiro[5.5]undecanylene), p-menthanylene, m-menthanylene, or bridged cycloalkylene (e.g., C6-C 20 The cycloalkylene group is optionally substituted with 0-20 (e.g., 1-20, 1-15, 1-10, 1-6, 1-4, 1-3, 2-6 or 1) independently selected from deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, oxo, C 2-6 Alkynyl or C 2-6 The substituents of the alkenyl group are substituted.

[0053] In some embodiments, Ring B represents C 5-30 Arylene, examples of which include but are not limited to C 5-20 Arylene, C 6-20 Arylene, C5- 15 Arylene and C 6-15 Arylene, such as phenylene or naphthylene. Arylene is optionally substituted by 0-20 (e.g., 1-6, 1-4, 1-3, 2-6 or 1) independently selected from deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, C 2-6 Alkynyl or C 2-6 The substituents of the alkenyl group are substituted.

[0054] In some embodiments, ring B represents a 5- to 30-membered heteroarylene group, examples of which are not limited to 5- to 20-membered heteroarylene groups, 5- to 15-membered, 5- to 10-membered, 5- to 9-membered, 5- to 8-membered, 5- to 7-membered, and 5- to 6-membered heteroarylene groups, such as furanylene, oxazolylene, isoxazolylene, oxadiazolylene, thienylene, thiazolylene, isothiazolylene, thiadiazolylene, pyrrolylene, imidazolylene, pyrazolylene, triazolylene, pyridinylene, pyrimidinylene, pyridazinylene, pyrazinylene, triazinylene, indolylene, isoindolylene, indolinylene, Benzofurylene, benzodihydropyranylene, isobenzofurylene, benzothiophenylene, indazolylene, benzimidazolylene, benzoxazolylene, benzisoxazolylene, benzothiazolylene, benzisothiazolylene, benzotriazolylene, benzo[2,1,3]oxadiazolylene, benzo[2,1,3]thiadiazolylene, benzo[1,2,3]thiadiazolylene, 2-oxo-2,3-dihydro-1H-benzo[d]imidazolylene, benzo[b][1,4]oxazinylene, 3,4-dihydro-2H-benzo[b][1,4]oxazinylene, quinolinylene, isoquinolinylene , 1,2,3,4-tetrahydroquinolinylidene, naphthyridinylidene, cinnolinylidene, quinazolinylidene, quinoxalinylidene, 1,2,3,4-tetrahydroquinoxalinylidene, phthalazinylidene, 5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazinylidene, 4,5,6,7-tetrahydrothieno[3,2-c]pyridinylidene, 5-oxo-6,7-dihydrothieno[3,2-d]pyrimidinylidene, thieno[2,3-d]pyrimidinylidene, thieno[3,2-d]pyrimidinylidene, isoxazolo[4,5-c]pyridinylidene, isoxazolo[4,5-c ]pyrimidinylene unit, isoxazolo[4,5-d]pyrimidinylene unit, pyrazolo[1,5-a]pyrimidinylene unit, pyrazolo[1,5-a]pyrimidinylene unit, imidazo[1,2-a]pyrimidinylene unit, 1H-pyrrolo[3,2-b]pyrimidinylene unit, 1H-pyrrolo[2,3-b]pyrimidinylene unit, pyrrolo[2,1-b]thiazolylene unit, imidazo[2,1-b]thiazolylene unit, 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidinylene unit, or 6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidinylene unit. The heteroarylene group is optionally substituted with 0-20 (e.g., 1-20, 1-15, 1-10, 1-6, 1-4, 1-3, 2-6, or 1) groups each independently selected from deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1- 6 alkoxy, halogen, amino, hydroxy, mercapto, cyano, C 2-6 Alkynyl or C 2-6The substituents of the alkenyl group are substituted.

[0055] In some embodiments of the present disclosure, when m1 represents 0, ie, ring B is absent, R c Connect directly to ring C.

[0056] In some embodiments of the present disclosure, ring C represents C 3-30 Cycloalkyl (e.g. C 3-20 Cycloalkyl, or C 3-15 cycloalkyl), 4 to 30-membered heterocyclyl (e.g., 4 to 20-membered heterocyclyl, or 4 to 15-membered heterocyclyl), C 5-30 Aryl (e.g. C 5-20 Aryl, or C 5-15 aryl) or 5 to 30 membered heteroaryl (e.g. 5 to 20 membered heteroaryl, or 5 to 15 membered heteroaryl). Ring C is optionally substituted by n3 R d3 Group substitution, each R d3 Deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, oxo, C 2-6 Alkynyl or C 2-6 alkenyl, and n4 represents an integer of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20.

[0057] In some embodiments, Ring C represents C 3-30 Cycloalkyl, examples of which include but are not limited to C 3-20 Cycloalkyl, C 3-15 Cycloalkyl and C 3- 11 Cycloalkyl, for example cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, cyclooctyl, decahydronaphthyl, octahydropentalenyl, octahydro-1H-indenyl, spirocycloalkyl (for example C5-C 20 spirocyclic groups, such as spiro[3.3]heptanyl, spiro[2.5]octanyl, spiro[3.5]nonanyl, spiro[3.5]nonenyl, spiro[4.4]nonanyl, spiro[4.5]decanyl, spiro[4.5]decenyl, spiro[5.5]undecyl), p-menthanyl, m-menthanyl, or bridged cycloalkyl groups (e.g., C6-C 20The cycloalkyl group is optionally substituted with 0-20 (e.g., 1-20, 1-15, 1-10, 0-10, 1-6, 1-4, 1-3, 2-6 or 1) independently selected from deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, oxo, C 2-6 Alkynyl and C 2-6 The substituents of the alkenyl group are substituted.

[0058] In some embodiments, ring C represents a 4- to 30-membered heterocyclic group, examples of which include, but are not limited to, 4- to 20-membered, 4- to 15-membered, 4- to 12-membered, 4- to 11-membered, 4- to 10-membered, 4- to 9-membered, 4- to 8-membered, 4- to 7-membered, 4- to 6-membered, 5- to 15-membered, and 5- to 9-membered heterocyclic groups, such as azetidinyl, oxetanyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, alkyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, oxazolidinyl, thiazolidinyl, piperidinyl, piperazinyl, tetrahydropyridinyl, dihydroxypiperidinyl, difluoropiperidinyl, morpholinyl, thiomorpholinyl, azepanyl, azocanyl, dioxanyl, azepanyl, azocanyl, diazepanyl (e.g., 1,4-diazepanyl, 4,5-diazepanyl, 1,3-diazepanyl), alkyl), diazabicyclo[3.2.1]octanyl, 3,8-diazabicyclo[3.2.1]octanyl, 2,5-diazabicyclo[2.2.1]octanyl, 3,6-diazabicyclo[3.1.1]heptanyl, 3-azabicyclo[3.2.1]octanyl, 3,8-diazabicyclo[3.2.1]octanyl, 2,5-diazabicyclo[2.2.2]octanyl, 3,6-diazabicyclo[3.1.1]heptanyl, 3-azabicyclo[3.2.1]octanyl, 3,8-diazabicyclo[3.2.1]octanyl, 3,6-diazabicyclo[3.2.2]octanyl, 3,8-diazabicyclo[3.2.1]octanyl, 3,6-diazabicyclo[3.2.2]octanyl, 3,6-diazabicyclo[3.1.1]heptanyl, 3,8-diazabicyclo[3.2.1]octanyl, 3,6-diazabicyclo[3.2.2]octanyl, 3,6-diazabicyclo[3.1.1]heptanyl, 3,6-diazabicyclo[3.2.1]oc ... The heterocyclic group is optionally substituted with 0-20 (e.g., 1-20, 1-15, 1-10, 0-10, 1-6, 1-4, 1-3, 2-6 or 1) each independently selected from deuterium, C 1-6 Alkyl, deuterated C1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, oxo, C 2-6 Alkynyl and C 2-6 The substituents of the alkenyl group are substituted.

[0059] In some embodiments, Ring C represents C 5-30 Aryl, examples of which include but are not limited to C 5-20 Aryl, C 6-20 Aryl, C 5-15 Aryl and C 6-15 Aryl, such as phenyl or naphthyl, which is optionally substituted by 0-20 (e.g., 1-7, 1-6, 0-7, 0-6, 1-4, 1-3, 2-6 or 1) each independently selected from deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1- 6 alkoxy, halogen, amino, hydroxy, mercapto, cyano, C 2-6 Alkynyl and C 2-6 The substituents of the alkenyl group are substituted.

[0060] In some embodiments, ring C represents a 5- to 30-membered heteroaryl, examples of which are not limited to 5- to 20-membered heteroaryl, 5- to 15-membered, 5- to 10-membered, 5- to 9-membered, 5- to 8-membered, 5- to 7-membered, and 5- to 6-membered heteroaryl, such as furyl, oxazolyl, isoxazolyl, oxadiazolyl, thienyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, triazinyl, indolyl, isoindolinyl, indolinyl, benzofuranyl, benzophenone ... dihydropyranyl, isobenzofuranyl, benzothiophenyl, indazolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzotriazolyl, benzo[2,1,3]oxadiazolyl, benzo[2,1,3]thiadiazolyl, benzo[1,2,3]thiadiazolyl, 2-oxo-2,3-dihydro-1H-benzo[d]imidazolyl, benzo[b][1,4]oxazinyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, quinolyl, isoquinolyl, 1,2,3,4- tetrahydroquinolinyl, naphthyridinyl, cinnolinyl, quinazolinyl, quinoxalinyl, 1,2,3,4-tetrahydroquinoxalinyl, phthalazinyl, 5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazinyl, 4,5,6,7-tetrahydrothieno[3,2-c]pyridinyl, 5-oxo-6,7-dihydrothieno[3,2-d]pyrimidinyl, thieno[2,3-d]pyrimidinyl, thieno[3,2-d]pyrimidinyl, isoxazolo[4,5-c]pyridinyl, isoxazolo[4,5-c]pyrimid ... oxazolo[4,5-d]pyrimidinyl, pyrazolo[1,5-a]pyridinyl, pyrazolo[1,5-a]pyrimidinyl, imidazo[1,2-a]pyridinyl, 1H-pyrrolo[3,2-b]pyridinyl, 1H-pyrrolo[2,3-b]pyridinyl, pyrrolo[2,1-b]thiazolyl, imidazo[2,1-b]thiazolyl, 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidinyl, or 6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidinyl. The heteroaryl group is optionally substituted with 0-20 (e.g., 1-20, 1-15, 1-10, 0-10, 1-6, 1-4, 1-3, 2-6, or 1) independently selected from deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, C 2-6 Alkynyl and C 2-6 The substituents of the alkenyl group are substituted.

[0061] In some embodiments of the present disclosure, the compound of formula (I) Some examples include, but are not limited to:

[0062] In some embodiments of the present disclosure, the compound of formula (I) is also a compound of formula (I-1): Among them, Z, R a1 、R a2 、R a3 、R a4 、(R a5 ) m 、Ring A1、(R d1 ) n1 、R c , Ring B, (R d2 ) n2 , m1, ring C and (R d3 ) n3 As defined above for compounds of formula (I) and various embodiments thereof; and wherein (i) R1 represents N(R w ), where R w Represents hydrogen or C 1-3 alkyl, and R2 represents a bond, or R2 represents CH2 or C(O); or (ii) R1 represents a bond, and R2 represents N(R w ), where R w Represents hydrogen or C 1-3 Alkyl, or R2 represents N(R w )C(O)*, where R w Represents hydrogen or C 1-3 Alkyl, or R2 represents -N=CH-*; and the symbol * indicates that R c connection point.

[0063] In some embodiments of the present disclosure, the compound of formula (I) is also a compound of formula (I-2): Among them, Z, R a1 、R a2 、R a3 、R a4 、(R a5 ) m 、Ring A1、(R d1 ) n1 、R c , Ring B, (R d2 ) n2 , m1, ring C and (R d3 ) n3 As defined above in the compounds of formula (I) and various embodiments thereof; and wherein R X represents NH, -N=CH-* or N(R w )C(O)*, where R wRepresents hydrogen or C 1-3 Alkyl, and the symbol * indicates that R c connection point.

[0064] In some embodiments of the present disclosure, the compound of formula (I) is also a compound of formula (I-3): Among them, Z, R a1 、R a2 、R a3 、R a4 、(R a5 ) m 、Ring A2、(R d4 ) n4 、R c , Ring B, (R d2 ) n2 , m1, ring C and (R d3 ) n3 As defined above in the compounds of formula (I) and various embodiments thereof; and wherein R y1 express The symbol ** indicates the point of attachment to ring A2; and R2 represents N(R w )C(O)*, where R w Represents hydrogen or C 1-3 Alkyl, and the symbol * indicates that R c connection point.

[0065] In some embodiments of the present disclosure, R y1 It represents -S-, -S-CH2- or -S-CH2-CH2-.

[0066] In some embodiments of the present disclosure, the compound of formula (I) is also a compound of formula (I-4): Among them, Z, R a1 、R a2 、R a3 、R a4 、(R a5 ) m , R, Ring B, (R d2 ) n2 , m1, ring C and (R d3 ) n3 As defined above for the compounds of formula (I) and its embodiments.

[0067] In some embodiments of the present disclosure, the compound of formula (I) is also a compound of formula (I-5): Among them, Z, R a1 、R a2 、R a3 、R a4 、(R a5 ) m, R, Ring B, (R d2 ) n2 , m1, ring C and (Rd3) n3 As defined above for compounds of formula (I) and its various embodiments; R c1 represents H, deuterium, halogen (such as fluorine, chlorine, bromine or iodine) or an optionally substituted straight or branched C 1-10 Alkyl (e.g., optionally substituted linear or branched C 1-6 Alkyl or optionally substituted linear or branched C 1-3 alkyl); and R c2 represents an optionally substituted C 3-20 Cycloalkyl (eg, optionally substituted C 3-20 Cycloalkyl, or optionally substituted C 3-15 cycloalkyl), optionally substituted C 5-30 Aryl (eg, optionally substituted C 5-20 Aryl, or optionally substituted C 5-15 aryl), an optionally substituted 4- to 30-membered heterocyclyl (e.g., an optionally substituted 4- to 20-membered heterocyclyl, or an optionally substituted 4- to 15-membered heterocyclyl), or an optionally substituted 5- to 30-membered heteroaryl (e.g., an optionally substituted 5- to 20-membered heteroaryl, or an optionally substituted 5- to 15-membered heteroaryl).

[0068] In some embodiments of the compounds of formula (I-5) disclosed herein, R c1 represents an optionally substituted straight or branched chain C 1-10 Alkyl. Straight or branched chain C 1-10 Examples of alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, tert-pentyl, hexyl, heptyl, and octyl. In some embodiments, the linear or branched C 1-10 The alkyl group may be optionally substituted by one or more (e.g., 1-20, 1-15, 1-10, 1-6, 1-4, 1-3, 2-6, or 1) groups independently selected from deuterium, halogen, amino, hydroxyl, mercapto, cyano, nitro, oxo, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkynyl or C 2-6 The substituents of the alkenyl group are substituted.

[0069] In some embodiments of the compounds of formula (I-5) disclosed herein, R c2 represents an optionally substituted C 3-30 Cycloalkyl (eg, optionally substituted C3-20 Cycloalkyl, or optionally substituted C 3-15 cycloalkyl), optionally substituted C 5-30 Aryl (eg, optionally substituted C 5-20 Aryl, or optionally substituted C 5-15 aryl), an optionally substituted 4- to 30-membered heterocyclyl (e.g., an optionally substituted 4- to 20-membered heterocyclyl, or an optionally substituted 4- to 15-membered heterocyclyl), or an optionally substituted 5- to 30-membered heteroaryl (e.g., an optionally substituted 5- to 20-membered heteroaryl, or an optionally substituted 5- to 15-membered heteroaryl). In some embodiments, C 3-30 Examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, cyclooctyl, decahydronaphthyl, octahydropentalenyl, octahydro-1H-indenyl, spirocycloalkyl (e.g., C5-C 15 Spirocyclyl, C5-C 20 Spirocyclyl or C5-C 25 spirocyclic groups, such as spiro[3.3]heptanyl, spiro[2.5]octanyl, spiro[3.5]nonanyl, spiro[3.5]nonenyl, spiro[4.4]nonanyl, spiro[4.5]decanyl, spiro[4.5]decenyl, and spiro[5.5]undecyl), p-menthanyl, m-menthanyl, or bridged cycloalkyl groups (e.g., C6-C 15 Bridged ring group, C6-C 20 Bridged ring group or C6-C 25 bridged ring group, such as adamantyl, noradamantyl, bornyl, norbornyl, bicyclo[2.2.1]heptanyl, 2-oxobicyclo[2.2.1]heptanyl, or bicyclo[2.2.1]heptenyl). In some embodiments, C 3-30 The cycloalkyl group may be optionally substituted by one or more (e.g., 1-20, 1-15, 1-10, 1-6, 1-4, 1-3, 2-6, or 1) groups independently selected from deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkenyl and C 2-6In some embodiments, examples of 4 to 30 membered heterocyclic groups include, but are not limited to, azetidinyl, oxetanyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, tetrahydrofuranyl, tetrahydropyranyl, dihydropyranyl, pyranyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, oxazolidinyl, thiazolidinyl, piperidinyl, piperazinyl, tetrahydropyridinyl, dihydroxypiperidinyl, difluoropiperidinyl, morpholinyl, thiomorpholinyl, azepanyl, azocanyl, dioxane, azepanyl, azocanyl, diazepanyl (e.g., 1,4-diazacycloheptane, 4,5-diazacycloheptane, and 1,3-diazacycloheptane), diazacycloheptane, bridged heterocyclic groups (e.g., 6 to 20 membered bridged heterocyclic groups, such as 6-azabicyclo[3.1.1]heptanyl, ]octanyl, 3,8-diazabicyclo[3.2.1]octanyl, 3,8-diazabicyclo[3.2.1]octanyl, 2,5-diazabicyclo[2.2.2]octanyl and quinuclidine), and azaspirocyclyl (e.g., a 5- to 20-membered azaspirocyclyl, such as 2,6-diazaspiro[3.3]heptanyl, 2,7-diazaspiro[3.5]nonanyl, 2,8-diazaspiro[4.5]decanyl, 3,9-diazaspiro[5.5]undecyl, 3-azaspiro[5.5]undecyl and 7-azaspiro[3.5]nonanyl), or octahydropyrrolo[3,4-c]pyrrolyl. In some embodiments, the 4- to 30-membered heterocyclyl is optionally substituted by one or more (e.g., 1-20, 1-15, 1-10, 1-6, 1-4, 1-3, 2-6, or 1) independently selected from deuterium, halogen, hydroxyl, thiol, amino, cyano, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkenyl and C 2-6 In some embodiments, C 5-30 Examples of aryl groups include, but are not limited to, phenyl or naphthyl. 5-30 The aryl group may be optionally substituted by one or more (e.g., 1-20, 1-15, 1-10, 1-6, 1-4, 1-3, 2-6, or 1) groups independently selected from deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C2-6 Alkenyl and C 2-6 In some embodiments, examples of 5- to 30-membered heteroaryl groups include, but are not limited to, furyl, oxazolyl, isoxazolyl, oxadiazolyl, thienyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, triazinyl, indolyl, isoindolyl, indolyl, benzofuranyl, chromanyl, isobenzofuranyl, benzothienyl, indazolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl , benzisothiazolyl, benzotriazolyl, benzo[2,1,3]oxadiazolyl, benzo[2,1,3]thiadiazolyl, benzo[1,2,3]thiadiazolyl, 2-oxo-2,3-dihydro-1H-benzo[d]imidazolyl, benzo[b][1,4]oxazinyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, quinolyl, isoquinolyl, 1,2,3,4-tetrahydroquinolyl, naphthyridinyl, cinnolinyl, quinazolinyl, quinoxalinyl, 1,2,3,4- Tetrahydroquinoxalinyl, phthalazinyl, 5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazinyl, 4,5,6,7-tetrahydrothieno[3,2-c]pyridinyl, 5-oxo-6,7-dihydrothieno[3,2-d]pyrimidinyl, thieno[2,3-d]pyrimidinyl, thieno[3,2-d]pyrimidinyl, isoxazolo[4,5-c]pyridinyl, isoxazolo[4,5-c]pyrimidinyl, isoxazolo[4,5-d]pyrimidinyl, pyrazole pyrimidinyl, 1H-pyrrolo[3,2-b]pyridinyl, 1H-pyrrolo[2,3-b]pyridinyl, 1H-pyrrolo[2,1-b]thiazolyl, 1H-imidazo[2,1-b]thiazolyl, 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidinyl, or 6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidinyl. In some embodiments, the 5- to 30-membered heteroaryl groups are optionally replaced by one or more (e.g., 1-20, 1-15, 1-10, 1-6, 1-4, 1-3, 2-6, or 1) groups independently selected from deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkenyl and C 2-6 The substituents of the alkynyl group are substituted.

[0070] In some embodiments of the present disclosure, the compound of formula (I) is also a compound of formula (II-1), a compound of formula (II-2), a compound of formula (II-3), or a compound of formula (II-4): Among them, Z, R a1 、R a2 、R a3 、R a4 、(R a5 ) m , R, R c , Ring B, (R d2 ) n2 , Ring C, (R d3 ) n3 and m1 are as defined above for the compound of formula (I) and its embodiments.

[0071] Particularly preferred are the compounds of Table 1 of the present invention and their salts (especially pharmaceutically acceptable salts, such as their hydrochlorides), enantiomers, diastereomers, solvates or polymorphs: Table 1 Compounds of the present invention Compound of formula (I')

[0072] The present disclosure provides a compound of formula (I') or its salt (including pharmaceutically acceptable salt), stereoisomer (including enantiomer, diastereomer), solvate, isotopically enriched analog or polymorph: Among them, Z, R a1 、R a2 、R a3 、R a4 、(R a5 ) m 、R1、R2、Ring A1、(R d1 ) n1 、R e and R f As defined above for the compound of formula (I') and its embodiments.

[0073] In some embodiments of the compounds of formula (I') of the present disclosure, R a1 、R a2 、R a3 and R a4 are the same or different and each independently represents H, deuterium (ie, D), halogen (such as fluorine, chlorine, bromine or iodine), C 1-6 Alkyl (e.g. C 1-3 Alkyl, such as methyl, ethyl, or propyl), halo C 1-6 Alkyl (e.g. halo-C 1-4 alkyl, such as trifluoromethyl), deuterated C 1-6 Alkyl, C 1-6 Alkoxy (e.g. C 1-4 Alkoxy, such as methoxy), deuterated C 1-6 Alkoxy or halogenated C 1-6 Alkoxy (e.g., halo-C 1-4 In some sub-embodiments of the present disclosure, R a1 、R a2 、R a3 and R a4 Each independently represents H.

[0074] In some embodiments of the disclosed compounds of formula (I'), Z represents C(O), CH2, or CD2.

[0075] In some embodiments of the disclosed compounds of formula (I'), Z represents C(O).

[0076] In some embodiments of the disclosed compounds of formula (I'), Z represents CH2.

[0077] In some embodiments of the disclosed compounds of formula (I'), Z represents CD2.

[0078] In some embodiments of the compounds of formula (I') disclosed herein, (R a5 ) m represents that the isoindoline ring of formula (I) attached thereto is optionally substituted by m R a5 Replace, each R a5 The same or different and each independently represents deuterium, halogen (such as fluorine, chlorine, bromine or iodine), hydroxyl, mercapto, nitro, amino, cyano, C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halo-C 1-6 Alkyl (e.g. halo-C 1-4Alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 Alkoxy (e.g. C 1-4 alkoxy, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy (e.g., halo-C 1-4 Alkoxy, for example F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-), C 2-6 Alkenyl (e.g. vinyl), C 2-6 Alkynyl (e.g., ethynyl) or heterocyclyl (e.g., 4- to 30-membered heterocyclyl, 4- to 20-membered heterocyclyl, and 4- to 15-membered heterocyclyl), the heterocyclyl being optionally substituted with one or more (e.g., 1-10, 1-6, 1-3, or 1) independently selected from halogen, C 1-6 alkyl and tert-butyloxycarbonyl, and m represents an integer of 0, 1, 2 or 3. In some sub-embodiments of the present disclosure, m represents an integer of 0, 1 or 2. In some sub-embodiments of the present disclosure, each R a5 The same or different and each independently represents deuterium, halogen (such as fluorine, chlorine, bromine or iodine), hydroxyl, mercapto, nitro, amino, cyano, C 1-4 Alkyl (e.g. C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl or tert-butyl), halogenated C 1-4 Alkyl (e.g. halo-C 1-3 Alkyl groups, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), C 1-4 Alkoxy (e.g. C 1-3 alkoxy, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), halo-C 1-4 Alkoxy (e.g., halo-C1-3 alkoxy, such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-) or a 4- to 15-membered heterocyclic group (such as piperazinyl), the 4- to 15-membered heterocyclic group is optionally substituted by one or more (e.g., 1-10, 1-6, 1-3, or 1) independently selected from halogen, C 1-6 The substituent is substituted by an alkyl group and a tert-butyloxycarbonyl group.

[0079] In the disclosed embodiments of compounds of formula (I'), the number of substituents is in principle not subject to any restrictions or automatically limited by the size of the building block.

[0080] In some embodiments of the compounds of formula (I') disclosed herein, ring A1 represents a heterocyclylene group containing at least 2 nitrogen atoms, such as a 4- to 30-membered heterocyclylene group, a 4- to 20-membered heterocyclylene group, or a 4- to 15-membered heterocyclylene group. Ring A1 is optionally substituted by n1 Rd1 groups, each Rd1 being independently deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano, oxo, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy or C 1-6 alkoxy, and n1 represents an integer of 0-20 (eg, an integer of 0-10).

[0081] In some embodiments of the compounds of formula (I') disclosed herein, ring A1 represents a 4- to 30-membered heterocyclylene group (including a 4- to 25-membered heterocyclylene group, a 4- to 20-membered heterocyclylene group, a 4- to 15-membered heterocyclylene group, and a 5- to 20-membered heterocyclylene group) containing at least 2 nitrogen atoms. Ring A1 is optionally substituted by n1 R d1 Group substitution, each R d1 are each independently deuterium, halogen (such as fluorine, chlorine, bromine or iodine), hydroxyl, mercapto, nitro, amino, cyano, oxo, C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), halogenated C 1-6 Alkyl (e.g. halo-C1-4 Alkyl groups, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), C 1-6 Alkoxy (e.g. C 1-4 Alkoxy, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), or halo-C 1-6 Alkoxy (e.g., halo-C 1-4 alkoxy, for example F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-), and n1 represents an integer of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20.

[0082] In some embodiments of the compounds of formula (I') of the present disclosure, ring A1 represents a 1,3-diazetidinylidene, an imidazolidinylidene, a pyrazolidinylidene, a piperazinylidene, a diazacycloheptylidene, a diazaoctyllidene, a diazabicyclo[3.1.1]heptanylidene, a diazabicyclo[2.2.1]heptanylidene, a diazabicyclo[3.2.1]octanylidene, a diazabicyclo[2.2.2]octanylidene, a 2,6-diazaspiro[3.3]heptanylidene, a 2,7-diazaspiro[3.5]nonanylidene, a 2,8-diazaspiro[4.5]decanylidene, a 3,9-diazaspiro[5.5]undecanylidene or an octahydropyrrolo[3,4-c]pyrroleylidene, which is optionally replaced by n1 R d1 Group substitution, each R d1 are each independently deuterium, halogen (such as fluorine, chlorine, bromine or iodine), hydroxyl, mercapto, nitro, amino, cyano, oxo, C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl groups, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), C 1-6 Alkoxy (e.g. C1-4 Alkoxy, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), or halo-C 1-6 Alkoxy (e.g., halo-C 1-4 alkoxy, for example F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-), and n1 represents an integer of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20.

[0083] In some embodiments of the compounds of formula (I') of the present disclosure, R1 represents a bond, and R2 represents N(R w ), where R w Represents hydrogen or C 1-3 Alkyl (such as methyl, ethyl and propyl); wherein the above groups are optionally selected from deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, oxo, C 2-6 Alkynyl or C 2-6 The substituents of the alkenyl group are substituted.

[0084] In some embodiments of the compounds of formula (I') of the present disclosure, R1 represents N(R w ), where R w represents hydrogen or optionally substituted by one or more independently selected aryl groups (e.g., C 5-30 Aryl, C 5-20 Aryl and C 5-15 aryl) and optionally substituted heteroaryl (e.g., 5- to 30-membered heteroaryl, 5- to 20-membered heteroaryl, and 5- to 15-membered heteroaryl) 1-3 In some embodiments of the compounds of formula (I') of the present disclosure, R w Represents hydrogen or C 1-3 Alkyl (such as methyl, ethyl and propyl), wherein the C 1-3 The alkyl group is optionally substituted with one or more substituents selected from the group consisting of: phenyl or naphthyl, which is optionally substituted with one or more (e.g., 1-7, 1-5, 1-4, 1-3 or 1) substituents each independently selected from halogen, amino, hydroxy, thiol, cyano, oxo, C 1-6 Alkyl, deuterated C1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkynyl and C 2-6 substituted alkenyl; and furyl, oxazolyl, isoxazolyl, oxadiazolyl, thienyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, triazinyl, indolyl, isoindolyl, indolinyl, benzofuranyl, chromanyl, isobenzofuranyl, benzothienyl, indazolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzotriazolyl, benzo[2,1,3]oxadiazolyl, benzo benzo[2,1,3]thiadiazolyl, benzo[1,2,3]thiadiazolyl, 2-oxo-2,3-dihydro-1H-benzo[d]imidazolyl, benzo[b][1,4]oxazinyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, quinolyl, isoquinolyl, 1,2,3,4-tetrahydroquinolyl, naphthyridinyl, cinnolinyl, quinazolinyl, quinoxalinyl, 1,2,3,4-tetrahydroquinoxalinyl, phthalazinyl, 5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazinyl , 4,5,6,7-tetrahydrothieno[3,2-c]pyridinyl, 5-oxo-6,7-dihydrothieno[3,2-d]pyrimidinyl, thieno[2,3-d]pyrimidinyl, thieno[3,2-d]pyrimidinyl, isoxazolo[4,5-c]pyridinyl, isoxazolo[4,5-c]pyrimidinyl, isoxazolo[4,5-d]pyrimidinyl, pyrazolo[1,5-a]pyridinyl, pyrazolo[1,5-a]pyrimidinyl, imidazo[1,2-a]pyridinyl, 1H-pyrrolo[3,2-b]pyridinyl yl, 1H-pyrrolo[2,3-b]pyridinyl, pyrrolo[2,1-b]thiazolyl, imidazo[2,1-b]thiazolyl, 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidinyl, and 6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidinyl, which are optionally substituted by one or more (e.g., 1-10, 1-7, 1-5, 1-4, 1-3 or 1) groups each independently selected from halogen, amino, hydroxy, thiol, cyano, oxo, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkynyl and C 2-6 Substitution of the alkenyl group by a substituent; and / or

[0085] In some embodiments of the compounds of formula (I') of the present disclosure, R1 represents N(R w ), where R w Indicates H or and R2 represents a bond.

[0086] In some embodiments of the compounds of formula (I') of the present disclosure, R e In some embodiments of the disclosed compounds of formula (I'), R e It represents C(O)O.

[0087] In some embodiments of the compounds of formula (I') of the present disclosure, R e Represents the following structure: where R e1 represents C(O), CH2 or halogenated CH2; Ring D represents an arylene group, (R e2 ) m2 represents a ring D optionally replaced by m2 R e2 Group substitution, each R e2 Each independently represents deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, oxo, C 2-6 Alkynyl or C 2-6 alkenyl, and m2 represents an integer of 0-20; and ring E represents a nitrogen-containing heterocyclic group, m4 represents an integer of 0 or 1, (R e3 ) m3 represents a ring E optionally surrounded by m3 R e3 Group substitution, each R e3 Each independently represents deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, oxo, C 2-6 Alkynyl or C 2-6 alkenyl, and m3 represents an integer of 0-20; and the symbol # indicates that R f connection point.

[0088] In some embodiments of the compounds of formula (I') disclosed herein, ring D represents C 5-30 Arylene, examples of which include but are not limited to C 5-20 Arylene, C 6-20 Arylene, C 5-15 Arylene and C 6-15Arylene, such as phenylene or naphthylene. Arylene is optionally replaced by m2 (such as an integer of 0-20 or an integer of 0-10, such as 1-6, 1-4, 1-3, 2-6 or 1) each independently selected from deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, C 2-6 Alkynyl or C 2-6 Substituent R of alkenyl e2 replace.

[0089] In some embodiments of the compounds of formula (I') of the present disclosure, m4 represents an integer of 1, and ring E represents a 4- to 30-membered nitrogen-containing heterocyclic group, examples of which are not limited to 4- to 20-membered, 4- to 15-membered, 4- to 12-membered, 4- to 11-membered, 4- to 10-membered, 4- to 9-membered, 4- to 8-membered, 4- to 7-membered, 4- to 6-membered, 5- to 15-membered, and 5- to 9-membered nitrogen-containing heterocyclic groups. yl, such as azetidinyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidinyl, piperazinyl, tetrahydropyridinyl, dihydroxypiperidinyl, difluoropiperidinyl, azepanyl, oxazolidinyl, diazepanyl (e.g., 1,4-diazepanyl, 4,5-diazepanyl, 1,3-diazepanyl), diazepanyl, nitrogen-containing bridged heterocyclic group ( For example, 6 to 20-membered nitrogen-containing subbridged heterocyclic groups, such as 6-azabicyclo[3.1.1]heptanylidene, 2,5-diazabicyclo[2.2.1]heptanylidene, 3,6-diazabicyclo[3.1.1]heptanylidene, 3-azabicyclo[3.2.1]octanylidene, 3,8-diazabicyclo[3.2.1]octanylidene, 2,5-diazabicyclo[2.2.2]octanylidene and quinuclidinyl), sub- Azaspirocyclyl (e.g., a 5- to 20-membered azaspirocyclyl, such as 2,6-diazaspiro[3.3]heptanediyl, 2,7-diazaspiro[3.5]nonanediyl, 2,8-diazaspiro[4.5]decanediyl, 3,9-diazaspiro[5.5]undecanediyl, 3-azaspiro[5.5]undecanediyl and 7-azaspiro[3.5]nonanediyl), or octahydropyrrolo[3,4-c]pyrrolediyl. The nitrogen-containing heterocyclyl is optionally substituted by m3 (e.g., 0-20, e.g., 1-20, 1-15, 1-10, 1-6, 1-4, 1-3, 2-6 or 1) each independently selected from deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, oxo, C 2-6 Alkynyl or C 2-6 Substituent R of alkenyl e3 replace.

[0090] In some embodiments of the compounds of formula (I') of the present disclosure, R e express The symbol # indicates that f connection point.

[0091] In some embodiments of the compounds of formula (I') of the present disclosure, R f Indicates C 1-10 Alkyl groups, examples of which include but are not limited to C 1-10 Alkyl, C 1-9 Alkyl, C 1-8 Alkyl, C 1-7 Alkyl, C 1-6 Alkyl, C 1-5 Alkyl, C 1-4 Alkyl, C 1-3 Alkyl, C 1-2 Alkyl and methyl groups, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, tert-pentyl, hexyl, heptyl, octyl, nonyl and decyl. 1-10 The alkyl group is optionally substituted with one or more (e.g., 1-20, such as 1-18, 1-15, 1-10, 1-6, 1-5, 1-4, 1-3, 1-3, 2-6, or 1) substituents independently selected from the group consisting of halogen (e.g., fluorine, chlorine, bromine, or iodine), optionally substituted aryl (e.g., optionally substituted C 5-30 Aryl, optionally substituted C 5-20 Aryl, or optionally substituted C 5-15 aryl), optionally substituted heteroaryl (e.g., optionally substituted 5- to 30-membered heteroaryl, optionally substituted 5- to 20-membered heteroaryl, or optionally substituted 5- to 15-membered heteroaryl), optionally substituted heterocyclyl (e.g., optionally substituted 4- to 30-membered heterocyclyl, optionally substituted 4- to 20-membered heterocyclyl, or optionally substituted 4- to 15-membered heterocyclyl), optionally substituted cycloalkyl (e.g., optionally substituted C 3-30 Cycloalkyl, optionally substituted C 3-20 Cycloalkyl, or optionally substituted C 3-15 cycloalkyl) and NR3R4, wherein R3 and R4 each independently represent H, C 1-3 Alkyl or optionally substituted cycloalkyl (eg, optionally substituted C 3-30 Cycloalkyl, optionally substituted C 3-20 Cycloalkyl, or optionally substituted C3-15 In some embodiments, examples of aryl groups include, but are not limited to, C 5-30 Aryl, C 5- 20 Aryl, C 6-20 Aryl, C 5-15 Aryl and C 6-15 In some embodiments, the aryl group may be optionally substituted by one or more (e.g., 1-20, 1-15, 1-10, 1-7, 1-6, 1-4, 1-3, 2-6, or 1) groups independently selected from halogen, amino, hydroxyl, thiol, cyano, oxo, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkynyl and C 2-6In some embodiments, examples of heteroaryl groups include, but are not limited to, 5- to 30-membered heteroaryl groups, 5- to 20-membered heteroaryl groups, 5- to 15-membered, 5- to 10-membered, 5- to 9-membered, 5- to 8-membered, 5- to 7-membered, and 5- to 6-membered heteroaryl groups, such as furyl, oxazolyl, isoxazolyl, oxadiazolyl, thienyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, triazinyl, indolyl, isoindolinyl, indolinyl, benzofuranyl, benzodiazoles, benzophenone ... benzo[b][1,4]oxazinyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, quinolyl, isoquinolyl, 1,2,3,4-tetrahydro-2H-benzo[b][1,4]oxazinyl, benzo[2,1,3]oxadiazolyl, benzo[2,1,3]thiadiazolyl, benzo[1,2,3]thiadiazolyl, 2-oxo-2,3-dihydro-1H-benzo[d]imidazolyl, benzo[b][1,4]oxazinyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, quinolyl, isoquinolyl, 1,2,3,4-tetrahydro-2H-benzo[b][1,4]oxazinyl, quinolinyl, naphthyridinyl, cinnolinyl, quinazolinyl, quinoxalinyl, 1,2,3,4-tetrahydroquinoxalinyl, phthalazinyl, 5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazinyl, 4,5,6,7-tetrahydrothieno[3,2-c]pyridinyl, 5-oxo-6,7-dihydrothieno[3,2-d]pyrimidinyl, thieno[2,3-d]pyrimidinyl, thieno[3,2-d]pyrimidinyl, isoxazolo[4,5-c]pyridinyl, isoxazolo[4,5-c]pyrimid ... oxazolo[4,5-d]pyrimidinyl, pyrazolo[1,5-a]pyridinyl, pyrazolo[1,5-a]pyrimidinyl, imidazo[1,2-a]pyridinyl, 1H-pyrrolo[3,2-b]pyridinyl, 1H-pyrrolo[2,3-b]pyridinyl, pyrrolo[2,1-b]thiazolyl, imidazo[2,1-b]thiazolyl, 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidinyl, or 6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidinyl. In some embodiments, the heteroaryl group may be optionally substituted by one or more (e.g., 1-20, 1-15, 1-10, 1-7, 1-6, 1-4, 1-3, 2-6, or 1) groups independently selected from halogen, amino, hydroxy, thiol, cyano, oxo, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkynyl and C 2-6In some embodiments, examples of heterocyclyl groups include, but are not limited to, 4- to 30-membered heterocyclyl, 4- to 20-membered heterocyclyl, 4- to 15-membered, 4- to 12-membered, 4- to 11-membered, 4- to 10-membered, 4- to 9-membered, 4- to 8-membered, 4- to 7-membered, 4- to 6-membered, 5- to 15-membered, and 5- to 9-membered heterocyclyl, such as azetidinyl, oxetanyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, tetrahydrofuranyl, tetrahydropyranyl, dihydropyranyl, pyranyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, oxazolidinyl, thiazolidinyl, piperidinyl, piperazinyl, tetrahydropyridinyl, dihydroxypiperidinyl, difluoropiperidinyl, morpholinyl, thiomorpholinyl, azepanyl, azocanyl, dioxanyl, azepanyl, azocanyl, diazepanyl (e.g., 1,4-diazepanyl, 4,5-diazepanyl, and 1,3-diazepanyl) alkyl), diazabicyclooctanyl, bridged heterocyclic groups (e.g., 6- to 20-membered bridged heterocyclic groups, such as 6-azabicyclo[3.1.1]heptyl, 2,5-diazabicyclo[2.2.1]heptyl, 3,6-diazabicyclo[3.1.1]heptyl, 3-azabicyclo[3.2.1]octanyl, 3,8-diazabicyclo[3.2.1]octanyl, 3,8-diazabicyclo[3.2.1]octanyl, 2,5-diazabicyclo[3.1.1]heptyl, [2.2.2] octyl and quinuclidine), and azaspirocyclyl (e.g., 5 to 20-membered azaspirocyclyl, such as 2,6-diazaspiro[3.3]heptyl, 2,7-diazaspiro[3.5]nonyl, 2,8-diazaspiro[4.5]decyl, 3,9-diazaspiro[5.5]undecyl, 3-azaspiro[5.5]undecyl and 7-azaspiro[3.5]nonyl), or octahydropyrrolo[3,4-c]pyrrolyl. In some embodiments, the heterocyclyl is optionally substituted by one or more (e.g., 1-20, 1-15, 1-10, 1-6, 1-4, 1-3, 2-6, or 1) groups each independently selected from halogen, amino, hydroxyl, thiol, cyano, oxo, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkynyl, C 2-6 Alkenyl, tert-butyloxycarbonyl and R h Substituents substituted. h represents an optionally substituted C 5-15 Aryl, examples of which include but are not limited to C 5-12 Aryl, C 6-12 Aryl and C 6-10 Aryl, such as phenyl or naphthyl. 5-15The aryl group may be optionally substituted with one or more (eg, 1-10, 1-6, 1-4, 1-3, 2-6 or 1) aryl groups selected from halogen, C 1-6 Alkyl and C 1-6 In some embodiments, examples of cycloalkyl include but are not limited to C 3-30 Cycloalkyl, C 3-20 Cycloalkyl, C 3-15 Cycloalkyl, C 3-11 Cycloalkyl, C 5-15 Cycloalkyl and C 7-15 Cycloalkyl, for example cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, cyclooctyl, decahydronaphthyl, octahydropentalenyl, octahydro-1H-indenyl, spirocycloalkyl (for example C5-C 15 Spirocyclyl, C5-C 20 Spirocyclyl or C5-C 25 spirocyclic groups, such as spiro[3.3]heptanyl, spiro[2.5]octanyl, spiro[3.5]nonanyl, spiro[3.5]nonenyl, spiro[4.4]nonanyl, spiro[4.5]decanyl, spiro[4.5]decenyl, and spiro[5.5]undecyl), p-menthanyl, m-menthanyl, or bridged cycloalkyl groups (e.g., C6-C 15 Bridged ring group, C6-C 20 Bridged ring group, C6-C 25 Bridged ring group and C7-C 15 In some embodiments, the cycloalkyl group is optionally substituted by one or more (e.g., 1-20, 1-15, 1-10, 1-6, 1-4, 1-3, 2-6 or 1) groups each independently selected from halogen, amino, hydroxyl, thiol, cyano, oxo, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkynyl, C 2-6 Alkenyl, tert-butyloxycarbonyl and R h substituted by a substituent, wherein R h represents an optionally substituted C 5-15 Aryl, examples of which include but are not limited to C 5-12 Aryl, C 6-12 Aryl and C 6-10 Aryl, such as phenyl or naphthyl, wherein the C 5-15The aryl group may be optionally substituted with one or more (eg, 1-10, 1-6, 1-5, 1-4, 1-3, 2-6 or 1) aryl groups selected from halogen, C 1-6 Alkyl and C 1-6 The substituents of the alkoxy group are substituted.

[0092] In some embodiments, R3 and R4 each independently represent H, C 1-3 Alkyl or optionally substituted cycloalkyl (eg, optionally substituted C 3-30 Cycloalkyl, optionally substituted C 3-20 Cycloalkyl, or optionally substituted C 3-15 In some embodiments, examples of cycloalkyl groups include but are not limited to C 3-30 Cycloalkyl, C 3-20 Cycloalkyl, C 3-15 Cycloalkyl, C 5-15 Cycloalkyl and C 7-15 Cycloalkyl, for example cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, cyclooctyl, decahydronaphthyl, octahydropentalenyl, octahydro-1H-indenyl, spirocycloalkyl (for example C5-C 15 Spirocyclyl, C5-C 20 Spirocyclyl or C5-C 25 spirocyclic groups, such as spiro[3.3]heptanyl, spiro[2.5]octanyl, spiro[3.5]nonanyl, spiro[3.5]nonenyl, spiro[4.4]nonanyl, spiro[4.5]decanyl, spiro[4.5]decenyl, and spiro[5.5]undecyl), p-menthanyl, m-menthanyl, or bridged cycloalkyl groups (e.g., C6-C 15 Bridged ring group, C6-C 20 Bridged ring group, C6-C 25 Bridged ring group and C7-C 15 In some embodiments, the cycloalkyl group is optionally substituted by one or more (e.g., 1-20, 1-15, 1-10, 1-6, 1-4, 1-3, 2-6 or 1) groups each independently selected from halogen, amino, hydroxyl, thiol, cyano, oxo, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkynyl, C 2- 6 alkenyl, tert-butyloxycarbonyl and R h substituted by a substituent, wherein R hrepresents an optionally substituted C 5-15 Aryl, examples of which include but are not limited to C 5-12 Aryl, C 6-12 Aryl and C 6-10 Aryl, such as phenyl or naphthyl, wherein the C 5-15 The aryl group may be optionally substituted with one or more (eg, 1-10, 1-6, 1-5, 1-4, 1-3, 2-6 or 1) aryl groups selected from halogen, C 1-6 Alkyl and C 1-6 In some embodiments, R3 represents H, and R4 represents a bridged cycloalkyl group (e.g., C6-C 15 Bridged ring group, C6-C 20 Bridged ring group, C6-C 25 Bridged ring group and C7-C 15 bridged ring group, such as adamantyl, noradamantyl, bornyl, norbornyl, bicyclo[2.2.1]heptyl, 2-oxobicyclo[2.2.1]heptyl or bicyclo[2.2.1]heptenyl), which is optionally substituted by one or more (e.g., 1-20, 1-15, 1-10, 1-6, 1-4, 1-3, 2-6 or 1) groups each independently selected from halogen, amino, hydroxyl, thiol, cyano, oxo, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkynyl, C 2-6 The substituents of the alkenyl group and the tert-butyloxycarbonyl group are substituted.

[0093] In some embodiments of the compounds of formula (I') of the present disclosure, R f Examples include, but are not limited to, methyl, isopropyl, tert-butyl,

[0094] Particularly preferred are the compounds in Table 2 of the present invention and their salts (especially pharmaceutically acceptable salts, such as their hydrochlorides), enantiomers, diastereomers, solvates or polymorphs: Table 2 Compounds of the present invention II. Other Forms of the Compounds (including Salts, Enantiomers, Stereoisomers, Solvates, Isotopically Enriched Analogs, or Polymorphs of the Compounds)

[0095] The compounds of the present disclosure have the structure of any one of Formula (I), (I-1), (I-2), (I-3), (I-4), (I-5), (II-1), (II-2), (II-3), (II-4), or (I'). Unless otherwise indicated, reference to the compounds of the present disclosure refers to compounds including any one of Formula (I), (I-1), (I-2), (I-3), (I-4), (I-5), (II-1), (II-2), (II-3), (II-4), or (I'), as well as specific compounds falling within the scope of these general formulas.

[0096] It should be recognized that the compounds of the present disclosure (including compounds of Formula (I) (I-1), (I-2), (I-3), (I-4), (I-5), (II-1), (II-2), (II-3), (II-4) or (I')) may have stereo configurations and therefore may exist in more than one stereoisomer form. The present disclosure also relates to optically enriched compounds having stereo configurations, such as about greater than 90% ee, such as about 95% ee or 97% ee, or greater than 99% ee, and mixtures thereof, including racemic mixtures. As used herein, "optically enriched" means that the mixture of enantiomers is composed of a significantly greater proportion of one enantiomer and can be described by enantiomeric excess (ee%). Purification of isomers and separation of isomeric mixtures can be achieved by standard techniques known in the art (e.g., column chromatography, preparative TLC, preparative HPLC, asymmetric synthesis (e.g., by using chiral intermediates) and / or chiral resolution, etc.).

[0097] In some embodiments, polymorphic forms of the compounds of the present disclosure (including compounds of Formula (I)-(1), (I-2), (I-3), (I-4), (I-5), (II-1), (II-2), (II-3), (II-4), or (I')) or salts of the compounds of the present disclosure are also provided. The salts of the compounds of the present disclosure may be pharmaceutically acceptable salts, including but not limited to hydrohalides (including hydrochlorides, hydrobromides), sulfates, maleates, sulfonates, citrates / citrates, lactates, lactobionates, L-tartrates, fumarates, L-malates, L-lactates, α-ketoglutarate, hippurates, D-glucuronates, D-gluconates, α-D-glucoheptonates, glycolates, mucates, L-ascorbic acid, orotates, picrates, glycinates, alanates, arginates, cinnamates, laurates, pamoates, sebacates, benzenesulfonates, methanesulfonates, ethanesulfonates, edisylate, formates, acetates, 2,2-dichloroacetates, pivalates, propionates, pentanoates, thiazolinates, thiazolinates, pyrimidines ... The compounds of the present invention may be present in the form of unsolvated or solvated pharmaceutically acceptable solvents such as water, ethanol, etc. The compounds of the present invention may be present in the form of unsolvated or solvated pharmaceutically acceptable solvents such as water, ethanol, etc. In some embodiments, the compounds of the present disclosure can be prepared as prodrugs or prodrugs. Prodrugs can be converted into parent drugs in the body and exert their effects. In some embodiments, isotope-labeled compounds of the present disclosure are also provided. Examples of isotopes include deuterium (D or 2 H). III. Pharmaceutical Compositions / Formulations

[0098] In some embodiments, the present disclosure provides a pharmaceutical composition comprising as an active ingredient a compound of the present disclosure (including a compound of Formula (I), Formula (I-1), Formula (I-2), Formula (I-3), Formula (I-4), Formula (I-5), Formula (II-1), Formula (II-2), Formula (II-3), Formula (II-4) or Formula (I')) or a pharmaceutically acceptable salt, solvate, isotopically enriched analog, polymorph, stereoisomer (including enantiomers), or mixture of stereoisomers, and at least one pharmaceutically acceptable carrier.

[0099] In some embodiments, pharmaceutically acceptable carriers include, but are not limited to, fillers, stabilizers, dispersants, suspending agents, diluents, excipients, thickeners, colorants, solvents, or encapsulating materials. A carrier must be "acceptable" if it is compatible with the other ingredients of the formulation (including the compounds useful in the present disclosure) and is not harmful to the patient. Some examples of materials that are pharmaceutically acceptable carriers include: sugars, such as lactose, glucose, and sucrose; starches, such as corn starch and potato starch; cellulose and its derivatives, such as sodium carboxymethylcellulose, ethylcellulose, and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients, such as cocoa butter and suppository waxes; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and soybean oil; glycols, such as propylene glycol; polyols, such as glycerol, sorbitol, mannitol, and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffers, such as magnesium hydroxide and aluminum hydroxide; phosphate buffered saline surfactants; polyoxyethylene, polyvinyl pyrrolidone, polyacrylamide, poloxamer; and other nontoxic compatible substances used in pharmaceutical formulations.

[0100] The pharmaceutical composition of the present disclosure further includes at least one second therapeutic agent, such as an anticancer agent. The second therapeutic agent can be combined with the compound of formula (I) (or a compound of formula (I-1), formula (I-2), formula (I-3), formula (I-4), formula (I-5), formula (II-1), formula (II-2), formula (II-3), formula (II-4), or formula (I')) described in the present disclosure to treat the disease or condition described in the present disclosure. The second therapeutic agent includes but is not limited to a chemotherapeutic agent, an immunotherapeutic agent, a gene therapy agent, etc.

[0101] The pharmaceutical composition of the present invention comprising as an active ingredient a compound of formula (I) (or a compound of formula (I-1), (I-2), (I-3), (I-4), (I-5), (II-1), (II-2), (II-3), (II-4) or (I')) or a pharmaceutically acceptable salt thereof can be administered by a suitable route of administration (including but not limited to nasal administration, inhalation administration, topical administration, oral administration, oral mucosal administration, rectal administration, pleural cavity administration, peritoneal administration, vaginal administration, intramuscular administration, subcutaneous administration, transdermal administration, endoscopic administration, orally administered). The compound of formula (I) can be prepared into a suitable dosage form, such as a spray preparation, a patch, a tablet (e.g., a conventional tablet, a dispersible tablet, an orally disintegrating tablet), a capsule (e.g., a soft capsule, a hard capsule, an enteric-coated capsule), a dragee, a lozenge, a powder, a granule, a powder injection, a suppository, or a liquid preparation (e.g., a suspension (e.g., an aqueous or oily suspension), a solution, an emulsion or a syrup), or a conventional injection form such as an injectable solution (e.g., a sterile injection solution prepared using water, Ringer's solution or isotonic sodium chloride solution as a carrier or solvent according to methods known in the art) or a lyophilized composition. Those skilled in the art can also prepare the compound of formula (I) into a conventional, dispersible, chewable, orally rapidly disintegrating or rapidly dissolving preparation, or a sustained-release capsule or a controlled-release capsule as needed.

[0102] As an active ingredient, a compound of formula (I) as described herein (or a compound of formula (I-1), (I-2), (I-3), (I-4), (I-5), (II-1), (II-2), (II-3), (II-4) or (I')) is contained in a pharmaceutically acceptable carrier or diluent in an amount sufficient to deliver a therapeutically effective amount for the indication to be treated to the subject without causing serious toxic effects in the treated subject. The dosage of the active compound for all diseases or conditions mentioned herein is, for example, from about 5 ng / kg subject weight / day to 500 mg / kg subject weight / day, from about 10 ng / kg subject weight / day to 300 mg / kg subject weight / day, for example, from 0.1 to 100 mg / kg subject weight / day, or from 0.5 to about 25 mg / kg subject weight / day.

[0103] The compound of formula (I) (or a compound of formula (I-1), (I-2), (I-3), (I-4), (I-5), (II-1), (II-2), (II-3), (II-4), or (I')) or a pharmaceutically acceptable salt thereof as disclosed herein can be conveniently administered in any suitable dosage form, the specifications of which include, but are not limited to, less than 1 mg, 1 mg to 3000 mg, 5 mg to 1000 mg, for example, 5 to 500 mg, or 25 to 250 mg of active ingredient per unit dosage form. IV. Kits / Packaging

[0104] The compound of formula (I) (or a compound of formula (I-1), formula (I-2), formula (I-3), formula (I-4), formula (I-5), formula (II-1), formula (II-2), formula (II-3), formula (II-4) or formula (I')) described in the present disclosure, or a pharmaceutically acceptable salt, solvate, isotopically enriched analog, polymorph, stereoisomer (including enantiomers), or mixture of stereoisomers thereof, is used as a medicament. The medicament of the present disclosure or the pharmaceutical composition of the present disclosure may be present in a medicine box / packaging product. The medicine box / packaging product may include a package or container. The package or container includes, but is not limited to, an ampoule, a blister pack, a pharmaceutical plastic bottle, a vial, a pharmaceutical glass bottle, a container, a syringe, a laminated flexible package, a co-extruded film infusion container, a test tube and a dispensing device, etc. The medicine box / packaging product may include instructions for use of the product. V. Methods of treatment and use

[0105] The compound of formula (I) (or a compound of formula (I-1), formula (I-2), formula (I-3), formula (I-4), formula (I-5), formula (II-1), formula (II-2), formula (II-3), formula (II-4) or formula (I')) described in the present invention, or a pharmaceutically acceptable salt, solvate, isotopically enriched analog, polymorph, stereoisomer (including enantiomers), or mixture of stereoisomers thereof, can also be used as a medicament. In particular, the compounds of formula (I) (or compounds of formula (I-1), (I-2), (I-3), (I-4), (I-5), (II-1), (II-2), (II-3), (II-4) or (I')) described herein, or pharmaceutically acceptable salts, solvates, isotopically enriched analogs, polymorphs, stereoisomers (including enantiomers), or mixtures of stereoisomers thereof can be used to prepare medicaments for preventing and / or treating diseases or conditions associated with cereblon proteins.

[0106] The disease or disorder associated with cereblon protein is selected from the group consisting of tumors, infectious diseases, inflammatory diseases, autoimmune diseases, anemia, hemorrhagic shock, transplant rejection, multiple organ dysfunction syndrome (MODS), sarcoidosis, adult respiratory distress syndrome, cardiovascular disease, Richter syndrome (RS), acute liver failure or diabetes.

[0107] The disease or condition associated with the cereblon protein is selected from the group consisting of: myeloma, including multiple myeloma, plasma cell myeloma, smoldering myeloma, smoldering multiple myeloma; myelofibrosis; bone marrow disease; myelodysplastic syndrome (MDS); previously treated myelodysplastic syndrome; transplant-related cancer; neutropenia; leukemia, including acute myeloid leukemia (AML), chronic myeloid leukemia (CML), chronic myeloid leukemia, acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), B-cell chronic lymphocytic leukemia, and leukemia. associated anemia, acute B-cell leukemia, T-cell leukemia, acute T-cell leukemia, lymphoma cell leukemia, monocytic leukemia, myelomonocytic leukemia; lymphoma, including diffuse large B-cell lymphoma, non-Hodgkin's lymphoma, Hodgkin's lymphoma, anaplastic lymphoma, anaplastic large cell lymphoma, CD20-positive lymphoma, mantle cell lymphoma, follicular lymphoma (FL), Burkitt's lymphoma, marginal zone lymphoma (MZL), primary lymphoma, B-cell lymphoma, relapsed B-cell non-Hodgkin's lymphoma, relapsed diffuse large B-cell lymphoma, relapsed longitudinal Patients with thymic (septal) large B-cell lymphoma, primary mediastinal (thymic) large B-cell lymphoma, relapsed transformed non-Hodgkin's lymphoma, refractory B-cell non-Hodgkin's lymphoma, refractory diffuse large B-cell lymphoma, refractory primary mediastinal (thymic) large B-cell lymphoma, and refractory transformed non-Hodgkin's lymphoma; thyroid cancer; melanoma; lung cancer, including adenocarcinoma, squamous cell carcinoma, non-small cell lung cancer, and small cell lung cancer; inflammatory myofibroblastic tumor; colorectal cancer; intestinal cancer; glioma; glioblastoma; astrocytoma; ovarian cancer; bronchogenic carcinoma; prostate cancer; breast cancer, including triple-negative breast cancer, incidental breast cancer, and Cowden disease pancreatic cancer; central nervous system cancer; neuroblastoma; glioma; peripheral neuroepithelial tumor; extramedullary plasmacytoma; plasmacytoma; gastric cancer; gastrointestinal stromal tumor; esophageal cancer; colorectal adenocarcinoma; esophageal squamous cell carcinoma; liver cancer; renal cell carcinoma; bladder cancer; endometrial cancer; uterine cancer; head and neck cancer; brain cancer; oral cancer; sarcomas, including rhabdomyosarcoma, various adipose tumors, Ewing sarcoma / primitive neuroectodermal tumors (Ewing / PNETs), and leiomyosarcoma; urothelial carcinoma; basal cell carcinoma; oral squamous cell carcinoma; bile duct cancer; bone cancer; cervical cancer; skin cancer; Richter syndrome (RS); sepsis syndrome;Autoimmune diseases, including rheumatoid arthritis, autoimmune encephalomyelitis, ankylosing spondylitis, psoriasis, psoriatic arthritis, systemic lupus erythematosus, multiple sclerosis, recurrent oral ulcers, Kawasaki disease, polymyositis / dermatomyositis, Sjögren's syndrome, atopic dermatitis, hidradenitis suppurativa, gout, type 1 diabetes, urticaria, inflammatory bowel disease (including Crohn's disease and ulcerative colitis); keratoconjunctivitis sicca; inflammatory diseases, including Crohn's disease and ulcerative colitis, pneumonia, osteoarthritis, synovitis, systemic inflammatory response syndrome, airway inflammation, bronchitis; cerebral malaria; infectious diseases, including Viral pneumonia, AIDS, COVID-19 novel coronavirus infection, Gram-negative bacterial infection, Gram-positive bacterial infection, tuberculosis, etc.; septic shock; tuberculosis; bacterial meningitis; chronic obstructive pulmonary disease; asthma; hemorrhagic shock; organ (including kidney, heart, lung) or tissue transplant rejection; diabetes; sarcoidosis; adult respiratory distress syndrome; anemia; pediatric aplastic anemia; cardiovascular disease (such as coronary heart disease, congestive heart failure, myocardial infarction, atherosclerosis); multiple organ failure caused by cachexia and septic shock; or acute liver failure.

[0108] The present disclosure provides a method for preventing and / or treating a disease or condition associated with cereblon protein in a subject, comprising administering to the subject a therapeutically effective amount of a compound of formula (I) (or a compound of formula (I-1), formula (I-2), formula (I-3), formula (I-4), formula (I-5), formula (II-1), formula (II-2), formula (II-3), formula (II-4), or formula (I')) described herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a compound of formula (I) (or a compound of formula (I-1), formula (I-2), formula (I-3), formula (I-4), formula (I-5), formula (II-1), formula (II-2), formula (II-3), formula (II-4), or formula (I')) described herein as an active ingredient, or a pharmaceutical composition comprising a compound of formula (I) (or a compound of formula (I-1), formula (I-2), formula (I-3), formula (I-4), formula (I-5), formula (II-1), formula (II-2), formula (II-3), formula (II-4), or formula (I')) described herein, or a pharmaceutically acceptable salt thereof.

[0109] In the method for preventing and / or treating a disease or condition associated with cereblon protein, a therapeutically effective amount of a compound of formula (I) (or a compound of formula (I-1), formula (I-2), formula (I-3), formula (I-4), formula (I-5), formula (II-1), formula (II-2), formula (II-3), formula (II-4), or formula (I')) described herein, or a pharmaceutical composition comprising a compound of formula (I) (or a compound of formula (I-1), formula (I-2), formula (I-3), formula (I-4), formula (I-5), formula (II-1), formula (II-2), formula (II-3), formula (II-4), or formula (I')) described herein as an active ingredient is administered to the subject by at least one administration route selected from nasal administration, inhalation administration, topical administration, oral administration, oral mucosal administration, rectal administration, pleural cavity administration, peritoneal administration, intramuscular administration, subcutaneous administration, transdermal administration, epidural cavity administration, intrathecal administration, and intravenous administration.

[0110] The term "treatment" or "treatment" refers to administering to a subject a compound of formula (I) (or a compound of formula (I-1), formula (I-2), formula (I-3), formula (I-4), formula (I-5), formula (II-1), formula (II-2), formula (II-3), formula (II-4), or formula (I')) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a compound of formula (I) (or a compound of formula (I-1), formula (I-2), formula (I-3), formula (I-4), formula (I-5), formula (II-1), formula (II-2), formula (II-3), formula (II-4), or formula (I')) or a pharmaceutically acceptable salt thereof as an active ingredient to slow down (mitigate) the development of an undesirable disease or condition (e.g., a tumor). Beneficial or desired clinical results of the present disclosure include, but are not limited to, alleviating symptoms, reducing the severity of the disease, stabilizing the state of the disease, delaying or slowing the progression of the disease, improving or alleviating the condition, and alleviating the disease.

[0111] A "therapeutically effective amount" of a compound of the present disclosure depends on a variety of factors, including the activity of the particular compound used, the metabolic stability and duration of action of the compound, the age, sex, and weight of the patient, the patient's overall medical condition, the route and timing of administration, the rate of excretion, concomitant medications, and the progression of the disease or condition being treated in the patient. One skilled in the art will be able to determine an appropriate dosage based on these and other factors.

[0112] It should be understood that the choice of using one or more active compounds and / or compositions and their dosages depends on the individual's basic conditions (generally, the individual's conditions should be optimized). Administration and dosing regimens should be within the capabilities of those skilled in the art, and appropriate dosages depend on many factors including the knowledge and ability level of the ordinary skilled physician, veterinarian, or researcher (see, for example, Li Jun, ed., "Clinical Pharmacology," 4th edition, People's Medical Publishing House (2008)).

[0113] The patient or subject for treatment is an animal, such as a mammal, including but not limited to primates (such as humans), cattle, sheep, goats, horses, dogs, cats, rabbits, guinea pigs, rats, mice, etc. VI. Preparation Method

[0114] The present disclosure also provides a method for preparing a compound of formula (I), which comprises using a compound of formula (M1) and a compound of formula (M2) as starting materials to prepare the compound of formula (I): where R a1 、R a2 、R a3 、R a4 、(R a5 ) m , Z, R, Ring B, Ring C, (R d2 ) n2 、(R d3 ) n3 , and m1 are as defined in the compounds of formula (I) and its various sub-embodiments disclosed herein; and R w3 Indicates CHO, COOH or where R c2 As defined in the compounds of formula (I) and its various subembodiments disclosed herein, and group LE represents Cl, Br, I, OMs, OTs, or ONs; wherein (1)-R w1 -R w2 express And R represents or (2)-R w1 -R w2 express And R represents or (3)-R w1 -R w2 represents -NH-NH2, and R represents -NH-NH-; or (4) -R w1 -R w2 express And R represents where R w 、Ring A1、(R d1 ) n1 , Ring A2 and (R d4 )n4 As defined in the compounds of formula (I) and its various sub-embodiments disclosed herein; wherein when R w3 When it represents CHO, R c3 and R c4 Indicates H; or when R w3 When it represents COOH, R c3 and R c4 together to form a carbonyl group; or when R w3 express When R c3 Represents H, and R c4 It is R c2 .

[0115] In some embodiments of the disclosed methods of preparing compounds of formula (I), when R w3 When CHO is represented, the compound of formula (M1) and the compound of formula (M2) undergo a reductive amination reaction to prepare a compound of formula (I), wherein R c3 and R c4 Indicates H.

[0116] In some embodiments of the method for preparing the compound of formula (I) disclosed herein, the reductive amination reaction can be carried out in the presence of sodium borohydride acetate and an organic solvent (e.g., 1,2-dichloroethane, N,N-dimethylformamide, or dichloromethane) at room temperature to 80°C (e.g., 40°C to 60°C, 40°C to 50°C, or 50°C to 60°C). Alternatively, the reductive amination reaction can be carried out in the presence of sodium borohydride and 1,4-dioxane at room temperature to 80°C (e.g., 40°C to 60°C, 40°C to 50°C, or 50°C to 60°C). In some embodiments, the molar ratio of the compound of formula (M1) to the compound of formula (M2) can be, for example, 1.0 to 2:1, 1:1.0 to 2, 1:1.1 to 2, 1:1.1 to 1.5, 1:1.1 to 1.2, or 1:1.2 to 1.3, etc.

[0117] In some embodiments of the disclosed methods of preparing compounds of formula (I), when R w3 When the compound of formula (M1) and the compound of formula (M2) undergo amide condensation reaction to prepare the compound of formula (I), wherein R c3 and R c4 Together they form a carbonyl group.

[0118] In some embodiments of the method for preparing the compound of formula (I) disclosed herein, the amide condensation reaction can be carried out in the presence of, for example, HATU / DIEA / DMF, or HATU / TEA / DMF, or HOAt / EDCI / TEA / DCM at room temperature. In some embodiments, the molar ratio of the compound of formula (M1) to the compound of formula (M2) can be, for example, 1.0-2:1, 1:1.0-2, 1:1.1-2, 1:1.1-1.5, 1:1.1-1.2, or 1:1.2-1.3, etc.

[0119] In some embodiments of the disclosed methods of preparing compounds of formula (I), when R w3 express When the compound of formula (M1) and the compound of formula (M2) undergo amine alkylation reaction to prepare the compound of formula (I), wherein R c3 Represents H, and R c4 It is R c2 .

[0120] In some embodiments of the method for preparing the compound of formula (I) disclosed herein, the amine alkylation reaction can be carried out in the presence of, for example, DIEA and sodium iodide, or triethylamine and sodium iodide, at room temperature to 80° C. (e.g., 40° C. to 60° C., 40° C. to 50° C., or 50° C. to 60° C.). In some embodiments, the molar ratio of the compound of formula (M1) to the compound of formula (M2) can be, for example, 1.0 to 2:1, 1:1.0 to 2, 1:1.1 to 2, 1:1.1 to 1.5, 1:1.1 to 1.2, or 1:1.2 to 1.3, etc.

[0121] In some embodiments of the method of preparing the compound of formula (I) disclosed herein, when -R w1 -R w2 express When the compound of formula (M1) is prepared by reacting the compound of formula (M3) with the compound of formula (M4) as starting materials, Y represents F or Br; W1 represents H, and W2 represents an amino-protecting group; or W1 represents an amino-protecting group, and W2 represents H.

[0122] In some embodiments of the method for preparing the compound of formula (I) disclosed herein, when Y represents F, the compound of formula (M3) and the compound of formula (M4) are subjected to a palladium-catalyzed coupling reaction to prepare the compound of formula (M1). In some embodiments of the method for preparing the compound of formula (I) disclosed herein, the palladium-catalyzed coupling reaction can be carried out in the presence of cesium carbonate, a palladium catalyst, and N,N-dimethylformamide at, for example, 50° C. to 100° C. (e.g., 80° C.).

[0123] In some embodiments of the method for preparing the compound of formula (I) disclosed herein, when Y represents Br, the compound of formula (M3) and the compound of formula (M4) undergo a substitution reaction to prepare the compound of formula (M1). In some embodiments of the method for preparing the compound of formula (I) disclosed herein, the substitution reaction can be carried out in the presence of N,N-diisopropylethylamine and dimethyl sulfoxide at, for example, 80° C. to 150° C. (e.g., 130° C.).

[0124] In some embodiments of the method for preparing the compound of formula (I) disclosed herein, the amino protecting group may be, for example, Boc. The removal of the protecting group can be achieved by techniques and methods well known to those skilled in the art. For example, the removal of the protecting group Boc can be achieved under acidic conditions such as hydrochloric acid or trifluoroacetic acid. VII. Definition

[0125] Unless otherwise specified, the following words, phrases and symbols used in this specification generally have the meanings described below.

[0126] In general, the nomenclature used herein (including IUPAC nomenclature) and the laboratory procedures described below (including for cell culture, organic chemistry, analytical chemistry and pharmacology, etc.) are those well known and commonly used in the art. Unless otherwise defined, all scientific and technical terms used herein in conjunction with the present disclosure described herein have the same meaning as commonly understood by those skilled in the art. In addition, in the claims and / or the specification, when the term "one" or "an" is used in conjunction with the term "comprising" or a noun, its meaning may be "one", but is also consistent with the meaning of "one or more", "at least one" and "one or more than one". Similarly, the term "another" or "other" can mean at least a second or more.

[0127] It should be understood that whenever various aspects are described herein using the terms "including" or "comprising," other similar aspects described by "consisting of" and / or "consisting essentially of" are also provided.

[0128] The term "about," used alone or in combination, is used herein to mean approximately, roughly, roughly, or around. When the term "about" is used in conjunction with a numerical range, it modifies that range by extending the boundaries above and below the numerical values ​​recited. Generally, the term "about" can modify a numerical value above and below the recited value by a variation, for example, 10%, 5%, 2%, or 1%, above or below the recited value.

[0129] In this document, the term " ... represents a bond" used alone or in combination means that it is a bond linker (ie, it does not exist). For example, the term "R c "Represents a key" means Rc is a bond linker. In other words, when R c When it is a bond, the ring B group of the structure of formula (I) is directly connected to the ring A in the structure of formula (I).

[0130] As used herein, the term "optionally substituted with" used alone or in combination means that the indicated group may be unsubstituted or substituted with one or more substituents as defined herein. The terms "optionally substituted with" and "unsubstituted or substituted" are used interchangeably herein. The term "substituted" generally means that one or more hydrogen atoms in the referenced structure are replaced with the same or different specific substituents. The number of substituents is not subject to any limitation in principle, or is automatically limited by the size of the building block (i.e., the total number of hydrogen atoms of the building block that can be replaced), or as explicitly defined herein.

[0131] In this document, a bond broken by a wavy line shows the point of attachment of the depicted group to the rest of the molecule. For example, the monovalent group R represents the group c Connected to R of the structure of formula (I).

[0132] As used herein, the term "substituted by one or more substituents selected from...", used alone or in combination, may mean that some or all of the hydrogen atoms of the group mentioned are replaced by substituents, and the number of substituents includes, but is not limited to, 1-40, such as 1-30, such as 1-25, 1-20, 1-15, 1-10, 1-5, 1-4, 1-3, 1-2 or 1. This number is not subject to any limitation in principle and is not automatically limited by the size of the building block. For example, when the group mentioned is a methyl group, the number of substituents may be 1-3.

[0133] As used herein, the term "deuterated," alone or in combination, means that one or more hydrogens of the referenced group are replaced by a deuterium atom.

[0134]

[0046] As used herein, the term "oxo" or "oxo," alone or in combination, refers to =0.

[0135] As used herein, the term "carbonyl," alone or in combination, refers to C(O) or C(=O).

[0136] As used herein, the term "halogen atom" or "halogen" alone or in combination refers to fluorine, chlorine, bromine or iodine.

[0137] As used herein, the term "alkyl" used alone or in combination refers to a straight chain or branched chain alkyl group. x -C y Alkyl" or "C x-y"alkyl" (x and y are each an integer) refers to a straight or branched chain alkyl group containing x to y carbon atoms. The term "C1-C 10 "Alkyl" refers to a straight or branched chain alkyl group containing 1 to 10 carbon atoms. The term "C1-C 10 Examples of "alkyl" include C 1-9 Alkyl, C 1-8 Alkyl, C 2-8 Alkyl, C 1-7 Alkyl, C 1-6 Alkyl, C 1-5 Alkyl, C 1-4 Representative examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, tert-pentyl, and hexyl. The term "C1-C3 alkyl" in this disclosure refers to a C1-C2 alkyl group. 1-3 "Alkyl" or "C1-C3 alkyl" refers to an alkyl group containing 1 to 3 carbon atoms, representative examples of which include methyl, ethyl, n-propyl and isopropyl. In the present disclosure, the "alkyl" is optionally substituted, and the substituents may be one or more (e.g., 1-10, 1-6, 1-5, 1-4, or 1-3) each independently selected from, for example, halogen, hydroxyl, cyano, C 1-3 Alkyl, C 1-3 Alkoxy, halogenated C 1-6 Alkoxy, halogenated C 1-6 Alkyl (e.g. trifluoromethyl), C 3-6 a cycloalkyl group, a 4-membered to 7-membered heterocyclic group, or a combination thereof.

[0138] As used herein, the term "haloalkyl" alone or in combination refers to a linear or branched alkyl group substituted with one or more halogens, wherein one or more hydrogen atoms in the alkyl group are replaced with halogen atoms. x -C y Alkyl" or "halogenated C x-y "alkyl" (x and y are each an integer) refers to a straight or branched chain alkyl group containing x to y carbon atoms substituted by one or more halogens. The term "halogenated C 1-10 "Alkyl" refers to a straight or branched chain alkyl group containing 1 to 10 carbon atoms substituted by one or more halogens. 1- 10 Examples of alkyl groups include halo-C 1-9 Alkyl groups, such as halogenated C 1-8 Alkyl, halogenated C 2-8 Alkyl, halogenated C 1-7 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-5 Alkyl, or halogenated C 1-4Representative examples include halogenated methyl, halogenated ethyl, halogenated n-propyl, halogenated isopropyl, halogenated n-butyl, halogenated isobutyl, halogenated sec-butyl, halogenated tert-butyl, halogenated pentyl, halogenated isopentyl, halogenated neopentyl, halogenated tert-pentyl, halogenated hexyl, halogenated heptyl, halogenated octyl, halogenated nonyl and halogenated decyl. The term "halogenated C 1-3 "Alkyl" or "halogenated C1-C3 alkyl" refers to an alkyl group containing 1 to 3 carbon atoms substituted by one or more halogens, representative examples of which include halomethyl (e.g., trifluoromethyl), haloethyl, halo-n-propyl, and halo-isopropyl.

[0139] As used herein, the term "deuterated alkyl" alone or in combination refers to a straight or branched chain alkyl group substituted with one or more deuterium atoms, wherein one or more hydrogen atoms in the alkyl group are replaced with deuterium atoms. x -C y Alkyl" or "deuterated C x-y "alkyl" (x and y are each an integer) refers to a straight or branched chain alkyl group containing x to y carbon atoms substituted by one or more deuterium atoms. The term "deuterated C 1-10 "Alkyl" refers to a straight or branched chain alkyl group containing 1 to 10 carbon atoms substituted by one or more deuterium atoms. 1-10 Examples of alkyl groups include deuterated C 1-9 Alkyl groups, such as deuterated C 1-8 Alkyl, deuterated C 2-8 Alkyl, deuterated C 1-7 Alkyl, deuterated C 1-6 Alkyl, deuterated C 1-5 Alkyl, or deuterated C 1-4 Representative examples include perdeuterated methyl (CD3), perdeuterated ethyl (CD3CD2), perdeuterated n-propyl, perdeuterated isopropyl, perdeuterated n-butyl, perdeuterated isobutyl, perdeuterated sec-butyl, perdeuterated tert-butyl, perdeuterated pentyl, perdeuterated isopentyl, perdeuterated neopentyl, perdeuterated tert-pentyl, and perdeuterated hexyl. The term "deuterated C 1-3 "Alkyl" or "deuterated C1-C3 alkyl" refers to an alkyl group containing 1 to 3 carbon atoms substituted by one or more deuterium atoms, representative examples of which include perdeuterated methyl (CD3-) and perdeuterated ethyl (CD3CD2).

[0140] As used herein, the term "alkoxy" used alone or in combination refers to a straight or branched chain alkoxy group having the formula alkyl-O-. Optionally, the alkyl portion of the alkoxy group may contain 1-10 (e.g., 1-6, 1-4, or 1-3) carbon atoms. Representative examples of "alkoxy" include, but are not limited to, methoxy, ethoxy, propoxy, isopropoxy, n-butoxy, isobutoxy, tert-butoxy, pentoxy, 2-pentoxy, isopentoxy, neopentoxy, hexoxy, 2-hexyloxy, 3-hexyloxy, 3-methylpentoxy, and the like. The term "C1-C6 alkoxy" or "C 1-3 "Alkoxy" refers to a straight or branched chain alkoxy group containing 1 to 6 carbon atoms. 1-6 Representative examples of alkoxy include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, butoxy, pentyloxy, and hexyloxy.

[0141] As used herein, the term "haloalkoxy" alone or in combination refers to an alkoxy group substituted with one or more halogens. Optionally, the alkyl portion of the alkoxy group may contain 1-10 (e.g., 1-6, 1-4, or 1-3) carbon atoms. Examples of "haloalkoxy" include halogenated C 1-6 Alkoxy and halogenated C 1-4 Representative examples include, but are not limited to, F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O-, or CH2ClCH2-O-.

[0142] In the present invention, the term "heteroaryl", used alone or in combination, refers to a 5- to 30-membered (alternatively 5- to 20-membered, 5- to 15-membered, 5- to 12-membered, 5- to 11-membered, 5- to 10-membered, 5- to 9-membered, 5- to 8-membered, 5- to 7-membered, 5- to 6-membered, 6- to 15-membered, 6- to 9-membered, 6- to 10-membered or 6- to 20-membered) monocyclic or bicyclic or polycyclic hydrocarbon group containing at least one aromatic ring having 1 or more (e.g., 1 to 6, or 1 to 5, or 1 to 4, or 1 to 3) heteroatoms independently selected from oxygen, nitrogen and sulfur. Bicyclic or polycyclic heteroaryl groups include bicyclic, tricyclic, tetracyclic or polycyclic heteroaryl groups, one of which is an aromatic ring having one or more (e.g., 1-4, 1-3, 1-2, or 1) heteroatoms independently selected from O, S, and N, and the other rings of which may be saturated, partially unsaturated, or aromatic and may be carbocyclic or contain one or more (e.g., 1-4, 1-3, 1-2, or 1) heteroatoms independently selected from O, S, and N. Examples of monocyclic heteroaryl groups include, but are not limited to, furanyl, oxazolyl, isoxazolyl, oxadiazolyl, thienyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, tetrazolyl, and triazinyl. Examples of bicyclic heteroaryl groups include, but are not limited to, indolyl, isoindolyl, isoindolinyl, benzofuranyl, isobenzofuranyl, benzothiophenyl, indazolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzotriazolyl, benzo[2,1,3]oxadiazolyl, benzo[2,1,3]thiadiazolyl, benzo[1,2,3]thiadiazolyl, quinolinyl, isoquinolinyl, naphthyridinyl, cinnolinyl, quinazolinyl, quinoxalinyl, phthalazinyl, oxazolopyridinyl, furopyridinyl, pteridinyl, purinyl, pyridopyridinyl, pyrazolo[1,5-a]pyridinyl, pyrazolo[1,5-a]pyrimidinyl, imidazo[1,2-a]pyridinyl, 1H-pyrrolo[3,2-b]pyridinyl, 1H-pyrrolo[2,3-b]pyridinyl, pyrrolo[2,1-b]thiazolyl, imidazo[2,1-b]thiazolyl, chromanyl and 6,7-dihydrothieno[3,2-d]pyrimidinyl. Examples of tricyclic or polycyclic heteroaryl groups include, but are not limited to, acridinyl, benzindolyl, carbazolyl, dibenzofuranyl, xanthenyl, 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidinyl, and 6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidinyl. The heteroaryl groups may be unsubstituted or substituted. Substituted heteroaryl refers to heteroaryl groups that are substituted one or more times (e.g., 1-4, 1-3, or 1-2 times) with substituents, wherein the substituents are optionally selected from, for example, deuterium, hydroxyl, amino, thiol, nitro, halogen, cyano, optionally deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, optionally deuterated C3-6 Cycloalkyl, optionally deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, optionally deuterated C 1-6 Alkyl-NH-, NH2-C 1-6 Alkylene, optionally deuterated C 1-6 Alkyl-NHC(O)-, optionally deuterated C 1-6 Alkyl-C(O)NH-, C 2-6 Alkynyl, C 2-6 or any combination thereof.

[0143] In the present invention, the term "heteroarylene" used alone or in combination refers to a divalent group of a 5- to 30-membered (alternatively 5- to 20-membered, 5- to 15-membered, 5- to 12-membered, 5- to 11-membered, 5- to 10-membered, 5- to 9-membered, 5- to 8-membered, 5- to 7-membered, 5- to 6-membered, 6- to 15-membered, 6- to 9-membered, 6- to 10-membered or 6- to 20-membered) monocyclic or bicyclic or polycyclic hydrocarbon containing at least one aromatic ring having 1 or more (e.g., 1 to 6, or 1 to 5, or 1 to 4, or 1 to 3) heteroatoms independently selected from oxygen, nitrogen and sulfur. Bicyclic or polycyclic heteroarylene groups include bicyclic, tricyclic, tetracyclic or polycyclic heteroarylene groups, one of which is an aromatic ring having one or more (e.g., 1-4, 1-3, 1-2, or 1) heteroatoms independently selected from O, S, and N, and the other rings may be saturated, partially unsaturated, or aromatic and may be carbocyclic or contain one or more (e.g., 1-4, 1-3, 1-2, or 1) heteroatoms independently selected from O, S, and N. Examples of monocyclic heteroarylene groups include, but are not limited to, furanylene, oxazolylene, isoxazolylene, oxadiazolylene, thienylene, thiazolylene, isothiazolylene, thiadiazolylene, pyrrolylene, imidazolylene, pyrazolylene, triazolylene, pyridinylene, pyrimidinylene, pyridazinylene, pyrazinylene, tetrazolylene, and triazinylene. Examples of bicyclic heteroarylene groups include, but are not limited to, indolylene, isoindolylene, isoindolylene, benzofurylene, isobenzofurylene, benzothiophenylene, indazolylene, benzimidazolylene, benzoxazolylene, benzisoxazolylene, benzothiazolylene, benzisothiazolylene, benzotriazolylene, benzo[2,1,3]oxadiazolylene, benzo[2,1,3]thiadiazolylene, benzo[1,2,3]thiadiazolylene, quinolinylene, isoquinolinylene, naphthyridinylene, cinnolinylene, quinazolinylene, quinoline oxalinyl, phthalazinyl, oxazolopyridylene, furopyridylene, pteridylene, purinylene, pyridopyridylene, pyrazolo[1,5-a]pyridinylene, pyrazolo[1,5-a]pyrimidinylene, imidazo[1,2-a]pyridinylene, 1H-pyrrolo[3,2-b]pyridinylene, 1H-pyrrolo[2,3-b]pyridinylene, pyrrolo[2,1-b]thiazolylene, imidazo[2,1-b]thiazolylene, chromanylene and 6,7-dihydrothieno[3,2-d]pyrimidinylene. Examples of tricyclic or polycyclic heteroarylene groups include, but are not limited to, acridinylene, benzindolylene, carbazolylene, dibenzofuranylene, xanthenylene, 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidinylene, and 6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidinylene. The heteroarylene groups may be unsubstituted or substituted.Substituted heteroarylene refers to a heteroarylene group substituted one or more times (e.g., 1-4, 1-3, or 1-2 times) with substituents, wherein the substituents are optionally selected from, for example, deuterium, hydroxy, amino, thiol, nitro, halogen, cyano, optionally deuterated C. 1-6 Alkyl, halogenated C 1-6 Alkyl, optionally deuterated C 3-6 Cycloalkyl, optionally deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, optionally deuterated C 1-6 Alkyl-NH-, NH2-C 1-6 Alkylene, optionally deuterated C 1-6 Alkyl-NHC(O)-, optionally deuterated C 1-6 Alkyl-C(O)NH-, C 2-6 Alkynyl, C 2-6 or any combination thereof.

[0144] As used herein, the term "aryl" alone or in combination refers to a monovalent aromatic hydrocarbon group comprising 5 to 30 (e.g., 5-20, 5-15, 5-12, 5-10, 5-9, 5-8, 5-7, 5-6, 6-15, 6-9, 6 to 10 members, or 6-20) carbon atoms and optionally comprising one or more fused rings, such as phenyl or naphthyl or fluorenyl. In the present disclosure, the "aryl" is an optionally substituted aryl. A substituted aryl refers to an aryl substituted one or more times (e.g., 1-4, 1-3, or 1-2 times) by a substituent, e.g., an aryl monosubstituted, disubstituted, trisubstituted, or polysubstituted aryl, wherein the substituent is optionally selected from, for example, deuterium, hydroxyl, amino, thiol, nitro, halogen, cyano, oxo, optionally deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, optionally deuterated C 3-6 Cycloalkyl, optionally deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, optionally deuterated C 1-6 Alkyl-NH-, NH2-C 1-6 Alkylene, optionally deuterated C 1-6 Alkyl-NHC(O)-, optionally deuterated C 1-6 Alkyl-C(O)NH-, C 2-6 Alkynyl, C 2-6 or any combination thereof.

[0145] In the present disclosure, the term "arylene", used alone or in combination, refers to a divalent aromatic hydrocarbon group containing 5 to 30 (e.g., 5-20, 5-15, 5-12, 5-10, 5-9, 5-8, 5-7, 5-6, 6-15, 6-9, 6 to 10 members, or 6-20) carbon atoms and optionally containing one or more fused rings, such as phenylene (e.g., ) or naphthylene or fluorenylene. In the present disclosure, the "arylene" is an optionally substituted arylene. Substituted arylene refers to an arylene substituted one or more times (e.g., 1-4, 1-3, or 1-2 times) by a substituent, for example, an arylene is monosubstituted, disubstituted, trisubstituted, or polysubstituted by a substituent, wherein the substituent is optionally selected from, for example, deuterium, hydroxyl, amino, thiol, nitro, halogen, cyano, oxo, optionally deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, optionally deuterated C 3-6 Cycloalkyl, optionally deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, optionally deuterated C 1-6 Alkyl-NH-, NH2-C 1-6 Alkylene, optionally deuterated C 1-6 Alkyl-NHC(O)-, optionally deuterated C 1-6 Alkyl-C(O)NH-, C 2-6 Alkynyl, C 2-6 or any combination thereof.

[0146] As used herein, the term "cycloalkyl" alone or in combination refers to a saturated or partially unsaturated (i.e., having one or more double bonds, but not fully conjugated) monocyclic, bicyclic, tricyclic, or polycyclic hydrocarbon radical containing, but not limited to, 3 to 30 carbon atoms (i.e., C 3-30 Cycloalkyl), 3 to 25 carbon atoms (i.e., C 3-25 Cycloalkyl), 3 to 20 carbon atoms (i.e., C 3-20 Cycloalkyl), 3 to 15 carbon atoms (i.e., C 3-15 Cycloalkyl), 3 to 12 carbon atoms (i.e., C 3-12 Cycloalkyl), 3 to 11 carbon atoms (i.e., C 3-11 Cycloalkyl), 3 to 10 carbon atoms (i.e., C 3-10 Cycloalkyl), 3 to 8 carbon atoms (i.e., C 3-8 Cycloalkyl), 3 to 7 carbon atoms (i.e., C 3-7 Cycloalkyl), 3 to 6 carbon atoms (i.e., C 3-6 Cycloalkyl), 4 to 20 carbon atoms (i.e., C 4-20 Cycloalkyl), 4 to 15 carbon atoms (i.e., C 4-15 Cycloalkyl), 4 to 12 carbon atoms (i.e., C4-12 cycloalkyl), and 4 to 10 carbon atoms (i.e., C 4-10 The term "cycloalkyl" includes monocyclic, bicyclic, tricyclic and polycyclic cycloalkyl groups having 3 to 30 carbon atoms. Examples of the term "cycloalkyl" include, but are not limited to, monocyclic cycloalkyl groups, bridged cycloalkyl groups (e.g., C 5-30 Bridged cycloalkyl, C 5-20 Bridged cycloalkyl, C 5-15 Bridged cycloalkyl and C 7-15 Bridged cycloalkyl), fused cycloalkyl (e.g. C 5-30 Condensed cycloalkyl, C 5-20 Condensed cycloalkyl, C 5-15 Condensed cycloalkyl, C 6-30 Condensed cycloalkyl, C 6-20 Condensed cycloalkyl, C 6-15 Condensed cycloalkyl, C 7-30 Condensed cycloalkyl, C 7-20 Condensed cycloalkyl, C 7-15 Fused cycloalkyl and C 8-15 fused cycloalkyl) and spirocycloalkyl (e.g. C 5- 30 Spiroalkyl, C 5-20 Spiroalkyl, C 5-15 Spiroalkyl, C 6-30 Spiroalkyl, C 6-20 Spiroalkyl, C 6-15 Spiroalkyl, C 7-30 Spiroalkyl, C 7-20 Spiroalkyl, C 7-15 Spiroalkyl and C 8-15 Representative examples of monocyclic cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, and cyclooctyl. Examples of fused cycloalkyl groups, spirocycloalkyl groups, and bridged cycloalkyl groups include, but are not limited to, decahydronaphthyl, octahydropentalenyl, octahydro-1H-indenyl, C 5-20 Spiroalkyl, C 5-15 Spirocycloalkyl, adamantyl, noradamantyl, bornyl and norbornyl (IUPAC system named bicyclo [2.2.1] heptyl). Herein, the "cycloalkyl" is optionally monosubstituted or polysubstituted, for example but not limited to, 2,2-, 2,3-, 2,4-, 2,5-, or 2,6-disubstituted cyclohexyl. The substituents of the substituted "cycloalkyl" are optionally one or more (for example 1-5, 1-4, 1-3, 1-2, or 1) each independently selected from, for example, deuterium, hydroxyl, amino, thiol, nitro, halogen, cyano, oxo, optionally deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, optionally deuterated C 3-6 Cycloalkyl, optionally deuterated C1-6 Alkoxy, halogenated C 1-6 Alkoxy, optionally deuterated C 1-6 Alkyl-NH-, NH2-C 1-6 Alkylene, optionally deuterated C 1-6 Alkyl-NHC(O)-, optionally deuterated C 1-6 Alkyl-C(O)NH-, C 2-6 Alkynyl, C 2-6 The term "C 3-6 Examples of "cycloalkyl" include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, and cyclohexyl.

[0147] In this document, the term “C x-y Spirocycloalkyl" (x and y are each an integer) refers to a spirocycloalkyl group containing x to y carbon atoms. The term "C 5-30 The term "spirocycloalkyl" refers to a spirocycloalkyl group containing 5 to 30 (for example, but not limited to, 5-20, 5-15, 7-20, 7-15, 5-11, 5-10, and 7-9) carbon atoms. 5-30 Spirocyclyl" includes "C 5-20 Spirocyclyl", "C 5-15 Spirocyclyl", "C 7-15 Spirocycloalkyl" and "C 7-20 Spirocycloalkyl”, representative examples of which include, but are not limited to, spiro[3.3]heptanyl, spiro[2.5]octanyl, spiro[3.5]nonanyl, spiro[3.5]nonenyl, spiro[4.4]nonanyl, spiro[4.5]decanyl, spiro[4.5]decenyl and spiro[5.5]undecyl. The “C 5-30 The spirocycloalkyl group is optionally further selected from, for example, deuterium, hydroxyl, amino, thiol, nitro, halogen, cyano, oxo, optionally deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, optionally deuterated C 3-6 Cycloalkyl, optionally deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, optionally deuterated C 1-6 Alkyl-NH-, NH2-C 1-6 Alkylene, optionally deuterated C 1-6 Alkyl-NHC(O)-, optionally deuterated C 1-6 Alkyl-C(O)NH-, C 2-6 Alkynyl, C 2-6 The alkylene group is substituted with one or more (e.g., 1-10, 1-6, 1-5, 1-4, or 1-3) of the substituents of the alkylene group or any combination thereof.

[0148] In this document, the term “C x-y "C-bridged cycloalkyl" (x and y are each an integer) refers to a bridged cycloalkyl group containing x to y carbon atoms. The term "C-bridged cycloalkyl" used alone or in combination in the present invention refers to a bridged cycloalkyl group containing x to y carbon atoms. 5-30 The term "bridged cycloalkyl" refers to a bridged cycloalkyl group containing 5 to 30 (for example, but not limited to, 5-20, 6-20, 7-20, 5-15, 7-15, 5-11, 5-10, and 7-9) carbon atoms. 5-30 "Bridged cycloalkyl" includes "C5-C 20 Bridged ring group", "C6-C 20 Bridged ring group", "C7-C 20 Bridged ring group", "C 5-15 Bridged cycloalkyl" and "C7-C 15 "bridged ring group", representative examples of which include but are not limited to adamantyl, noradamantyl, bornyl, norbornyl (systematically named bicyclo[2.2.1]heptyl), 2-oxobicyclo[2.2.1]heptyl, bicyclo[2.2.1]heptenyl and cubanyl. The "C 5-30 The bridged cycloalkyl group is optionally substituted with 1 to 10 (e.g., 1-6, 1-5, 1-4, or 1-3) substituents each independently selected from the group consisting of deuterium, hydroxyl, amino, thiol, nitro, halogen, cyano, oxo, optionally deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, optionally deuterated C 3-6 Cycloalkyl, optionally deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, optionally deuterated C 1-6 Alkyl-NH-, NH2-C 1-6 Alkylene, optionally deuterated C 1-6 Alkyl-NHC(O)-, optionally deuterated C 1-6 Alkyl-C(O)NH-, C 2-6 Alkynyl, C 2-6 or any combination thereof.

[0149] In the present invention, the term "cycloalkylene" used alone or in combination refers to a saturated or partially unsaturated (i.e., having one or more double bonds, but not completely conjugated) monocyclic, bicyclic, tricyclic, or polycyclic hydrocarbon divalent group, which contains, but is not limited to, 3 to 30 carbon atoms (i.e., C 3-30 Cycloalkylene), 3 to 25 carbon atoms (i.e., C 3-25 Cycloalkylene), 3 to 20 carbon atoms (i.e., C 3- 20 Cycloalkylene), 3 to 15 carbon atoms (i.e., C 3-15Cycloalkylene), 3 to 12 carbon atoms (i.e., C 3-12 Cycloalkylene), 3 to 11 carbon atoms (i.e., C 3-11 Cycloalkylene), 3 to 10 carbon atoms (i.e., C 3-10 Cycloalkylene), 3 to 8 carbon atoms (i.e., C 3-8 Cycloalkylene), 3 to 7 carbon atoms (i.e., C 3-7 Cycloalkylene), 3 to 6 carbon atoms (i.e., C 3-6 Cycloalkylene), 4 to 20 carbon atoms (i.e., C 4-20 Cycloalkylene), 4 to 15 carbon atoms (i.e., C 4-15 Cycloalkylene), 4 to 12 carbon atoms (i.e., C 4-12 cycloalkylene), and 4 to 10 carbon atoms (i.e., C 4-10 The term "cycloalkylene" includes monocyclic, bicyclic, tricyclic and polycyclic hydrocarbon divalent groups having 3 to 30 carbon atoms. Examples of the term "cycloalkylene" include, but are not limited to, monocyclic cycloalkylene, bridged cycloalkylene (e.g., C 5-30 Cycloalkylene bridged, C 5-20 Cycloalkylene bridged, C 5-15 Bridged cycloalkyl and C 7-15 bridged cycloalkylene), fused cycloalkylene (e.g. C 5-30 Fused cycloalkylene, C 5-20 Fused cycloalkylene, C 5-15 Fused cycloalkylene, C 6-30 Fused cycloalkylene, C 6-20 Fused cycloalkylene, C 6-15 Fused cycloalkylene, C 7- 30 Fused cycloalkylene, C 7-20 Fused cycloalkylene, C 7-15 Fused cycloalkylene and C 8-15 fused cycloalkylene) and spirocycloalkylene (e.g. C 5-30 Spirocycloalkylene, C 5-20 Spirocycloalkylene, C 5-15 Spirocycloalkylene, C 6-30 Spirocycloalkylene, C 6-20 Spirocycloalkylene, C 6-15 Spirocycloalkylene, C 7-30 Spirocycloalkylene, C 7-20 Spirocycloalkylene, C 7-15 Spirocycloalkylene and C 8-15Representative examples of monocyclic cycloalkylene groups include, but are not limited to, cyclopropylene, cyclobutylene, cyclopentylene, cyclopentenylene, cyclohexylene, cyclohexenylene, cycloheptylene, and cyclooctylene. Examples of fused cycloalkylene groups, spirocycloalkylene groups, and bridged cycloalkylene groups include, but are not limited to, decahydronaphthylene, octahydropentalenylene, octahydro-1H-indenylene, 2,3-dihydro-1H-indenylene, C 5-20 Spirocyclylene (e.g. C 5-15 spirocyclylene), adamantylene, noradamantylene and norbornylene (IUPAC system named bicyclo[2.2.1]heptanylene). In the present disclosure, the "cycloalkylene" is optionally monosubstituted or polysubstituted, for example but not limited to, 2,2-, 2,3-, 2,4-, 2,5-, or 2,6-disubstituted cyclohexylene. The substituents of the substituted "cycloalkylene" are optionally one or more (e.g., 1-5, 1-4, 1-3, 1-2, or 1) each independently selected from deuterium, hydroxyl, amino, thiol, nitro, halogen, cyano, oxo, optionally deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, optionally deuterated C 3-6 Cycloalkyl, optionally deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, optionally deuterated C 1-6 Alkyl-NH-, NH2-C 1-6 Alkylene, optionally deuterated C 1-6 Alkyl-NHC(O)-, optionally deuterated C 1-6 Alkyl-C(O)NH-, C 2-6 Alkynyl, C 2-6 alkenyl or any combination thereof.

[0150] In this document, the term “C x-y Spirocycloalkylene" or "C x-y Spirocyclylene" (x and y are each an integer) refers to a spirocycloalkylene group containing x to y carbon atoms. The term "C 5-30 Spirocycloalkylene refers to a spirocycloalkylene group containing 5 to 30 (e.g., 5-20, 5-15, 7-20, 7-15, 5-11, 5-10, 7-9) carbon atoms. The term "C 5-30 Spirocycloalkylene" includes "C 5-20 Spirocycloalkylene", "C 5-15 Spirocycloalkylene", "C 7-15 Spirocycloalkylene" and "C 7-20Spirocycloalkylene”, representative examples of which include, but are not limited to, spiro[3.3]heptanene, spiro[2.5]octanene, spiro[3.5]nonanene, spiro[3.5]nonenene, spiro[4.4]nonanene, spiro[4.5]decanene, spiro[4.5]decenene, and spiro[5.5]undecanene. The “C 5-30 The spirocycloalkylene group is optionally further substituted with one or more (e.g., 1-10, 1-6, 1-5, 1-4, or 1-3) groups independently selected from deuterium, hydroxyl, amino, thiol, nitro, halogen, cyano, oxo, optionally deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, optionally deuterated C 3-6 Cycloalkyl, optionally deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, optionally deuterated C 1-6 Alkyl-NH-, NH2-C 1-6 Alkylene, optionally deuterated C 1-6 Alkyl-NHC(O)-, optionally deuterated C 1-6 Alkyl-C(O)NH-, C 2-6 Alkynyl, C 2-6 The present invention is substituted with alkenyl or any combination thereof.

[0151] In this document, the term “C x-y "Cycloalkylene" or "C x-y "C-bridged cycloalkyl" (x and y are each an integer) refers to a bridged cycloalkyl group containing x to y carbon atoms. The term "C-bridged cycloalkyl" used alone or in combination in the present invention refers to a bridged cycloalkyl group containing x to y carbon atoms. 5-30 "Cycloalkylene" refers to a cycloalkylene group containing from 5 to 30 (for example, but not limited to, 5-20, 6-20, 7-20, 5-15, 7-15, 5-11, 5-10, and 7-9) carbon atoms. The term "C 5-30 "Cycloalkylene bridged" includes "C 5-20 Sub-bridged cycloalkyl", "C 6-20 Sub-bridged cycloalkyl", "C 7-20 Sub-bridged cycloalkyl", "C 5-15 "Cycloalkylene" and "C 7-15 "C-bridged cycloalkylene", representative examples of which include, but are not limited to, adamantylene, noradamantylene, bornylene, bicyclo[2.2.1]heptanylene, 2-oxobicyclo[2.2.1]heptanylene, bicyclo[2.2.1]heptenylene and cubanylene. The "C-bridged cycloalkylene" is a cycloalkylene radical having a cycloalkylene radical, ... 5-30 The "bridged cycloalkylene" may be further optionally substituted with one or more (e.g., 1-10, 1-6, 1-5, 1-4, or 1-3) groups each independently selected from deuterium, hydroxyl, amino, thiol, nitro, halogen, cyano, oxo, optionally deuterated C1-6 Alkyl, halogenated C 1-6 Alkyl, optionally deuterated C 3-6 Cycloalkyl, optionally deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, optionally deuterated C 1-6 Alkyl-NH-, NH2-C 1-6 Alkylene, optionally deuterated C 1-6 Alkyl-NHC(O)-, optionally deuterated C 1-6 Alkyl-C(O)NH-, C 2-6 Alkynyl, C 2-6 The present invention is substituted with alkenyl or any combination thereof.

[0152] As used herein, the term "heterocyclyl" or "heterocycloalkyl," alone or in combination, refers to a 4- to 30-membered (alternatively 4- to 30-membered, 4- to 25-membered, 4- to 20-membered, 4- to 15-membered, 4- to 14-membered, 4- to 13-membered, 4- to 12-membered, 4- to 11-membered, 4- to 10-membered, 4- to 9-membered, 4- to 8-membered, 4- to 7-membered, 4- to 6-membered, 4- to 5-membered, 5- to 9-membered, 5- to 30-membered, 5- to 20-membered, or 5- to 15-membered) monocyclic, bicyclic, tricyclic, or polycyclic saturated or partially unsaturated (i.e., having one or more double bonds, but not fully conjugated) cyclic hydrocarbon group containing one or more (e.g., 1 to 5, 1 to 4, 1 to 3, 1 to 2, or 1) heteroatoms independently selected from sulfur, oxygen, and nitrogen. Examples of the term “heterocyclyl” include, but are not limited to, monocyclic heterocyclyl (e.g., 4- to 30-membered monocyclic heterocyclyl and 4- to 20-membered monocyclic heterocyclyl), bridged heterocyclyl (e.g., 5- to 30-membered bridged heterocyclyl, 5- to 20-membered bridged heterocyclyl, 7- to 20-membered bridged heterocyclyl and 7- to 15-membered bridged heterocyclyl), fused heterocyclyl (e.g., 5- to 30-membered fused heterocyclyl and 5- to 20-membered fused heterocyclyl) and spiro heterocyclyl (e.g., 5- to 30-membered spiro heterocyclyl and 5- to 20-membered spiro heterocyclyl). Representative examples of monocyclic heterocyclyl groups include, but are not limited to, azetidinyl, oxetanyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, oxazolidinyl, thiazolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, dioxanyl, azepanyl, azocanyl, diazepanyl (e.g., 1,4-diazepan-1-yl), and diazacyclooctanyl. Examples of bridged heterocyclic groups, fused heterocyclic groups, and spiro heterocyclic groups include, but are not limited to, 6-azabicyclo[3.1.1]heptan-3-yl, 2,5-diazabicyclo[2.2.1]heptan-2-yl, 3,6-diazabicyclo[3.1.1]heptan-3-yl, 3-azabicyclo[3.2.1]octan-8-yl, 3,8-diazabicyclo[3.2.1]octan-8-yl, 3,8-diazabicyclo[3.2.1]octan-3-yl, 2,5-diazabicyclo[2.2.2 ] octan-2-yl, quinuclidine, octahydro-1H-indolyl, pyrrolidinyl and cyclopropyl, cyclopentyl and aziridine, pyrrolidinyl and cyclobutyl, pyrrolidinyl and pyrrolidinyl (for example, hexahydropyrrolo [3, 4-c] pyrrolyl), pyrrolidinyl and piperidinyl, pyrrolidinyl and piperazinyl, pyrrolidinyl and morpholinyl, piperidinyl and morpholinyl, and azaspirocyclyl (for example, 5 to 20-membered azaspirocyclyl, for example, 3-azaspiro [5.5] undec-3-yl and 7-azaspiro [3.5] nonanyl). The heterocyclyl may be unsubstituted or substituted as clearly defined (for example, mono-, di-, tri-, or polysubstituted), wherein the substituents are optionally selected from deuterium, hydroxyl, amino, thiol, nitro, halogen, cyano, oxo, optionally deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, optionally deuterated C3-6 Cycloalkyl, optionally deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, optionally deuterated C 1-6 Alkyl-NH-, NH2-C 1-6 Alkylene, optionally deuterated C 1-6 Alkyl-NHC(O)-, optionally deuterated C 1-6 Alkyl-C(O)NH-, C 2-6 Alkynyl, C 2-6 or any combination thereof.

[0153] As used herein, the term "nitrogen-containing heterocyclyl" or "nitrogen-containing heterocycloalkyl", alone or in combination, refers to a 4- to 30-membered (e.g., 4- to 30-membered, 4- to 25-membered, 4- to 20-membered, 4- to 15-membered, 4- to 14-membered, 4- to 13-membered, 4- to 12-membered, 4- to 11-membered, 4- to 10-membered, 4- to 9-membered, 4- to 8-membered, 4- to 7-membered, 4- to 6-membered, 4- to 5-membered, 5- to 9-membered, 5- to 30-membered, 5- to 20-membered, or 5- to 15-membered) monocyclic, bicyclic, tricyclic, or polycyclic saturated or partially unsaturated (i.e., having one or more double bonds, but not fully conjugated) cyclic hydrocarbon group containing one nitrogen atom and optionally containing one or more (e.g., containing 1 to 5, 1 to 4, 1 to 3, 1 to 2, or 1) heteroatoms independently selected from sulfur, oxygen, and nitrogen. Examples of the term “nitrogen-containing heterocyclic group” include, but are not limited to, nitrogen-containing monocyclic heterocyclic groups (e.g., 4- to 30-membered nitrogen-containing monocyclic heterocyclic groups and 4- to 20-membered nitrogen-containing monocyclic heterocyclic groups), nitrogen-containing bridged heterocyclic groups (e.g., 5- to 30-membered nitrogen-containing bridged heterocyclic groups, 5- to 20-membered nitrogen-containing bridged heterocyclic groups, 5- to 15-membered nitrogen-containing bridged heterocyclic groups, 7- to 20-membered nitrogen-containing bridged heterocyclic groups, or 7- to 15-membered nitrogen-containing bridged heterocyclic groups), nitrogen-containing fused heterocyclic groups (e.g., 5- to 30-membered nitrogen-containing fused heterocyclic groups and 5- to 20-membered nitrogen-containing fused heterocyclic groups), and nitrogen-containing spiro heterocyclic groups (e.g., 5- to 30-membered nitrogen-containing spiro heterocyclic groups and 5- to 20-membered nitrogen-containing spiro heterocyclic groups). Representative examples of nitrogen-containing monocyclic heterocyclic groups include, but are not limited to, azetidinyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, oxazolidinyl, thiazolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, azepanyl, azocanyl, diazepanyl (e.g., 1,4-diazepan-1-yl), and diazacyclooctanyl. Examples of nitrogen-containing bridged heterocyclic groups, nitrogen-containing fused heterocyclic groups, and nitrogen-containing spiro heterocyclic groups include, but are not limited to, 6-azabicyclo[3.1.1]heptan-3-yl, 2,5-diazabicyclo[2.2.1]heptan-2-yl, 3,6-diazabicyclo[3.1.1]heptan-3-yl, 3-azabicyclo[3.2.1]octan-8-yl, 3,8-diazabicyclo[3.2.1]octan-8-yl, 3,8-diazabicyclo[3.2.1]octan-3-yl, 2,5-diazabicyclo[2. 2.2] octan-2-yl, quinuclidinyl, octahydro-1H-indolyl, pyrrolidinyl and cyclopropyl, cyclopentyl and aziridine, pyrrolidinyl and cyclobutyl, pyrrolidinyl and pyrrolidinyl (for example, hexahydropyrrolo [3, 4-c] pyrrolyl), pyrrolidinyl and piperidinyl, pyrrolidinyl and piperazinyl, pyrrolidinyl and morpholinyl, piperidinyl and morpholinyl, and azaspirocyclic groups (for example, 5- to 20-membered azaspirocyclic groups, such as 3-azaspiro [5.5] undec-3-yl and 7-azaspiro [3.5] nonanyl). The nitrogen-containing heterocyclic group may be unsubstituted or substituted as clearly defined (for example, mono-, di-, tri-, or polysubstituted), wherein the substituents are optionally selected from deuterium, hydroxyl, amino, thiol, nitro, halogen, cyano, oxo, optionally deuterated C 1-6Alkyl, halogenated C 1-6 Alkyl, optionally deuterated C 3-6 Cycloalkyl, optionally deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, optionally deuterated C 1-6 Alkyl-NH-, NH2-C 1-6 Alkylene, optionally deuterated C 1-6 Alkyl-NHC(O)-, optionally deuterated C 1-6 Alkyl-C(O)NH-, C 2-6 Alkynyl, C 2- 6 alkenyl or any combination thereof.

[0154] As used herein, the term "heterocyclylene" or "heterocycloalkylene", used alone or in combination, refers to a 4- to 30-membered monocyclic, bicyclic, tricyclic or polycyclic saturated or partially unsaturated (i.e., having one or more double bonds but not fully conjugated) divalent cyclic hydrocarbon group containing one or more (e.g., 1 to 5, 1 to 4, 1 to 3, 1 to 2 or 1) heteroatoms independently selected from sulfur, oxygen and nitrogen. Examples of the term “heterocyclylene” include, but are not limited to, monocyclic heterocyclylene (e.g., 4- to 30-membered monocyclic heterocyclylene, and 4- to 20-membered monocyclic heterocyclylene), bridged heterocyclylene (e.g., 5- to 30-membered bridged heterocyclylene, 5- to 20-membered bridged heterocyclylene, 7- to 20-membered bridged heterocyclylene, or 7- to 15-membered bridged heterocyclylene), fused heterocyclylene (e.g., 5- to 30-membered fused heterocyclylene, and 5- to 20-membered fused heterocyclylene), and spiro heterocyclylene (e.g., 5- to 30-membered spiro heterocyclylene, and 5- to 20-membered spiro heterocyclylene). Representative examples of monocyclic heterocyclylene groups include, but are not limited to, azetidinylene, oxetanylene, pyrrolidinylene, imidazolidinylene, pyrazolidinylene, tetrahydrofuranylene, dihydropyranylene, tetrahydropyranylene, tetrahydrothiophenylene, tetrahydrothiopyranylene, oxazolidinylene, thiazolidinylene, piperidinylene, piperazinylene, morpholinylene, thiomorpholinylene, azepanylene, azoctanylene, dioxanylene, diazepanylene (e.g., 1,4-diazepanylene, 4,5-diazepanylene, 1,3-diazepanylene), and diazaoctanylene. Examples of bridged heterocyclyls, fused heterocyclyls, and spiro heterocyclyls include, but are not limited to, 6-azabicyclo[3.1.1]heptanylene, 2,5-diazabicyclo[2.2.1]heptanylene, 3,6-diazabicyclo[3.1.1]heptanylene, 3-azabicyclo[3.2.1]octanylene, 3,8-diazabicyclo[3.2.1]octanylene, 2,5-diazabicyclo[2.2.2]octanylene, quinuclidinyl, octahydro-1H-indole,

[0065] ] pyrrolidinyl, ... 1-6 Alkyl, halogenated C 1-6 Alkyl, optionally deuterated C 3-6 Cycloalkyl, optionally deuterated C 1-6 Alkoxy, halogenated C 1-6Alkoxy, optionally deuterated C 1-6 Alkyl-NH-, NH2-C 1-6 Alkylene, optionally deuterated C 1-6 Alkyl-NHC(O)-, optionally deuterated C 1-6 Alkyl-C(O)NH-, C 2-6 Alkynyl, C 2-6 or any combination thereof.

[0155] As used herein, the term “nitrogen-containing heterocyclylene” or “nitrogen-containing heterocycloalkylene”, alone or in combination, refers to a 4- to 30-membered (e.g., 4- to 30-membered, 4- to 25-membered, 4- to 20-membered, 4- to 15-membered, 4- to 14-membered, 4- to 12-membered, 4- to 11-membered, 4- to 10-membered, 4- to 9-membered, 4- to 8-membered, 4- to 7-membered, 4- to 6-membered, 4- to 5-membered, 5- to 9-membered, 5- to 30-membered, 5- to 20-membered, or 5- to 15-membered) monocyclic, bicyclic, tricyclic, or polycyclic saturated or partially unsaturated (i.e., having one or more double bonds, but not fully conjugated) divalent cyclic hydrocarbon group containing one nitrogen atom and optionally containing one or more (e.g., containing 1 to 5, 1 to 4, 1 to 3, 1 to 2, or 1) heteroatoms independently selected from sulfur, oxygen, and nitrogen. Examples of the term “nitrogen-containing heterocyclylene” include, but are not limited to, nitrogen-containing monocyclic heterocyclylene (e.g., a 4- to 30-membered nitrogen-containing monocyclic heterocyclylene, and a 4- to 20-membered nitrogen-containing monocyclic heterocyclylene), nitrogen-containing bridged heterocyclyl (e.g., a 5- to 30-membered nitrogen-containing bridged heterocyclyl, a 5- to 20-membered nitrogen-containing bridged heterocyclyl, a 7- to 20-membered nitrogen-containing bridged heterocyclyl, or a 7- to 15-membered nitrogen-containing bridged heterocyclyl), nitrogen-containing fused heterocyclyl (e.g., a 5- to 30-membered nitrogen-containing fused heterocyclyl and a 5- to 20-membered nitrogen-containing fused heterocyclyl), and nitrogen-containing spiro heterocyclyl (e.g., a 5- to 30-membered nitrogen-containing spiro heterocyclyl and a 5- to 20-membered nitrogen-containing spiro heterocyclyl). Representative examples of nitrogen-containing monocyclic heterocyclylene groups include, but are not limited to, azetidinylene, pyrrolidinylene, imidazolidinylene, pyrazolidinylene, oxazolidinylene, thiazolidinylene, piperidinylene, piperazinylene, morpholinylene, thiomorpholinylene, azepanylene, azepanylene, diazepanylene (e.g., 1,4-diazepanylene, 4,5-diazepanylene, 1,3-diazepanylene), and diazepanylene. Examples of nitrogen-containing bridged heterocyclic groups, nitrogen-containing fused heterocyclic groups, and nitrogen-containing spiro heterocyclic groups include, but are not limited to, 6-azabicyclo[3.1.1]heptanylidene, 2,5-diazabicyclo[2.2.1]heptanylidene, 3,6-diazabicyclo[3.1.1]heptanylidene, 3-azabicyclo[3.2.1]octanylidene, 3,8-diazabicyclo[3.2.1]octanylidene, 2,5-diazabicyclo[2.2.2]octanylidene, quinuclidinyl, octahydro-1H -indolylene, pyrrolidinylcyclopropylidene, cyclopentylaziridinylene, pyrrolidinylcyclobutylene, pyrrolidinylpyrrolidinylene (e.g., hexahydropyrrolo[3,4-c]pyrrolidinylene), pyrrolidinylpiperidinylene, pyrrolidinylpiperazinylene, pyrrolidinylmorpholinylene, piperidinylmorpholinylene, and azaspirocyclylene (e.g., 5- to 20-membered azaspirocyclylene, such as 3-azaspiro[5.5]undecanediylene and 7-azaspiro[3.5]nonanediylene).The nitrogen-containing heterocyclylene group may be unsubstituted or substituted as explicitly defined (e.g., mono-, di-, tri-, or polysubstituted), wherein the substituents may be optionally selected from deuterium, hydroxyl, amino, thiol, nitro, halogen, cyano, oxo, optionally deuterated C. 1-6 Alkyl, halogenated C 1-6 Alkyl, optionally deuterated C 3-6 Cycloalkyl, optionally deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, optionally deuterated C 1-6 Alkyl-NH-, NH2-C 1-6 Alkylene, optionally deuterated C 1-6 Alkyl-NHC(O)-, optionally deuterated C 1-6 Alkyl-C(O)NH-, C 2-6 Alkynyl, C 2-6 or any combination thereof.

[0156] As used herein, the term "monoazabridged ring subunit", used alone or in combination, refers to a 5 to 30-membered (e.g., 5 to 30-membered, 5 to 25-membered, 5 to 20-membered, 5 to 15-membered, 5 to 14-membered, 5 to 12-membered, 5 to 11-membered, 5 to 10-membered, 5 to 9-membered, 5 to 8-membered, 5 to 7-membered, 5 to 6-membered, 7 to 30-membered, 7 to 20-membered, or 7 to 15-membered) bicyclic, tricyclic, or polycyclic saturated or partially unsaturated (i.e., having one or more double bonds, but not completely conjugated) divalent bridged ring hydrocarbon group containing one nitrogen atom. Examples of monoazabridged ring subunits include, but are not limited to, 6-azabicyclo[3.1.1]heptanyl subunit, 3-azabicyclo[3.2.1]octanyl subunit, and quinuclidinyl subunit. The monoazabridged ring subunit may be unsubstituted or substituted as defined herein (e.g., substituted with one or more substituents), wherein the substituents are optionally selected from deuterium, hydroxyl, amino, thiol, nitro, halogen, cyano, oxo, optionally deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, optionally deuterated C 3-6 Cycloalkyl, optionally deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, optionally deuterated C 1-6 Alkyl-NH-, NH2-C 1-6 Alkylene, optionally deuterated C 1-6 Alkyl-NHC(O)-, optionally deuterated C 1-6 Alkyl-C(O)NH-, C 2-6 Alkynyl, C 2-6or any combination thereof. The number of substituents is not subject to any limitation in principle or is automatically limited by the size of the building block. For example, the number of substituents can be one or more, such as 1-20, 1-15, 1-10, 1-6, 1-4, 1-3, 2-6, or 1.

[0157] As used herein, the term "monoazaspirocyclic subunit", used alone or in combination, refers to a 5 to 30-membered (e.g., 5 to 30-membered, 5 to 25-membered, 5 to 20-membered, 5 to 15-membered, 5 to 14-membered, 5 to 12-membered, 5 to 11-membered, 5 to 10-membered, 5 to 9-membered, 5 to 8-membered, 5 to 7-membered, 5 to 6-membered, 7 to 30-membered, 7 to 20-membered, or 7 to 15-membered) bicyclic, tricyclic, or polycyclic saturated or partially unsaturated (i.e., having one or more double bonds, but not completely conjugated) divalent spirocyclic hydrocarbon group containing a nitrogen atom. Examples of monoazaspirocyclic subunits include, but are not limited to, 3-azaspiro[5.5]undecane subunits and 7-azaspiro[3.5]nonane subunits. The monoazaspirocyclic substituent may be unsubstituted or substituted as defined herein (e.g., substituted with one or more substituents), wherein the substituents are optionally selected from deuterium, hydroxyl, amino, thiol, nitro, halogen, cyano, oxo, optionally deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, optionally deuterated C 3-6 Cycloalkyl, optionally deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, optionally deuterated C 1-6 Alkyl-NH-, NH2-C 1-6 Alkylene, optionally deuterated C 1-6 Alkyl-NHC(O)-, optionally deuterated C 1-6 Alkyl-C(O)NH-, C 2-6 Alkynyl, C 2-6 or any combination thereof. The number of substituents is not subject to any limitation in principle or is automatically limited by the size of the building block. For example, the number of substituents can be one or more, such as 1-20, 1-15, 1-10, 1-6, 1-4, 1-3, 2-6, or 1.

[0158] As used herein, the term "alkynyl" alone or in combination refers to a straight or branched monovalent hydrocarbon group containing 2 to 8 (e.g., 2 to 6, 2 to 5, 2 to 4, more preferably 2) carbon atoms and having one or more (e.g., 1 to 3, 1 to 2, or 1) carbon-carbon triple bonds. Examples of "alkynyl" include C 2-8 Alkynyl, C 2-6 Alkynyl or C 2-4 Alkynyl, representative examples of which include, but are not limited to, ethynyl, 1-propynyl, 1-butynyl, and 1,3-diynyl.

[0159] As used herein, the term "alkenyl" alone or in combination refers to a straight or branched monovalent hydrocarbon group containing 2 to 8 carbon atoms (e.g., 2 to 6, 2 to 5 carbon atoms, or 2 to 4, 2 to 3 or 2 carbon atoms) having one or more (e.g., 1 to 3, 1 to 2 or 1) carbon-carbon double bonds. Examples of "alkenyl" include C 2-8 Alkenyl, C 2-6 Alkenyl or C 2-4 Alkenyl, representative examples of which include, but are not limited to, vinyl (e.g., CH2=CH-), 1-propenyl, allyl, 1-butenyl, 2-butenyl, 3-butenyl, isobutenyl, pentenyl, n-penta-2,4-dienyl, 1-methyl-but-1-enyl, 2-methyl-but-1-enyl, 3-methyl-but-1-enyl, 1-methyl-but-2-ylidene, 2-methyl-but-2-ylidene, 3-methyl-but-2-ylidene, 1-methyl-but-3-enyl, 2-methyl-but-3-enyl, 3-methyl-but-3-enyl, and hexenyl.

[0160] As used herein, the term "bornyl" or "bornane" (also known as 1,7,7-trimethylbicyclo[2.2.1]heptane; camphane; bornylane) has the definition known to those skilled in the art. As used herein, the term "bornyl" or "bornyl" refers to a monovalent radical of bornane, i.e., the radical remaining after any one of the hydrogen atoms in bornane is removed. Representative examples of "bornyl" include, but are not limited to, 1,7,7-trimethylbicyclo[2.2.1]heptane-2-yl, 1,7,7-trimethylbicyclo[2.2.1]heptane-3-yl, 1,7,7-trimethylbicyclo[2.2.1]heptane-4-yl, 1,7,7-trimethylbicyclo[2.2.1]heptane-5-yl, or 1,7,7-trimethylbicyclo[2.2.1]heptane-6-yl,

[0161] As used herein, the term "bicyclo[2.2.1]heptane" (also known as bicyclo[2.2.1]heptane) or "norbornane" has the meaning known to those skilled in the art. As used herein, "bicyclo[2.2.1]heptane" or "norbornane" refers to a monovalent radical of bicyclo[2.2.1]heptane, i.e., the radical remaining after any one of the hydrogen atoms in bicyclo[2.2.1]heptane is removed. Representative examples of "bicyclo[2.2.1]heptane" include, but are not limited to, bicyclo[2.2.1]heptane-2-yl, bicyclo[2.2.1]heptane-3-yl, bicyclo[2.2.1]heptane-4-yl, bicyclo[2.2.1]heptane-5-yl, and bicyclo[2.2.1]heptane-6-yl.

[0162] As used herein, the term "bicyclo[2.2.1]heptene" (also known as bicyclo[2.2.1]heptene) has the same definition as known to those skilled in the art. As used herein, "bicyclo[2.2.1]heptenyl" refers to a monovalent radical of bicyclo[2.2.1]heptene, i.e., the radical remaining after any one of the hydrogen atoms in bicyclo[2.2.1]heptene is removed. Representative examples of "bicyclo[2.2.1]heptenyl" include, but are not limited to, bicyclo[2.2.1]hept-5-en-2-yl, bicyclo[2.2.1]hept-5-en-3-yl, and bicyclo[2.2.1]hept-5-en-7-yl.

[0163] In this article, the term "adamantane" (also known as Tricyclo[3.3.1.1 3，7 ]decane) has a definition known to those skilled in the art, and its structural formula is shown below, for example: As used herein, "adamantyl" refers to a monovalent radical of adamantane, i.e., the radical remaining after any hydrogen atom in adamantane is removed. Representative examples of "adamantyl" include, but are not limited to, 1-adamantyl, 2-adamantyl, 3-adamantyl, 4-adamantyl, 5-adamantyl, 6-adamantyl, 7-adamantyl, 8-adamantyl, 9-adamantyl, and 10-adamantyl.

[0164] In this document, the term "noradamantane" (also known as noradamantane or octahydro-2,5-methanopentalene) has the definition known to those skilled in the art, and its structural formula is shown below, for example: As used herein, "noradamantyl" refers to a monovalent radical of noradamantane, i.e., the radical remaining after any hydrogen atom in noradamantane is removed. Representative examples of "noradamantyl" include, but are not limited to, 1-noradamantyl, 2-noradamantyl, 3-noradamantyl, 4-noradamantyl, 5-noradamantyl, 6-noradamantyl, 7-noradamantyl, 8-noradamantyl, and 9-noradamantyl.

[0165] As used herein, the term "adamantanamine" has the meaning known to those skilled in the art, i.e., refers to an adamantane having an amino substituent, wherein the amino group can replace a hydrogen on any carbon position of the adamantane. An example of an "adamantanamine" can be adamantane-1-amine (also known as adamantane-1-amine or Tricyclo[3.3.1.1 3，7 ]decan-1-amine; CAS: 768-94-5), having the following structural formula

[0166] Salts or pharmaceutically acceptable salts, enantiomers, stereoisomers, solvates, prodrugs, and polymorphs of the compounds of the present disclosure (including the compounds of formula (I), formula (I-1), formula (I-2), formula (I-3), formula (I-4), formula (I-5), formula (II-1), formula (II-2), formula (II-3), formula (II-4), and formula (I')) are also encompassed within the scope of the present disclosure.

[0167] In all embodiments of the present disclosure, the salt or pharmaceutically acceptable salt of the compound of formula (I) (and compounds of formula (I-1), formula (I-2), formula (I-3), formula (I-4), formula (I-5), formula (II-1), formula (II-2), formula (II-3), formula (II-4), and formula (I')) refers to a non-toxic inorganic or organic acid and / or base addition salt. Examples include sulfate, hydrohalide (including hydrochloride, hydrobromide), citrate / citrate, maleate, lactate, lactobionate, L-tartrate, fumarate, L-malate, L-lactate, α-ketoglutarate, hippurate, D-glucuronate, D-gluconate, α-D-glucoheptonate, glycolate, mucate, L-ascorbate, orotate, picrate, glycinate, alanine, arginine, cinnamate, laurate, pamoate, sebacate, benzenesulfonate, methanesulfonate, ethanesulfonate, edisylate, formate, acetate, 2,2-dichloroacetate, pivalate, propionate, valerate, palmitate, triphenylacetate, 2,3-dichloroacetate, methyl benzo ... -ethyl-succinate, iodate, nicotinate, L-pyroglutamate, L-proline salt, ferulate, 2-hydroxyethanesulfonate, nitrate, gentisate, cholate, salicylate, terephthalate, glutarate, adipate, stearate, oleate, undecylenate, camphorate, camphorsulfonate, dodecylsulfonate, phosphate, thiocyanate, dihydrogenphosphate, pyrophosphate, metaphosphate, oxalate, carbonate, malonate, benzoate, mandelate, succinate, pyruvate, p-chlorobenzenesulfonate, 1,5-naphthalenedisulfonate, 3-hydroxy-2-naphthoate, 1-hydroxy-2-naphthoate, 2-naphthoate, glycolate, trifluoroacetate, terephthalate and p-toluenesulfonate, etc.

[0168] "Pharmaceutically acceptable carrier" refers to a pharmaceutically acceptable material, such as a filler, stabilizer, dispersant, suspending agent, diluent, excipient, thickener, solvent, or encapsulating material, that carries or transports a compound useful in the present disclosure into or to a patient so that it can perform its intended function. Typically, such a construct carries or transports a compound from one organ or part of the body to another. A carrier must be "acceptable" if it is compatible with the other ingredients of the formulation (including the compound useful in the present disclosure) and is not harmful to the patient. Some examples of materials that can be used as pharmaceutically acceptable carriers include: sugars, such as lactose, glucose, and sucrose; starches, such as corn starch and potato starch; cellulose and its derivatives, such as sodium carboxymethylcellulose, ethylcellulose, and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients, such as cocoa butter and suppository waxes; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and soybean oil; glycols, such as propylene glycol; polyols, such as glycerol, sorbitol, mannitol, and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffers, such as magnesium hydroxide and aluminum hydroxide; phosphate buffered saline as a surfactant; and other nontoxic, compatible substances used in pharmaceutical formulations.

[0169] The term "room temperature" of the present disclosure refers to ambient temperature, for example, a temperature of 20-30°C.

[0170] As used herein, "stereoisomers" refer to compounds that have identical chemical constitution but differ in the way the atoms or groups are arranged in space. Stereoisomers include enantiomers, diastereomers, conformers (rotamers), geometric isomers (cis / trans) isomers, atropisomers, and the like.

[0171] As used herein, the term "solvate" refers to an association or complex of one or more solvent molecules and a compound of the present invention. Examples of solvents include water, isopropanol, ethanol, methanol, DMSO, ethyl acetate, acetic acid, and ethanolamine. The term "hydrate" refers to a complex in which the solvent molecule is water.

[0172] As used herein, the term "chiral" refers to a molecule that is non-superimposable on its mirror image, while "achiral" refers to a molecule that is superimposable on its mirror image.

[0173] As used herein, the term "enantiomers" refers to two non-superimposable isomers of a compound that are mirror images of each other.

[0174] As used herein, the term "diastereoisomer" refers to stereoisomers that have two or more chiral centers and whose molecules are not mirror images of each other. Diastereoisomers have different physical properties, such as melting points, boiling points, spectral properties, and reactivity. Diastereomeric mixtures can be separated by high-resolution analytical procedures such as electrophoresis and chromatography, for example, HPLC.

[0175] As used herein, the term "prodrug" refers to a compound that can be converted into its biologically active form in vivo, for example, by hydrolysis in the blood. When the prodrug is administered to a patient, it releases the parent compound in vivo. Prodrugs are typically prepared by modifying functional groups, and these modifications can be removed by conventional manipulations (e.g., acid / base hydrolysis) or by cleavage in vivo, thereby releasing the parent drug. Prodrugs include, for example, compounds of the present invention in which a hydroxyl, amino, or sulfhydryl group is bound to any group that, when administered to a patient, can cleave to reform the hydroxyl, amino, or sulfhydryl group. Thus, representative examples of prodrugs include, but are not limited to, acetate / amide, formate / amide, tert-butyloxycarbonyl (Boc), and benzoate / amide derivatives of the hydroxyl, sulfhydryl, and amino functional groups of compounds of formula (I) and compounds of formula (II). In addition, in the case of carboxylic acids (-COOH), esters such as methyl and ethyl esters can be used. These esters may themselves be active and / or may be hydrolyzed under in vivo conditions. Suitable pharmaceutically acceptable, in vivo hydrolysable ester groups include those which break down readily in the human body to leave the parent acid or a salt thereof.

[0176] In this document, "p-menthane" (also known as p-methane) has a definition known to those skilled in the art, and its structural formula is shown below: In this article, "p-menthanyl" refers to a monovalent group of p-menthane, that is, the group remaining after any hydrogen on any carbon position of p-menthane is removed. Representative examples include but are not limited to

[0177] In this document, "m-menthane" (also known as m-methane) has a definition known to those skilled in the art, and its structural formula is shown below: In this article, "m-menthanyl" refers to a monovalent group of m-menthane, that is, the group remaining after any hydrogen on any carbon position of m-menthane is removed. Representative examples include but are not limited to

[0178] In this document, “quinuclidine” (also known as Quinuclidine), whose chemical name is 1-azabicyclo[2.2.2]octane, has the definition known to those skilled in the art, and its structural formula is shown below: In this article, "quinuclidine" refers to a monovalent group of quinuclidine, that is, the group remaining after any hydrogen on any carbon position of quinuclidine is removed. Representative examples include but are not limited to BRIEF DESCRIPTION OF THE DRAWINGS

[0179] FIG1 shows the results of a Western Blot experiment showing that the compounds of the present invention degrade target substrate proteins in hPBMC cells. Example

[0180] In the following description, numerous specific details are set forth in order to provide a thorough understanding of the present invention. The present invention may be practiced without some or all of these specific details. In other cases, well-known process operations are not described in detail in order to avoid unnecessary obfuscation of the present invention. Although the present invention will be described in conjunction with specific embodiments, it should be understood that this is not intended to limit the invention to these embodiments.

[0181] The following abbreviations are used throughout the specification and examples: AcOH acetic acid Boc tert-butoxycarbonyl DCM dichloromethane DIEA or DIPEA N,N-diisopropylethylamine DMF N,N-dimethylformamide DMSO dimethyl sulfoxide EA ethyl acetate ESI electrospray ionization equiv EtOH ethanol EtOAc ethyl acetate HPLC high performance liquid chromatography HRMS high resolution mass spectrometry LC-MS liquid chromatography-mass spectrometry LRMS low resolution mass spectrometry LC liquid chromatography Me methyl MeCN acetonitrile MeOH methanol MS mass spectrometry MsCl methanesulfonyl chloride MsO- methanesulfonyloxy Ms2O methanesulfonic anhydride 1H NMR nuclear magnetic resonance spectroscopy MeO- methoxy ONs o-nitrobenzenesulfonyl rt room temperature tBu tert-butyl TEA triethylamine TFA trifluoroacetic acid TfO- trifluoromethanesulfonyloxy TLC thin layer chromatography TMS trimethylsilyl TsO- p-toluenesulfonyloxy Xantphos 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene X-Phos 2-dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl

[0182] In the present invention, 1 H NMR spectra were measured using a Bruker-500 MHz nuclear magnetic resonance spectrometer, using CD3OD (δ = 3.31 ppm) containing 0.1% TMS (as internal standard) as solvent; or CDCl3 (δ = 7.26 ppm) containing 0.1% TMS (as internal standard) as solvent; or DMSO-d6 (δ = 2.50 ppm) containing 0.03% TMS (as internal standard) as solvent. LC-MS spectra were measured on a Sciex API 2000 mass spectrometer equipped with an Agilent 1100 binary pump, DAD, and ELSD, or on an Agilent 1260-6125B single quadrupole liquid-mass spectrometer equipped with an Agilent 1260 quaternary pump, DAD, and ELSD. HPLC preparations were measured on a SHIMADZU LC-20AP instrument. HPLC purity was measured on a SHIMADZU LC-30AP or Waters 1525 instrument; supercritical fluid chromatography (SFC) separation was performed on a Daicel All reactions were carried out under air atmosphere unless otherwise specified and were followed by TLC or LC-MS.

[0183] Solvent and reagent treatment was as follows: the reaction solvents DCM, DMF, anhydrous EtOH, and anhydrous MeOH were purchased from Sinopharm Group; preparative-grade CH3CN and deionized water were used for HPLC preparation; other reaction substrates, reagents, and drugs, unless otherwise specified, were directly purchased from commercial channels or synthesized using or according to methods known in the art.

[0184] Unless otherwise specified, the materials and reagents used in the following examples can be purchased from commercial sources and used directly, or can be synthesized using or according to methods known in the art.

[0185] General synthetic method

[0186] The compounds and / or pharmaceutically acceptable salts thereof disclosed herein can be synthesized using commercially available raw materials by synthetic techniques known in the art. The synthetic schemes described below illustrate the preparation methods of most compounds. The starting materials or reagents used in each scheme can be purchased from commercial sources or prepared by methods known to those skilled in the art. Salts, racemates, enantiomers, phosphates, sulfates, hydrochlorides and prodrug forms of the compounds of formula (I) disclosed herein can be prepared by those skilled in the art according to conventional techniques in the art.

[0187] Synthesis Scheme 1: Solution 1

[0188] In Scheme 1, Z, R a1 、R a2 、R a3 、R a4 、(R a5 ) m , Ring B, (R d2 ) n2 , m1, ring C and (R d3 ) n3 As defined in the compounds of formula (I) and its various subembodiments disclosed herein. In Scheme 1, (i) R La1 and R La3 N(R w ), R La2 express R La4 express where R w 、Ring A1、(R d1 ) n1 As defined in the compounds of formula (I) and its various sub-embodiments disclosed herein; or (ii) R La1 and R La3 express R La2 Indicates -NH2, R La4 represents NH or -N=; or (iii) R La1 and R La3 Indicates NH, R La2 Indicates -NH2, R La4 represents NH or -N=; or (iv) R La2 express Among them, ring A2, (R d4 ) n4As defined in the compounds of formula (I) and various sub-embodiments thereof disclosed herein, R La1 and R La3 express The symbol ** indicates the point of attachment to ring A2, and R La4 express

[0189] The reductive amination reaction in Synthesis Scheme 1 can be performed using conventional techniques and methods well known to those skilled in the art. For example, the reductive amination reaction can be performed in the presence of sodium acetate borohydride and N,N-dimethylformamide, or sodium cyanoborohydride and 1,2-dichloroethane, at room temperature to 80°C (e.g., room temperature to 50°C, 40°C to 60°C, 40°C to 50°C, or 50°C to 60°C). The molar ratio of substrate 1-1 to substrate 1-2 can be, for example, 1:1.1-3, 1:1.1-2, 1:1.1-1.5, 1:1.1-1.2, or 1:1.2-1.3.

[0190] For example, the specific operations of solution 1 can be as follows:

[0191] Substrate 1-1 (1.0 eq.) and aldehyde substrate 1-2 (2.0 eq.) were dissolved in N,N-dimethylformamide, and AcOH (1 drop) was added to the solution. The reaction solution was stirred at 50°C for 2 hours, then cooled to room temperature. Sodium acetate borohydride (4.0 eq.) was then added to the reaction solution, and stirring was continued for 17 hours. LCMS confirmed the reaction was complete. The reaction solution was filtered, and the filtrate was purified by HPLC to obtain the title compound.

[0192] Synthesis Scheme 2: Option 2

[0193] In scheme 2, Z, R a1 、R a2 、R a3 、R a4 、(R a5 ) m 、R c2 , Ring B, (R d2 ) n2 , m1, ring C and (R d3 ) n3 As defined in the compounds of formula (I) and its various subembodiments disclosed herein. Group LE represents Cl, Br, I, OMs, OTs, or ONs. In Scheme 2, (i) R Lb1 and R Lb3 Indicates NH, R Lb2 express R Lb4 express Among them, ring A1, (R d1 ) n1As defined in the compounds of formula (I) and its various sub-embodiments disclosed herein; or (ii) R Lb1 and R Lb3 and represents NH, R Lb2 Indicates -NH2, R Lb4 represents NH; or (iii) R Lb1 and R Lb3 express R Lb2 Indicates -NH2, R Lb4 Represents NH, wherein ring A1, (R d1 ) n1 As defined in the compounds of formula (I) and its various sub-embodiments disclosed herein; or (iv) R Lb2 express Among them, ring A2, (R d4 ) n4 As defined in the compounds of formula (I) and various sub-embodiments thereof disclosed herein, R Lb1 and R Lb3 express The symbol ** indicates the point of attachment to ring A2, and R Lb4 express

[0194] The amine alkylation reaction in Scheme 2 can be carried out, for example, in the presence of DIEA and sodium iodide, or triethylamine and sodium iodide, at room temperature to 80°C (e.g., 40°C to 60°C, 40°C to 50°C, or 50°C to 60°C). The molar ratio of substrate 2-1 to substrate 2-2 can be, for example, 1:1.1-2, 1:1.1-1.5, 1:1.1-1.2, or 1:1.2-1.3.

[0195] For example, the specific operations of solution 2 can be as follows:

[0196] Substrate 2-1 (1.0 eq.) and substrate 2-2 (1.2 eq.) were dissolved in N,N-dimethylformamide. Triethylamine (3.0 eq.) and sodium iodide (1.0 eq.) were added to the solution, and the reaction mixture was stirred at room temperature for 18 hours. LCMS confirmed the reaction was complete. The reaction mixture was filtered, and the filtrate was purified by HPLC to obtain the target compound.

[0197] Synthesis Scheme 3: Option 3

[0198] In scheme 3, Z, R a1 、R a2 、R a3 、R a4 、(R a5 ) m , Ring B, (R d2 ) n2, m1, ring C and (R d3 ) n3 As defined in the compounds of formula (I) and its various subembodiments disclosed herein. In Scheme 3, (i) R Lc1 and R Lc3 and represents NH, R Lc2 express R Lc4 express Among them, ring A1, (R d1 ) n1 As defined in the compounds of formula (I) and its various sub-embodiments disclosed herein; or (ii) R Lc1 and R Lc3 and represents NH, R Lc2 Indicates -NH2, R Lc4 represents NH; or (iii) R Lc1 and R Lc3 express R Lc2 Indicates -NH2, R Lc4 represents NH; or (iv) R Lc2 express Among them, ring A2, (R d4 ) n4 As defined in the compounds of formula (I) and various sub-embodiments thereof disclosed herein, R Lc1 and R Lc3 express The symbol ** indicates the point of attachment to ring A2, and R Lc4 express

[0199] The specific operations of Solution 3 can be as follows:

[0200] Substrate 3-1 (1.0 eq.) and substrate 3-2 (1.2 eq.) were dissolved in N,N-dimethylformamide. HATU (1.5 eq.) and triethylamine (3.0 eq.) were added to the solution, and the reaction mixture was stirred at room temperature for 18 hours. LCMS confirmed the reaction was complete. The reaction mixture was filtered, and the filtrate was purified by HPLC to yield the title compound.

[0201] Synthesis Scheme 4: Urea Formation (Triphosgene) Option 4

[0202] In scheme 4, Z, R a1 、R a2 、R a3 、R a4 、(R a5 ) m 、R w 、Ring A1、(Rd1 ) n1 、(R d2 ) n2 , m1, ring C and (R d3 ) n3 As defined in the compounds of formula (I) and its various sub-embodiments disclosed herein. Ring B represents a nitrogen-containing heterocycle.

[0203] The specific operations of Solution 4 can be as follows:

[0204] Substrate 4-2 (1.0 eq.) and triphosgene (0.5 eq.) were dissolved in dichloromethane. Triethylamine (3.0 eq.) was added to the solution, and the reaction was stirred at room temperature for 0.5 hours. A solution of substrate 4-1 in DMF was then added to the reaction solution, and the reaction was stirred for another 17 hours. LCMS confirmed the reaction was complete. The reaction solution was filtered, and the filtrate was purified by HPLC to yield the title compound.

[0205] Synthesis Scheme 5: Option 5

[0206] In scheme 5, Z, R a1 、R a2 、R a3 、R a4 、(R a5 ) m As defined in the compounds of formula (I) and various subembodiments thereof of the present disclosure.

[0207] The palladium-catalyzed coupling reaction in Synthesis Scheme 5 can be a conventional technique and method well known to those skilled in the art.

[0208] General procedure for Scheme 5: Dissolve the halogenated substrate 5-1 (1.0 eq.) and the amino substrate 5-2 (1.2 eq.) in N,N-dimethylformamide. Add palladium catalyst (0.2 eq.) and cesium carbonate (3.0 eq.). After the reaction flask was flushed with nitrogen three times, the reaction mixture was stirred at 80°C for 18 hours. LCMS confirmed the reaction was complete. The reaction mixture was filtered, and the filtrate was purified by HPLC (eluent (v / v): acetonitrile / 0.05% aq. HCl = 5%-90%) to obtain the title compound.

[0209] Synthesis Scheme A1: Plan A1

[0210] In Scheme A1, Z, R a1 、R a2 、R a3 、R a4 、(R a5 ) m 、R w , Ring A1 and (R d1) n1 As defined in the compounds of formula (I) and various subembodiments thereof of the present disclosure.

[0211] The palladium-catalyzed coupling reaction and deprotection in Synthesis Scheme A1 can be conventional techniques and methods well known to those skilled in the art.

[0212] The specific operations of Plan A1 can be as follows:

[0213] Step 1: In a 100 ml single-necked flask at room temperature, compound A-1 (1.0 eq.), compound A-1-1 (1.2 eq.), cesium carbonate (2.0 eq.), palladium catalyst (0.025 eq.), and N,N-dimethylformamide were added in sequence. Under a nitrogen atmosphere, the reaction mixture was heated to 80°C and stirred for 16 hours. TLC confirmed the reaction was complete. The reaction mixture was cooled to room temperature, diluted with water, and extracted three times with ethyl acetate. The organic phases were combined. The combined organic phases were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography to obtain compound A-1-2 (gray solid, 73% yield).

[0214] Step 2: In a 100 mL single-necked flask, add trifluoroacetic acid to a solution of compound A-1-2 in dichloromethane at room temperature. Stir the reaction for 1 hour. TLC confirms the reaction is complete. Concentrate the reaction mixture under reduced pressure and lyophilize to obtain compound A-1-3.

[0215] Synthesis Scheme A2: Option A2

[0216] In scheme A2, Z, R a1 、R a2 、R a3 、R a4 、(R a5 ) m 、R w , Ring A1 and (R d1 ) n1 As defined in the compounds of formula (I) and various subembodiments thereof of the present disclosure.

[0217] The palladium-catalyzed coupling reaction and deprotection in Synthesis Scheme A2 can be conventional techniques and methods well known to those skilled in the art.

[0218] The specific operations of Plan A2 can be as follows:

[0219] Step 1: In a 100 ml single-necked flask at room temperature, compound A-1 (1.0 eq.), compound A-2-1 (1.2 eq.), cesium carbonate (2.0 eq.), palladium catalyst (0.025 eq.), and N,N-dimethylformamide were added in sequence. Under a nitrogen atmosphere, the reaction mixture was heated to 80°C and stirred for 16 hours. TLC confirmed the reaction was complete. The reaction mixture was cooled to room temperature, diluted with water, and extracted three times with ethyl acetate. The organic phases were combined. The combined organic phases were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography to obtain compound A-2-2 (gray solid, 73% yield).

[0220] Step 2: In a 100 mL single-necked flask, add trifluoroacetic acid to a solution of compound A-2-2 in dichloromethane at room temperature. Stir the reaction for 1 hour. TLC confirms the reaction is complete. Concentrate the reaction mixture under reduced pressure and lyophilize to obtain compound A-2-3.

[0221] Synthesis Scheme B1: Plan B1

[0222] In Scheme B1, R a1 、R a2 、R a3 、R a4 、R w , Ring A1 and (R d1 ) n1 As defined in the compounds of formula (I) and its various subembodiments disclosed herein. X represents H or F.

[0223] The substitution reaction and deprotection in Synthesis Scheme B1 can be conventional techniques and methods well known to those skilled in the art.

[0224] The specific operations of Plan B1 can be as follows:

[0225] Step 1: At room temperature, compound B-1 (1.0 eq.), compound B-1-1 (1.2 eq.), N,N-diisopropylethylamine (5.0 eq.), and dimethyl sulfoxide were added sequentially to a 100 ml single-necked flask. Under a nitrogen atmosphere, the reaction mixture was heated to 130°C and stirred for 16 hours. TLC confirmed the reaction was complete. The reaction mixture was cooled to room temperature, diluted with water, and extracted three times with ethyl acetate. The organic phases were combined. The combined organic phases were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography to obtain compound B-1-2 (gray solid, 62% yield).

[0226] Step 2: In a 100 mL single-necked flask, add trifluoroacetic acid to a solution of compound B-1-2 in dichloromethane at room temperature. Stir the reaction for 1 hour. TLC confirms the reaction is complete. Concentrate the reaction mixture under reduced pressure and lyophilize to obtain compound B-1-3.

[0227] Synthesis Scheme B2: Plan B2

[0228] In Scheme B2, R a1 、R a2 、R a3 、R a4 、R w , Ring A1 and (R d1 ) n1 As defined in the compounds of formula (I) and its various subembodiments disclosed herein. X represents H or F.

[0229] The substitution reaction and deprotection in Synthesis Scheme B2 can be conventional techniques and methods well known to those skilled in the art.

[0230] The specific operations of Plan B2 can be as follows:

[0231] Step 1: At room temperature, compound B-1 (1.0 eq.), compound B-2-1 (1.2 eq.), N,N-diisopropylethylamine (5.0 eq.), and dimethyl sulfoxide were added sequentially to a 100 ml single-necked flask. Under a nitrogen atmosphere, the reaction mixture was heated to 130°C and stirred for 16 hours. TLC confirmed the reaction was complete. The reaction mixture was cooled to room temperature, diluted with water, and extracted three times with ethyl acetate. The organic phases were combined. The combined organic phases were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography to obtain compound B-2-2 (gray solid, yield 62%).

[0232] Step 2: In a 100 mL single-necked flask, add trifluoroacetic acid to a solution of compound B-2-2 in dichloromethane at room temperature. Stir the reaction for 1 hour. TLC confirms the reaction is complete. Concentrate the reaction mixture under reduced pressure and lyophilize to obtain compound B-2-3.

[0233] Synthesis Scheme C: Plan C

[0234] In Scheme C, R a1 、R a2 、R a3 、R a4 , Z, (R a5 ) m , Ring A2 and (R d4 ) n4 As defined in the compounds of formula (I) and various subembodiments thereof of the present disclosure.

[0235] Depending on the target compound, the above schemes and their reaction substrates, reaction conditions (including reaction amount, temperature, time, etc.), post-treatment, etc. can be appropriately modified and adjusted by techniques and methods well known to those skilled in the art to obtain the desired target compound, and the obtained target compound can be further modified by substituents, etc. according to methods well known to those skilled in the art to obtain other target compounds.

[0236] It should be understood that in each of the above-mentioned synthesis schemes, when the group contains active hydrogen or reactive groups that do not need to participate in the reaction of the scheme, the active hydrogen or reactive group can be protected by techniques and methods well known to those skilled in the art, such as protecting groups. For example, when the reactive group is a piperidinyl or piperazinyl group, conventional protecting groups such as Boc can be used to protect the hydrogen on N. For example, when the reactive group is -CHO, conventional protecting groups can be used to protect the aldehyde group, such as to form acetal. The removal of the protecting group can be achieved by techniques well known to those skilled in the art. For example, the removal of the protecting group Boc can be achieved under acidic conditions such as hydrochloric acid or trifluoroacetic acid. For another example, the removal of the acetal protecting group can be achieved under acidic conditions such as sulfuric acid, hydrochloric acid, or trifluoroacetic acid. Examples

[0237] Example A-1: ​​Preparation of compound GT-04304

[0238] The target compound GT-04304 (gray solid, 6.5 g, yield 97%) was prepared by referring to the method of Synthesis Scheme A1. 1 H NMR (400MHz, MeOD-d4) δ7.57 (d, J=8.4Hz, 1H), 7.05 (s, 1H), 6.95 (dd, J=8.4, 1.8Hz, 1H), 5.08 (dd, J=13.3, 5.2Hz, 1H), 4.44-4.31 (m, 2H), 3.3 8(t, J=5.1Hz, 4H), 3.03 (s, 4H), 2.86 (dd, J=13.3, 5.3Hz, 1H), 2.81-2.72 (m, 1H), 2.45 (dd, J=13.1, 4.7Hz, 1H), 2.17-2.09 (m, 1H). LCMS (ESI) C 17 H 22 N5O3 + [M+H] + : Calculated value 344.17, measured value 344.2.

[0239] Example A-2: Preparation of compound GT-06985

[0240] The target compound GT-06985 (gray solid, 11.7 g, yield 99%) was prepared according to the method of synthesis scheme A1. 1 H NMR (400MHz, MeOD) δ7.49 (d, J=8.3Hz, 1H), 7.457.36 (m, 1H), 5.09 (dd, J=13.3, 5.1Hz, 1H), 4.47 (q, J=16.7Hz, 2H), 3.44-3.36 (m , 4H), 3.09 (d, J = 4.6Hz, 4H), 2.95-2.85 (m, 1H), 2.81-2.75 (m, 1H), 2.48 (qd, J = 13.2, 4.7Hz, 1H), 2.19-2.10 (m, 1H). LCMS (ESI) C 17 H 21 FN5O3 + [M+H] + : Calculated value 362.16, measured value 362.2.

[0241] Example A-3: Preparation of compound GT-06988

[0242] The target compound GT-06988 (grey solid, 7.9 g, yield 97%) was prepared by referring to the method of Synthesis Scheme A1. 1 H NMR (400MHz, DMSO-d6) δ10.96 (s, 1H), 8.74 (s, 2H), 7.73 (s, 1H), 7.36 (d, J=10. 7Hz, 1H), 7.31 (d, J=7.2Hz, 1H), 5.05 (dd, J=13.3, 5.0Hz, 1H), 4.32 (d, J=16.8Hz , 1H), 4.20 (d, J=16.9Hz, 1H), 3.25 (s, 4H), 2.98 (s, 4H), 2.92-2.82 (m, 1H), 2.59 (d, J=17.2Hz, 1H), 2.36 (dd, J=13.2, 4.4Hz, 1H), 2.04-1.91 (m, 1H).LCMS (ESI) C 17 H 21 FN5O3 + [M+H] + : Calculated value 362.16, measured value 362.2.

[0243] Example A-4: Preparation of compound GT-06989

[0244] The target compound GT-06989 (gray solid, 5.4 g, yield 87%) was prepared by referring to the method of Synthesis Scheme A1. 1H NMR (400MHz, MeOD) δ6.77 (s, 1H), 6.65 (d, J=12.1Hz, 1H), 5.03 (dd, J=13.3, 5.1Hz, 1H), 4.35 (q, J=17.0Hz, 2H), 3.38 (t, J=4.8Hz , 4H), 3.02 (s, 4H), 2.85 (dd, J=13.3, 5.2Hz, 1H), 2.792.69 (m, 1H), 2.42 (dd, J=13.1, 4.7Hz, 1H), 2.17-2.07 (m, 1H).LCMS (ESI) C 17 H 21 FN5O3 + [M+H] + : Calculated value 362.16, measured value 362.2.

[0245] Example A-5: Preparation of compound GT-07368

[0246] The target compound GT-07368 (gray solid, 5.4 g, yield 98%) was prepared by referring to the method of Synthesis Scheme A1. 1 H NMR (400MHz, DMSO-d6) δ10.98 (s, 1H), 8.78 (s, 2H), 7.30 (t, J=7.6Hz, 1H), 7.17 (s , 1H), 7.08 (dd, J=7.6, 4.4Hz, 2H), 5.09 (dd, J=13.2, 5.2Hz, 1H), 4.36 (d, J=17.6H z, 1H), 4.24 (d, J = 17.6Hz, 1H), 3.24 (s, 4H), 2.93 (s, 4H), 2.89 (d, J = 5.2Hz, 1H), 2 .62(d, J=17.2Hz, 1H), 2.40(qd, J=13.2, 4.4Hz, 1H), 2.071.97(m, 1H).LCMS(ESI)C 17 H 22 N5O3 + [M+H] + : Calculated value 344.17, measured value 344.1.

[0247] Example A-6: Preparation of compound GT-05579

[0248] The target compound GT-05579 (gray solid, 4.1 g, yield 97%) was prepared by referring to the method of Synthesis Scheme A1. 1H NMR (400MHz, DMSO-d6) δ11.07 (s, 1H), 8.85 (s, 2H), 8.35 (s, 1H), 7.64 (d, J= 8.3Hz, 1H), 7.23 (s, 1H), 7.06 (d, J=7.8Hz, 1H), 5.05 (dd, J=12.9, 5.3Hz, 1H ), 3.68 (d, J = 4.3Hz, 1H), 3.31 (d, J = 18.6Hz, 4H), 2.88 (td, J = 14.6, 5.2Hz, 4H), 2.56 (dd, J = 20.1, 10.7Hz, 2H), 2.01 (dd, J = 9.9, 4.8Hz, 1H). LCMS (ESI) C 17 H 20 N5O4 + [M+H] + : Calculated value 358.15, measured value 358.1.

[0249] Example A-7: Preparation of compound GT-04310

[0250] The target compound GT-04310 (light yellow solid, 1.5 g, yield 96%) was prepared by referring to the method of synthetic scheme B1. 1 H NMR (400MHz, DMSO-d6) δ11.09 (s, 1H), 8.84 (s, 1H), 8.42 (s, 1H), 7.65 (d, J = 10.3Hz, 1H), 7.57 (d, J = 7.0Hz, 1H), 5.08 (dd, J = 12.8, 5.4Hz, 1H), 3.30 (s, 4H), 2.97 (d, J=33.3Hz, 4H), 2.93-2.83 (m, 1H), 2.56 (dd, J=22.6, 11.2Hz, 2H), 2.05-1.97 (m, 1H).LCMS(ESI)C 17 H 19 FN5O4 + [M+H] + : Calculated value 376.14, measured value 376.2.

[0251] Example A-8: Preparation of compound GT-07007

[0252] The target compound GT-07007 (gray solid, 3.6 g, yield 92%) was prepared by referring to the method of synthetic scheme B2. 1H NMR (400MHz, DMSO-d6) δ11.09 (s, 1H), 9.48 (s, 2H), 7.74 (d, J = 8.5Hz, 1H), 7.41 (d, J = 2.0Hz, 1H), 7.30 (dd, J = 8.5, 2.0Hz, 1H), 5.09 ( dd, J=12.9, 5.4Hz, 1H), 3.58 (s, 4H), 3.02 (s, 4H), 2.92-2.83 (m, 1H), 2.57 (dd, J=19.3, 10.3Hz, 2H), 2.08-1.99 (m, 1H). LCMS (ESI) C 17 H 20 N5O4 + [M+H] + : Calculated value 358.15, measured value 358.2.

[0253] Example A-9: Preparation of compound GT-07051

[0254] The target compound GT-07051 (gray solid, 1.6 g, yield 97%) was prepared by referring to the method of synthetic scheme B2. 1 H NMR (400MHz, DMSO-d6) δ10.95 (s, 1H), 9.65 (s, 2H), 7.55 (d, J=8.4Hz, 1H), 7.13-7.06 (m, 2H), 5.05 (dd, J=13.3, 5.1Hz, 1H), 4.34 (d, J=17.0Hz, 1H), 4. 23(t, J=17.0Hz, 1H), 3.46-3.30(m, 4H), 3.11(brs, 4H), 2.94-2.84(m, 1H) , 2.58 (d, J=17.2Hz, 1H), 2.43-2.31 (m, 1H), 1.98-1.90 (m, 1H).LCMS (ESI) C 17 H 22 N5O3 + [M+H] + : Calculated value 344.17, measured value 344.2.

[0255] Example A-10: Preparation of compound GT-07008

[0256] The target compound GT-07008 was prepared according to the method of synthetic scheme C.

[0257] Step 1: In a 100 ml single-necked flask, (1-aminopiperidin-4-yl)methanol (1.0 eq.) was dissolved in 1,4-dioxane. (Boc)2O (1.2 eq.) and triethylamine (3.0 eq.) were added sequentially. The reaction mixture was stirred at room temperature for 16 hours. TLC confirmed the reaction was complete. The reaction mixture was concentrated under reduced pressure, and the resulting concentrate was washed with water and extracted three times with ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The resulting residue was purified by column chromatography (eluent: petroleum ether:ethyl acetate = 0-50%) to yield tert-butyl (4-(hydroxymethyl)piperidin-1-yl)carbamate (white solid, 80% yield).

[0258] Step 2: In a 100 ml single-necked flask, tert-butyl (4-(hydroxymethyl)piperidin-1-yl)carbamate (1.0 eq.) was dissolved in dichloromethane. MsCl (1.2 eq.) and triethylamine (3.0 eq.) were added sequentially. The reaction mixture was stirred at room temperature for 1 hour. TLC confirmed the reaction was complete. The reaction mixture was washed with water and extracted three times with dichloromethane. The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The resulting residue was purified by column chromatography (eluent: petroleum ether:ethyl acetate = 0-40%) to provide (1-((tert-butoxycarbonyl)amino)piperidin-4-yl)methyl methanesulfonate (white solid, 85% yield).

[0259] Step 3: In a 100 ml single-necked flask, (1-((tert-Butoxycarbonyl)amino)piperidin-4-yl)methyl methanesulfonate (1.3 eq.) and 3-(5-mercapto-1-oxoisoindolin-2-yl)piperidine-2,6-dione (1.0 eq.) were dissolved in dimethyl sulfoxide, and triethylamine (3.0 eq.) was added to the solution. The reaction solution was stirred at room temperature for 16 hours. TLC confirmed the reaction was complete. The reaction solution was washed with water and extracted three times with ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The resulting residue was purified by column chromatography (eluent: petroleum ether:ethyl acetate = 0-50%) to yield tert-butyl (4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)thio)methyl)piperidin-1-yl)carbamate (white solid, 50% yield).

[0260] Step 4: At room temperature, trifluoroacetic acid was added to a solution of tert-butyl (4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)thio)methyl)piperidin-1-yl)carbamate in dichloromethane in a 100 mL single-necked flask. The reaction was stirred for 1 hour. TLC confirmed the reaction was complete. The reaction solution was concentrated under reduced pressure and lyophilized to obtain compound GT-07008 (gray solid, 0.6 g, 93% yield). 1H NMR (400MHz, MeOD-d4) 611.80 (s, 1H), 10.03 (s, 1H), 8.48-8.43 (m, 1H), 8.38 (s , 1H), 8.25 (d, J=7.1Hz, 1H), 5.91 (dd, J=13.3, 5.1Hz, 1H), 5.17 (dd, J=50.0, 17 .4Hz, 2H), 4.26 (s, 4H), 3.86 (d, J=6.1Hz, 2H), 3.77-3.68 (m, 1H), 3.42 (d, J=17 .0Hz, 1H), 3.30-3.12(m, 2H), 2.89-2.68(m, 3H), 2.27-2.16(m, 2H).LCMS(ESI)C 19 H 25 N4O3S + [M+H] + : Calculated value 389.16, measured value 389.2.

[0261] Example A-11: Preparation of compound GT-07966

[0262] The target compound GT-07966 (yellow solid, 1.56 g, yield 94%) was prepared by referring to the method of Synthesis Scheme A1. 1 H NMR (400MHz, DMSO-d6) δ10.93 (s, 1H), 8.99 (s, 2H), 7.56 (s, 1H), 7.46 (d, J=8.4Hz, 1 H), 6.94 (s, 1H), 6.87 (d, J=8.4Hz, 1H), 5.03 (dd, J=13.2, 5.2Hz, 1H), 4.31 (d, J=16. 8Hz, 1H), 4.18 (d, J=16.8Hz, 1H), 4.08-4.01 (m, 2H), 2.99-2.82 (m, 5H), 2.58 (d, J=1 6.8Hz, 1H), 2.33 (dd, J=13.2, 4.4Hz, 1H), 2.15 (d, J=8.8Hz, 2H), 1.98-1.89 (m, 3H). LCMS(ESI)C 19 H 24 N5O3 + Calculated value: 370.19; measured value: 370.1.

[0263] Example A-12: Preparation of compound GT-08008

[0264] The target compound GT-08008 (yellow solid, 1.7 g, yield 83%) was prepared by referring to the method of Synthesis Scheme A1. 1H NMR (400MHz, DMSO-d6) δ10.93 (s, 1H), 9.49 (s, 1H), 7.98 (s, 1H), 7.47 (d, J=8.4Hz, 2H), 7.03 ( s, 1H), 6.96 (d, J=8.4Hz, 1H), 5.03 (dd, J=13.2, 5.2Hz, 1H), 4.30 (dd, J=11.2, 5.6Hz, 3H), 4.1 8(d, J=16.8Hz, 1H), 3.46 (d, J=10.4Hz, 2H), 3.34 (d, J=11.2Hz, 2H), 2.96-2.85 (m, 1H), 2.75- 2.64 (m, 1H), 2.58 (d, J=16.8Hz, 1H), 2.35 (ddd, J=26.0, 13.2, 4.4Hz, 2H), 1.98-1.91 (m, 1H). LCMS(ESI)C 18 H 22 N5O3 + Calculated value: 356.16; measured value: 356.1.

[0265] Example A-13: Preparation of compound GT-08009

[0266] The target compound GT-08009 (yellow solid, 1.2 g, yield 75%) was prepared by referring to the method of Synthesis Scheme A1. 1 H NMR (400MHz, DMSO-d6) δ10.93 (s, 1H), 9.03 (s, 1H), 8.77 (s, 1H), 7.72 (s, 1H), 7.45 (d, J = 8.4Hz, 1H), 6.96 (s, 1H), 6.86 (d, J=8.4Hz, 1H), 5.03 (dd, J=13.2, 5.2Hz, 1H), 4.30 (d, J=16.4Hz, 2H), 4 .17(d, J=16.8Hz, 1H), 3.63(s, 1H), 3.15(s, 2H), 3.07-2.77(m, 2H), 2.58(d, J=16.8Hz, 1H), 2.3 9-2.14 (m, 2H), 1.95 (dd, J=9.2, 3.6Hz, 1H), 1.75 (d, J=10.8Hz, 1H), 0.83 (dd, J=9.6, 6.8Hz, 1H). LCMS(ESI)C 18 H 22 N5O3 + Calculated value: 356.17; measured value: 356.1.

[0267] Example A-14: Preparation of compound GT-08007

[0268] The target compound GT-08007 (brown solid, 1.1 g, yield 99%) was prepared by referring to the method of Synthesis Scheme A1. 1 H NMR (400MHz, DMSO-d6) δ10.94 (s, 1H), 8.91 (s, 2H), 7.73 (s, 1H), 7.45 (d, J=8.4Hz, 1H) , 6.96 (s, 1H), 6.87 (d, J = 8.4Hz, 1H), 5.03 (dd, J = 13.2, 5.2Hz, 1H), 4.31 (d, J = 16.8Hz, 1 H), 4.18 (d, J=16.8Hz, 1H), 3.26 (d, J=4.8Hz, 4H), 3.12 (s, 2H), 2.91 (ddd, J=18.4, 13. 6, 6.4Hz, 3H), 2.59 (d, J=16.8Hz, 1H), 2.35 (qd, J=13.2, 4.4Hz, 1H), 2.04-1.82 (m, 3H). LCMS(ESI).C 18 H 24 N5O3 + [M+H] + : Calculated value, 358.18; measured value, 358.2.

[0269] Example A-15: Preparation of compound GT-08006

[0270] The target compound GT-08006 (brown solid, 980 mg, yield 95%) was prepared by referring to the method of Synthesis Scheme A1. 1 H NMR (400MHz, DMSO-d6) δ10.99 (s, 1H), 9.02 (s, 2H), 7.49 (d, J=8.4Hz, 1H), 7.28 (d, J=1 6.8Hz, 1H), 6.94 (s, 1H), 6.88 (d, J=8.4Hz, 1H), 5.08 (dd, J=13.2, 5.2Hz, 1H), 4.35 (d, J=16.8Hz, 1H), 4.21 (d, J=16.8Hz, 1H), 3.80 (t, J=6.0Hz, 4H), 3.01-2.90 (m, 1H), 2.64 (d, J=16.8Hz, 5H), 2.39 (ddd, J=26.0, 13.2, 4.4Hz, 1H), 1.99 (dd, J=17.6, 10.4Hz, 5H). LCMS(ESI)C 20 H 26 N5O3 + [M+H] + : Calculated value, 384.20; measured value, 384.3.

[0271] Example A-16: Preparation of compound GT-07965

[0272] The target compound GT-07965 (off-white solid, 1.1 g, yield 99%) was prepared by referring to the method of Synthesis Scheme A1. 1 H NMR (400MHz, DMSO-d6) δ10.94 (s, 1H), 8.93 (s, 1H), 8.76 (s, 1H), 7.44 (d, J=8.4H z, 1H), 7.24 (s, 1H), 6.95 (s, 1H), 6.89 (d, J = 8.0Hz, 1H), 5.03 (dd, J = 13.2, 4.8Hz, 1H), 4.29(d, J=16.8Hz, 1H), 4.19(s, 1H), 3.47(s, 2H), 3.10-2.82(m, 7H), 2.68( s, 2H), 2.59 (d, J=17.6Hz, 1H), 2.34 (dt, J=22.4, 11.2Hz, 1H), 2.02-1.90 (m, 1H). LCMS(ESI)C 19 H 24 N5O3 + [M+H] + : Calculated value, 370.18; measured value, 370.1.

[0273] Example 1: Preparation of compound GT-06422

[0274] The target compound GT-06422 (white solid, 15 mg, yield 25%) was prepared by referring to the method of Synthesis Scheme 2. 1 H NMR (400MHz, DMSO-d6) δ11.66 (s, 1H), 11.07 (s, 1H), 7.95-7.79 (m, 3H), 7.63 ( d, J=8.2Hz, 1H), 7.54-7.30 (m, 7H), 7.23-7.19 (m, 1H), 7.08-6.96 (m, 1H), 5.05 (dd, J=12.6, 5.3Hz, 1H), 3.30-3.15(m, 6H), 3.15-3.01(m, 2H), 2.96-2.78(m, 2H), 2.58(d, J=17.6Hz, 1H), 2.45-2.33(m, 1H), 2.05-1.95(m, 1H).LCMS(ESI)C 30 H 30 N5O4 + [M+H] + : Calculated value 524.23, measured value 524.3.

[0275] Example 2: Preparation of compound GT-06401

[0276] The target compound GT-06401 (white solid, 10 mg, yield 16%) was prepared by referring to the method of Synthesis Scheme 2. 1 H NMR (400MHz, DMSO-d6) δ10.99 (s, 1H), 7.87-7.73 (m, 1H), 7.68-7.53 (m, 2H), 7.48-7.39(m, 2H), 7.36-7.23(m, 2H), 7.22-7.05(m, 3H), 6.97-6.93(m, 1H), 4 .97(dd, J=12.7, 5.5Hz, 1H), 3.21-3.11(m, 4H), 3.11-2.91(m, 4H), 2.80-2.76 (m, 2H), 2.53-2.48 (m, 1H), 2.41-2.33 (m, 1H), 1.99-1.87 (m, 1H).LCMS (ESI) C 30 H 28 F2N5O4 + [M+H] + : Calculated value 560.21, measured value 560.2.

[0277] Example 3: Preparation of compound GT-06509

[0278] The target compound GT-06509 (white solid, 41 mg, yield 66%) was prepared by referring to the method of Synthesis Scheme 2. 1 H NMR (400MHz, DMSO-d6) δ11.00 (s, 1H), 9.69 (s, 1H), 8.30 (s, 1H), 7.54 (d, J= 8.3Hz, 1H), 7.19-7.12 (m, 4H), 6.95 (d, J=7.6Hz, 1H), 4.97 (dd, J=12.7, 5.3 Hz, 1H), 3.61-3.48 (m, 2H), 3.05-2.73 (m, 8H), 2.51 (d, J=18.1Hz, 1H), 2.48 -2.46(m,1H),2.20(brs,5H),1.99-1.86(m,1H),1.64(brs,4H).LCMS(ESI)C 30 H 33 FN5O4 + [M+H] + : Calculated value 546.25, measured value 546.3.

[0279] Example 4: Preparation of compound GT-07045

[0280] The target compound GT-07045 (white solid, 34 mg, yield 53%) was prepared by referring to the method of Synthesis Scheme 1.1 H NMR (400MHz, DMSO-d6) δ10.99 (s, 1H), 10.17 (s, 1H), 8.32 (s, 1H), 7.54 (d, J=8.3Hz, 1H), 7.43 ( d, J=8.2Hz, 2H), 7.19 (d, J=8.3Hz, 2H), 7.12 (s, 1H), 6.95 (s, 1H), 4.97 (dd, J=12.8, 5.4Hz, 1H) , 4.30 (s, 2H), 3.76 (t, J=5.3Hz, 2H), 3.61 (s, 2H), 3.39-3.31 (m, 2H), 3.07-3.01 (m, 2H), 2.98- 2.85(m, 4H), 2.81-2.76(m, 1H), 2.49-2.43(m, 2H), 2.30(s, 2H), 1.96-1.89(m, 1H).LCMS(ESI)C 29 H 31 ClN5O5 + [M+H] + : Calculated value 564.20, measured value 564.2.

[0281] Example 5: Preparation of compound GT-06423

[0282] The target compound GT-06423 (white solid, 14 mg, yield 24%) was prepared by referring to the method of Synthesis Scheme 2. 1 H NMR (400MHz, DMSO-d6) δ11.37 (s, 1H), 11.09 (s, 1H), 7.94-7.74 (m, 3H), 7.64 (d, J=10.2Hz, 1H), 7.60-7.26 (m, 8H), 5.07 (dd, J=12.9, 5.3H z, 1H), 3.31-3.17 (m, 6H), 3.13-3.06 (m, 2H), 2.94-2.83 (m, 2H), 2.59 (d, J=19.6Hz, 1H), 2.49-2.42 (m, 1H), 2.07-1.96 (m, 1H). LCMS (ESI) C 30 H 29 FN5O4 + [M+H] + : Calculated value 542.22, measured value 542.3.

[0283] Example 6: Preparation of compound GT-06402

[0284] The target compound GT-06402 (white solid, 14 mg, yield 22%) was prepared by referring to the method of Synthesis Scheme 2. 1H NMR (400MHz, DMSO-d6) δ11.09 (s, 1H), 7.96-7.78 (m, 1H), 7.64 (d, J = 10.3Hz, 2H), 7.59-7.41 (m, 4H), 7.34-7.01 (m, 3H), 5.07 (dd, J = 12.6, 5.4Hz, 1H), 3.29-3.17(m, 4H), 3.17-2.95(m, 4H), 2.95-2.81(m, 2H), 2.61-2.56(m, 2H), 2.49-2.38(m, 1H), 2.06-1.94(m, 1H).LCMS(ESI)C 30 H 27 F3N5O4 + [M+H] + : Calculated value 578.20, measured value 578.2.

[0285] Example 7: Preparation of compound GT-06510

[0286] The target compound GT-06510 (white solid, 41 mg, yield 67%) was prepared by referring to the method of Synthesis Scheme 2. 1 H NMR (400MHz, DMSO-d6) δ11.08 (s, 1H), 9.68 (s, 1H), 8.41 (s, 1H), 7.64 (d, J=10.3H z, 1H), 7.52 (d, J=6.9Hz, 1H), 7.27-7.20 (m, 3H), 5.06 (dd, J=12.8, 5.4Hz, 1H), 3. 65-3.58(m, 2H), 3.21-3.13(m, 2H), 3.10-3.05(m, 1H), 3.04-2.78(m, 6H), 2.58(d , J=19.8Hz, 1H), 2.39-2.20(m, 5H), 2.06-1.96(m, 1H), 1.71(brs, 4H).LCMS(ESI)C 30 H 32 F2N5O4 + [M+H] + : Calculated value 564.24, measured value 564.3.

[0287] Example 8: Preparation of compound GT-06961

[0288] The target compound GT-06961 (white solid, 15 mg, yield 24%) was prepared by referring to the method of Synthesis Scheme 1. 1H NMR (400MHz, DMSO-d6) δ11.01 (s, 1H), 9.89 (s, 1H), 8.34 (s, 1H), 7.56 (d, J=10.3Hz, 1H) , 7.43 (d, J=7.7Hz, 3H), 7.19 (d, J=8.2Hz, 2H), 4.99 (dd, J=12.8, 5.4Hz, 1H), 4.27 (s, 2H) , 3.77(t, J=5.1Hz, 2H), 3.62(s, 2H), 3.44-3.38(m, 2H), 3.16-3.03(m, 2H), 3.03-2.84(m , 4H), 2.83-2.77(m, 1H), 2.53-2.46(m, 2H), 2.30(s, 2H), 2.00-1.86(m, 1H).LCMS(ESI)C 29 H 30 ClFN5O5 + [M+H] + : Calculated value 582.19, measured value 582.2.

[0289] Example 9: Preparation of compound GT-06398

[0290] The target compound GT-06398 (white solid, 14 mg, yield 22%) was prepared by referring to the method of Synthesis Scheme 2. 1 H NMR (400MHz, DMSO-d6) δ10.86 (s, 1H), 7.88-7.78 (m, 1H), 7.70-7.59 (m, 2H), 7.53-7.41 (m, 2H), 7.38 (d , J=8.4Hz, 1H), 7.35-7.26 (m, 1H), 7.24-7.10 (m, 2H), 6.85 (s, 1H), 6.79 (d, J=8.6Hz, 1H), 4.95 (dd, J=13 .2, 5.2Hz, 1H), 4.22 (d, J=16.9Hz, 1H), 4.09 (d, J=16.9Hz, 1H), 3.24-3.09 (m, 4H), 3.06-2.93 (m, 2H), 2. 87-2.85(m, 3H), 2.66(s, 1H), 2.51(d, J=17.8Hz, 1H), 2.32-2.22(m, 1H), 1.95-1.81(m, 1H).LCMS(ESI)C 30 H 30 F2N5O3 + [M+H] + : Calculated value 546.23, measured value 546.2.

[0291] Example 10: Preparation of compound GT-06426

[0292] The target compound GT-06426 (white solid, 18 mg, yield 28%) was prepared by referring to the method of Synthesis Scheme 2. 1 H NMR (400MHz, DMSO-d6) δ10.86 (s, 1H), 7.96-7.75 (m, 3H), 7.66-7.58 (m, 1H), 7.38 (d, J=8. 1Hz, 1H), 7.33-7.14 (m, 4H), 6.85 (s, 1H), 6.82-6.72 (m, 1H), 4.95 (dd, J=13.3, 5.1Hz, 1H) , 4.22 (d, J = 17.0Hz, 1H), 4.09 (d, J = 16.9Hz, 1H), 3.19-3.08 (m, 4H), 3.07-2.95 (m, 4H), 2. 87-2.77(m, 2H), 2.51(d, J=17.2Hz, 1H), 2.32-2.22(m, 1H), 1.96-1.80(m, 1H).LCMS(ESI)C 30 H 30 F2N5O3 + [M+H] + : Calculated value 546.23, measured value 546.2.

[0293] Example 11: Preparation of compound GT-06427

[0294] The target compound GT-06427 (white solid, 23 mg, yield 34%) was prepared by referring to the method of Synthesis Scheme 2. 1 H NMR (400MHz, DMSO-d6) δ10.86 (s, 1H), 7.91-7.74 (m, 2H), 7.58-7.27 (m, 7H), 6.8 4 (s, 1H), 6.78 (d, J = 7.7Hz, 1H), 4.95 (dd, J = 13.4, 5.0Hz, 1H), 4.22 (d, J = 16.7Hz , 1H), 4.09 (d, J=17.0Hz, 1H), 3.20-3.12 (m, 4H), 3.04-2.92 (m, 4H), 2.89-2.77 ( m, 2H), 2.51 (d, J = 17.6Hz, 1H), 2.31-2.22 (m, 1H), 1.91-1.84 (m, 1H). LCMS (ESI) C 30 H 30 Cl2N5O3 + [M+H] + : Calculated value 578.17, measured value 578.2.

[0295] Example 12: Preparation of compound GT-06428

[0296] The target compound GT-06428 (white solid, 23 mg, yield 35%) was prepared by referring to the method of Synthesis Scheme 2. 1 H NMR (400MHz, DMSO-d6) δ11.12 (s, 1H), 10.86 (s, 1H), 7.66 (d, J = 8.4Hz, 4H), 7.39 (d, J = 8.2Hz, 1H), 6.94 (d, J=8.4Hz, 4H), 6.86 (s, 1H), 6.79 (d, J=8.6Hz, 1H), 5.40 (d, J=9.4Hz, 1H), 4.96 (dd, J=13.2, 5.2Hz, 1H), 4.22 (d, J=16.9Hz, 1H), 4.09 (d, J=17.0Hz, 1H), 3.68 (s, 6H), 3.19-3.09 (m, 4H), 3.01 (s , 4H), 2.87-2.80 (m, 1H), 2.51 (d, J=17.4Hz, 1H), 2.31-2.25 (m, 1H), 1.95-1.79 (m, 1H).LCMS (ESI) C 32 H 35 N5NaO5 + [M+Na] + : Calculated value 592.25, measured value 592.3.

[0297] Example 13: Preparation of compound GT-06499

[0298] The target compound GT-06499 (white solid, 29 mg, yield 46%) was prepared by referring to the method of Synthesis Scheme 1. 1 H NMR (400MHz, DMSO-d6) δ10.87 (s, 1H), 10.62 (s, 1H), 7.91 (s, 1H), 7.74-7.70 (m, 2H), 7.60 (s, 1H), 7.50 (d, J=8.6Hz, 4H), 7.40 (d, J=8.3Hz, 1H), 6.86 (s, 1H), 6.79 (d, J=8.3Hz, 1H), 4.96 (dd, J=13.2, 5.1Hz, 1 H), 4.35 (d, J=3.8Hz, 2H), 4.23 (d, J=16.9Hz, 1H), 4.10 (d, J=17.0Hz, 1H), 3.26-3.22 (m, 4H), 3.10-3.0 3(m, 2H), 2.95-2.78(m, 3H), 2.52(d, J=16.4Hz, 1H), 2.32-3.23(m, 1H), 1.92-1.87(m, 1H).LCMS(ESI)C 30 H 31 ClN5O3+ [M+H] + : Calculated value 544.21, measured value 544.2.

[0299] Example 14: Preparation of compound GT-06500

[0300] The target compound GT-06500 (white solid, 32 mg, yield 51%) was prepared by referring to the method of Synthesis Scheme 1. 1 H NMR (400MHz, DMSO-d6) δ10.87 (s, 1H), 10.57 (s, 1H), 7.74-7.67 (m, 4H), 7.63 (d, J=8.0Hz, 2H), 7.48 (d, J=8.6Hz, 2H), 7.40 (d, J=8.4Hz, 1H), 6.86 (s, 1H), 6.80 (d, J=8.3Hz, 1H), 4.96 (dd, J=13.3, 5.0Hz , 1H), 4.32(brs, 2H), 4.23(d, J=17.0Hz, 1H), 4.10(d, J=17.0Hz, 1H), 3.27-3.16(m, 4H), 3.10-3.00( m, 2H), 2.94-2.77 (m, 3H), 2.52 (d, J=17.3Hz, 1H), 2.34-2.21 (m, 1H), 1.94-1.83 (m, 1H). LCMS (ESI) C 30 H 31 ClN5O3 + [M+H] + : Calculated value 544.21, measured value 544.2.

[0301] Example 15: Preparation of compound GT-06505

[0302] The target compound GT-06505 (white solid, 20 mg, yield 32%) was prepared by referring to the method of Synthesis Scheme 2. 1 H NMR (400MHz, DMSO-d6) δ10.94 (s, 1H), 7.44 (d, J=8.4Hz, 1H), 7.24-7.16 (m, 4 H), 6.90 (s, 1H), 6.84 (d, J=8.2Hz, 1H), 5.02 (dd, J=13.3, 5.2Hz, 1H), 4.28 (d , J=16.9Hz, 1H), 4.15 (d, J=16.9Hz, 1H), 2.94-2.82 (m, 5H), 2.59 (d, J=17.4H z, 1H), 2.32-2.25 (m, 7H), 1.98-1.93 (m, 1H), 1.71-1.64 (m, 8H). LCMS (ESI) C 30 H35 FN5O3 + [M+H] + : Calculated value 532.27, measured value 532.3.

[0303] Example 16: Preparation of compound GT-06501

[0304] The target compound GT-06501 (white solid, 12 mg, yield 19%) was prepared by referring to the method of Synthesis Scheme 1. 1 H NMR (400MHz, DMSO-d6) δ10.93 (s, 1H), 10.26 (s, 1H), 7.44 (d, J=8.3Hz, 1H), 7.35-7.21 (m, 4H), 6.89 (s, 1H), 6.83 (d, J=8.9Hz, 1H), 5.02 (dd, J=13.2, 4.7Hz, 1H), 4.37 (s, 2H) , 4.28 (d, J = 16.8Hz, 1H), 4.14 (d, J = 16.8Hz, 1H), 3.84 (t, J = 5.1Hz, 2H), 3.65 (s, 2H), 3 .05-2.83(m,7H),2.61-2.54(m,2H),2.44-2.29(m,4H),2.01-1.88(m,1H).LCMS(ESI)C 29 H 33 FN5O4 + [M+H] + : Calculated value 534.25, measured value 534.3.

[0305] Example 17: Preparation of compound GT-06511

[0306] The target compound GT-06511 (white solid, 22 mg, yield 34%) was prepared by referring to the method of Synthesis Scheme 1. 1H NMR (400MHz, DMSO-d6) δ10.93 (s, 1H), 10.18 (s, 1H), 7.51 (d, J = 8.4Hz, 2H), 7.44 (d, J = 8.4Hz, 1H), 7. 27 (d, J=8.4Hz, 2H), 6.90 (s, 1H), 6.84 (d, J=8.0Hz, 1H), 5.02 (dd, J=13.2, 5.0Hz, 1H), 4.36 (s, 2H), 4 .28(d, J=16.8Hz, 1H), 4.14(d, J=16.9Hz, 1H), 3.84(t, J=5.4Hz, 2H), 3.72-3.62(m, 2H), 3.17-2.76( m, 8H), 2.58 (d, J=18.9Hz, 1H), 2.56-2.53 (m, 1H), 2.41-2.33 (m, 3H), 1.99-1.93 (m, 1H). LCMS (ESI) C 29 H 33 ClN5O4 + [M+H] + : Calculated value 550.22, measured value 550.3.

[0307] Example 18: Preparation of compound GT-06502

[0308] The target compound GT-06502 (white solid, 19 mg, yield 28%) was prepared by referring to the method of Synthesis Scheme 1. 1 H NMR (400MHz, DMSO-d6) δ10.93 (s, 1H), 10.20 (s, 1H), 7.50 (d, J = 8.4Hz, 2H), 7.44 (d, J = 8.4Hz, 1 H), 7.25 (d, J=8.4Hz, 2H), 6.90 (s, 1H), 6.84 (d, J=8.4Hz, 1H), 5.02 (dd, J=13.3, 5.0Hz, 1H), 4. 37 (s, 2H), 4.28 (d, J = 17.0Hz, 1H), 4.14 (d, J = 16.9Hz, 1H), 3.67 (brs, 2H), 3.06-2.83 (m, 7H), 2 .64-2.52(m, 3H), 2.35-2.32(m, 1H), 2.24(s, 2H), 2.00-1.88(m, 1H), 1.23(s, 6H).LCMS(ESI)C 31 H 37 ClN5O4 + [M+H] + : Calculated value 578.25, measured value 578.3.

[0309] Example 19: Preparation of compound GT-06420

[0310] The target compound GT-06420 (white solid, 18 mg, yield 30%) was prepared by referring to the method of Synthesis Scheme 1. 1 H NMR (400MHz, DMSO-d6) δ11.29 (s, 1H), 10.89 (s, 1H), 7.80-7.73 (m, 2H), 7.48-7.38 (m, 4H), 7 .37-7.29(m, 4H), 7.27-7.13(m, 2H), 5.55(s, 1H), 4.97(dd, J=13.3, 4.9Hz, 1H), 4.38(d, J=16 .9Hz, 1H), 4.20 (d, J=16.7Hz, 1H), 3.53-3.44 (m, 1H), 3.18-3.07 (m, 4H), 3.04-2.98 (m, 2H), 2.87-2.78(m, 2H), 2.52(d, J=18.1Hz, 1H), 2.34-2.26(m, 1H), 1.93-1.85(m, 1H).LCMS(ESI)C 30 H 31 FN5O3 + [M+H] + : Calculated value 528.24, measured value 528.3.

[0311] Example 20: Preparation of compound GT-06399

[0312] The target compound GT-06399 (white solid, 11 mg, yield 17%) was prepared by referring to the method of Synthesis Scheme 1. 1 H NMR (400MHz, DMSO-d6) δ10.89 (s, 1H), 7.83-7.72 (m, 1H), 7.70-7.51 (m, 2H), 7.51-7.38 ( m, 2H), 7.36-7.28 (m, 2H), 7.26-7.05 (m, 3H), 4.97 (dd, J=13.2, 4.9Hz, 1H), 4.38 (d, J=16. 8Hz, 1H), 4.20 (d, J=16.7Hz, 1H), 3.22-3.10 (m, 4H), 3.07-2.98 (m, 2H), 2.88-2.75 (m, 3H ), 2.66 (s, 1H), 2.51 (d, J = 17.5Hz, 1H), 2.36-2.24 (m, 1H), 1.94-1.83 (m, 1H).LCMS (ESI) C 30 H 29 F3N5O3 + [M+H] + : Calculated value 564.22, measured value 564.2.

[0313] Example 21: Preparation of compound GT-06506

[0314] The target compound GT-06506 (white solid, 13 mg, yield 22%) was prepared by referring to the method of Synthesis Scheme 2. 1 H NMR (400MHz, DMSO-d6) δ10.89 (s, 1H), 9.50 (s, 1H), 7.64 (s, 1H), 7.31 (d, J=8.2Hz, 1H) , 7.19-7.13 (m, 4H), 4.97 (dd, J=13.2, 5.1Hz, 1H), 4.38 (d, J=16.7Hz, 1H), 4.20 (d, J=16 .8Hz, 1H), 3.56-3.48(m, 2H), 3.07-2.95(m, 4H), 2.92-2.82(m, 4H), 2.52(d, J=17.4Hz , 1H), 2.38-2.24(m, 2H), 2.19(brs, 4H), 1.92-1.83(m, 1H), 1.64(brs, 4H).LCMS(ESI)C 30 H 34 F2N5O3 + [M+H] + : Calculated value 550.26, measured value 550.3.

[0315] Example 22: Preparation of compound GT-06507

[0316] The target compound GT-06507 (white solid, 33 mg, yield 54%) was prepared by referring to the method of Synthesis Scheme 2. 1 H NMR (400MHz, DMSO-d6) δ10.95 (s, 1H), 9.90 (s, 1H), 7.72 (s, 1H), 7.34 (d, J = 10.7Hz, 1H), 7.24 (d, J=8.5Hz, 4H), 5.03 (dd, J=13.2, 5.1Hz, 1H), 4.29 (d, J=16.9Hz, 1H), 4. 16(d, J=16.9Hz, 1H), 3.63-3.58(m, 2H), 3.15-2.95m, 3H), 2.94-2.86(m, 5H), 2.59( d, J=16.8Hz, 1H), 2.35-2.21(m, 6H), 1.97-1.93(m, 1H), 1.71(brs, 4H).LCMS(ESI)C 30 H 34 F2N5O3 + [M+H] + : Calculated value 550.26, measured value 550.3.

[0317] Example 23: Preparation of compound GT-06421

[0318] The target compound GT-06421 (white solid, 12 mg, yield 20%) was prepared by referring to the method of Synthesis Scheme 2. 1 H NMR (400MHz, DMSO-d6) δ11.61 (s, 1H), 10.95 (s, 1H), 8.13-7.98 (m, 1H), 7.97-7.81 (m, 3H), 7. 51-7.38 (m, 6H), 6.74-6.65 (m, 1H), 6.62-6.58 (m, 1H), 4.98 (dd, J=13.3, 5.1Hz, 1H), 4.31 (d, J =17.3Hz, 1H), 4.17 (d, J = 16.9Hz, 1H), 3.60-3.52 (m, 1H), 3.26-3.14 (m, 4H), 3.11-3.05 (m, 3H) , 2.97-2.80 (m, 2H), 2.58 (d, J=17.7Hz, 1H), 2.34-2.29 (m, 1H), 2.00-1.89 (m, 1H).LCMS (ESI) C 30 H 31 FN5O3 + [M+H] + : Calculated value 528.24, measured value 528.2.

[0319] Example 24: Preparation of compound GT-06400

[0320] The target compound GT-06400 (white solid, 24 mg, yield 38%) was prepared by referring to the method of Synthesis Scheme 2. 1 H NMR (400MHz, DMSO-d6) δ10.95 (s, 1H), 8.17-8.13 (m, 1H), 7.94-7.79 (m, 1H), 7.77-7.62 (m, 1H), 7 .59-7.35(m, 4H), 7.31-7.12(m, 2H), 6.68(s, 1H), 6.65-6.50(m, 1H), 4.98(dd, J=13.2, 5.0Hz, 1H ), 4.31 (d, J=17.2Hz, 1H), 4.17 (d, J=16.9Hz, 1H), 3.28-3.17 (m, 4H), 3.13-3.04 (m, 2H), 2.94-2. 84(m, 3H), 2.74(s, 1H), 2.58(d, J=16.3Hz, 1H), 2.36-2.25(m, 1H), 2.01-1.88(m, 1H).LCMS(ESI)C 30 H 29 F3N5O3+ [M+H] + : Calculated value 564.22, measured value 564.3.

[0321] Example 25: Preparation of compound GT-06508

[0322] The target compound GT-06508 (white solid, 38 mg, yield 62%) was prepared by referring to the method of Synthesis Scheme 2. 1 H NMR (400MHz, DMSO-d6) δ10.87 (s, 1H), 10.19 (s, 1H), 7.97 (s, 1H), 7.16 (dd, J=13.1, 4.4 Hz, 3H), 6.59 (s, 1H), 6.52 (d, J=12.1Hz, 1H), 4.91 (dd, J=13.3, 5.1Hz, 1H), 4.22 (d, J=1 7.3Hz, 1H), 4.08 (d, J=17.3Hz, 1H), 3.54-3.45 (m, 2H), 3.13-2.95 (m, 3H), 2.91-2.73 (m , 5H), 2.56-2.46(m, 1H), 2.36-2.12(m, 6H), 1.96-1.82(m, 1H), 1.63(s, 4H).LCMS(ESI)C 30 H 34 F2N5O3 + [M+H] + : Calculated value 550.26, measured value 550.3.

[0323] Example 26: Preparation of compound GT-06863

[0324] The target compound GT-06863 (white solid, 25 mg, yield 36%) was prepared by referring to the method of Synthesis Scheme 4. 1 H NMR (400MHz, DMSO-d6) δ10.86 (s, 1H), 7.38 (d, J = 8.4Hz, 1H), 7.26 (d, J = 4.4Hz, 2H), 7.14-7 .05 (m, 1H), 6.87 (s, 1H), 6.79 (d, J=8.1Hz, 1H), 4.96 (dd, J=13.2, 5.0Hz, 1H), 4.24 (d, J=16. 9Hz, 1H), 4.10 (d, J=16.9Hz, 1H), 3.34-3.14 (m, 9H), 2.98-2.87 (m, 4H), 2.88-2.77 (m, 1H), 2 .70-2.61(m, 3H), 2.52(d, J=16.8Hz, 1H), 2.34-2.21(m, 1H), 1.92-1.87(m, 1H).LCMS(ESI)C28 H 32 Cl2N7O4 + [M+H] + : Calculated value 600.19, measured value 600.2.

[0325] Example 27: Preparation of Compound GT-06864

[0326] The target compound GT-06864 (white solid, 26 mg, yield 41%) was prepared by referring to the method of Synthesis Scheme 4. 1 H NMR (400MHz, DMSO-d6) δ10.87 (s, 1H), 7.39 (d, J=8.4Hz, 1H), 7.29 (s, 2H), 7.14 (t, J=8 .7Hz, 2H), 6.91 (s, 1H), 6.83 (d, J=8.1Hz, 1H), 4.96 (dd, J=13.2, 5.1Hz, 1H), 4.30-4.0 9(m,5H),3.39(brs.4H),3.32-3.26(m,2H),3.20(brs,4H),2.90-2.78(m,1H),2.75-2 .66(m, 3H), 2.52(d, J=16.9Hz, 1H), 2.35-2.21(m, 1H), 1.91-1.87(m, 1H).LCMS(ESI)C 28 H 33 FN7O4 + [M+H] + : Calculated value 550.26, measured value 550.3.

[0327] Example 28: Preparation of compound GT-06865

[0328] The target compound GT-06865 (white solid, 35 mg, yield 53%) was prepared by referring to the method of Synthesis Scheme 4. 1 H NMR (400MHz, DMSO-d6) δ10.87 (s, 1H), 7.39 (d, J = 8.3Hz, 1H), 7.22 (d, J = 8.9Hz, 2H), 6.99 (d, J=8.9Hz, 2H), 6.90 (s, 1H), 6.82 (d, J=8.3Hz, 1H), 4.96 (dd, J=13.3, 5.1Hz, 1 H), 4.27-4.01(m, 5H), 3.33-3.23(m, 6H), 3.12(brs, 4H), 2.90-2.77(m, 1H), 2.76-2. 60(m, 3H), 2.52(d, J=16.8Hz, 1H), 2.33-2.24(m, 1H), 1.97-1.87(m, 1H).LCMS(ESI)C28 H 33 ClN7O4 + [M+H] + : Calculated value 566.23, measured value 566.2.

[0329] Example 29: Preparation of compound GT-06866

[0330] The target compound GT-06866 (white solid, 36 mg, yield 51%) was prepared by referring to the method of Synthesis Scheme 4. 1 H NMR (400MHz, DMSO-d6) δ10.94 (s, 1H), 7.47 (d, J = 8.3Hz, 1H), 7.42 (d, J = 8.8Hz, 2H), 7.03 (d, J=8.8Hz, 2H), 7.00 (s, 1H), 6.91 (d, J=8.0Hz, 1H), 5.03 (dd, J=13.2, 5.0Hz, 1H), 4.34-4.20(m, 5H), 3.36(brs, 6H), 3.20(brs, 4H), 2.99-2.88(m, 1H), 2.86-2.7 1(m, 3H), 2.59(d, J=17.5Hz, 1H), 2.41-2.33(m, 1H), 1.98-1.90(m, 1H).LCMS(ESI)C 28 H 33 BrN7O4 + [M+H] + : Calculated value 610.18, measured value 610.2.

[0331] Example 30: Preparation of compound GT-06867

[0332] The target compound GT-06867 (white solid, 25 mg, yield 38%) was prepared by referring to the method of Synthesis Scheme 4. 1 H NMR (400MHz, DMSO-d6) δ10.94 (s, 1H), 7.46 (d, J=8.3Hz, 1H), 7.14-7.08 (m, 1H ), 7.04-6.98 (m, 2H), 6.90-6.86 (m, 2H), 5.03 (dd, J=13.3, 5.1Hz, 1H), 4.37-4 .19(m,5H),3.35(brs,6H),3.06(brs,4H),2.97-2.85(m,1H),2.81-2.72(m,3 H), 2.59 (d, J=16.6Hz, 1H), 2.39-2.32 (m, 1H), 1.99-1.90 (m, 1H).LCMS (ESI) C 28 H 32 F2N7O4+ [M+H] + : Calculated value 568.25, measured value 568.3.

[0333] Example 31: Preparation of compound GT-06868

[0334] The target compound GT-06868 (white solid, 15 mg, yield 24%) was prepared by referring to the method of Synthesis Scheme 4. 1 H NMR (400MHz, DMSO-d6) δ10.86 (s, 1H), 7.38 (d, J=8.4Hz, 1H), 7.22 (dd, J=8.4, 5.7Hz, 2H), 7.04 (t, J=8.8 Hz, 2H), 6.86 (s, 1H), 6.78 (d, J=8.4Hz, 1H), 4.96 (dd, J=13.3, 5.0Hz, 1H), 4.24 (d, J=16.8Hz, 1H), 4.10 (d , J=16.9Hz, 1H), 3.65(d, J=12.7Hz, 2H), 3.27-3.15(m, 5H), 2.90-2.72(m, 4H), 2.69-2.61(m, 4H), 2.52(d , J=16.6Hz, 1H), 2.33-2.20(m, 1H), 1.93-1.82(m, 1H), 1.70-1.67(m, 2H), 1.54-1.45(m, 2H).LCMS(ESI)C 29 H 34 FN6O4 + [M+H] + : Calculated value 549.26, measured value 549.3.

[0335] Example 32: Preparation of compound GT-06869

[0336] The target compound GT-06869 (white solid, 18 mg, yield 26%) was prepared by referring to the method of Synthesis Scheme 4. 1H NMR (400MHz, DMSO-d6) δ10.86 (s, 1H), 7.44 (dd, J=7.7, 1.6Hz, 1H), 7.38 (d, J=8.3Hz, 1H), 7.35-7.26 (m, 2H), 6 .86 (s, 1H), 6.78 (d, J = 8.1Hz, 1H), 4.96 (dd, J = 13.2, 5.0Hz, 1H), 4.24 (d, J = 16.9Hz, 1H), 4.10 (d, J = 16.9Hz, 1H ), 3.68 (d, J=13.2Hz, 2H), 3.27-3.19 (m, 5H), 3.11 (t, J=12.0Hz, 2H), 2.86-2.78 (m, 3H), 2.80-2.62 (m, 3H), 2. 52(d, J=16.7Hz, 1H), 2.32-2.22(m, 1H), 1.91-1.84(m, 1H), 1.72-1.69(m, 2H), 1.57-1.49(m, 2H).LCMS(ESI)C 29 H 33 Cl2N6O4 + [M+H] + : Calculated value 599.19, measured value 599.2.

[0337] Example 33: Preparation of compound GT-06870

[0338] The target compound GT-06870 (white solid, 19 mg, yield 28%) was prepared by referring to the method of Synthesis Scheme 4. 1 H NMR (400MHz, DMSO-d6) δ10.86 (s, 1H), 7.38 (d, J=8.4Hz, 1H), 7.34-7.25 (m, 1H), 7.24-7.15 (m, 2H), 6.86 (s, 1H), 6.78 (d, J=8.3Hz, 1H), 4.95 (dd, J=13.3, 5.1Hz, 1H), 4.24 (d, J=17.0Hz, 1H), 4.10 (d, J=17.0Hz, 1H), 3. 68 (d, J=13.1Hz, 2H), 3.35-3.14 (m, 5H), 3.07 (t, J=12.0Hz, 1H), 2.87-2.77 (m, 3H), 2.72-2.61 (m, 3H), 2.51 (d, J=16.6Hz, 1H), 2.32-2.22(m, 1H), 1.92-1.86(m, 1H), 1.71-1.68(m, 2H), 1.58-1.50(m, 2H).LCMS(ESI)C 29 H 33 ClFN6O4 + [M+H]+ : Calculated value 583.22, measured value 583.3.

[0339] Example 34: Preparation of compound GT-06871

[0340] The target compound GT-06871 (white solid, 22 mg, yield 33%) was prepared by referring to the method of Synthesis Scheme 4. 1 H NMR (400MHz, DMSO-d6) δ10.86 (s, 1H), 7.38 (d, J=8.3Hz, 1H), 7.23-7.18 (m, 1H), 7.14-7.08 (m, 2H), 6.86 (s , 1H), 6.78 (d, J=8.3Hz, 1H), 4.96 (dd, J=13.3, 5.1Hz, 1H), 4.24 (d, J=16.9Hz, 1H), 4.10 (d, J=16.9Hz, 1H), 3.66(d, J=12.9Hz, 2H), 3.25-3.16(m, 4H), 3.00-2.95(m, 1H), 2.88-2.78(m, 4H), 2.69-2.61(m, 3H), 2.52( d, J=17.0Hz, 1H), 2.32-2.22(m, 1H), 1.93-1.86(m, 1H), 1.73-1.66(m, 2H), 1.63-1.54(m, 2H).LCMS(ESI)C 29 H 33 F2N6O4 + [M+H] + : Calculated value 567.25, measured value 567.3.

[0341] Example 35: Preparation of compound GT-06436

[0342] The target compound GT-06436 (light yellow solid, 43 mg, yield 64%) was prepared by referring to the method of Synthesis Scheme 2. 1H NMR (400MHz, DMSO-d6) δ11.08 (s, 1H), 9.37 (s, 1H), 8.98 (s, 1H), 8.21 (dd, J=7.9, 1.6Hz, 2 H), 7.67-7.55 (m, 4H), 7.25 (s, 1H), 7.06 (s, 1H), 5.06 (dd, J=12.9, 5.3Hz, 1H), 4.65 (d, J=2 8.9Hz, 2H), 3.51 (d, J=33.9Hz, 4H), 3.38 (s, 1H), 3.10 (d, J=31.6Hz, 4H), 2.88 (dd, J=10.1 , 7.0Hz, 1H), 2.59 (d, J=17.2Hz, 1H), 2.54 (d, J=4.5Hz, 1H), 2.09-1.95 (m, 1H).LCMS (ESI) C 28 H 28 N7O4 + [M+H] + : Calculated value 526.22, measured value 526.2.

[0343] Example 36: Preparation of compound GT-06437

[0344] The target compound GT-06437 (light yellow solid, 37 mg, yield 53%) was prepared by referring to the method of Synthesis Scheme 2. 1 H NMR (400MHz, DMSO-d6) δ11.09(s, 1H), 10.94(s, 1H), 9.37(s, 1H), 8.97(s, 1H ), 8.21 (dd, J=7.9, 1.6Hz, 2H), 7.66 (d, J=10.3Hz, 1H), 7.58 (d, J=7.4Hz, 3H), 5.08 (dd, J=12.8, 5.4Hz, 1H), 4.65 (d, J=30.2Hz, 2H), 3.55 (s, 6H), 3.14 (s, 4 H), 2.99-2.80 (m, 1H), 2.59 (d, J=18.0Hz, 1H), 2.09-1.96 (m, 1H).LCMS (ESI) C 28 H 27 FN7O4 + [M+H] + : Calculated value 544.21, measured value 544.3.

[0345] Example 37: Preparation of compound GT-06438

[0346] The target compound GT-06438 (gray solid, 42 mg, yield 62%) was prepared by referring to the method of Synthesis Scheme 2. 1H NMR (400MHz, DMSO-d6) δ11.03 (d, J=59.2Hz, 2H), 9.37 (d, J=1.3Hz, 1H), 8.98 (d, J=1.1Hz, 1H), 8.22 ( dd, J=7.9, 1.6Hz, 2H), 7.68-7.50 (m, 3H), 6.77-6.53 (m, 2H), 4.99 (dd, J=13.3, 5.0Hz, 1H), 4.60 (s, 2 H), 4.25 (dd, J=55.3, 17.3Hz, 2H), 3.60 (dd, J=20.2, 16.2Hz, 5H), 3.09 (dd, J=29.4, 21.6Hz, 4H), 2.9 5-2.85 (m, 1H), 2.59 (d, J=16.9Hz, 1H), 2.33 (tt, J=13.3, 6.8Hz, 1H), 2.04-1.88 (m, 1H).LCMS(ESI)C 28 H 29 FN7O3 + [M+H] + : Calculated value 530.23, measured value 530.3.

[0347] Example 38: Preparation of compound GT-06439

[0348] The target compound GT-06439 (orange solid, 42 mg, yield 64%) was prepared by referring to the method of Synthesis Scheme 2. 1 H NMR (400MHz, DMSO-d6) δ10.98 (d, J=32.6Hz, 2H), 9.38 (d, J=1.4Hz, 1H), 8.98 (d, J=1.4Hz, 1H), 8.22 (dd, J= 7.9, 1.7Hz, 2H), 7.62-7.55 (m, 3H), 7.47 (d, J=8.3Hz, 1H), 7.01-6.83 (m, 2H), 5.04 (dd, J=13.3, 5.1Hz, 1H), 4.62 (s, 2H), 4.24 (dd, J=52.7, 17.0Hz, 2H), 3.57 (d, J=11.5Hz, 3H), 3.13 (d, J=11.2Hz, 2H), 2.92 (ddd, J=1 7.4, 16.5, 9.6Hz, 3H), 2.59 (d, J=16.6Hz, 1H), 2.35 (dd, J=12.9, 4.4Hz, 1H), 2.08-1.89 (m, 1H).LCMS(ESI)C 28 H 30 N7O3 + [M+H] + : Calculated value 512.24 measured value 512.3.

[0349] Example 39: Preparation of compound GT-06440

[0350] The target compound GT-06440 (gray solid, 31 mg, yield 46%) was prepared by referring to the method of Synthesis Scheme 2. 1 H NMR (400MHz, DMSO-d6) δ10.97 (s, 2H), 9.38 (d, J=1.4Hz, 1H), 8.97 (d, J=1.4Hz, 1H), 8.22 (dd, J=7.9, 1. 7Hz, 2H), 7.62-7.54 (m, 3H), 7.43 (d, J=8.2Hz, 1H), 7.32 (t, J=7.7Hz, 1H), 5.05 (dd, J=13.3, 5.1Hz, 1H) , 4.61 (s, 2H), 4.46 (d, J = 16.8Hz, 1H), 4.28 (d, J = 16.8Hz, 1H), 3.56 (s, 2H), 3.42 (s, 3H), 3.11 (s, 4H), 2 .97-2.85 (m, 1H), 2.59 (d, J=17.2Hz, 1H), 2.40 (qd, J=13.5, 4.5Hz, 1H), 2.03-1.92 (m, 1H).LCMS (ESI) C 28 H 29 FN7O3 + [M+H] + : Calculated value 530.23, measured value 530.3.

[0351] Example 40: Preparation of compound GT-06441

[0352] The target compound GT-06441 (light yellow solid, 38 mg, yield 48%) was prepared by referring to the method of Synthesis Scheme 3. 1 H NMR (400MHz, DMSO-d6) δ11.06 (s, 1H), 7.60 (d, J=8.3Hz, 1H), 7.57-7.52 (m, 3H), 7.52- 7.49 (m, 1H), 7.45 (dd, J=13.4, 8.4Hz, 3H), 7.39 (d, J=6.4Hz, 1H), 7.15 (s, 1H), 7.02 (d, J=7.7Hz, 1H), 5.04 (dd, J=12.8, 5.4Hz, 1H), 3.40 (s, 4H), 3.21 (s, 2H), 2.94-2.78 (m, 2 H), 2.58 (d, J=18.1Hz, 3H), 2.47 (dd, J=9.5, 4.5Hz, 1H), 2.04-1.94 (m, 1H).LCMS (ESI) C 30 H 28 ClFN5O4+ [M+H] + : Calculated value 572.18, measured value 572.2.

[0353] Example 41: Preparation of compound GT-06442

[0354] The target compound GT-06442 (light yellow solid, 41 mg, yield 50%) was prepared by referring to the method of Synthesis Scheme 3. 1 H NMR (400MHz, DMSO-d6) δ11.08 (s, 1H), 8.12 (s, 1H), 7.62 (d, J=10.3Hz, 1H), 7.55 (dd , J=7.2, 5.4Hz, 3H), 7.45 (dd, J=18.9, 7.6Hz, 4H), 7.39-7.35 (m, 1H), 5.06 (dd, J=12. 8, 5.4Hz, 1H), 3.35 (s, 3H), 3.27 (d, J=6.9Hz, 1H), 2.88 (ddd, J=16.8, 13.8, 5.4Hz, 2H ), 2.74(s, 1H), 2.65-2.51(m, 4H), 2.50-2.44(m, 1H), 2.05-1.95(m, 1H).LCMS(ESI)C 30 H 26 ClFN5O5 + [M+H] + : Calculated value 590.16, measured value 590.2.

[0355] Example 42: Preparation of compound GT-06443

[0356] The target compound GT-06443 (white solid, 44 mg, yield 55%) was prepared by referring to the method of Synthesis Scheme 3. 1 H NMR (400MHz, DMSO-d6) δ10.86 (s, 1H), 7.47 (dt, J=7.4, 3.1Hz, 3H), 7.44-7.33 (m, 4H), 7. 31 (d, J=6.5Hz, 1H), 6.59 (s, 1H), 6.45 (d, J=12.4Hz, 1H), 4.90 (dd, J=13.3, 5.1Hz, 1H), 4. 22 (d, J=17.2Hz, 1H), 4.07 (d, J=17.2Hz, 1H), 3.31 (s, 4H), 3.22 (s, 1H), 3.10 (s, 1H), 2.8 9-2.70(m, 2H), 2.50(d, J=16.5Hz, 2H), 2.40-2.15(m, 2H), 1.91-1.81(m, 1H).LCMS(ESI)C 30 H 28ClFN5O4 + [M+H] + : Calculated value 576.18, measured value 576.2.

[0357] Example 43: Preparation of compound GT-06444

[0358] The target compound GT-06444 (white solid, 36 mg, yield 47%) was prepared by referring to the method of Synthesis Scheme 3. 1 H NMR (400MHz, DMSO-d6) δ10.93 (s, 1H), 7.57-7.52 (m, 3H), 7.52-7.40 (m, 5H), 7.40-7. 36 (m, 1H), 6.89 (s, 1H), 6.81 (d, J=8.3Hz, 1H), 5.01 (dd, J=13.3, 5.1Hz, 1H), 4.21 (dd, J=54.5, 16.9Hz, 2H), 3.48 (s, 2H), 3.18 (s, 1H), 2.89 (ddd, J=18.7, 13.5, 5.2Hz, 2H), 2 .68(s, 1H), 2.58(d, J=16.9Hz, 2H), 2.48-2.26(m, 2H), 1.99-1.90(m, 1H).LCMS(ESI)C 30 H 29 ClN5O4 + [M+H] + : Calculated value 558.19, measured value 558.2.

[0359] Example 44: Preparation of compound GT-06445

[0360] The target compound GT-06445 (white solid, 32 mg, yield 40%) was prepared by referring to the method of Synthesis Scheme 3. 1 H NMR (400MHz, DMSO-d6) δ10.88 (s, 1H), 7.50-7.45 (m, 3H), 7.43-7.38 (m, 2H), 7.38-7. 33 (m, 2H), 7.32-7.28 (m, 2H), 7.17 (t, J=7.7Hz, 1H), 4.96 (dd, J=13.3, 5.0Hz, 1H), 4. 37 (d, J=16.7Hz, 1H), 4.19 (d, J=16.7Hz, 1H), 3.13 (s, 2H), 2.93-2.74 (m, 2H), 2.73-2 .56(m, 2H), 2.51(d, J=16.4Hz, 2H), 2.41-2.24(m, 2H), 1.93-1.82(m, 1H).LCMS(ESI)C 30 H 28ClFN5O4 + [M+H] + : Calculated value 576.18, measured value 576.2.

[0361] Example 45: Preparation of compound GT-06446

[0362] The target compound GT-06446 (white solid, 23 mg, yield 33%) was prepared by referring to the method of Synthesis Scheme 2. 1 H NMR (400MHz, DMSO-d6) δ10.96 (s, 2H), 9.37 (d, J=1.3Hz, 1H), 8.98 (d, J=1.2Hz, 1H), 8.22 (dd, J= 7.9, 1.6Hz, 2H), 7.68-7.49 (m, 3H), 7.33 (dd, J=29.4, 8.9Hz, 2H), 5.05 (dd, J=13.3, 5.1Hz, 1H), 4.61 (s, 2H), 4.26 (dd, J=50.0, 16.9Hz, 2H), 3.56 (s, 2H), 3.40 (s, 3H), 3.13 (s, 4H), 2.89 (d, J=1 3.1Hz, 1H), 2.59 (d, J=16.5Hz, 1H), 2.37 (dd, J=13.1, 4.4Hz, 1H), 2.03-1.90 (m, 1H).LCMS(ESI)C 28 H 29 FN7O3 + [M+H] + : Calculated value 530.23, measured value 530.3.

[0363] Example 46: Preparation of compound GT-06447

[0364] The target compound GT-06447 (white solid, 26 mg, yield 33%) was prepared by referring to the method of Synthesis Scheme 3. 1H NMR (400MHz, DMSO-d6) δ10.95 (s, 1H), 7.587.52 (m, 3H), 7.49 (dd, J=12.6, 6.8Hz, 2H), 7.4 3 (d, J=8.5Hz, 2H), 7.37 (d, J=6.7Hz, 1H), 7.34 (s, 1H), 7.23 (d, J=7.2Hz, 1H), 5.03 (dd, J= 13.2, 5.1Hz, 1H), 4.24 (dd, J=53.3, 17.0Hz, 2H), 3.38 (s, 2H), 3.21 (s, 2H), 3.01-2.81 (m, 2H), 2.64 (t, J=33.9Hz, 4H), 2.33 (dd, J=13.1, 4.5Hz, 2H), 2.01-1.89 (m, 1H).LCMS (ESI) C 30 H 28 ClFN5O4 + [M+H] + : Calculated value 576.18, measured value 576.3.

[0365] Example 47: Preparation of compound GT-06460

[0366] The target compound GT-06460 (white solid, 44 mg, yield 58%) was prepared by referring to the method of Synthesis Scheme 3. 1 H NMR (400MHz, DMSO-d6) δ11.06 (s, 1H), 7.96 (s, 1H), 7.59 (d, J = 8.3Hz, 1H), 7.27 (d, J = 5.6Hz, 2H), 7.18 (t, J = 8.9 Hz, 2H), 7.12 (s, 1H), 7.00 (d, J=7.5Hz, 1H), 5.03 (dd, J=12.8, 5.4Hz, 1H), 4.16 (s, 1H), 3.43 (dd, J=28.9, 7.6Hz , 2H), 3.32 (t, J=6.5Hz, 2H), 2.85 (ddd, J=74.1, 39.8, 33.0Hz, 3H), 2.57 (d, J=17.2Hz, 2H), 2.41 (dd, J=34.8, 11 .0Hz, 3H), 2.11 (d, J=17.9Hz, 1H), 2.02-1.87 (m, 2H), 1.46 (d, J=9.9Hz, 2H), 0.99 (d, J=13.1Hz, 6H).LCMS (ESI) C 32 H 35 FN5O5 + [M+H] + : Calculated value 588.26, measured value 588.3.

[0367] Example 48: Preparation of compound GT-06461

[0368] The target compound GT-06461 (white solid, 48 mg, yield 62%) was prepared by referring to the method of Synthesis Scheme 3. 1 H NMR (400MHz, DMSO-d6) δ11.00 (s, 1H), 8.02 (s, 1H), 7.53 (d, J = 10.3Hz, 1H), 7.36 (d, J = 7.0Hz, 1 H), 7.23-7.15 (m, 2H), 7.09 (t, J=8.9Hz, 2H), 4.98 (dd, J=12.7, 5.4Hz, 1H), 4.11 (s, 1H), 3.64- 3.29 (m, 2H), 3.21 (d, J = 25.2Hz, 1H), 2.93-2.58 (m, 3H), 2.50 (d, J = 19.5Hz, 3H), 2.41-2.20 (m, 3H), 2.06 (s, 1H), 1.96-1.78 (m, 2H), 1.39 (d, J = 9.8Hz, 2H), 0.92 (d, J = 10.6Hz, 6H). LCMS (ESI) C 32 H 34 F2N5O5 + [M+H] + : Calculated value 606.25, measured value 606.3.

[0369] Example 49: Preparation of compound GT-06462

[0370] The target compound GT-06462 (white solid, 40 mg, yield 54%) was prepared by referring to the method of Synthesis Scheme 3. 1 H NMR (400MHz, DMSO-d6) δ10.93 (s, 1H), 7.41 (d, J=8.4Hz, 1H), 7.27 (dd, J=8.7, 5.6Hz, 2H), 7.17 ( t, J=8.9Hz, 3H), 6.86 (s, 1H), 6.79 (d, J=8.3Hz, 1H), 5.01 (dd, J=13.3, 5.1Hz, 1H), 4.20 (dd, J=5 4.5, 16.9Hz, 2H), 3.32-3.01 (m, 3H), 2.952.67 (m, 2H), 2.58 (d, J=16.8Hz, 2H), 2.33 (ddd, J=23. 6, 17.6, 12.0Hz, 5H), 2.17-1.83 (m, 4H), 1.51-1.36 (m, 2H), 0.99 (d, J=13.0Hz, 6H). LCMS (ESI) C 32 H 37 FN5O4 +[M+H] + : Calculated value 574.28, measured value 574.3.

[0371] Example 50: Preparation of compound GT-06463

[0372] The target compound GT-06463 (white solid, 35 mg, yield 46%) was prepared by referring to the method of Synthesis Scheme 3. 1 H NMR (400MHz, DMSO-d6) δ10.95 (s, 1H), 7.36 (d, J=8.2Hz, 1H), 7.337.23 (m, 3H), 7.18 (dd, J=17.3, 8.4Hz, 3H), 5.03 (dd, J=13.3, 5.0Hz, 1H), 4.43 (d, J=16.7Hz, 1H), 4.25( d, J=16.7Hz, 1H), 3.37(s, 3H), 3.022.83(m, 2H), 2.58(d, J=13.4Hz, 3H), 2.462.28(m , 4H), 2.00 (t, J=42.5Hz, 4H), 1.54-1.40 (m, 2H), 0.99 (d, J=11.2Hz, 6H).LCMS (ESI) C 32 H 36 F2N5O4 + [M+H] + : Calculated value 592.27, measured value 592.3.

[0373] Example 51: Preparation of compound GT-06464

[0374] The target compound GT-06464 (white solid, 46 mg, yield 61%) was prepared by referring to the method of Synthesis Scheme 3. 1 H NMR (400MHz, DMSO-d6) δ10.94 (s, 1H), 7.55 (s, 1H), 7.33-7.23 (m, 2H), 7.17 (t, J=8.9Hz, 2H), 6 .64 (s, 1H), 6.50 (d, J = 12.3Hz, 1H), 4.97 (dd, J = 13.3, 5.1Hz, 1H), 4.28 (d, J = 17.2Hz, 1H), 4.14 ( d, J=17.2Hz, 1H), 3.353.25 (m, 3H), 2.98-2.72 (m, 2H), 2.63 (dd, J=45.2, 12.5Hz, 3H), 2.47-2.2 5 (m, 4H), 1.97 (dd, J=46.3, 41.1Hz, 4H), 1.53-1.39 (m, 2H), 0.99 (d, J=13.3Hz, 6H). LCMS (ESI) C 32 H36 F2N5O4 + [M+H] + : Calculated value 592.27, measured value 592.3.

[0375] Example 52: Preparation of compound GT-06465

[0376] The target compound GT-06465 (white solid, 14 mg, yield 41%) was prepared by referring to the method of Synthesis Scheme 3. 1 H NMR (400MHz, DMSO-d6) δ10.99 (s, 1H), 7.93 (s, 1H), 7.52 (d, J=8.4Hz, 1H), 7.34 ( d, J=8.5Hz, 2H), 7.18 (d, J=8.1Hz, 2H), 7.05 (s, 1H), 6.93 (d, J=8.2Hz, 1H), 4.96 ( dd, J=12.8, 5.3Hz, 1H), 4.11 (s, 1H), 2.86-2.58 (m, 3H), 2.58-2.46 (m, 3H), 2.39- 2.23(m, 3H), 2.11-1.78(m, 4H), 1.38(s, 2H), 0.92(d, J=10.3Hz, 6H).LCMS(ESI)C 32 H 35 ClN5O5 + [M+H] + : Calculated value 604.23, measured value 604.3.

[0377] Example 53: Preparation of compound GT-06466

[0378] The target compound GT-06466 (white solid, 16 mg, yield 46%) was prepared by referring to the method of Synthesis Scheme 3. 1 H NMR (400MHz, DMSO-d6) δ11.01 (s, 1H), 8.01 (s, 1H), 7.54 (d, J=10.3Hz, 1H), 7.41 7.31 (m, 3H), 7.17 (d, J=8.3Hz, 2H), 4.99 (dd, J=12.8, 5.4Hz, 1H), 4.13 (s, 1H), 3.56-3.30 (m, 2H), 2.92-2.61 (m, 3H), 2.53 ( dd, J=32.1, 16.3Hz, 3H), 2.31 (dd, J=55.2, 10.1Hz, 3H), 2.19-1.75 (m, 4H), 1.38 (s, 2H), 0.92 (d, J=3.9Hz, 6H). LCMS (ESI) C 32 H 34 ClFN5O5+ [M+H] + : Calculated value 622.22, measured value 622.3.

[0379] Example 54: Preparation of compound GT-06467

[0380] The target compound GT-06467 (white solid, 8 mg, yield 22%) was prepared by referring to the method of Synthesis Scheme 3. 1 H NMR (400MHz, DMSO-d6) δ10.88 (s, 1H), 7.31 (dd, J=15.6, 8.4Hz, 3H), 7.23-7.07 (m, 4H), 4.96 (dd, J=13.3, 5.1Hz, 1H), 4.36 (d, J=16.8Hz, 1H), 4.18 (d, J=16.8Hz , 1H), 3.32 (s, 3H), 2.95-2.69 (m, 2H), 2.54 (t, J=22.2Hz, 4H), 2.41-2.17 (m, 4H ), 2.10-1.82 (m, 3H), 1.39 (d, J = 10.8Hz, 2H), 0.92 (d, J = 8.0Hz, 6H). LCMS (ESI) C 32 H 36 ClFN5O4+ + [M+H] + : Calculated value 608.24, measured value 608.3.

[0381] Example 55: Preparation of compound GT-06468

[0382] The target compound GT-06468 (white solid, 15 mg, yield 44%) was prepared by referring to the method of Synthesis Scheme 3. 1 H NMR (400MHz, DMSO-d6) δ10.87 (s, 1H), 7.51 (s, 1H), 7.33 (d, J = 8.5Hz, 2H), 7.18 (d, J = 8.3Hz, 2H), 6.58 (s, 1H), 6.44 (d, J = 12.3Hz, 1H), 4.90 (dd, J = 13.3, 5.1Hz, 1H), 4.21 (d, J = 17.2Hz, 1H), 4.07 (d , J=17.2Hz, 1H), 3.29-2.97 (m, 3H), 2.88-2.67 (m, 2H), 2.56 (dd, J=44.4, 12.2Hz, 3H), 2.38-2.18 (m, 4H), 1.91 (dd, J = 44.6, 39.7Hz, 4H), 1.39 (d, J = 9.8Hz, 2H), 0.92 (d, J = 10.8Hz, 6H). LCMS (ESI) C 32 H36 ClFN5O4 + [M+H] + : Calculated value 608.24, measured value 608.3.

[0383] Example 56: Preparation of compound GT-06469

[0384] The target compound GT-06469 (yellow solid, 10 mg, yield 13%) was prepared by referring to the method of Synthesis Scheme 1. 1 H NMR (400MHz, DMSO-d6) δ10.99 (s, 1H), 9.87 (s, 1H), 8.32 (s, 1H), 7.54 (d, J= 8.3Hz, 1H), 7.40 (d, J=8.1Hz, 2H), 7.15-7.07 (m, 3H), 6.95 (d, J=6.6Hz, 1H), 4.97(dd, J=12.7, 5.2Hz, 1H), 3.55(s, 2H), 3.05-2.74(m, 8H), 2.62-2.46(m , 2H), 2.27(s, 2H), 2.05-1.85(m, 4H), 1.41(s, 2H), 0.90(s, 6H).LCMS(ESI)C 32 H 37 ClN5O4 + [M+H] + : Calculated value 590.25, measured value 590.3.

[0385] Example 57: Preparation of compound GT-06470

[0386] The target compound GT-06470 (yellow solid, 18 mg, yield 28%) was prepared by referring to the method of Synthesis Scheme 1. 1 H NMR (400MHz, DMSO-d6) δ11.08 (s, 1H), 9.82 (s, 1H), 8.42 (s, 1H), 7.64 (d, J = 10.3Hz, 1H), 7.50 (dd, J=17.3, 7.6Hz, 3H), 7.16 (d, J=8.3Hz, 2H), 5.06 (dd, J=12.8, 5.4Hz, 1H ), 3.63 (s, 2H), 3.17 (d, J = 11.5Hz, 3H), 3.12-2.79 (m, 6H), 2.56 (dd, J = 15.6, 12.3Hz, 2H), 2.33(s, 2H), 2.06-1.98(m, 3H), 1.49(t, J=5.9Hz, 2H), 0.97(s, 6H).LCMS(ESI)C 32 H 36 ClFN5O4 +[M+H] + : Calculated value 608.24, measured value 608.3.

[0387] Example 58: Preparation of compound GT-06471

[0388] The target compound GT-06471 (yellow solid, 13 mg, yield 19%) was prepared by referring to the method of Synthesis Scheme 1. 1 H NMR (400MHz, DMSO-d6) δ10.96 (s, 1H), 9.70 (s, 1H), 7.73 (s, 1H), 7.48 (d, J = 8.3Hz, 2H), 7.38 (d, J = 8.2Hz, 1H), 7.27 (t, J=7.8Hz, 1H), 7.17 (d, J=8.3Hz, 2H), 5.04 (dd, J=13.3, 5.1Hz, 1H), 4.45 (d, J=16.8Hz, 1H), 4. 27 (d, J=16.8Hz, 1H), 3.61 (s, 2H), 3.31-3.25 (m, 1H), 3.09 (d, J=12.2Hz, 2H), 2.89 (dd, J=22.5, 8.7Hz, 5H) , 2.70-2.52(m, 2H), 2.45-2.28(m, 3H), 2.06-1.90(m, 3H), 1.49(t, J=6.0Hz, 2H), 0.98(s, 6H).LCMS(ESI)C 32 H 38 ClFN5O3 + [M+H] + : Calculated value 594.26, measured value 594.3.

[0389] Example 59: Preparation of compound GT-06472

[0390] The target compound GT-06472 (yellow solid, 13 mg, yield 20%) was prepared by referring to the method of Synthesis Scheme 1. 1H NMR (400MHz, DMSO-d6) δ10.95 (s, 1H), 9.94 (s, 1H), 7.99 (s, 1H), 7.46 (t, J=9.6Hz, 2H), 7.16 (d , J=8.3Hz, 2H), 6.71-6.54(m, 2H), 4.98(dd, J=13.3, 5.1Hz, 1H), 4.29(d, J=17.1Hz, 1H), 4.15(d , J=17.1Hz, 1H), 3.61 (s, 2H), 3.28-3.23 (m, 1H), 3.08-2.84 (m, 7H), 2.63-2.53 (m, 2H), 2.32 (d, J=12.6Hz, 3H), 2.05(s, 2H), 1.99-1.91(m, 1H), 1.49(t, J=6.2Hz, 2H), 0.97(s, 6H).LCMS(ESI)C 32 H 38 ClFN5O3 + [M+H] + : Calculated value 594.26, measured value 594.3.

[0391] Example 60: Preparation of compound GT-06473

[0392] The target compound GT-06473 (yellow solid, 14 mg, yield 21%) was prepared by referring to the method of Synthesis Scheme 1. 1 H NMR (400MHz, DMSO-d6) 611.08 (d, J=8.3Hz, 1H), 9.92 (s, 1H), 8.38 (s, 1H), 7.61 ( d, J=8.3Hz, 1H), 7.27-6.94 (m, 6H), 5.04 (dd, J=12.8, 5.4Hz, 1H), 3.70-3.52 (m, 2H), 3.37(s, 1H), 3.32(s, 2H), 3.12-2.83(m, 6H), 2.56(dd, J=17.4, 12.2Hz, 2H) , 2.34 (s, 2H), 2.09-1.95 (m, 3H), 1.49 (t, J=6.4Hz, 2H), 0.98 (s, 6H).LCMS (ESI) C 32 H 37 FN5O4 + [M+H] + : Calculated value 574.28, measured value 574.3.

[0393] Example 61: Preparation of compound GT-06474

[0394] The target compound GT-06474 (yellow solid, 14 mg, yield 20%) was prepared by referring to the method of Synthesis Scheme 1. 1 H NMR (400MHz, DMSO-d6) δ11.08 (s, 1H), 9.69 (s, 1H), 8.41 (s, 1H), 7.64 (d, J = 10.3Hz, 1H), 7.52 (d, J=6.8Hz, 1H), 7.27-7.12 (m, 4H), 5.06 (dd, J=12.8, 5.4Hz, 1H), 3.64 (s , 2H), 3.31-3.23(m, 2H), 3.14(d, J=11.5Hz, 2H), 3.08-2.82(m, 5H), 2.68-2.53(m, 2 H), 2.31 (s, 2H), 2.08-1.96 (m, 3H), 1.48 (d, J=6.1Hz, 2H), 0.98 (s, 6H). LCMS (ESI) C 32 H 36 F2N5O4 + [M+H] + : Calculated value 592.27, measured value 592.3.

[0395] Example 62: Preparation of compound GT-06475

[0396] The target compound GT-06475 (yellow solid, 12 mg, yield 18%) was prepared by referring to the method of Synthesis Scheme 1. 1 H NMR (400MHz, DMSO-d6) δ10.96 (s, 1H), 9.75 (s, 1H), 7.73 (s, 1H), 7.38 (d, J = 8.2Hz, 1H), 7.22 (dt, J = 13.9, 8.6Hz, 5H), 5.04 (dd, J=13.3, 5.1Hz, 1H), 4.45 (d, J=16.9Hz, 1H), 4.27 (d, J=16.8Hz, 1H), 3.61 (d, J=3.8H z, 2H), 3.33-3.32 (m, 1H), 3.10 (t, J=11.5Hz, 2H), 2.92 (dd, J=19.3, 11.8Hz, 5H), 2.57 (dd, J=17.7, 10.6H z, 2H), 2.45-2.28 (m, 3H), 2.06 (s, 2H), 2.00-1.91 (m, 1H), 1.49 (t, J=6.1Hz, 2H), 0.98 (s, 6H). LCMS (ESI) C 32 H 38 F2N5O3 + [M+H] + : Calculated value 578.29, measured value 578.3.

[0397] Example 63: Preparation of compound GT-06476

[0398] The target compound GT-06476 (yellow solid, 10 mg, yield 14%) was prepared by referring to the method of Synthesis Scheme 1. 1 H NMR (400MHz, DMSO-d6) δ10.94 (s, 1H), 9.94 (s, 1H), 7.98 (s, 1H), 7.21 (dt, J=14.0, 8.5Hz, 4H), 6.74-6.51 (m, 2H), 4.98 (dd, J=13.3, 5.0Hz, 1H), 4.29 (d, J=17.2Hz, 1H), 4.15 (d, J=17 .2Hz, 1H), 3.60(s, 2H), 3.31-3.28(m, 1H), 3.14-2.81(m, 7H), 2.62-2.52(m, 2H), 2.38-2. 25(m, 3H), 2.05(s, 2H), 1.98-1.89(m, 1H), 1.49(t, J=6.1Hz, 2H), 0.98(s, 6H).LCMS(ESI)C 32 H 38 F2N5O3 + [M+H] + : Calculated value 578.29, measured value 578.3.

[0399] Example 64: Preparation of compound GT-06536

[0400] The target compound GT-06536 (yellow solid, 14 mg, yield 20%) was prepared by referring to the method of Synthesis Scheme 1. 1 H NMR (400MHz, DMSO-d6) δ10.94 (d, J=7.6Hz, 1H), 9.85 (s, 1H), 7.60 (d, J=19.5Hz, 1H), 7.44 (d, J=8.4Hz, 1 H), 7.25 (t, J=8.8Hz, 2H), 7.17 (dd, J=8.4, 5.7Hz, 2H), 6.90 (s, 1H), 6.84 (d, J=8.7Hz, 1H), 5.02 (dd, J=13 .2, 5.0Hz, 1H), 4.21 (dd, J=52.6, 16.8Hz, 2H), 3.60 (s, 2H), 3.30-3.26 (m, 1H), 3.05-2.80 (m, 7H), 2.65-2 .52(m, 2H), 2.33(s, 3H), 2.05(s, 2H), 1.99-1.92(m, 1H), 1.49(t, J=6.0Hz, 2H), 0.98(s, 6H).LCMS(ESI)C 32 H39 FN5O3 + [M+H] + : Calculated value 560.30, measured value 560.4.

[0401] Example 65: Preparation of compound GT-06537

[0402] The target compound GT-06537 (yellow solid, 15 mg, yield 19%) was prepared by referring to the method of Synthesis Scheme 1. 1 H NMR (400MHz, DMSO-d6) δ10.88 (s, 1H), 9.73 (s, 1H), 7.65 (s, 1H), 7.39 (t, J=9.4Hz, 2H), 7.27 (d, J=10.7H z, 1H), 7.16 (d, J=7.2Hz, 1H), 7.08 (t, J=9.1Hz, 2H), 4.96 (dd, J=13.3, 5.0Hz, 1H), 4.15 (dd, J=50.2, 16. 9Hz, 2H), 3.54 (s, 2H), 3.34 (s, 1H), 3.05 (s, 2H), 2.942.75 (m, 5H), 2.50 (dd, J=16.8, 10.8Hz, 2H), 2.29 ( dd, J=15.7, 11.4Hz, 3H), 1.97 (s, 2H), 1.93-1.83 (m, 1H), 1.42 (t, J=6.1Hz, 2H), 0.90 (s, 6H). LCMS (ESI) C 32 H 38 ClFN5O3 + [M+H] + : Calculated value 594.26, measured value 594.3.

[0403] Example 66: Preparation of compound GT-06538

[0404] The target compound GT-06538 (yellow solid, 18 mg, yield 21%) was prepared by referring to the method of Synthesis Scheme 1. 1H NMR (400MHz, DMSO-d6) δ10.88 (s, 1H), 9.62 (s, 1H), 7.64 (s, 1H), 7.28 (d, J=10.7Hz, 1H), 7.17 (dd , J=10.0, 7.8Hz, 3H), 7.10 (t, J=7.0Hz, 2H), 4.96 (dd, J=13.2, 5.1Hz, 1H), 4.15 (dd, J=49.8, 16.9 Hz, 2H), 3.54 (s, 2H), 3.23-3.19 (m, 1H), 3.02 (s, 2H), 2.93-2.77 (m, 5H), 2.56-2.44 (m, 2H), 2.24 (d, J=7.6Hz, 2H), 1.98 (s, 2H), 1.93-1.84 (m, 1H), 1.42 (t, J=6.2Hz, 2H), 0.90 (s, 6H).LCMS (ESI) C 32 H 38 F2N5O3 + [M+H] + : Calculated value 578.29, measured value 578.3.

[0405] Example 67: Preparation of compound GT-06539

[0406] The target compound GT-06539 (white solid, 10 mg, yield 14%) was prepared by referring to the method of Synthesis Scheme 3. 1 H NMR (400MHz, DMSO-d6) δ10.95 (s, 1H), 7.40 (d, J = 8.4Hz, 2H), 7.32 (d, J = 10.7Hz, 1H), 7.2 9-7.19 (m, 4H), 5.03 (dd, J=13.3, 5.0Hz, 1H), 4.23 (dd, J=52.6, 17.0Hz, 2H), 3.44 (s, 2H) , 3.00 (s, 2H), 2.90 (dd, J=11.1, 6.2Hz, 1H), 2.59 (d, J=15.6Hz, 4H), 2.47-2.28 (m, 4H), 2 .13 (s, 1H), 1.99-1.91 (m, 2H), 1.47 (d, J = 9.9Hz, 2H), 0.99 (d, J = 8.2Hz, 6H). LCMS (ESI) C 32 H 36 ClFN5O4 + [M+H] + : Calculated value 608.24, measured value 608.3.

[0407] Example 68: Preparation of compound GT-06540

[0408] The target compound GT-06540 ​​(white solid, 30 mg, yield 39%) was prepared by referring to the method of Synthesis Scheme 3. 1 H NMR (400MHz, DMSO-d6) δ10.94 (s, 1H), 7.367.28 (m, 2H), 7.26 (dd, J=8.5, 5.7Hz, 2H), 7.18 (dd , J=16.6, 7.8Hz, 3H), 5.02 (dd, J=13.2, 5.1Hz, 1H), 4.22 (dd, J=52.8, 16.9Hz, 2H), 3.42 (s, 2H) , 3.29 (d, J = 6.1Hz, 2H), 2.92-2.84 (m, 1H), 2.58 (d, J = 16.8Hz, 4H), 2.48-2.28 (m, 4H), 2.12 (s, 1H), 1.93 (d, J=15.0Hz, 2H), 1.46 (dd, J=11.4, 5.8Hz, 2H), 0.99 (d, J=11.1Hz, 6H). LCMS (ESI) C 32 H 36 F2N5O4 + [M+H] + : Calculated value 592.27, measured value 592.3.

[0409] Example 69: Preparation of compound GT-06541

[0410] The target compound GT-06541 (white solid, 13 mg, yield 19%) was prepared by referring to the method of Synthesis Scheme 2. 1 H NMR (400MHz, DMSO-d6) δ11.88 (s, 1H), 11.07 (s, 1H), 8.44 (s, 1H), 7.92 (s, 3H), 7.62 (d, J = 8.2Hz, 1H), 7.27 (d, J = 35.7Hz, 5H), 7.01 (s, 1H), 5.6 9 (s, 1H), 5.04 (dd, J=12.7, 5.3Hz, 1H), 3.32-3.04 (m, 7H), 2.89 (dd, J=22.2, 9.2Hz, 2H), 2.58 (d, J=17.9Hz, 2H), 2.06-1.88 (m, 1H). LCMS (ESI) C 30 H 28 F2N5O4 + [M+H] + : Calculated value 560.21, measured value 560.2.

[0411] Example 70: Preparation of compound GT-06542

[0412] The target compound GT-06542 (white solid, 22 mg, yield 30%) was prepared by referring to the method of Synthesis Scheme 2. 1 H NMR (400MHz, DMSO-d6) δ12.06 (s, 1H), 11.07 (s, 1H), 8.46 (s, 1H), 7.84 (d, J=39.2Hz, 3H), 7.65-7.47 (m, 5H), 7.22 (s, 1H), 7.02 (s, 1H), 5.6 9 (s, 1H), 5.05 (dd, J=12.7, 5.4Hz, 1H), 3.23 (s, 4H), 3.06 (s, 3H), 2.98-2.81 (m, 2H), 2.58 (d, J=18.1Hz, 2H), 2.06-1.94 (m, 1H). LCMS (ESI) C 30 H 28 Cl2N5O4 + [M+H] + : Calculated value 592.15, measured value 592.2.

[0413] Example 71: Preparation of compound GT-06543

[0414] The target compound GT-06543 (white solid, 4 mg, yield 5%) was prepared by referring to the method of Synthesis Scheme 2. 1 H NMR (400MHz, DMSO-d6) δ11.45 (s, 1H), 11.07 (s, 1H), 8.46 (s, 1H), 7.76 (d, J=8.2H z, 4H), 7.63 (d, J = 8.2Hz, 1H), 7.23 (d, J = 8.5Hz, 1H), 7.01 (d, J = 8.3Hz, 5H), 5.48 (d , J=8.1Hz, 1H), 5.05 (dd, J=12.9, 5.2Hz, 1H), 3.75 (s, 6H), 3.19 (d, J=10.3Hz, 4H), 3.10(s, 3H), 2.97-2.78(m, 2H), 2.68-2.54(m, 2H), 2.03-1.94(m, 1H).LCMS(ESI)C 32 H 34 N5O6 + [M+H] + : Calculated value 584.25, measured value 584.3.

[0415] Example 72: Preparation of compound GT-06544

[0416] The target compound GT-06544 (yellow solid, 27 mg, yield 39%) was prepared by referring to the method of Synthesis Scheme 1. 1H NMR (400MHz, DMSO-d6) δ11.08 (s, 1H), 10.91 (s, 1H), 8.44 (s, 1H), 8.00 (s, 1H), 7.79 (d, J=8.5H z, 3H), 7.64 (d, J=8.3Hz, 1H), 7.58 (t, J=5.9Hz, 4H), 7.24 (s, 1H), 7.04 (s, 1H), 5.05 (dd, J=12. 8, 5.3Hz, 1H), 4.42 (s, 2H), 3.40 (s, 2H), 3.32-3.19 (m, 2H), 3.13 (d, J=10.8Hz, 2H), 3.03 (s, 2H) ), 2.89 (dd, J=15.6, 10.1Hz, 1H), 2.60 (dd, J=36.5, 18.6Hz, 2H), 2.08-1.95 (m, 1H).LCMS (ESI) C 30 H 29 ClN5O4 + [M+H] + : Calculated value 558.19, measured value 558.2.

[0417] Example 73: Preparation of compound GT-06545

[0418] The target compound GT-06545 (yellow solid, 24 mg, yield 35%) was prepared by referring to the method of Synthesis Scheme 1. 1 H NMR (400MHz, DMSO-d6) δ11.09 (d, J=8.4Hz, 1H), 10.81 (s, 1H), 8.44 (s, 1H), 7.84-7 .69(m, 6H), 7.64(d, J=8.3Hz, 1H), 7.55(d, J=8.6Hz, 2H), 7.24(s, 1H), 7.04(s, 1H), 5.06 (dd, J=12.9, 5.3Hz, 1H), 4.40 (s, 2H), 3.14 (d, J=11.4Hz, 2H), 3.07-2.92 (m, 2H ), 2.89 (dd, J=15.6, 10.4Hz, 1H), 2.65-2.52 (m, 2H), 2.10-1.91 (m, 1H).LCMS (ESI) C 30 H 29 ClN5O4 + [M+H] + : Calculated value 558.19, measured value 558.2.

[0419] Example 74: Preparation of compound GT-06546

[0420] The target compound GT-06546 (yellow solid, 26 mg, yield 38%) was prepared by referring to the method of Synthesis Scheme 1. 1 H NMR (400MHz, DMSO-d6) δ11.07 (s, 1H), 10.15 (s, 1H), 8.38 (s, 1H), 7.62 (t, J=8.9Hz, 1 H), 7.28 (d, J=7.3Hz, 3H), 7.23-7.13 (m, 1H), 7.03 (s, 1H), 5.04 (dd, J=12.7, 5.3Hz, 1H ), 4.36 (s, 2H), 3.84 (t, J=5.3Hz, 2H), 3.67 (s, 2H), 3.40 (s, 2H), 3.32-3.19 (m, 2H), 3 .18-2.85(m, 6H), 2.58(d, J=18.3Hz, 2H), 2.38(s, 1H), 2.04-1.96(m, 1H).LCMS(ESI)C 29 H 31 FN5O5 + [M+H] + : Calculated value 548.23, measured value 548.2.

[0421] Example 75: Preparation of compound GT-06547

[0422] The target compound GT-06547 (yellow solid, 26 mg, yield 36%) was prepared by referring to the method of Synthesis Scheme 1. 1 H NMR (400MHz, DMSO-d6) δ11.00 (s, 1H), 10.00 (s, 1H), 8.30 (s, 1H), 7.54 (d, J=8.3Hz, 1H) , 7.43 (d, J=8.3Hz, 2H), 7.17 (d, J=8.2Hz, 2H), 7.12 (s, 1H), 6.94 (d, J=7.6Hz, 1H), 4.97 (dd, J=12.8, 5.4Hz, 1H), 4.29 (s, 2H), 3.62 (s, 2H), 2.93 (s, 6H), 2.79 (dd, J=16.7, 5.0H z, 2H), 2.51 (d, J=18.3Hz, 3H), 2.17 (s, 2H), 1.94-1.88 (m, 1H), 1.16 (s, 6H). LCMS (ESI) C 31 H 35 ClN5O5 + [M+H] + : Calculated value 592.23, measured value 592.3.

[0423] Example 76: Preparation of compound GT-07057

[0424] The target compound GT-07057 (white solid, 29 mg, yield 43%) was prepared by referring to the method of Synthesis Scheme 3. 1 H NMR (500MHz, DMSO-d6) δ11.08 (s, 1H), 7.66 (d, J=8.5Hz, 1H), 7.37 (d, J=8.4Hz, 2H), 7.33-7.30 (m, 2H), 7.25-7.20 (m, 2H), 5.07 (dd, J=12.8, 5.4 Hz, 1H), 4.24-3.90 (m, 6H), 2.92-2.84 (m, 1H), 2.65-2.55 (m, 4H), 2.27 ( brs, 2H), 2.14-1.97(m, 3H), 1.44-1.39(m, 2H), 0.98(s, 6H).LCMS(ESI)C 32 H 35 ClN5O5 + [M+H] + : Calculated value 604.23, measured value 604.3.

[0425] Example 77: Preparation of compound GT-07058

[0426] The target compound GT-07058 (white solid, 48 mg, yield 68%) was prepared by referring to the method of Synthesis Scheme 3. 1 H NMR (500MHz, DMSO-d6) δ11.07 (s, 1H), 9.80 (d, J = 1.8Hz, 1H), 8.81 (d, J = 1.8Hz, 1H), 7.4 8-7.40 (m, 3H), 7.25 (d, J=8.5Hz, 2H), 6.86 (d, J=1.3Hz, 1H), 6.21 (s, 1H), 5.04 (dd, J=12 .8, 5.4Hz, 1H), 2.94-2.79 (m, 1H), 2.59-2.56 (m, 1H), 2.48-2.46 (m, 1H), 2.35 (t, J=6.2 Hz, 2H), 2.10 (s, 2H), 2.03-1.97 (m, 1H), 1.46 (t, J=6.4Hz, 2H), 1.02 (s, 6H). LCMS (ESI) C 28 H 28 ClN4O5 + [M+H] + : Calculated value 535.17, measured value 535.2.

[0427] Example 78: Preparation of compound GT-07059

[0428] The target compound GT-07059 (white solid, 26 mg, yield 39%) was prepared by referring to the method of Synthesis Scheme 3. 1 H NMR (500MHz, DMSO-d6) δ10.98 (s, 1H), 7.62 (d, J = 8.0Hz, 1H), 7.54 (s, 1H), 7.41 (d, J = 8.0Hz, 1H), 7.36 (d, J = 8.5Hz, 2H), 7.20 (d, J=8.5Hz, 2H), 5.09 (dd, J=13.3, 5.1Hz, 1H), 4.41 (d, J=17.4Hz, 1H), 4.29 (d, J=17.4Hz, 1H), 3.03-2.8 6(m, 4H), 2.64-2.58(m, 2H), 2.42-2.36(m, 2H), 2.27(s, 2H), 2.21-2.15(m, 1H), 2.08(d, J=1.7Hz, 2H), 2.04-1.94( m, 1H), 1.80 (d, J = 12.5Hz, 2H), 1.57 (s, 1H), 1.41 (t, J = 6.3Hz, 2H), 1.35 (d, J = 9.6Hz, 2H), 0.98 (s, 6H). LCMS (ESI) C 34 H 40 ClN4O4S + [M+H] + : Calculated value 635.25, measured value 635.3.

[0429] Example 79: Preparation of compound GT-07066

[0430] The target compound GT-07066 (white solid, 26 mg, yield 38%) was prepared according to the method of Synthesis Scheme 7. 1H NMR (500 MHz, DMSO-d6) δ 10.94 (s, 1H), 8.70 (s, 1H), 7.50 (d, J = 8.5 Hz, 1H), 7.40-7.34 (m, 2H), 7.30 (d, J = 8.6 Hz, 1H), 7.26-7.19 (m, 1H), 7.08-6.99 (m, 2H), 5.04 (dd, J = 13.3, 5.1 Hz, 1H), 4.31 (d, J = 16.9 Hz, 1H), 4.19 (d, J=16.9Hz, 1H), 3.33-3.20 (m, 3H), 2.96-2.83 (m, 1H), 2.63-2.54 (m, 4H), 2.52-2.50 (m, 1H), 2.44-2.31 (m, 2H), 2.27 (brs, 2H), 2.08-2.05 (m, 2H), 2.01-1.89 (m, 1H), 1.43-1.35 (m, 2H), 0.98 (s, 6H). LCMS (ESI) C32 H 37 ClN5O4 + [M+H] + : Calculated value 590.25, measured value 590.3.

[0431] Example 80: Preparation of compound GT-06911

[0432] The target compound GT-06911 (white solid, 14 mg, yield 35%) was prepared by referring to the method of Synthesis Scheme 2. 1 H NMR (400MHz, DMSO-d6) δ11.10 (s, 1H), 8.80 (d, J=4.0Hz, 1H), 8.03-7.89 (m, 1H), 7.89-7.61 (m, 3H), 7.60-7.32 (m, 6H), 7.32-7.00 (m , 2H), 5.09 (dd, J=12.9, 5.4Hz, 1H), 3.81 (s, 3H), 3.30-3.06 (m, 6H), 2.87 (t, 1H), 2.70-2.53 (m, 2H), 2.08-1.97 (m, 1H). LCMS (ESI) C 29 H 29 N6O4 + [M+H]+: calculated 525.22, found 525.3.

[0433] Example 81: Preparation of compound GT-06902

[0434] The target compound GT-06902 (white solid, 16 mg, yield 40%) was prepared by referring to the method of Synthesis Scheme 1. 1 H NMR (400MHz, DMSO-d6) δ11.09 (s, 1H), 7.90 (d, J=6.1, 3.2Hz, 1H), 7.70 (d, J=8.5Hz, 1H), 7.56-7.49 (m, 3H), 7.43-7.35 (m, 5H), 7.32-7.24 (m, 2H), 5 .08(dd, J=12.9, 5.3Hz, 1H), 3.68-3.59(m, 4H), 3.20-3.11(m, 4H), 2.88( td, J=14.2, 7.5Hz, 1H), 2.66-2.52(m, 2H), 2.13-1.88(m, 1H).LCMS(ESI)C 30 H 27 ClN5O4 + [M+H] + : Calculated value 556.17, measured value 556.2.

[0435] Example 82: Preparation of compound GT-07209

[0436] The target compound GT-07209 (white solid, 5 mg, yield 6%) was prepared by referring to the method of Synthesis Scheme 1. 1 H NMR (400MHz, DMSO-d6) δ11.08 (s, 1H), 7.93-7.87 (m, 1H), 7.69 (d, J=8.5Hz, 1H), 7.57-7.46 (m, 3H), 7.42-7.35 (m, 4H), 7.32-7.25 (m, 2H), 5.07 (dd, J=13.0, 5.4Hz, 1H), 3.63 (s, 4H), 3.27-3.20 (m, 2H), 3.16 (s, 4H), 2.94-2.76 (m, 2H), 2.59 (d, J=16.6Hz, 1H), 2.08-1.98 (m, 1H). LCMS(ESI)C 30 H 29 ClN5O4 + [M+H]+: Calculated 558.19, Found 558.2

[0437] Example 83: Preparation of compound GT-06903

[0438] The target compound GT-06903 (white solid, 22 mg, yield 56%) was prepared by referring to the method of Synthesis Scheme 1. 1 H NMR (400MHz, DMSO-d6) δ11.10 (s, 1H), 7.74-7.61 (m, 1H), 7.46-7.31 (m, 3H), 7.31-7.21 (m, 4H), 5.09 (dd, J=12.8, 5.4Hz, 1H), 3.70-3.52 ( m, 5H), 3.21 (d, J = 25.8Hz, 2H), 3.14-2.64 (m, 5H), 2.64-2.54 (m, 2H), 2.50-2.30 (m, 3H), 2.06-2.00 (m, 1H), 1.80-1.60 (m, 3H). LCMS (ESI) C 30 H 31 FN5O4 + [M+H] + : Calculated value 544.24, measured value 554.3.

[0439] Example 84: Preparation of compound GT-07211

[0440] The target compound GT-07211 (white solid, 22 mg, yield 27%) was prepared by referring to the method of Synthesis Scheme 1. 1H NMR (400MHz, DMSO-d6) δ11.08 (s, 1H), 10.70 (s, 1H), 7.69 (dd, J=14.0, 8.4Hz, 1H), 7.45-7.19 (m, 6H), 5.08 (dd, J=12.9, 5.5Hz, 1H ), 3.55(s, 6H), 3.11-2.80(m, 5H), 2.66-2.52(m, 2H), 2.42-2.32(m, 1H), 2.26(s, 3H), 2.09-1.96(m, 1H), 1.69(s, 4H).LCMS(ESI)C 30 H 33 FN5O4 + [M+H] + : Calculated value 546.25, measured value 546.3.

[0441] Example 85: Preparation of compound GT-06904

[0442] The target compound GT-06904 (white solid, 20 mg, yield 49%) was prepared by referring to the method of Synthesis Scheme 1. 1 H NMR (400MHz, DMSO-d6) δ11.09 (s, 1H), 7.69 (d, J=8.5Hz, 1H), 7.46 (d, J=8.5H z, 2H), 7.39-7.31 (m, 3H), 7.30-7.22 (m, 2H), 5.07 (dd, J=12.9, 5.4Hz, 1H), 4. 37 (s, 2H), 3.82 (t, J=5.5Hz, 2H), 3.62-3.54 (m, 4H), 3.07-2.96 (m, 4H), 2.93 -2.83(m,1H),2.66-2.53(m,2H),2.48(s,2H),2.06-1.98(m,1H).LCMS(ESI)C 29 H 29 ClN5O5 + [M+H] + : Calculated value 562.19, measured value 562.2.

[0443] Example 86: Preparation of compound GT-07212

[0444] The target compound GT-07212 (white solid, 8 mg, yield 10%) was prepared by referring to the method of Synthesis Scheme 1. 1H NMR (400MHz, DMSO-d6) δ11.08 (d, J=3.8Hz, 1H), 7.78-7.65 (m, 1H), 7.52-7.24 (m, 6H), 5.14-4.94 (m, 1H), 4.32 (d, J=34.9Hz, 2H), 3.81 (t, J=5 .4Hz, 2H), 3.66-3.54(m, 6H), 3.15-2.97(m, 4H), 2.91-2.81(m, 1H), 2.64-2.53(m, 2H), 2.48-2.31(m, 2H), 2.03(t, J=12.3Hz, 1H).LCMS(ESI)C 29 H 31 ClN5O5 + [M+H] + : Calculated value 564.20, measured value 564.2

[0445] Example 87: Preparation of compound GT-06905

[0446] The target compound GT-06905 (white solid, 13 mg, yield 31%) was prepared by referring to the method of Synthesis Scheme 1. 1 H NMR (400MHz, DMSO-d6) δ11.10 (s, 1H), 7.70 (d, J = 8.5Hz, 1H), 7.47-7.42 (m, 2H), 7.37 (d , J=2.1Hz, 1H), 7.30-7.25 (m, 2H), 7.25-7.20 (m, 2H), 5.09 (dd, J=12.9, 5.4Hz, 1H), 3.6 2-3.55(m, 4H), 3.05-2.94(m, 4H), 2.93-2.83(m, 1H), 2.67-2.54(m, 2H), 2.40(s, 2H), 2 .18 (s, 2H), 2.04 (dd, J=9.0, 3.7Hz, 1H), 1.47 (t, J=6.5Hz, 2H), 0.99 (s, 6H).LCMS (ESI) C 32 H 35 ClN5O4 + [M+H] + : Calculated value 588.24, measured value 588.3.

[0447] Example 88: Preparation of compound GT-07214

[0448] The target compound GT-07214 (white solid, 18 mg, yield 25%) was prepared by referring to the method of Synthesis Scheme 1. 1H NMR (400MHz, DMSO-d6) δ11.08 (s, 1H), 10.83 (s, 1H), 7.69 (dd, J=14.3, 8.5Hz, 1H), 7.4 1(ddd, J=24.0, 15.3, 5.1Hz, 3H), 7.32-7.18 (m, 3H), 5.08 (dd, J=12.9, 5.6Hz, 1H), 3.57 (d, J=4.8Hz, 4H), 3.09-2.79 (m, 5H), 2.63-2.53 (m, 3H), 2.37 (d, J=5.1Hz, 1H), 2.21 (d, J=43.8Hz, 2H), 2.02 (d, J=11.7Hz, 3H), 1.44 (s, 2H), 0.97 (d, J=5.0Hz, 6H). LCMS (ESI) C 32 H 37 ClN5O4 + [M+H] + : Calculated value 590.25, measured value 590.3.

[0449] Example 89: Preparation of compound GT-06907

[0450] The target compound GT-06907 (light yellow solid, 28 mg, yield 43%) was prepared by referring to the method of Synthesis Scheme 1. 1 H NMR (500MHz,) δ11.13 (s, 1H), 11.03 (s, 1H), 8.07 (d, J = 7.6Hz, 1H), 7.83 (s, 1H), 7.6 5 (d, J=8.3Hz, 2H), 7.51 (d, J=8.4Hz, 2H), 7.42-7.39 (m, 1H), 7.39-7.37 (m, 1H), 7.35 (s, 1H), 7.34 (s, 1H), 7.26 (d, J=7.4Hz, 1H), 7.24 (s, 1H), 5.02 (dd, J=12.8, 5.4Hz, 1 H), 2.82 (d, J=2.0Hz, 1H), 2.51 (t, J=15.2Hz, 2H), 1.96 (d, J=5.0Hz, 1H). LCMS (ESI) C 26 H 20 ClN4O4 + [M+H] + : Calculated value 487.12, measured value 487.2.

[0451] Example 90: Preparation of compound GT-06908

[0452] The target compound GT-06908 (light yellow solid, 21 mg, yield 33%) was prepared by referring to the method of Synthesis Scheme 1. 1H NMR (500MHz,) δ11.01 (s, 1H), 10.79 (s, 1H), 7.60 (d, J=8.3Hz, 1H), 7.52 (s, 1H), 7.25-7.20 (m, 2H), 7.18 (d, J=8.9Hz, 2H), 4.99 (dd, J=12.8, 5.4H z, 1H), 3.26 (s, 1H), 2.81 (d, J=2.0Hz, 1H), 2.58-2.45 (m, 2H), 2.40 (d, J=4.6Hz, 1H), 2.36 (s, 2H), 1.95 (d, J=5.4Hz, 1H), 1.66 (s, 4H). LCMS (ESI) C 26 H 24 FN4O4 + [M+H] + : Calculated value 475.18, measured value 475.3.

[0453] Example 91: Preparation of compound GT-06909

[0454] The target compound GT-06909 (light yellow solid, 10 mg, yield 15%) was prepared by referring to the method of Synthesis Scheme 1. 1 H NMR (500MHz,) δ11.10 (s, 1H), 10.90 (s, 1H), 7.69 (d, J=8.3Hz, 1H), 7.61 (s, 1H) , 7.50 (d, J=8.4Hz, 2H), 7.26 (d, J=8.4Hz, 2H), 7.20 (s, 1H), 5.09 (dd, J=12.8, 5. 4Hz, 1H), 2.92-2.89 (m, 1H), 2.60 (d, J=19.8Hz, 1H), 2.54 (s, 2H), 2.23 (s, 2H), 2.06-2.02(m, 1H), 1.54(t, J=6.5Hz, 2H), 1.25(s, 2H), 1.02(s, 6H).LCMS(ESI)C 28 H 28 ClN4O4 + [M+H] + : Calculated value 519.18, measured value 519.2.

[0455] Example 92: Preparation of compound GT-06906

[0456] The target compound GT-06906 (light yellow solid, 6 mg, yield 10%) was prepared by referring to the method of Synthesis Scheme 1. LCMS (ESI) C 25 H 22 N5O4 + [M+H] +: Calculated value 456.17, measured value 456.2.

[0457] Example 93: Preparation of compound GT-06910

[0458] The target compound GT-06910 (light yellow solid, 10 mg, yield 12%) was prepared by referring to the method of Synthesis Scheme 1. LCMS (ESI) C 28 H 28 ClN4O4 + [M+H] + : Calculated value 519.18, measured value 519.2.

[0459] Example 94: Preparation of compound GT-06962

[0460] The target compound GT-06962 (17 mg, white solid, yield 27%) was prepared by referring to the method of Synthesis Scheme 1. 1 H NMR (400MHz, MeOD) δ7.49 (d, J=8.5Hz, 2H), 7.45 (d, J=8.2Hz, 1H), 7.37-7.31 (m, 1H), 7.24 (d , J=8.4Hz, 2H), 5.08 (dd, J=13.3, 5.1Hz, 1H), 4.45 (q, J=16.7Hz, 2H), 4.33 (s, 2H), 3.94 (t, J= 5.5Hz, 2H), 3.79 (s, 2H), 3.52 (d, J=8.9Hz, 2H), 3.20-3.09 (m, 2H), 3.03-2.93 (m, 4H), 2.87 ( dd, J=13.4, 5.2Hz, 1H), 2.80-2.71(m, 1H), 2.55-2.42(m, 3H), 2.17-2.11(m, 1H).LCMS(ESI)C 29 H 32 ClFN5O4 + [M+H] + : Calculated value 558.21, measured value 568.3.

[0461] Example 95: Preparation of compound GT-06963

[0462] The target compound GT-06963 (17 mg, white solid, yield 27%) was prepared by referring to Synthesis Scheme 1. 1H NMR (400MHz, MeOD) δ7.47 (d, J=8.2Hz, 2H), 7.23 (d, J=8.2Hz, 2H), 6.72 (s, 1H), 6.60 (d, J=12.7Hz, 1H), 5.03 (dd, J=13.8, 5.5Hz, 1H), 4.42-4.25 (m, 4H), 4.01-3.87 (m, 2 H), 3.85-3.71(m, 2H), 3.54-3.45(m, 2H), 3.19-3.07(m, 2H), 3.05-2.84(m, 5H), 2.8 0-2.71(m, 1H), 2.54-2.45(m, 2H), 2.44-2.37(m, 1H), 2.18-2.03(m, 1H).LCMS(ESI)C 29 H 32 ClFN5O4 + [M+H] + : Calculated value 558.21, measured value 568.3.

[0463] Example 96: Preparation of compound GT-07990

[0464] The target compound GT-07990 (27 mg, white solid, yield 48%) was prepared according to the method of synthesis scheme 1. LCMS (ESI) C 34 H 42 ClN6O5 + [M+H] + : Calculated value 649.29, measured value 649.2.

[0465] Example 97: Preparation of compound GT-07996

[0466] The target compound GT-07996 (33 mg, white solid, yield 58%) was prepared according to the method of synthesis scheme 1. LCMS (ESI) C 34 H 40 ClN6O6 + [M+H] + : Calculated value 663.27, measured value 663.2.

[0467] Example 98: Preparation of compound GT-08034

[0468] The target compound GT-08034 (10 mg, white solid, yield 55%) was prepared by referring to Synthesis Scheme 1. 1H NMR (400MHz, MeOD) δ7.55-7.47 (m, 3H), 7.36-7.28 (m, 2H), 6.99 (s, 1H), 6.92-6.88 (m, 1H), 5.28-5.00 (m, 3H), 4.40-4.31 (m, 1H), 4.14 (s, 1H), 3.84 (s, 1H), 3.67-3.61 (m, 2H), 3.53-3.48 (m, 1H), 3.30 (s, 4H), 3.17-3.10 (m, 2H), 3.02-2.83 (m, 2H), 2.82 -2.68(m, 2H), 2.55-2.36(m, 1H), 2.20-2.09(m, 1H), 2.09-1.98(m, 2H).LCMS(ESI)C 29 H 34 ClFN6O3 + [M+H] + : Calculated value 549.24, measured value 549.2.

[0469] Example 99: Preparation of compound GT-08040

[0470] The target compound GT-08040 (15 mg, white solid, yield 66%) was prepared by referring to Synthesis Scheme 1. 1 H NMR (400MHz, MeOD) δ7.59 (d, J=8.2Hz, 1H), 7.52 (d, J=8.3Hz, 2H), 7.33-7.23 (m, 3H), 7.06 (d, J=8.0Hz, 1H), 5.04 (dd, J=13.3, 6.2Hz, 1H), 4 .13(s,2H),3.84(s,2H),3.67-3.56(m,2H),3.56-3.46(m,2H),3.12(s,4H),2.99(s,2H),2.88-2.64(m,5H),2.14-2.04(m,1H).LCMS(ESI)C 29 H 32 ClN6O4 + [M+H] + : Calculated value 563.22 Measured value 563.2.

[0471] Example 100: Preparation of compound GT-08865

[0472] The target compound GT-08865 (46 mg, white solid, yield 46%) was prepared by referring to the method of synthesis scheme 5. 1H NMR (400MHz, DMSO-d6) δ11.10 (s, 1H), 7.62 (t, J = 7.5Hz, 1H), 7.50 (d, J = 8.3Hz, 1H), 7.28 (s, 1H), 7.11 (d, J = 6.7Hz, 1H), 5.16-4.98 (m, 1H), 2.84 (d, J=36.1Hz, 6H), 2.59 (d, J=18.7Hz, 5H), 2.08-1.98 (m, 1H), 1.04 (s, 9H).LCMS(ESI)C 21 H 28 N5O4 + [M+H] + : Calculated value 414.21, measured value 414.3.

[0473] Example 101: Preparation of compound GT-08531

[0474] The target compound GT-08531 (630 mg, white solid, yield 35%) was prepared by referring to the method of synthesis scheme 5. 1 H NMR (400MHz, DMSO-d6) δ11.06 (s, 1H), 8.05 (s, 1H), 7.60 (d, J = 8.3Hz, 1H), 7.14 (s, 1H), 7.01 (d, J = 7.8Hz, 1H), 5.04 (dd, J = 12.9, 5.4Hz, 1H), 2.9 2-2.83 (m, 1H), 2.73 (dd, J=45.1, 17.9Hz, 4H), 2.57 (dd, J=19.7, 5.9Hz, 4H), 2.46 (d, J=4.3Hz, 2H), 2.20 (s, 3H), 2.03-1.96 (m, 1H). LCMS (ESI) C 18 H 22 N5O4 + [M+H] + : Calculated value 372.17, measured value 372.2.

[0475] Example 102: Preparation of Compound GT-08644

[0476] The target compound GT-08644 (110 mg, white solid, yield 38%) was prepared by referring to the method of Synthesis Scheme 5. 1H NMR (400MHz, DMSO-d6) δ10.93 (s, 1H), 7.43 (d, J=8.3Hz, 1H), 7.25 (s, 1H), 6.90 (s, 1 H), 6.85-6.78 (m, 1H), 5.02 (dd, J=13.3, 5.1Hz, 1H), 4.30 (d, J=16.8Hz, 1H), 4.16 (d , J=16.8Hz, 1H), 2.95-2.85 (m, 1H), 2.72 (s, 4H), 2.59 (d, J=17.5Hz, 2H), 2.45 (s, 2H) ), 2.34 (ddd, J=26.4, 13.3, 4.4Hz, 2H), 2.20 (s, 3H), 1.99-1.91 (m, 1H).LCMS (ESI) C 18 H 24 N5O3 + [M+H] + : Calculated value 358.19, measured value 358.2.

[0477] Example 103: Preparation of compound GT-08711

[0478] The target compound GT-08711 (43 mg, white solid, yield 21%) was prepared by referring to the method of synthetic scheme 5. 1 H NMR (400MHz, DMSO-d6) δ11.06 (s, 1H), 8.01 (s, 1H), 7.60 (d, J=8.3Hz, 1H), 7.16 (s, 1H), 7.03 (s, 1H), 5.04 (dd, J=12.9, 5.4Hz, 1H), 2.93-2.82 (m, 2H), 2.70 (d, J=23.7Hz, 4H), 2.65-2.52 (m, 4H), 2.15-1.55 (m, 2H), 1.04 (s, 9H). LCMS (ESI) C 21 H 28 N5O4 + [M+H] + : Calculated value 414.21, measured value 414.3.

[0479] Example 104: Preparation of Compound GT-09057

[0480] The target compound GT-09057 (63 mg, white solid, yield 41%) was prepared by referring to the method of synthesis scheme 5. 1H NMR (400MHz, DMSO-d6) δ11.01 (s, 1H), 9.71 (s, 1H), 7.31 (t, J=7.7Hz, 1H), 7.14 (s, 1H), 7.09 (s, 1H), 7.07 (d, J=1.2Hz, 1H), 5.10 (dd, J=13.3, 5.0Hz, 1H), 4.35 (d, J=17.4Hz, 1H), 4.22 (d, J=17.4Hz, 1H), 3 .46-3.43 (m, 2H), 3.21 (d, J=8.7Hz, 2H), 3.15 (d, J=12.9Hz, 2H), 2.99-2.89 (m, 1H), 2.84 (s, 3H), 2.7 9 (s, 2H), 2.62 (d, J=17.1Hz, 1H), 2.39 (ddd, J=26.5, 13.3, 4.4Hz, 1H), 2.07-1.98 (m, 1H).LCMS (ESI) C 18 H 24 N5O3 + [M+H] + : Calculated value 358.19, measured value 358.2.

[0481] Example 105: Preparation of compound GT-09058

[0482] The target compound GT-09058 (190 mg, white solid, yield 50%) was prepared by referring to the method of synthesis scheme 5. 1 H NMR (400MHz, DMSO-d6) δ11.11 (s, 1H), 9.75 (s, 1H), 7.95 (s, 1H), 7.65 (dd, J=8 .4, 7.2Hz, 1H), 7.54 (d, J=8.5Hz, 1H), 7.15 (d, J=6.7Hz, 1H), 5.07 (dd, J=12.7 , 5.4Hz, 1H), 3.47 (s, 2H), 3.27 (s, 2H), 3.09 (s, 4H), 2.93 (d, J=5.9Hz, 1H), 2. 83(s, 3H), 2.59(d, J=19.1Hz, 1H), 2.54(s, 1H), 2.10-1.99(m, 1H).LCMS(ESI)C 18 H 22 N5O4 + [M+H] + : Calculated value 372.17, measured value 372.2.

[0483] Example 106: Preparation of Compound GT-09917

[0484] The target compound GT-09917 (51 mg, white solid, yield 31%) was prepared by referring to the method of Synthesis Scheme 5. 1 H NMR (400MHz, DMSO-d6) δ11.09 (s, 1H), 8.15 (s, 1H), 7.57 (d, J=8.2Hz, 1H), 7.51-7.39 (m, 1H), 5.05 (dd, J=12.8, 5.4Hz, 1H), 3. 35-3.30 (m, 4H), 2.88-2.82 (m, 1H), 2.73 (s, 4H), 2.63-2.51 (m, 2H), 2.02 (d, J = 5.7Hz, 1H), 1.41 (d, J = 8.2Hz, 9H). LCMS (ESI) C 22 H 27 FN5O6 + [M+H] + : Calculated value 476.19, measured value 476.2.

[0485] Example 107: Preparation of compound GT-09918

[0486] The target compound GT-09918 (53 mg, white solid, yield 34%) was prepared by referring to the method of synthetic scheme 5. 1 H NMR (400MHz, DMSO-d6) δ11.08 (s, 1H), 8.51 (s, 1H), 7.00 (s, 1H), 6.79 (s, 1H), 5.05 (dd, J=12.8, 5.4Hz, 1H), 3.36 (s, 4H), 2.88 (ddd , J=16.8, 14.0, 5.5Hz, 4H), 2.58 (dd, J=17.2, 2.4Hz, 2H), 2.46 (dd, J=13.3, 4.3Hz, 1H), 2.05-1.97 (m, 1H), 1.42 (s, 9H). LCMS (ESI) C 22 H 27 FN5O6 + [M+H] + : Calculated value 476.19, measured value 476.2.

[0487] Example 108: Preparation of compound GT-09919

[0488] The target compound GT-09919 (32 mg, white solid, yield 19%) was prepared by referring to the method of synthetic scheme 5. 1H NMR (400MHz, DMSO-d6) δ11.03 (s, 1H), 8.03 (s, 1H), 6.79 (s, 1H), 6.47 (s, 1H), 5.00 (dd, J=12.8, 5.4Hz, 1H), 3.47 (d, J=11.2Hz, 4H), 3.35 ( s, 4H), 3.30 (s, 4H), 3.16 (s, 4H), 2.90-2.83 (m, 1H), 2.61-2.52 (m, 2H), 1.97 (dd, J=10.8, 5.7Hz, 1H), 1.42 (d, J=3.1Hz, 18H). LCMS (ESI) C 31 H 44 N7O8 + [M+H] + : Calculated value 642.32, measured value 642.4.

[0489] Example 109: Preparation of compound GT-08710

[0490] The target compound GT-08710 (68 mg, white solid, yield 35%) was prepared by referring to the method of synthetic scheme 5. 1 H NMR (400MHz, DMSO-d6) δ11.06 (s, 1H), 8.06 (s, 1H), 7.60 (d, J = 8.3Hz, 1H), 7.15 (s, 1H), 7.02 (d, J = 7.1Hz, 1H), 5 .04 (dd, J=12.9, 5.3Hz, 1H), 2.95-2.51 (m, 12H), 1.99 (dd, J=9.5, 6.3Hz, 1H), 1.00 (d, J=5.3Hz, 6H).LCMS (ESI) C 20 H 26 N5O4 + [M+H] + : Calculated value 400.20, measured value 400.3.

[0491] Example 110: Preparation of compound GT-08881

[0492] The target compound GT-08881 (53 mg, white solid, yield 36%) was prepared by referring to the method of Synthesis Scheme 5. 1H NMR (400MHz, DMSO-d6) δ10.93 (s, 1H), 7.43 (d, J = 8.3Hz, 1H), 7.27 (s, 1H), 6.90 (s , 1H), 6.83 (d, J=8.2Hz, 1H), 5.02 (dd, J=13.3, 5.1Hz, 1H), 4.29 (d, J=16.8Hz, 1H), 4.16 (d, J=16.9Hz, 1H), 2.96-2.82 (m, 2H), 2.74 (s, 5H), 2.58 (d, J=16.4Hz, 4H), 2. 33 (dd, J=13.1, 4.4Hz, 1H), 1.93 (dd, J=12.0, 6.9Hz, 1H), 1.02 (s, 6H).LCMS(ESI)C 20 H 27 N5O3 + [M+H] + : Calculated value 385.21, measured value 385.3.

[0493] Example 111: Preparation of compound GT-08880

[0494] The target compound GT-08880 (16 mg, white solid, yield 20%) was prepared by referring to the method of Synthesis Scheme 5. 1 H NMR (400MHz, DMSO-d6) δ11.01 (s, 1H), 7.28 (t, J=7.5Hz, 1H), 7.04 (dd, J=15.3, 7.4Hz, 2H), 6.76 (s, 1H), 5.09 (dd, J=13.1, 4.8Hz, 1H) , 4.28 (dd, J=39.5, 17.3Hz, 2H), 3.00-2.85 (m, 2H), 2.82-2.53 (m, 8H), 2.44-2.25 (m, 2H), 2.08-2.00 (m, 1H), 0.99 (s, 6H). LCMS (ESI) C 20 H 28 N5O3 + [M+H] + : Calculated value 386.22, measured value 386.3.

[0495] Example 112: Preparation of compound GT-08866

[0496] The target compound GT-08866 (142 mg, white solid, yield 38%) was prepared by referring to Synthesis Scheme 5. 1H NMR (400MHz, DMSO-d6) δ 11.10 (s, 1H), 7.61 (t, J = 7.6Hz, 1H), 7.49 (d, J = 8.4Hz, 1H), 7.33 (s, 1H), 7.10 (d, J = 6.8Hz, 1H), 5.05 (d d, J=12.3, 4.9Hz, 1H), 2.81 (dd, J=41.7, 21.4Hz, 5H), 2.69-2.51 (m, 7H), 2.07-1.97 (m, 1H), 0.98 (d, J=6.2Hz, 6H). LCMS (ESI) C 20 H 26 N5O4 + [M+H] + : Calculated value 400.20, measured value 400.3.

[0497] Example 113: Preparation of compound GT-09018

[0498] The target compound GT-09018 (8 mg, white solid, yield 18%) was prepared by referring to the method of synthesis scheme 5. 1 H NMR (400MHz, DMSO-d6) δ10.92 (s, 1H), 8.20 (s, 1H), 7.42 (d, J=8.4Hz, 1H), 7. 19 (s, 1H), 6.90 (s, 1H), 6.82 (d, J = 8.3Hz, 1H), 5.01 (dd, J = 13.3, 5.1Hz, 1H), 4.29 (d, J=16.8Hz, 1H), 4.15 (d, J=16.8Hz, 1H), 2.89 (s, 2H), 2.76-2.56 (m, 8 H), 2.33 (qd, J=13.7, 9.0Hz, 1H), 2.01-1.90 (m, 1H), 1.03 (s, 9H).LCMS (ESI) C 21 H 30 N5O3 + [M+H] + : Calculated value 400.23, measured value 400.3.

[0499] Example 114: Preparation of Compound GT-09138

[0500] The target compound GT-09138 (13 mg, white solid, yield 20%) was prepared by referring to the method of Synthesis Scheme 5. 1H NMR (400MHz, MeOD) δ7.35 (t, J=7.7Hz, 1H), 7.25 (d, J=3.4Hz, 1H), 7.23 (dd, J=4.7, 0.9Hz, 1H), 5.14 (dd, J=13.2, 5.2Hz, 1H), 4.44 (s, 2H), 3.6 4(d, J=12.2Hz, 2H), 3.42-3.32(m, 4H), 3.02-2.86(m, 3H), 2.84-2.75(m, 1H), 2.57-2.45(m, 1H), 2.26-2.12(m, 1H), 1.47(s, 9H).LCMS(ESI)C 21 H 30 N5O3 + [M+H] + : Calculated value 400.23, measured value 400.3.

[0501] Example 115: Preparation of compound GT-09129

[0502] The target compound GT-09129 (24 mg, white solid, yield 39%) was prepared by referring to Synthesis Scheme 2. 1 H NMR (400MHz, MeOD) δ7.73 (d, J=8.2Hz, 2H), 7.68 (d, J=8.2Hz, 2H), 7.56 (d, J=8.4Hz, 1H), 7.04 (s, 1H) , 6.96 (dd, J=8.4, 1.7Hz, 1H), 5.08 (dd, J=13.3, 5.1Hz, 1H), 4.46 (s, 2H), 4.43-4.28 (m, 4H), 3.54 (d, J =12.4Hz, 2H), 3.48-3.41(m, 4H), 3.29-3.16(m, 3H), 3.06-2.93(m, 4H), 2.82-2.72(m, 1H), 2.51-2.40 (m, 1H), 2.20-2.08 (m, 1H), 1.94 (d, J=14.7Hz, 2H), 1.88-1.75 (m, 3H), 1.57-1.52 (m, 1H). LCMS (ESI) C 30 H 39 N6O3 + [M+H] + : Calculated value 531.31, measured value 531.3.

[0503] Example 116: Preparation of Compound GT-09130

[0504] The target compound GT-09130 (13 mg, white solid, yield 26%) was prepared by referring to Synthesis Scheme 2. 1H NMR (400MHz, MeOD) δ7.73 (d, J=8.1Hz, 2H), 7.68 (d, J=8.1Hz, 2H), 7.48 (t, J=7.3Hz, 1H), 7.44-7.38 (m , 1H), 5.09 (dd, J=13.3, 5.1Hz, 1H), 4.53-4.45 (m, 4H), 4.36 (s, 2H), 3.55 (d, J=11.3Hz, 2H), 3.45-4.3 9(m, 4H), 3.28-3.22(m, 2H), 3.13-3.03(m, 4H), 2.77(d, J=15.6Hz, 1H), 2.56-2.41(m, 1H), 2.37-2.32 (m, 1H), 2.24-2.10 (m, 1H), 1.94 (d, J=14.2Hz, 2H), 1.89-1.73 (m, 3H), 1.55-1.51 (m, 1H).LCMS (ESI) C 30 H 38 FN6O3 + [M+H] + : Calculated value 549.30, measured value 549.3.

[0505] Example 117: Preparation of Compound GT-09131

[0506] The target compound GT-09131 (33 mg, white solid, yield 67%) was prepared by referring to Synthesis Scheme 2. 1 H NMR (400MHz, MeOD) δ7.74 (d, J=8.2Hz, 2H), 7.69 (d, J=8.2Hz, 2H), 7.41 (d, J=7.0Hz, 1H), 7.35 (d, J=10.5Hz, 1H), 5.09 (dd, J=13.3, 5.2Hz, 1H), 4.47 (s, 2H), 4.43-4.29 (m, 4H), 3.55 (d, J=12.2Hz, 2H), 3.47-3.40 (m, 4H) ), 3.25 (d, J=12.1Hz, 2H), 3.16-3.06 (m, 2H), 3.04-2.95 (m, 2H), 2.82-2.72 (m, 1H), 2.53-2.42 (m, 1H), 2.40 -2.33(m, 1H), 2.24-2.10(m, 1H), 1.94(d, J=14.5Hz, 2H), 1.86-1.75(m, 3H), 1.56-1.51(m, 1H).LCMS(ESI)C 30 H 38 FN6O3 + [M+H] + : Calculated value 549.30, measured value 549.3.

[0507] Example 118: Preparation of compound GT-09132

[0508] The target compound GT-09132 (29 mg, white solid, yield 59%) was prepared by referring to Synthesis Scheme 2. 1 H NMR (400MHz, MeOD) δ7.73 (d, J=8.2Hz, 2H), 7.69 (d, J=8.2Hz, 2H), 6.78 (s, 1H), 6.67 (d, J=11.9H z, 1H), 5.04 (dd, J=13.3, 5.1Hz, 1H), 4.46 (s, 2H), 4.42-4.27 (m, 4H), 3.53 (d, J=12.3Hz, 2H), 3. 48-3.39 (m, 4H), 3.25-3.20 (m, 2H), 3.00 (t, J=12.1Hz, 4H), 2.80-2.71 (m, 1H), 2.53-2.28 (m, 2H ), 2.20-2.07(m, 1H), 1.94(d, J=14.5Hz, 2H), 1.86-1.75(1m, 3H), 1.59-1.44(m, 1H).LCMS(ESI)C 30 H 38 FN6O3 + [M+H] + : Calculated value 549.30, measured value 549.3.

[0509] Example 119: Preparation of compound (GT-09133

[0510] The target compound GT-09133 (32 mg, white solid, yield 65%) was prepared by referring to Synthesis Scheme 2. 1H NMR (400MHz, MeOD) δ7.74 (d, J=8.2Hz, 2H), 7.68 (d, J=8.3Hz, 2H), 7.32 (d, J=7.7Hz, 1H), 7.23 (d, J=6.5H z, 1H), 7.21-7.15 (m, 1H), 5.15 (dd, J=13.2, 5.2Hz, 1H), 4.56-4.45 (m, 4H), 4.35 (s, 2H), 3.57-3.49 (m, 2H ), 3.47-3.41(m, 4H), 3.02-2.96(m, 4H), 2.82-2.77(m, 1H), 2.58-2.50(m, 1H), 2.48-2.34(m, 2H), 2.31-2 .27(m, 1H), 2.24-2.10(m, 1H), 1.92(d, J=15.2Hz, 2H), 1.85-1.77(m, 3H), 1.59-1.45(m, 1H).LCMS(ESI)C 30 H 39 N6O3 + [M+H] + : Calculated value 531.31, measured value 531.3.

[0511] Example 120: Preparation of Compound GT-09134

[0512] The target compound GT-09134 (24 mg, white solid, yield 49%) was prepared according to the method of synthesis scheme 2. LCMS (ESI) C 32 H 41 N6O3 + [M+H] + : Calculated value 557.32, measured value 557.3.

[0513] Example 121: Preparation of compound GT-09135

[0514] The target compound GT-09135 (30 mg, white solid, yield 61%) was prepared by referring to Synthesis Scheme 2. 1H NMR (400MHz, MeOD) δ7.79 (d, J=8.2Hz, 2H), 7.69 (d, J=8.2Hz, 2H), 7.57 (d, J=8.3Hz, 1H), 7.02 (s, 1H), 6. 95 (d, J=8.3Hz, 1H), 5.08 (dd, J=13.3, 5.1Hz, 1H), 4.46-4.29 (m, 6H), 4.01 (s, 2H), 3.46 (d, J=12.6Hz, 2H) , 3.19-3.11(m, 4H), 3.06-2.94(m, 2H), 2.93-2.83(m, 1H), 2.80-2.74(m, 1H), 2.51-2.44(m, 4H), 2.41-2 .33(m, 1H), 2.19-2.11(m, 2H), 1.93(d, J=15.0Hz, 2H), 1.88-1.73(m, 3H), 1.60-1.47(m, 1H).LCMS(ESI)C 32 H 41 N6O3 + [M+H] + : Calculated value 557.32, measured value 557.3.

[0515] Example 122: Preparation of Compound GT-09197

[0516] The target compound GT-09197 (16 mg, white solid, yield 33%) was prepared by referring to Synthesis Scheme 2. 1 H NMR (400MHz, MeOD) δ7.66 (s, 4H), 7.57 (d, J = 8.2Hz, 1H), 7.08 (s, 1H), 6.98 (d, J = 8.2Hz, 1H), 5.08 ( dd, J=13.3, 5.1Hz, 1H), 4.63 (s, 2H), 4.42-4.30 (m, 2H), 4.45-4.27 (m, 4H), 4.05 (t, J=10.8Hz, 2H), 3.88 (s, 1H), 3.40 (d, J=11.4Hz, 2H), 3.03-2.81 (m, 5H), 2.73 (d, J=15.6Hz, 1H), 2.49-2.30 (m, 2H) , 2.18-2.04 (m, 5H), 1.91 (d, J = 14.7Hz, 2H), 1.79 (t, J = 12.8Hz, 3H), 1.57-1.42 (m, 1H).LCMS (ESI) C 33 H 43 N6O3 + [M+H] + : Calculated value 571.34, measured value 571.3.

[0517] Example 123: Preparation of Compound GT-09198

[0518] The target compound GT-09198 (26 mg, white solid, yield 53%) was prepared by referring to Synthesis Scheme 2. 1 H NMR (400MHz, MeOD) δ7.75 (d, J=8.1Hz, 2H), 7.68 (d, J=8.0Hz, 2H), 7.56 (d, J=8.5Hz, 1H), 7.06 (s, 1H), 6.95 (d, J=8. 0Hz, 1H), 5.08 (dd, J=13.3, 5.1Hz, 1H), 4.49 (s, 2H), 4.46-4.29 (m, 4H), 3.67-3.54 (m, 2H), 3.54-3.44 (m, 4H), 3.28- 3.24 (m, 1H), 3.15-3.08 (m, 2H), 3.03-2.98 (m, 2H), 2.92-2.84 (m, 1H), 2.80-2.74 (m, 1H), 2.46 (dd, J=13.2, 4.4Hz, 1 H), 2.42-2.33 (m, 1H), 2.24-2.09 (m, 3H), 1.92 (t, J=13.8Hz, 2H), 1.89-1.73 (m, 3H), 1.56-1.49 (m, 1H).LCMS (ESI) C 31 H 41 N6O3 + [M+H] + : Calculated value 545.32, measured value 545.3.

[0519] Example 124: Preparation of Compound GT-09199

[0520] The target compound GT-09199 (33 mg, white solid, yield 67%) was prepared by referring to Synthesis Scheme 2. 1 H NMR (400MHz, MeOD) δ7.68-7.52 (m, 5H), 7.12-7.03 (m, 1H), 6.99-6.92 (m, 1H), 5.08 (dd, J=13.3, 5.0Hz, 1H), 4.42-4.23 (m, 7H), 3.79-3.57 (m, 3 H), 3.22-3.00(m, 4H), 2.92-2.84(m, 2H), 2.81-2.66(m, 2H), 2.54-2.37(m, 2H), 2.20-2.12(m, 2H), 1.84(brs, 4H), 1.67(brs, 2H).LCMS(ESI)C 31 H 39 N6O3 + [M+H]+ : Calculated value 543.31, measured value 543.3.

[0521] Example 125: Preparation of Compound GT-09200

[0522] The target compound GT-09200 (33 mg, white solid, yield 67%) was prepared by referring to Synthesis Scheme 2. 1 H NMR (400MHz, MeOD) δ7.79 (d, J=8.1Hz, 2H), 7.68 (d, J=8.1Hz, 2H), 7.58-7.51 (m, 1H), 7.07 (s, 1H), 6.99-6.91 (m, 1H), 5.07 (dd, J=13.3, 5.0Hz, 1H), 4.56 (d, J=13.2Hz, 1H), 4.45-4.31 (m, 6H), 3.83-3.74 (m, 1H), 3.69-3.5 3 (m, 1H), 3.45 (d, J = 12.2Hz, 3H), 3.03-2.97 (m, 3H), 2.86 (dd, J = 12.5, 3.9Hz, 1H), 2.76 (d, J = 17.8Hz, 1H), 2. 50-2.34(m, 4H), 2.26-2.07(m, 2H), 1.94(d, J=14.2Hz, 2H), 1.85-1.78(m, 3H), 1.58-1.44(m, 1H).LCMS(ESI)C 31 H 39 N6O3 + [M+H] + : Calculated value 543.31, measured value 543.3.

[0523] Example 126: Preparation of Compound GT-09201

[0524] The target compound GT-09201 (34 mg, white solid, yield 69%) was prepared by referring to the method of synthesis scheme 2. 1H NMR (400MHz, MeOD) δ7.82 (d, J=8.0Hz, 2H), 7.67 (d, J=8.2Hz, 2H), 7.54 (d, J=8.4Hz, 1H), 7.20 (s, 1H), 7.08 (d, J=8.4 Hz, 1H), 5.08 (dd, J=13.3, 5.1Hz, 1H), 4.49 (s, 2H), 4.43-4.30 (m, 4H), 3.60 (d, J=11.5Hz, 2H), 3.52 (s, 2H), 3.45 (d, J =12.1Hz, 2H), 3.37-3.34(m, 2H), 3.00(dt, J=12.5, 6.3Hz, 2H), 2.91-2.82(m, 1H), 2.81-2.70(m, 1H), 2.51-2.42(m, 1H), 2.39-2.24(m, 3H), 2.19-2.06(m, 3H), 1.93(d, J=14.5Hz, 2H), 1.87-1.77(m, 3H), 1.57-1.47(m, 1H).LCMS(ESI)C 32 H 41 N6O3 + [M+H] + : Calculated value 557.32, measured value 557.3.

[0525] Example 127: Preparation of Compound GT-09202

[0526] The target compound GT-09202 (37 mg, white solid, yield 75%) was prepared by referring to Synthesis Scheme 2. 1 H NMR (400MHz, MeOD) δ7.74 (d, J=8.2Hz, 2H), 7.69 (d, J=8.2Hz, 2H), 7.61 (d, J=8.3Hz, 1H), 7.32 (s, 1H), 7. 12 (d, J=7.3Hz, 1H), 5.06 (dd, J=12.5, 5.5Hz, 1H), 4.47 (s, 2H), 4.36 (s, 2H), 3.55 (d, J=12.2Hz, 2H), 3.4 8-3.41 (m, 4H), 3.25 (d, J=12.6Hz, 2H), 3.13-2.98 (m, 4H), 2.90-2.80 (m, 1H), 2.77-2.74 (m, 1H), 2.68-2 .65(m, 1H), 2.13-2.09(m, 1H), 1.94(d, J=14.6Hz, 2H), 1.85-1.75(m, 3H), 1.55-1.49(m, 1H).LCMS(ESI)C 30 H 37 N6O4 +[M+H] + : Calculated value 545.29, measured value 545.3.

[0527] Example 128: Preparation of compound GT-09203

[0528] The target compound GT-09203 (14 mg, white solid, yield 28%) was prepared by referring to the method of synthesis scheme 2. 1 H NMR (400MHz, MeOD) δ7.80-7.72 (m, 5H), 7.47 (d, J=2.2Hz, 1H), 7.36 (dd, J=8.5, 2.3Hz, 1H), 5.09 (dd, J=12. 4, 5.4Hz, 1H), 4.39 (s, 2H), 4.06 (d, J=14.0Hz, 2H), 3.92-3.85 (m, 2H), 3.74-3.65 (m, 4H), 3.50 (d, J=12.1H z, 2H), 3.29-3.25 (m, 1H), 3.02 (td, J=12.3, 2.8Hz, 2H), 2.90-2.81 (m, 1H), 2.80-2.74 (m, 1H), 2.73 (s, 1H) , 2.70 (s, 1H), 2.19-2.06 (m, 1H), 1.94 (d, J=14.0Hz, 2H), 1.89-1.76 (m, 3H), 1.62-1.47 (m, 1H).LCMS (ESI) C 30 H 37 N6O4 + [M+H] + : Calculated value 545.29, measured value 545.3.

[0529] Example 129: Preparation of Compound GT-09213

[0530] The target compound GT-09213 (24 mg, white solid, yield 49%) was prepared by referring to the method of synthesis scheme 2. 1H NMR (400MHz, MeOD) δ7.76 (q, J=8.3Hz, 4H), 7.69 (d, J=8.5Hz, 1H), 7.20 (s, 1H), 7.18 (dd, J=8.5, 2.2Hz, 1 H), 5.11 (dd, J=13.3, 5.1Hz, 1H), 4.51-4.32 (m, 5H), 3.96-3.85 (m, 5H), 3.66-3.58 (m, 4H), 3.50 (d, J=12. 3Hz, 2H), 3.05-2.98 (m, 2H), 2.92-2.84 (m, 1H), 2.82-2.72 (m, 1H), 2.47 (dd, J=13.2, 4.7Hz, 1H), 2.43-2 .33(m, 1H), 2.23-2.10(m, 1H), 1.94(d, J=14.0Hz, 2H), 1.89-1.80(m, 3H), 1.61-1.49(m, 1H).LCMS(ESI)C 30 H 39 N6O3 + [M+H] + : Calculated value 531.31, measured value 531.3.

[0531] Example 130: Preparation of compound GT-09708

[0532] The target compound GT-09708 (36 mg, white solid, yield 48%) was prepared by referring to Synthesis Scheme 3. 1 H NMR (400MHz, DMSO-d6) δ10.96 (s, 1H), 7.43 (t, J=8.8Hz, 4H), 7.32 (d, J=8.8Hz, 2H), 7.19 (d, J=8.4Hz, 2H), 6.97 (d, J=8.9Hz, 2H), 5.04 (dd, J=13.2, 5.1Hz, 1H), 4.45 (d, J=16.7Hz, 1H), 4.27 (d, J=16.7Hz, 1H), 3.77 (d, J=13.8Hz, 2H) , 3.70-3.52 (m, 4H), 3.37-3.28 (m, 4H), 3.20 (t, J=12.0Hz, 2H), 2.90-2.73 (m, 6H), 2.59 (d, J=16.3Hz, 1H), 2.39 (d, J=12.7Hz, 1H), 2.34-2.22(m, 3H), 2.11(s, 2H), 1.99-1.94(m, 1H), 1.48(t, J=6.4Hz, 2H), 1.02(s, 6H).LCMS(ESI)C 43 H 50 ClFN7O4 + [M+H]+ : Calculated value 782.36, measured value 782.4.

[0533] Example 131: Preparation of compound GT-09709

[0534] The target compound GT-09709 (20 mg, white solid, yield 28%) was prepared by referring to the method of synthesis scheme 1. 1 H NMR (400MHz, DMSO-d6) δ10.96 (s, 1H), 9.38 (s, 1H), 7.76 (s, 1H), 7.41 (d, J=8.2Hz, 1H), 7.29 (t, J=7. 7Hz, 2H), 6.94 (d, J=8.0Hz, 1H), 6.83 (d, J=8.0Hz, 1H), 5.04 (dd, J=13.3, 5.0Hz, 1H), 4.45 (d, J=16.8H z, 1H), 4.27 (d, J=16.8Hz, 1H), 4.21 (s, 2H), 3.81 (s, 3H), 3.30-3.27 (m, 2H), 3.24-3.15 (m, 2H), 3.07 (s, 4H), 2.96-2.84 (m, 1H), 2.59 (d, J=17.3Hz, 1H), 2.44-2.35 (m, 1H), 1.98-1.94 (m, 1H). LCMS (ESI) C 25 H 29 FN5O5 + [M+H] + : Calculated value 498.21, measured value 498.2.

[0535] Example 132: Preparation of Compound GT-09741

[0536] The target compound GT-09741 (19 mg, white solid, yield 33%) was prepared by referring to Synthesis Scheme 3. 1H NMR (400MHz, DMSO-d6) δ10.95 (s, 1H), 7.36 (d, J = 7.7Hz, 1H), 7.27 (t, J = 7.7Hz, 1H), 7.17 (d, J = 8.1Hz, 2H), 7.11 ( d, J=8.1Hz, 2H), 5.03 (dd, J=13.3, 5.1Hz, 1H), 4.43 (d, J=16.8Hz, 1H), 4.25 (d, J=16.8Hz, 1H), 4.10 (q, J=6.4Hz, 1H), 3.67-3.58(m, 1H), 2.95-2.83(m, 1H), 2.75-2.54(m, 5H), 2.42-2.40(m, 4H), 2.37-2.29(m, 1H), 2.02-1.90( m, 1H), 1.85-1.78 (m, 1H), 1.34 (d, J = 7.1Hz, 1H), 1.28 (d, J = 6.8Hz, 3H), 0.86 (dd, J = 6.6, 1.3Hz, 6H). LCMS (ESI) C 30 H 37 FN5O4 + [M+H] + : Calculated value 550.28, measured value 550.3.

[0537] Example 133: Preparation of Compound GT-09971

[0538] The target compound GT-09971 (9 mg, white solid, yield 23%) was prepared by referring to Synthesis Scheme 2. 1 H NMR (400MHz, MeOD) δ7.69-7.66(m, 4H), 7.57-7.51(m, 5H), 7.07-7.03(m, 2H), 5.82(s, 1H), 5.17-5.06(m, 1H), 4.46-4.35(m, 2H), 3.80-3.60(m, 2H), 3.27-3. 18(m, 3H), 3.12-3.02(m, 3H), 2.99-2.96(m, 1H), 2.92-2.89(m, 1H), 2.82-2.7 6(m, 1H), 2.70-2.60(m, 1H), 2.52-2.39(m, 1H), 2.23-2.11(m, 1H).LCMS(ESI)C 32 H 32 Cl2N5O3 + [M+H] + : Calculated value 604.19, measured value 604.2.

[0539] Example 134: Preparation of Compound GT-09972

[0540] The target compound GT-09972 (25 mg, white solid, yield 49%) was prepared by referring to Synthesis Scheme 3. 1 H NMR (400MHz, DMSO-d6) δ10.94 (s, 1H), 7.56-7.52 (m, 3H), 7.50-7.40 (m, 6H) , 6.82 (s, 1H), 6.74 (d, J=8.1Hz, 1H), 5.03 (dd, J=13.3, 5.1Hz, 1H), 4.31 (dd, J=16.7, 6.2Hz, 1H), 4.18(d, J=17.0Hz, 1H), 2.96-2.86(m, 2H), 2.78-2.65( m, 5H), 2.62-2.55 (m, 4H), 2.43-2.32 (m, 2H), 2.02-1.92 (m, 1H). LCMS (ESI) C 32 H 31 ClN5O4 + [M+H] + : Calculated value 584.21, measured value 584.2.

[0541] Example 135: Preparation of Compound GT-09973

[0542] The target compound GT-09973 (35 mg, white solid, yield 68%) was prepared by referring to Synthesis Scheme 3. 1 H NMR (400MHz, DMSO-d6) δ10.92 (s, 1H), 7.57-7.51 (m, 3H), 7.50-7.40 (m, 6H), 6.84 (s, 1H) , 6.77 (d, J=8.0Hz, 1H), 5.00 (dd, J=13.2, 5.0Hz, 1H), 4.53 (s, 1H), 4.27 (dd, J=16.9, 3.2H z, 1H), 4.14 (dd, J=17.0, 3.3Hz, 1H), 3.54-3.42 (m, 2H), 2.97-2.81 (m, 2H), 2.71-2.65 (m, 2H), 2.63-2.54(m, 3H), 2.35-2.24(m, 1H), 1.99-1.79(m, 2H), 1.69(brs, 1H).LCMS(ESI)C 32 H 31 ClN5O4 + [M+H] + : Calculated value 584.21, measured value 584.2.

[0543] Example 136: Preparation of Compound GT-09974

[0544] The target compound GT-09974 (29 mg, white solid, yield 57%) was prepared by referring to Synthesis Scheme 3. 1 H NMR (400MHz, DMSO-d6) δ10.92 (s, 1H), 7.56-7.52 (m, 3H), 7.49-7.39 (m, 7H), 6.87 (s, 1H), 6.79 (d, J=8.1Hz, 1H), 5.01 (dd, J=13.3, 5.1Hz, 1H), 4.28 (d, J=16.9Hz, 1H), 4.14 (d, J=16.9Hz, 1H), 3.54-3.43(m, 4H), 3.21(s, 2H), 2.96-2.83(m, 1H), 2.59-2.54(m, 2H), 2.38-2.25(m, 2H), 1.97-1.91(m, 1H), 1.55(brs, 2H), 1.44(brs, 2H).LCMS(ESI)C 33 H 33 ClN5O4 + [M+H] + : Calculated value 598.22, measured value 598.3.

[0545] Example 137: Preparation of Compound GT-09975

[0546] The target compound GT-09975 (26 mg, white solid, yield 50%) was prepared by referring to Synthesis Scheme 3. 1 H NMR (400MHz, DMSO-d6) δ10.93 (s, 1H), 7.56-7.51 (m, 3H), 7.51-7.38 (m, 6H), 6.90 (s, 1H), 6.83 (s, 1H), 5.02 (dd, J=13.3, 5.1Hz, 1H), 4.30 (d, J=16.8Hz, 1H), 4.19 (d , J=16.8Hz, 1H), 3.61-3.57(m, 4H), 3.26-3.11(m, 1H), 3.05-2.75(m, 4H), 2.58(d , J=16.9Hz, 2H), 2.40-2.26(m, 1H), 1.97-1.93(m, 1H), 1.69(brs, 1H).LCMS(ESI)C 31 H 31 ClN5O4 + [M+H] + : Calculated value 572.21, measured value 572.2.

[0547] Example 138: Preparation of Compound GT-09976

[0548] The target compound GT-09976 (32 mg, white solid, yield 62%) was prepared by referring to the method of Synthesis Scheme 3. 1 H NMR (400MHz, DMSO-d6) δ10.92 (s, 1H), 7.57-7.53 (m, 5H), 7.49-7.42 (m, 4H), 6.86 (s, 1H) , 6.79 (d, J=8.3Hz, 1H), 5.01 (dd, J=13.3, 5.0Hz, 1H), 4.28 (d, J=16.9Hz, 1H), 4.15 (d, J=1 7.0Hz, 1H), 3.60 (s, 1H), 3.23 (s, 2H), 3.12-2.99 (m, 1H), 2.94-2.83 (m, 1H), 2.70-2.63 ( m, 1H), 2.60-2.55 (m, 2H), 2.37-2.28 (m, 1H), 2.04-1.87 (m, 2H), 1.64 (s, 1H).LCMS (ESI) C 31 H 29 ClN5O4 + [M+H] + : Calculated value 570.19, measured value 570.2.

[0549] Example 139: Preparation of Compound GT-09977

[0550] The target compound GT-09977 (29 mg, white solid, yield 56%) was prepared by referring to Synthesis Scheme 3. 1 H NMR (400MHz, DMSO-d6) δ10.92 (s, 1H), 7.58-7.51 (m, 4H), 7.50-7.36 (m, 5H), 6.91 (s, 1H), 6.81 (d, J=8.4Hz, 1H), 5.08-4.96 (m, 1H), 4.33-4.24 (m, 1H), 4.15 (d, J=1 6.3Hz, 1H), 3.68-3.63(m, 4H), 3.21-3.08(m, 1H), 2.97-2.81(m, 2H), 2.58(d, J=1 8.1Hz, 2H), 2.37-2.29(m, 1H), 2.02-1.87(m, 1H), 1.82-1.64(m, 1H).LCMS(ESI)C 31 H 29 ClN5O4 + [M+H] + : Calculated value 570.19, measured value 570.2.

[0551] Example 140: Preparation of Compound GT-09978

[0552] The target compound GT-09978 (27 mg, white solid, yield 52%) was prepared by referring to Synthesis Scheme 3. 1 H NMR (400MHz, DMSO-d6) δ10.92 (s, 1H), 7.60-7.44 (m, 7H), 7.39 (d, J=8.4Hz, 2H), 6.95 (s , 1H), 6.88 (t, J=8.7Hz, 1H), 5.01 (dd, J=13.3, 5.1Hz, 1H), 4.28 (d, J=16.8Hz, 1H), 4.13 (dd, J=17.0, 3.4Hz, 1H), 3.56-3.51(m, 4H), 3.30-3.18(m, 2H), 2.98-2.84(m, 2H), 2.58 (d, J=16.8Hz, 2H), 2.36-2.30(m, 1H), 2.07-1.88(m, 2H), 1.66-1.53(m, 1H).LCMS(ESI)C 32 H 31 ClN5O4 + [M+H] + : Calculated value 584.21, measured value 584.3.

[0553] Example 141: Preparation of compound GT-09980

[0554] The target compound GT-09980 (14 mg, white solid, yield 26%) was prepared by referring to the method of Synthesis Scheme 3. 1 H NMR (400MHz, DMSO-d6) δ10.94 (s, 1H), 7.43 (s, 1H), 7.40 (d, J = 8.0Hz, 2H), 7.29 (d, J = 8.4Hz, 2H), 6.78 (s, 1H), 6.74-6.67 (m, 1H), 5.03 (dd, J=13.4, 4.3Hz, 1H), 4.30 (d, J=16.7Hz, 1H), 4 .17(d, J=16.8Hz, 1H), 3.32-3.20(m, 5H), 2.95-2.84(m, 2H), 2.72-2.63(m, 2H), 2.63-2.55( m, 4H), 2.39-2.27 (m, 4H), 1.98-1.91 (m, 1H), 1.45 (t, J=6.3Hz, 2H), 0.99 (s, 6H). LCMS (ESI) C 34 H 39 ClN5O4 + [M+H] + : Calculated value 616.27, measured value 616.3.

[0555] Example 142: Preparation of Compound GT-09981

[0556] The target compound GT-09981 (24 mg, white solid, yield 44%) was prepared by referring to the method of Synthesis Scheme 3. 1 H NMR (400MHz, DMSO-d6) δ10.92 (s, 1H), 7.42-7.38 (m, 3H), 7.28 (d, J = 8.5Hz, 2H), 6.82 (s, 1H), 6.75 (d, J = 7.6Hz, 1H), 5.00 (dd, J=13.2, 5.0Hz, 1H), 4.37 (d, J=4.3Hz, 1H), 4.27 (dd, J=16.9, 3.5Hz, 1H), 4.13 (dd, J=16.9, 2.5Hz, 1H), 3.7 5(s, 1H), 3.32-3.21(m, 2H), 2.95-2.73(m, 3H), 2.57(d, J=17.3Hz, 2H), 2.41-2.27(m, 3H), 2.24-2.18(m, 1H), 2.00- 1.88 (m, 2H), 1.78 (brs, 1H), 1.65 (brs, 1H), 1.51-1.43 (m, 2H), 1.27-1.16 (m, 1H), 0.99 (d, J=4.2Hz, 6H). LCMS (ESI) C 34 H 39 ClN5O4 + [M+H] + : Calculated value 616.27, measured value 616.3.

[0557] Example 143: Preparation of Compound GT-09982

[0558] The target compound GT-09982 (18 mg, white solid, yield 34%) was prepared by referring to Synthesis Scheme 3. 1H NMR (400MHz, DMSO-d6) δ10.93 (s, 1H), 7.43-7.36 (m, 3H), 7.28 (d, J=8.4Hz, 2H), 6.85 (s, 1H) , 6.77 (d, J=8.3Hz, 1H), 5.01 (dd, J=13.4, 5.1Hz, 1H), 4.28 (d, J=16.8Hz, 1H), 4.14 (d, J=16.9 Hz, 1H), 3.25-3.15 (m, 3H), 2.94-2.85 (m, 1H), 2.58 (d, J=17.7Hz, 2H), 2.35-2.24 (m, 5H), 2. 14(s, 3H), 2.01-1.86(m, 1H), 1.43-1.40(m, 5H), 1.35-1.19(m, 2H), 0.98(s, 6H).LCMS(ESI)C 35 H 41 ClN5O4 + [M+H] + : Calculated value 630.28, measured value 630.3.

[0559] Example 144: Preparation of Compound GT-09983

[0560] The target compound GT-09983 (19 mg, white solid, yield 35%) was prepared by referring to the method of Synthesis Scheme 3. 1 H NMR (400MHz, DMSO-d6) δ10.92 (s, 1H), 7.44-7.36 (m, 3H), 7.32-7.25 (m, 2H), 6.84 (d, J=6.5Hz, 1H), 6.76 (t, J=8.1Hz, 1H), 5.01 (dd, J=13.2, 5.0Hz, 1H), 4.28 (d, J=16.8Hz, 1H), 4.14 (d, J=16.8Hz, 1H), 3.34-3. 18(m, 3H), 3.03-2.83(m, 2H), 2.80-2.65(m, 2H), 2.58(d, J=15.9Hz, 2H), 2.39-2.32(m, 4H), 2.23-2.08( m, 1H), 1.95-1.91 (m, 2H), 1.74 (brs, 1H), 1.65-1.51 (m, 1H), 1.51-1.37 (m, 2H), 0.99 (s, 6H). LCMS (ESI) C 33 H 39 ClN5O4 + [M+H] + : Calculated value 604.27, measured value 604.3.

[0561] Example 145: Preparation of Compound GT-09984

[0562] The target compound GT-09984 (37 mg, white solid, yield 68%) was prepared by referring to Synthesis Scheme 3. 1 H NMR (400MHz, DMSO-d6) δ10.92 (s, 1H), 7.43-7.40 (m, 3H), 7.29 (d, J=8.5Hz, 2H), 6.83 (s, 1H), 6.7 7 (d, J=8.4Hz, 1H), 5.01 (dd, J=13.2, 5.1Hz, 1H), 4.27 (d, J=17.0Hz, 1H), 4.13 (d, J=16.8Hz, 1H), 3 .99 (s, 1H), 3.67 (s, 1H), 3.34-2.99 (m, 3H), 2.89-2.84 (m, 1H), 2.57 (d, J=19.2Hz, 2H), 2.41-2.1 8(m, 4H), 2.00-1.85(m, 3H), 1.48-1.41(m, 2H), 1.29(brs, 1H), 0.96(d, J=3.3Hz, 6H).LCMS(ESI)C 33 H 37 ClN5O4 + [M+H] + : Calculated value 602.25, measured value 602.3.

[0563] Example 146: Preparation of Compound GT-09985

[0564] The target compound GT-09985 (36 mg, white solid, yield 66%) was prepared by referring to Synthesis Scheme 3. 1 H NMR (400MHz, DMSO-d6) δ10.92 (s, 1H), 7.50-7.32 (m, 4H), 7.28 (d, J=8.4Hz, 1H), 6.88 (s, 1H) , 6.79 (d, J=8.0Hz, 1H), 5.01 (dd, J=13.0, 4.7Hz, 1H), 4.27 (d, J=17.1Hz, 1H), 4.14 (d, J=16.7 Hz, 1H), 3.40-3.22 (m, 4H), 2.99-2.81 (m, 2H), 2.65-2.52 (m, 2H), 2.43-2.29 (m, 3H), 2.28-2. 13(m, 2H), 2.01-1.85(m, 2H), 1.76-1.65(m, 1H), 1.50-1.39(m, 2H), 0.99(s, 6H).LCMS(ESI)C 33 H 37 ClN5O4 +[M+H] + : Calculated value 602.25, measured value 602.3.

[0565] Example 147: Preparation of Compound GT-09986

[0566] The target compound GT-09986 (25 mg, white solid, yield 46%) was prepared by referring to Synthesis Scheme 3. 1 H NMR (400MHz, DMSO-d6) δ10.92 (s, 1H), 7.46-7.34 (m, 4H), 7.21 (d, J=8.0Hz, 1H), 7.02-6.82 (m, 2H), 5.01 (dd, J=13.3, 5.1Hz, 1H), 4.28 (d, J=16.7Hz, 1H), 4.13 (d, J=16.8Hz, 1H), 3.36-3.24 (m, 2H), 3.2 4-3.08 (m, 2H), 3.00 (s, 1H), 2.95-2.81 (m, 1H), 2.58 (d, J=16.4Hz, 2H), 2.38-2.28 (m, 4H), 2.20-2. 06(m, 1H), 2.03-1.88(m, 3H), 1.72(brs, 1H), 1.52-1.34(m, 3H), 0.98(d, J=14.1Hz, 6H).LCMS(ESI)C 34 H 39 ClN5O4 + [M+H] + : Calculated value 616.27, measured value 616.3.

[0567] Example 148: Preparation of Compound GT-09987

[0568] The target compound GT-09987 (25 mg, white solid, yield 47%) was prepared by referring to Synthesis Scheme 3. 1H NMR (400MHz, DMSO-d6) δ10.94 (s, 1H), 7.42 (d, J=8.4Hz, 1H), 7.36-7.25 (m, 2H), 7.17 (t, J=7.9Hz, 2H), 6.87-6.61 (m, 2H), 5.03 (dd, J=13.2, 5.0Hz, 1H), 4.30 (d, J=17.0Hz, 1H), 4.16 (d, J=16.9Hz, 1H), 3.38-3.31 (m, 5H), 2.98-2.84 (m, 2H), 2.60-2.51 (m, 4H), 2.44-2.20(m, 5H), 2.05-1.88(m, 2H), 1.45(t, J=6.0Hz, 2H), 0.99(s, 6H).LCMS(ESI)C 34 H 39 FN5O4 + [M+H] + : Calculated value 600.30, measured value 600.4.

[0569] Example 149: Preparation of Compound GT-09988

[0570] The target compound GT-09988 (32 mg, white solid, yield 61%) was prepared by referring to Synthesis Scheme 3. 1 H NMR (400MHz, DMSO-d6) δ10.92 (s, 1H), 7.41 (d, J=8.3Hz, 1H), 7.30 (dd, J=8.5, 5.7Hz, 2H), 7.16 (t, J=8.8Hz, 2H), 6.82 (s, 1H), 6.75 (d, J=8.2Hz, 1H), 5.01 (dd, J=13.3, 5.1Hz, 1H), 4.36 (s, 1H), 4.27 (dd, J=16.9, 3.6Hz, 1H), 4.13 (dd, J=17.0, 2.6Hz, 1H), 3 .76 (s, 1H), 2.89-2.83 (m, 1H), 2.80 (d, J=9.8Hz, 2H), 2.59-2.52 (m, 3H), 2.46-2.39 (m, 2H), 2.39-2.27 (m, 2H), 2.26-2.13 (m, 1 H), 2.01-1.86 (m, 2H), 1.77 (brs, 1H), 1.64 (brs, 1H), 1.54-1.39 (m, 2H), 1.20-1.16 (m, 1H), 0.99 (d, J=3.8Hz, 6H). LCMS (ESI) C 34 H 39 FN5O4 + [M+H] +: Calculated value 600.30, measured value 600.4.

[0571] Example 150: Preparation of compound GT-09989

[0572] The target compound GT-09989 (28 mg, white solid, ...

Claims

1. A compound of formula (I) or a salt, enantiomer, stereoisomer, isotopically enriched analog, solvate or polymorph thereof, in Z represents C(O), CH2 or CD2; R a1 、R a2 、R a3 and R a4 Each independently represents hydrogen, deuterium, halogen, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy or halogenated C 1-6 alkoxy; (R a5 ) m represents that the isoindoline ring connected thereto is optionally replaced by m R a5 Replace, each R a5 The same or different and each independently represents deuterium, halogen, hydroxyl, mercapto, nitro, amino, cyano, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkenyl or C 2-6 Alkynyl; m represents an integer 0, 1, 2 or 3; R stands for: wherein Ring A1 represents a heterocyclic group containing at least 2 nitrogen atoms, (R d1 ) n1 Indicates that ring A1 is optionally replaced by n1 R d1 Group substitution, each R d1 Each independently represents deuterium, halogen, hydroxyl, mercapto, nitro, amino, cyano, oxo, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy or C 1-6 alkoxy, and n1 represents an integer of 0-20; and R1 represents N(R w ), where R w Represents hydrogen or C 1-3 alkyl, and R2 represents a bond, or R2 represents CH2 or C(O); or R1 represents a bond, and R2 represents N(R w ), where R w Represents hydrogen or C 1-3 Alkyl, or R2 represents N(R w )C(O)*, where R w Represents hydrogen or C 1-3 Alkyl, or R2 represents -N=CH-*; or R stands for: where R X represents NH, -N=CH-* or N(R w )C(O)*, where R w Represents hydrogen or C 1-3 alkyl; or R stands for: wherein Ring A2 represents a heterocyclic group containing one nitrogen atom, (R d4 ) n4 represents ring A2 optionally replaced by n4 R d4 Group substitution, each R d4 Each independently represents deuterium, halogen, hydroxyl, mercapto, nitro, amino, cyano, oxo, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy or C 1-6 alkoxy, and n4 represents an integer of 0-20; and where R y1 express The symbol ** indicates the point of attachment to Ring A2; and R y2 N(R w ) or N(R w )C(O)*, where R w Represents hydrogen or C 1-3 alkyl; The symbol * in the above formula indicates c connection points; and R c Indicates CR c1 R c2 , where R c1 and R c2 Each independently represents H, deuterium, halogen, an optionally substituted linear or branched alkyl group, an optionally substituted cycloalkyl group, an optionally substituted heterocyclyl group, an optionally substituted aryl group or an optionally substituted heteroaryl group, or R c Indicates a key; Ring B represents a cycloalkylene group, a heterocyclylene group, an arylene group or a heteroarylene group, m1 represents an integer of 0 or 1, (R d2 ) n2 Indicates that ring B is optionally replaced by n2 R d2 Group substitution, each R d2 Each independently represents deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, oxo, C 2-6 Alkynyl or C 2-6 alkenyl, and n2 represents an integer of 0 to 20; and Ring C represents a heterocyclic group, a cycloalkyl group, an aryl group or a heteroaryl group, (R d3 ) n3 represents ring C optionally replaced by n3 R d3 Group substitution, each R d3 Each independently represents deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, oxo, C 2-6 Alkynyl or C 2-6 alkenyl, and n3 represents an integer of 0-20; Provided that the following compounds are not included: 3-(5-((4-benzhydrylpiperazin-1-yl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-((4′-chloro-[1,1′-biphenyl]-2-yl)methyl)piperazin-1-yl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-((4′-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-yl)methyl)piperazin-1-yl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; and 3-(5-((4-(4′-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-carbonyl)piperazin-1-yl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione.

2. The compound of formula (I) or a salt, enantiomer, stereoisomer, solvate or polymorph thereof according to claim 1, wherein (i)R a1 、R a2 、R a3 and R a4 Each independently represents H; and / or (ii) Ring A1 represents a 4- to 30-membered heterocyclylene group (including a 4- to 20-membered heterocyclylene group and a 4- to 15-membered heterocyclylene group) containing at least 2 nitrogen atoms, (R d1 ) n1 Indicates that ring A1 is optionally replaced by n1 R d1 Group substitution, each R d1 are independently deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano, oxo, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy or C 1-6 alkoxy, and n1 represents an integer of 0-20; and / or (iii) R1 represents N(R w ), where R w Represents hydrogen or C 1-3 alkyl, and R2 represents a bond; or (iv) R1 represents N(R w ), where R w Represents hydrogen or C 1-3 alkyl, and R2 represents CH2 or C(O); or (v) R1 represents a bond, and R2 represents N(R w ), where R w Represents hydrogen or C 1-3 alkyl; or (vi) R1 represents a bond, and R2 represents N(R w )C(O)*, where R w Represents hydrogen or C 1-3 alkyl; or (vii) R1 represents a bond, and R2 represents -N=CH-*; and / or (viii) Ring A2 represents a 4- to 30-membered heterocyclylene group (including a 4- to 20-membered heterocyclylene group and a 4- to 15-membered heterocyclylene group) containing one nitrogen atom, (R d4 ) n4 represents ring A2 optionally replaced by n4 R d4 Group substitution, each R d4 are independently deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano, oxo, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1- 6 alkoxy or C 1-6 alkoxy, and n4 represents an integer of 0-20; and / or (iv)R c Indicates CR c1 R c2 , where R c1 and R c2 Each independently represents H, deuterium, halogen, an optionally substituted linear or branched C 1- 10 Alkyl, optionally substituted C 3-30 Cycloalkyl, optionally substituted C 5-30 aryl, optionally substituted 4- to 30-membered heterocyclyl, or optionally substituted 5- to 30-membered heteroaryl, or R c Represents a key; and / or (v) Ring B represents a 4- to 30-membered heterocyclylene group, C 3-30 Cycloalkylene, C 5-30 Arylene or 5 to 30 membered heteroarylene, m1 represents an integer of 0 or 1, (R d2 ) n2 Indicates that ring B is optionally replaced by n2 R d2 Group substitution, each R d2 Deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, oxo, C 2-6 Alkynyl or C 2-6 alkenyl, and n2 represents an integer from 0 to 20; and / or (vi) Ring C represents C 3-30 Cycloalkyl, 4 to 30 membered heterocyclic group, C 5-30 Aryl or 5- to 30-membered heteroaryl, (R d3 ) n3 represents ring C optionally replaced by n3 R d3 Group substitution, each R d3 Deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, oxo, C 2-6 Alkynyl or C 2-6 alkenyl, and n3 represents an integer of 0-20.

3. The compound of formula (I) or a salt, enantiomer, stereoisomer, solvate or polymorph thereof according to claim 1, wherein R represents one of the following formulae: Among them, each R w Each independently represents hydrogen or C 1-3 alkyl; Each ring A1 independently represents a heterocyclic group containing at least 2 nitrogen atoms, (R d1 ) n1 Indicates that ring A1 is optionally replaced by n1 R d1 Group substitution, each R d1 Each independently represents deuterium, halogen, hydroxyl, mercapto, nitro, amino, cyano, oxo, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy or C 1-6 alkoxy, and n1 represents an integer of 0-20; Ring A2 represents a heterocyclic group containing one nitrogen atom, (R d4 ) n4 represents ring A2 optionally replaced by n4 R d4 Group substitution, each R d4 Each independently represents deuterium, halogen, hydroxyl, mercapto, nitro, amino, cyano, oxo, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy or C 1-6 alkoxy, and n4 represents an integer of 0-20; and The symbol * indicates that c connection point.

4. A compound of formula (I) or a salt, enantiomer, stereoisomer, solvate or polymorph thereof as claimed in any one of claims 1 to 3, wherein (i) each ring A1 independently represents a 4- to 20-membered heterocyclylene group (including a 4- to 15-membered heterocyclylene group) containing at least 2 nitrogen atoms, (R d1 ) n1 Indicates that ring A1 is optionally replaced by n1 R d1 Group substitution, each R d1 are independently deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano, oxo, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy or C 1-6 alkoxy, and n1 represents an integer of 0-20; or (ii) Ring A2 represents a 4- to 20-membered heterocyclic group (including a 4- to 15-membered heterocyclic group) containing one nitrogen atom, (R d4 ) n4 represents ring A2 optionally replaced by n4 R d4 Group substitution, each R d4 are independently deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano, oxo, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy or C 1-6 alkoxy, and n4 represents an integer of 0-20; and / or (iii) the R c1 and R c2 Each independently represents H, deuterium, halogen, an optionally substituted linear or branched C 1-6 Alkyl, optionally substituted C 3-20 Cycloalkyl (including optionally substituted C 3-15 cycloalkyl), optionally substituted C 5-20 Aryl (including optionally substituted C 5-15 aryl), optionally substituted 4 to 20 membered heterocyclyl (including optionally substituted 4 to 15 membered heterocyclyl), or optionally substituted 5 to 20 membered heteroaryl (including optionally substituted 5 to 15 membered heteroaryl); and / or (iv) the ring B represents a 4- to 20-membered heterocyclylene group (including a 4- to 15-membered heterocyclylene group), C 3-20 Cycloalkylene (including C 3-15 Cycloalkylene), C 5-20 Arylene (including C 5-15 arylene) or 5 to 20 membered heteroarylene (including 5 to 15 membered heteroarylene), m1 represents an integer of 0 or 1, (R d2 ) n2 Indicates that ring B is optionally replaced by n2 R d2 Group substitution, each R d2 Deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, oxo, C 2-6 Alkynyl or C 2-6 alkenyl, and n2 represents an integer from 0 to 20; and / or (v) The ring C represents C 3-20 Cycloalkyl (including C 3-15 cycloalkyl), 4 to 20 membered heterocyclic group (including 4 to 15 membered heterocyclic group), C 5-20 Aryl (including C 5-15 aryl) or 5- to 20-membered heteroaryl (including 5- to 15-membered heteroaryl), (R d3 ) n3 Indicates that the ring C is optionally replaced by n3 R d3 Group substitution, each R d3 Deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, oxo, C 2-6 Alkynyl or C 2-6 alkenyl, and n3 represents an integer of 0-20.

5. The compound of formula (I) or a salt, enantiomer, stereoisomer, solvate or polymorph thereof according to claim 1, wherein (i) Z represents C(O) or CH2; and / or (ii) each ring A1 independently represents a 1,3-diazetidinylidene, an imidazolidinylidene, a pyrazolidinylidene, a piperazinylidene, a diazaheptanylidene, a diazaoctanylidene, a diazabicyclo[3.1.1]heptanylidene, a diazabicyclo[2.2.1]heptanylidene, a diazabicyclo[3.2.1]octanylidene, a diazabicyclo[2.2.2]octanylidene, a 2,6-diazaspiro[3.3]heptanylidene, a 2,7-diazaspiro[3.5]nonanylidene, a 2,8-diazaspiro[4.5]decanylidene, a 3,9-diazaspiro[5.5]undecanylidene or an octahydropyrrolo[3,4-c]pyrroleylidene, which is optionally replaced by n1 R d1 Group substitution, each R d1 are independently deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano, oxo, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy or C 1-6 alkoxy, and n1 represents an integer of 0-20 (e.g., an integer of 0-10); or (iii) the ring A2 represents an azetidinyl, pyrrolidinyl, piperidinyl, dihydroxypiperidinyl, difluoropiperidinyl, azepanyl, octanyl, a monoazabridged ring subunit (e.g., a 6- to 20-membered monoazabridged ring subunit, such as a 6-azabicyclo[3.1.1]heptanyl subunit, a 3-azabicyclo[3.2.1]octanyl subunit and a quinuclidinyl subunit) or a monoazaspirosubunit (e.g., a 5- to 20-membered monoazaspirosubunit, such as a 3-azaspiro[5.5]undecyl subunit and a 7-azaspiro[3.5]nonanyl subunit), which is optionally substituted by n4 R d4 Group substitution, each R d4 are independently deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano, oxo, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy or C 1-6 alkoxy, and n4 represents an integer of 0-20 (eg, an integer of 0-10); and / or (iv)R c1 and R c2 Each independently represents: H, deuterium, halogen or optionally substituted linear or branched C 1-10 alkyl; or Cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, cyclooctyl, decahydronaphthyl, octahydropentalenyl, octahydro-1H-indenyl, spirocycloalkyl (e.g., C5-C 20 spirocyclic groups, such as spiro[3.3]heptanyl, spiro[2.5]octanyl, spiro[3.5]nonanyl, spiro[3.5]nonenyl, spiro[4.4]nonanyl, spiro[4.5]decanyl, spiro[4.5]decenyl, spiro[5.5]undecyl), p-menthanyl, m-menthanyl, or bridged cycloalkyl groups (e.g., C6-C 20 Bridged ring groups, such as adamantyl, noradamantyl, bornyl, norbornyl, bicyclo[2.2.1]heptanyl, 2-oxobicyclo[ 2.2.1]heptyl or bicyclo[2.2.1]heptenyl), which may be substituted by one or more (e.g., 1-10) groups independently selected from deuterium, halogen, hydroxy, thiol, nitro, amino, cyano, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkenyl and C 2-6 Substitution of the alkynyl group by a substituent; or azetidinyl, oxetanyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, oxazolidinyl, thiazolidinyl, piperidinyl, piperazinyl, tetrahydropyridinyl, dihydroxypiperidinyl, difluoropiperidinyl, morpholinyl, thiomorpholinyl, azepanyl, azocanyl, dioxanyl, azepanyl, azocanyl, diazepanyl (e.g., 1,4-diazacycloheptyl, 4,5-diazacycloheptyl, 1,3-diazacycloheptyl), diazacycloheptyl, bridged heterocyclic groups (e.g., 6- to 20-membered bridged heterocyclic groups, such as 6-azabicyclo[3.1.1]heptyl, 2,5-diazabicyclo[2.2.1]heptyl, 3,6-diazabicyclo[3.1.1]heptyl, 3- ]octanyl, 3,8-diazabicyclo[3.2.1]octanyl, 3,8-diazabicyclo[3.2.1]octanyl, 2,5-diazabicyclo[2.2.2]octanyl and quinuclidine), and azaspirocyclyl (e.g., 5- to 20-membered azaspirocyclyl, such as 2,6-diazaspiro[3.3]heptyl, 2,7-diazaspiro[3.5]nonyl, 2,8-diazaspiro[4.5]decyl, 3,9-diazaspiro[5.5]undecyl, 3-azaspiro[5.5]undecyl and 7-azaspiro[3.5]nonyl), or octahydropyrrolo[3,4-c]pyrrolyl, which is optionally substituted by one or more (e.g., 1-10) groups each independently selected from deuterium, halogen, hydroxy, thiol, amino, cyano, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkenyl and C 2-6 Substitution of the alkynyl group by a substituent; or Phenyl or naphthyl, which may be optionally substituted by one or more (e.g. 1-7) independently selected from deuterium, halogen, hydroxyl, mercapto, nitro, amino, cyano, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2- 6 alkenyl and C 2-6 Substitution of the alkynyl group by a substituent; or furyl, oxazolyl, isoxazolyl, oxadiazolyl, thienyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, triazinyl, indolyl, isoindolyl, indolyl, benzofuranyl, chromanyl, isobenzofuranyl, benzothienyl, indazolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzotriazolyl, benzo[2,1,3]oxadiazolyl, benzo[ 2,1,3]thiadiazolyl, benzo[1,2,3]thiadiazolyl, 2-oxo-2,3-dihydro-1H-benzo[d]imidazolyl, benzo[b][1,4]oxazinyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, quinolyl, isoquinolyl, 1,2,3,4-tetrahydroquinolyl, naphthyridinyl, cinnolinyl, quinazolinyl, quinoxalinyl, 1,2,3,4-tetrahydroquinoxalinyl, phthalazinyl, 5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3 -a]pyrazinyl, 4,5,6,7-tetrahydrothieno[3,2-c]pyridinyl, 5-oxo-6,7-dihydrothieno[3,2-d]pyrimidinyl, thieno[2,3-d]pyrimidinyl, thieno[3,2-d]pyrimidinyl, isoxazolo[4,5-c]pyridinyl, isoxazolo[4,5-c]pyrimidinyl, isoxazolo[4,5-d]pyrimidinyl, pyrazolo[1,5-a]pyridinyl, pyrazolo[1,5-a]pyrimidinyl, imidazo[1,2-a]pyridinyl, 1 H-pyrrolo[3,2-b]pyridinyl, 1H-pyrrolo[2,3-b]pyridinyl, pyrrolo[2,1-b]thiazolyl, imidazo[2,1-b]thiazolyl, 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidinyl, or 6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidinyl, which may be substituted by one or more (e.g., 1-10) groups independently selected from deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1- 6 alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkenyl and C 2-6 Substitution of the alkynyl group by a substituent; and / or (v) The ring B represents: Cyclopropylene, cyclobutylene, cyclopentylene, cyclopentenylene, cyclohexylene, cyclohexenylene, cycloheptylene, cyclooctylene, decahydronaphthylene, octahydropentalenylene, octahydro-1H-indenylene, 2,3-dihydro-1H-indenylene, spirocycloalkylene (e.g., C5-C 20 Spirocycloalkylene, such as spiro[3.3]heptanylene, spiro[2.5]octanylene, spiro[3.5]nonanylene, spiro[3.5]nonenylene, spiro[4.4]nonanylene, spiro[4.5]decanylene, spiro[4.5]decenylene, spiro[5.5]undecanylene), p-menthanylene, m-menthanylene, or bridged cycloalkylene (e.g., C6-C 20 Bridged cycloalkylene, for example adamantylene, noradamantylene, bornylene, norbornylene, bicyclo[2.2.1]heptanylene, 2-oxobicyclo[ 2.2.1] heptanylene or bicyclo[2.2.1] heptenylene), which may be optionally substituted by 0-20 (e.g. 0-10) each independently selected from deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, oxo, C 2-6 Alkynyl or C 2-6 Substitution of the alkenyl group by a substituent; or Azetidinyl, oxetanyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, tetrahydrofuranyl, dihydropyranyl, tetrahydropyranyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, oxazolidinyl, thiazolidinyl, piperidinyl, piperazinyl, tetrahydropyridinyl, dihydroxypiperidinyl, difluoropiperidinyl, morpholinyl, thiomorpholinyl, dioxane, thiophene, Azacycloheptane, azacyclooctanyl, diazacycloheptane group (e.g., 1,4-diazacycloheptane group, 4,5-diazacycloheptane group, 1,3-diazacycloheptane group), diazacyclooctanyl group, subbridged heterocyclic group (e.g., 6- to 20-membered subbridged heterocyclic group, e.g., 6-azabicyclo[3.1.1]heptane group, 2,5-diazabicyclo[2.2.1]heptane group), 1, 2, 3, 6-diazabicyclo[3.1.1]heptanylene, 3-azabicyclo[3.2.1]octanylene, 3, 8-diazabicyclo[3.2.1]octanylene, 2, 5-diazabicyclo[2.2.2]octanylene and quinuclidinylene), azaspirocyclyl (e.g., a 5- to 20-membered azaspirocyclyl, e.g., a 2, 6-diazaspiro[3.3]heptanylene, 2,7-diazaspiro[3.5]nonanediyl, 2,8-diazaspiro[4.5]decanediyl, 3,9-diazaspiro[5.5]undecanediyl, 3-azaspiro[5.5]undecanediyl and 7-azaspiro[3.5]nonanediyl), or octahydropyrrolo[3,4-c]pyrrolediyl, which is optionally substituted by 0-20 (e.g., 0-10) each independently selected from deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, oxo, C 2-6 Alkynyl or C 2-6 Substitution of the alkenyl group by a substituent; or Phenylene or naphthylene, which may be optionally substituted by 0-20 (e.g. 0-6) each independently selected from deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, C 2-6 Alkynyl or C 2-6 Substitution of the alkenyl group by a substituent; or furylene, oxazolylene, isoxazolylene, oxadiazolylene, thienylene, thiazolylene, isothiazolylene, thiadiazolylene, pyrrolylene, imidazolylene, pyrazolylene, triazolylene, pyridinylene, pyrimidinylene, pyridazinylene, pyrazinylene, triazinylene, indolylene, isoindolylene, indolylene, benzofuranylene, chromanylene, isobenzofuranylene, benzothienylene, indazolylene, benzimidazolylene, benzoxazolylene, benzoisoxazolylene, benzothiazolylene, benzoisothiazolylene, benzotriazolylene oxazolyl, benzo[2,1,3]oxadiazolyl, benzo[2,1,3]thiadiazolyl, benzo[1,2,3]thiadiazolyl, 2-oxo-2,3-dihydro-1H-benzo[d]imidazolylidene, benzo[b][1,4]oxazinyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, quinolinyl, isoquinolinyl, 1,2,3,4-tetrahydroquinolinyl, naphthyridinyl, cinnolinyl, quinazolinyl, quinoxalinyl, 1,2,3,4-tetrahydroquinoxalinyl, phthalazinyl, 5-[[(4-( ... ,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine subunit, 4,5,6,7-tetrahydrothieno[3,2-c]pyridinyl subunit, 5-oxo-6,7-dihydrothieno[3,2-d]pyrimidine subunit, thieno[2,3-d]pyrimidine subunit, thieno[3,2-d]pyrimidine subunit, isoxazolo[4,5-c]pyrimidine subunit, isoxazolo[4,5-c]pyrimidine subunit, isoxazolo[4,5-d]pyrimidine subunit, pyrazolo[1,5-a]pyridinyl subunit, pyrazolo[1,5 -a] pyrimidinyl, imidazo[1,2-a]pyrimidinyl, 1H-pyrrolo[3,2-b]pyrimidinyl, 1H-pyrrolo[2,3-b]pyrimidinyl, pyrrolo[2,1-b]thiazolyl, imidazo[2,1-b]thiazolyl, 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidinyl, or 6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidinyl, which is optionally substituted by 0-20 (e.g., 0-10) units each independently selected from deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, C 2-6 Alkynyl or C 2-6 Substitution of the alkenyl group by a substituent; and / or (vi) The ring C represents: Cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, cyclooctyl, decahydronaphthyl, octahydropentalenyl, octahydro-1H-indenyl, spirocycloalkyl (e.g., C5-C 20 spirocyclic groups, such as spiro[3.3]heptanyl, spiro[2.5]octanyl, spiro[3.5]nonanyl, spiro[3.5]nonenyl, spiro[4.4]nonanyl, spiro[4.5]decanyl, spiro[4.5]decenyl, spiro[5.5]undecyl), p-menthanyl, m-menthanyl, or bridged cycloalkyl groups (e.g., C6-C 20 Bridged ring groups, such as adamantyl, noradamantyl, bornyl, norbornyl, bicyclo[2.2.1]heptanyl, 2-oxobicyclo[ 2.2.1]heptyl or bicyclo[2.2.1]heptenyl), which may be optionally substituted by 0-20 (e.g., 0-10) each independently selected from deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, oxo, C 2-6 Alkynyl and C 2-6 Substitution of the alkenyl group by a substituent; or azetidinyl, oxetanyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, oxazolidinyl, thiazolidinyl, piperidinyl, piperazinyl, tetrahydropyridinyl, dihydroxypiperidinyl, difluoropiperidinyl, morpholinyl, thiomorpholinyl, azepanyl, azocanyl, dioxanyl, azepanyl, azocanyl, diazepanyl (e.g., 1,4-diazepanyl, 4,5-diazepanyl, 1,3-diazepanyl), diazepanyl, bridged heterocyclic groups (e.g., 6- to 20-membered bridged heterocyclic groups, such as 6-azabicyclo[3.1.1]heptyl, 2,5-diazabicyclo[2.2.1]heptyl, 3, 6-diazabicyclo[3.1.1]heptyl, 3-azabicyclo[3.2.1]octyl, 3,8-diazabicyclo[3.2.1]octyl, 2,5-diazabicyclo[2.2.2]octyl and quinuclidine), and azaspirocyclyl (e.g., 5- to 20-membered azaspirocyclyl, such as 2,6-diazaspiro[3.3]heptyl, 2,7-diazaspiro[3.5]nonyl, 2,8-diazaspiro[4.5]decyl, 3,9-diazaspiro[5.5]undecyl, 3-azaspiro[5.5]undecyl and 7-azaspiro[3.5]nonyl), or octahydropyrrolo[3,4-c]pyrrolyl, which is optionally substituted by 0-20 (e.g., 0-10) each independently selected from deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, oxo, C 2-6 Alkynyl and C 2-6 Substitution of the alkenyl group by a substituent; or phenyl or naphthyl, which may be optionally substituted by 0-20 (e.g. 0-6) each independently selected from deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, C 2-6 Alkynyl and C 2-6 Substitution of the alkenyl group by a substituent; or furyl, oxazolyl, isoxazolyl, oxadiazolyl, thienyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, triazinyl, indolyl, isoindolyl, indolyl, benzofuranyl, chromanyl, isobenzofuranyl, benzothienyl, indazolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzotriazolyl, benzo[2,1,3]oxadiazole yl, benzo[2,1,3]thiadiazolyl, benzo[1,2,3]thiadiazolyl, 2-oxo-2,3-dihydro-1H-benzo[d]imidazolyl, benzo[b][1,4]oxazinyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, quinolyl, isoquinolyl, 1,2,3,4-tetrahydroquinolyl, naphthyridinyl, cinnolinyl, quinazolinyl, quinoxalinyl, 1,2,3,4-tetrahydroquinoxalinyl, phthalazinyl, 5,6,7,8-tetrahydro-[1,2, 4]triazolo[4,3-a]pyrazinyl, 4,5,6,7-tetrahydrothieno[3,2-c]pyridinyl, 5-oxo-6,7-dihydrothieno[3,2-d]pyrimidinyl, thieno[2,3-d]pyrimidinyl, thieno[3,2-d]pyrimidinyl, isoxazolo[4,5-c]pyridinyl, isoxazolo[4,5-c]pyrimidinyl, isoxazolo[4,5-d]pyrimidinyl, pyrazolo[1,5-a]pyridinyl, pyrazolo[1,5-a]pyrimidinyl, imidazole oxazolo[1,2-a]pyridinyl, 1H-pyrrolo[3,2-b]pyridinyl, 1H-pyrrolo[2,3-b]pyridinyl, pyrrolo[2,1-b]thiazolyl, imidazo[2,1-b]thiazolyl, 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidinyl, or 6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidinyl, which is optionally substituted by 0-20 (e.g., 0-10) each independently selected from deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, C 2-6 Alkynyl and C 2-6 The substituents of the alkenyl group are substituted.

6. The compound of formula (I) or a salt, enantiomer, stereoisomer, solvate or polymorph thereof according to claim 1, wherein (i) R represents one of the following structures: The symbol * indicates that c connection points; and / or (ii) in the compound of formula (I) A section represents one of the following structures:

7. The compound of formula (I) or a salt, enantiomer, stereoisomer, solvate or polymorph thereof according to claim 1, which is selected from the compounds in Table 1.

8. A compound of formula (I) or a salt, enantiomer, stereoisomer, solvate or polymorph thereof as claimed in any one of claims 1 to 7, which is a hydrohalide salt (including hydrochloride, hydrobromide), sulfate, citrate / citrate, maleate, lactate, lactobionate, L-tartrate, fumarate, L-malate, L-lactate, α-ketoglutarate, hippurate, D-glucuronate, D-gluconate, α-D-glucoheptonate, glycolate, mucate, L-ascorbate, orotate, picrate, glycinate, alanine salt, arginine salt, cinnamate, laurate, pamoate, sebacate, benzenesulfonate, methanesulfonate, ethanesulfonate, edisylate, formate, acetate, 2, 2-dichloroacetate, pivalate, propionate, valerate, palmitate, triphenylacetate, 2-ethyl-succinate, iodate, nicotinate, L-pyroglutamate, L-proline, ferulate, 2-hydroxyethanesulfonate, nitrate, gentisate, cholate, salicylate, terephthalate, glutarate, adipate, stearate, oleate, undecenoate, camphorate, camphorsulfonate, dodecylsulfonate, phosphate, thiocyanate, dihydrogenphosphate, pyrophosphate, metaphosphate, oxalate, carbonate, malonate, benzoate, mandelate, succinate, pyruvate, p-chlorobenzenesulfonate, 1,5-naphthalenedisulfonate, 3-hydroxy-2-naphthoate, 1-hydroxy-2-naphthoate, 2-naphthalenesulfonate, trifluoroacetate, glycolate, or p-toluenesulfonate.

9. A compound of formula (I') or a salt, enantiomer, stereoisomer, isotopically enriched analog, solvate or polymorph thereof, in Z represents C(O), CH2 or CD2; R a1 、R a2 、R a3 and R a4 Each independently represents hydrogen, deuterium, halogen, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy or halogenated C 1-6 alkoxy; (R a5 ) m represents that the isoindoline ring connected thereto is optionally replaced by m R a5 Replace, each R a5 The same or different and each independently represents deuterium, halogen, hydroxyl, mercapto, nitro, amino, cyano, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl or heterocyclic group, the heterocyclic group is optionally substituted by one or more independently selected from halogen, C 1-6 Substitution with a substituent consisting of an alkyl group and a tert-butyloxycarbonyl group; m represents an integer 0, 1, 2 or 3; Ring A1 represents a 4- to 30-membered heterocyclic group containing at least 2 nitrogen atoms, (R d1 ) n1 Indicates that ring A1 is optionally replaced by n1 R d1 Group substitution, each R d1 Each independently represents deuterium, halogen, hydroxyl, mercapto, nitro, amino, cyano, oxo, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy or C 1-6 alkoxy, and n1 represents an integer of 0-20; and R1 represents N(R w ), where R w represents hydrogen or C optionally substituted by one or more substituents independently selected from the group consisting of optionally substituted aryl and optionally substituted heteroaryl 1-3 alkyl, and R2 represents a bond; or R1 represents a bond, and R2 represents N(R w ), where R w Represents hydrogen or C 1-3 alkyl; and R e Indicates a key, or R e Indicates C(O)O, or R e Represents the following structure: R e1 represents C(O), CH2 or halogenated CH2; Ring D represents an arylene group, (R e2 ) m2 represents a ring D optionally replaced by m2 R e2 Group substitution, each R e2 Each independently represents deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, oxo, C 2-6 Alkynyl or C 2-6 alkenyl, and m2 represents an integer of 0-20; and Ring E represents a nitrogen-containing heterocyclic group, m4 represents an integer of 0 or 1, (R e3 ) m3 represents a ring E optionally surrounded by m3 R e3 Group substitution, each R e3 Each independently represents deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, oxo, C 2-6 Alkynyl or C 2-6 alkenyl, and m3 represents an integer of 0-20; The symbol # indicates the same as R f connection points; and R f Indicates C 1-10 Alkyl, the C 1-10 The alkyl group is optionally substituted with one or more substituents independently selected from the group consisting of halogen, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclyl, optionally substituted cycloalkyl, and NR3R4, wherein R3 and R4 each independently represent H, C 1-3 alkyl or optionally substituted cycloalkyl; Provided that the following compounds are not included: 3-(5-((4-benzhydrylpiperazin-1-yl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-((4'-chloro-[1,1'-biphenyl]-2-yl)methyl)piperazin-1-yl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; and 3-(5-((4-((4′-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-yl)methyl)piperazin-1-yl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione.

10. The compound of formula (I') according to claim 9, or a salt, enantiomer, stereoisomer, solvate or polymorph thereof, wherein (i)R a1 、R a2 、R a3 and R a4 Each independently represents H; and / or (ii) Ring A1 represents a 4- to 20-membered heterocyclylene group containing at least 2 nitrogen atoms, (R d1 ) n1 Indicates that ring A1 is optionally replaced by n1 R d1 Group substitution, each R d1 are independently deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano, oxo, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy or C 1-6 alkoxy, and n1 represents an integer of 0-20; and / or (iii) R1 represents N(R w ), where R w represents hydrogen or optionally substituted by one or more independently selected C 5-30 C substituted with a substituent consisting of an aryl group and an optionally substituted 5- to 30-membered heteroaryl group 1-3 alkyl, and R2 represents a bond; or (iv) R1 represents a bond, and R2 represents N(R w ), where R w Represents hydrogen or C 1-3 Alkyl; and / or (v)R e Indicates a key, or R e represents C(O)O; or (vi) Ring D represents C 5-30 Arylene, (R e2 ) m2 represents a ring D optionally replaced by m2 R e2 Group substitution, each R e2 Each independently represents deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, oxo, C 2-6 Alkynyl or C 2-6 alkenyl, and m2 represents an integer of 0-20; and / or (vii) Ring E represents a 4- to 30-membered nitrogen-containing heterocyclic group, m4 represents an integer of 0 or 1, (R e3 ) m3 represents a ring E optionally surrounded by m3 R e3 Group substitution, each R e3 Each independently represents deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, oxo, C 2-6 Alkynyl or C 2-6 alkenyl, and m3 represents an integer from 0 to 20; and / or (viii)R f Indicates C 1-10 Alkyl, the C 1-10 The alkyl group is optionally substituted with one or more substituents independently selected from the group consisting of halogen, optionally substituted C 5-30 aryl, optionally substituted 5- to 30-membered heteroaryl, optionally substituted 4- to 30-membered heterocyclyl, optionally substituted C 3-30 Cycloalkyl and NR3R4, wherein R3 and R4 each independently represent H, C 1-3 Alkyl or optionally substituted C 3-30 Cycloalkyl; and / or (ix)R a5 Deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl or 4 to 20 membered heterocyclic group, the 4 to 20 membered heterocyclic group is optionally substituted by one or more independently selected from halogen, C 1-6 Substitution with a substituent consisting of an alkyl group and a tert-butyloxycarbonyl group; wherein the C 5-30 The aryl group and the 5 to 30 membered heteroaryl group are each independently optionally substituted by one or more halogen, amino, hydroxy, mercapto, cyano, oxo, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkynyl and C 2-6 The substituents of the alkenyl group are substituted, and the 4 to 30-membered heterocyclic group and the C 3-30 Each cycloalkyl group is independently optionally substituted with one or more alkyl radicals selected from halogen, amino, hydroxy, mercapto, cyano, oxo, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkynyl, C 2-6 Alkenyl, tert-butyloxycarbonyl and optionally substituted C 5-15 The aryl group is substituted with a substituent wherein the C 5-15 Aryl is optionally substituted by one or more alkyl radicals selected from halogen, C 1-6 Alkyl and C 1-6 The substituents of the alkoxy group are substituted.

11. The compound of formula (I') according to claim 9 or 10, or a salt, enantiomer, stereoisomer, solvate or polymorph thereof, wherein (i) Ring A1 represents a 4- to 15-membered heterocyclylene group containing at least 2 nitrogen atoms, (R d1 ) n1 Indicates that ring A1 is optionally replaced by n1 R d1 Group substitution, each R d1 are independently deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano, oxo, C 1-6 Alkyl, deuterated C 1- 6-alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy or C 1-6 alkoxy, and n1 represents an integer of 0-20; and / or (ii) R1 represents N(R w ), where R w represents hydrogen or optionally substituted by one or more independently selected C 5-20 Aryl (including optionally substituted C 5-15 aryl) and an optionally substituted 5- to 20-membered heteroaryl (including an optionally substituted 5- to 15-membered heteroaryl) 1-3 alkyl, and R2 represents a bond; or (iii) Ring D represents C 5-20 Arylene (including C 5-15 arylene), (R e2 ) m2 represents a ring D optionally replaced by m2 R e2 Group substitution, each R e2 Each independently represents deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, oxo, C 2-6 Alkynyl or C 2-6 alkenyl, and m2 represents an integer of 0-20; and / or (iv) Ring E represents a 4- to 20-membered nitrogen-containing heterocyclic group (including a 4- to 15-membered nitrogen-containing heterocyclic group), m4 represents an integer of 0 or 1, (R e3 ) m3 represents a ring E optionally surrounded by m3 R e3 Group substitution, each R e3 Each independently represents deuterium, C 1-6 Alkyl, deuterated C 1- 6-alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, oxo, C 2-6 Alkynyl or C 2-6 alkenyl, and m3 represents an integer from 0 to 20; and / or (v)R f Indicates C 1-10 Alkyl, the C 1-10 The alkyl group is optionally substituted with one or more substituents independently selected from the group consisting of halogen, optionally substituted C 5-20 Aryl (including optionally substituted C 5-15 aryl), optionally substituted 5- to 20-membered heteroaryl (including optionally substituted 5- to 15-membered heteroaryl), optionally substituted 4- to 20-membered heterocyclyl (including optionally substituted 4- to 15-membered heterocyclyl), optionally substituted C 3-20 Cycloalkyl (including optionally substituted C 3-15 cycloalkyl) and NR3R4, wherein R3 and R4 each independently represent H, C 1-3 Alkyl or optionally substituted C 3-20 Cycloalkyl (including optionally substituted C 3-15 cycloalkyl); and / or (vi)R a5 Deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl or 4 to 15 membered heterocyclic group, the 4 to 15 membered heterocyclic group is optionally substituted by one or more independently selected from halogen, C 1-6 Substitution with a substituent consisting of an alkyl group and a tert-butyloxycarbonyl group; wherein the C 5-20 The aryl group and the 5 to 20 membered heteroaryl group are each independently optionally substituted by one or more halogen, amino, hydroxy, mercapto, cyano, oxo, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkynyl and C 2-6 The substituents of the alkenyl group are substituted, and the 4 to 20-membered heterocyclic group and the C 3-20 Each cycloalkyl group is independently optionally substituted with one or more substituents selected from the group consisting of halogen, amino, hydroxy, mercapto, cyano, oxo, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkynyl, C 2-6 alkenyl, tert-butyloxycarbonyl and optionally substituted by one or more halogen, C 1-6 Alkyl and C 1-6 Alkoxy substituents substituted C 5-15 Aryl.

12. The compound of formula (I') according to any one of claims 9 to 11, or a salt, enantiomer, stereoisomer, solvate or polymorph thereof, wherein (i) Ring A1 represents a 1,3-diazetidinylidene, an imidazolidinylidene, a pyrazolidinylidene, a piperazinylidene, a diazaheptanylidene, a diazaoctanylidene, a diazabicyclo[3.1.1]heptanylidene, a diazabicyclo[2.2.1]heptanylidene, a diazabicyclo[3.2.1]octanylidene, a diazabicyclo[2.2.2]octanylidene, a 2,6-diazaspiro[3.3]heptanylidene, a 2,7-diazaspiro[3.5]nonanylidene, a 2,8-diazaspiro[4.5]decanylidene, a 3,9-diazaspiro[5.5]undecanylidene or an octahydropyrrolo[3,4-c]pyrroleylidene, which is optionally substituted by n1 R d1 Group substitution, each R d1 are independently deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano, oxo, C 1-6 Alkyl, deuterated C 1- 6-alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy or C 1-6 alkoxy, and n1 represents an integer of 0-20 (e.g., an integer of 0-10); and / or (ii)R w Represents hydrogen or C 1-3 Alkyl, wherein the C 1-3 The alkyl group is optionally substituted with one or more substituents selected from the group consisting of: Phenyl or naphthyl, which may be optionally substituted by one or more (e.g. 1-7) independently selected from halogen, amino, hydroxy, mercapto, cyano, oxo, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkynyl and C 2-6 Substitution of the alkenyl group with a substituent; and furyl, oxazolyl, isoxazolyl, oxadiazolyl, thienyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, triazinyl, indolyl, isoindolyl, indolyl, benzofuranyl, chromanyl, isobenzofuranyl, benzothienyl, indazolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzotriazolyl, benzo[2,1,3]oxadiazolyl, benzo [2,1,3]thiadiazolyl, benzo[1,2,3]thiadiazolyl, 2-oxo-2,3-dihydro-1H-benzo[d]imidazolyl, benzo[b][1,4]oxazinyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, quinolyl, isoquinolyl, 1,2,3,4-tetrahydroquinolyl, naphthyridinyl, cinnolinyl, quinazolinyl, quinoxalinyl, 1,2,3,4-tetrahydroquinoxalinyl, phthalazinyl, 5,6,7,8-tetrahydro-[1,2,4]triazolo[4, 3-a]pyrazinyl, 4,5,6,7-tetrahydrothieno[3,2-c]pyridinyl, 5-oxo-6,7-dihydrothieno[3,2-d]pyrimidinyl, thieno[2,3-d]pyrimidinyl, thieno[3,2-d]pyrimidinyl, isoxazolo[4,5-c]pyridinyl, isoxazolo[4,5-c]pyrimidinyl, isoxazolo[4,5-d]pyrimidinyl, pyrazolo[1,5-a]pyridinyl, pyrazolo[1,5-a]pyrimidinyl, imidazo[1,2-a]pyridinyl, 1H-pyrrolo[3,2-b]pyridinyl, 1H-pyrrolo[2,3-b]pyridinyl, pyrrolo[2,1-b]thiazolyl, imidazo[2,1-b]thiazolyl, 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidinyl, and 6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidinyl, which may be substituted by one or more (e.g., 1-10) groups independently selected from halogen, amino, hydroxy, thiol, cyano, oxo, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkynyl and C 2-6 Substitution of the alkenyl group by a substituent; and / or (iii) Ring D represents a phenylene group or a naphthylene group, which is optionally substituted by m2 R e2 Group substitution, each R e2 Each independently represents deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, oxo, C 2-6 Alkynyl or C 2-6 alkenyl, and m2 represents an integer of 0-20 (e.g., an integer of 0-10); and / or (iv) Ring E represents an azetidinyl group, a pyrrolidinyl group, an imidazolidinyl group, a pyrazolidinyl group, a piperidinyl group, a piperazinyl group, a tetrahydropyridinyl group, a dihydroxypiperidinyl group, a difluoropiperidinyl group, an azepanyl group, an azepanyl group, a diazepanyl group (e.g., a 1,4-diazacycloheptanyl group, a 4,5-diazacycloheptanyl group, a 1,3-diazacycloheptanyl group), a diazacyclooctanyl group, a nitrogen-containing bridged heterocyclic group (e.g., a 6- to 20-membered nitrogen-containing bridged heterocyclic group, such as a 6-azabicyclo[3.1.1]heptanyl group, a 2,5-diazabicyclo[2.2.1]heptanyl group, a 3,6-diazabicyclo[3.1.1]heptanyl group) 1-Hydroxy-1-pyrrole-2-yl]pyrrole-3-yl, 2-Hydroxy-1-pyrrole-4-yl, 2-Hydroxy-1-pyrrole-5-yl, 2-Hydroxy-1-pyrrole-6-yl, 2-Hydroxy-1-pyrrole-7-yl, 2-Hydroxy-1-pyrrole-8-yl, 2-Hydroxy-1-pyrrole-9-yl, 2-Hydroxy-1-pyrrole-10-yl, 2-Hydroxy-1-pyrrole-11-yl, 2-Hydroxy-1-pyrrole-12-yl, 2-Hydroxy-1-pyrrole-13-yl, 2-Hydroxy-1-pyrrole-8-yl, 2-Hydroxy-1-pyrrole-9-yl, 2-Hydroxy-1-pyrrole-14-yl, 2-Hydroxy-1-pyrrole-15-yl, 2-Hydroxy-1-pyrrole-16-yl, 2-Hydroxy-1-pyrrole-17-yl, 2-Hydroxy-1-pyrrole-18-yl, e3 Group substitution, each R e3 Each independently represents deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, oxo, C 2-6 Alkynyl or C 2-6 alkenyl, m3 represents an integer of 0-20 (e.g., an integer of 0-10), and m4 represents an integer of 0 or 1; and / or (v)R f Indicates C 1-10 Alkyl, the C 1-10 The alkyl group is optionally substituted with one or more substituents independently selected from the group consisting of: halogen; Phenyl or naphthyl, which may be optionally substituted by one or more (e.g. 1-7) independently selected from halogen, amino, hydroxy, mercapto, cyano, oxo, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkynyl and C 2-6 Substitution of alkenyl groups by substituents; furyl, oxazolyl, isoxazolyl, oxadiazolyl, thienyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, triazinyl, indolyl, isoindolyl, indolyl, benzofuranyl, chromanyl, isobenzofuranyl, benzothienyl, indazolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzotriazolyl, benzo[2,1,3]oxadiazolyl, benzo [2,1,3]thiadiazolyl, benzo[1,2,3]thiadiazolyl, 2-oxo-2,3-dihydro-1H-benzo[d]imidazolyl, benzo[b][1,4]oxazinyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, quinolyl, isoquinolyl, 1,2,3,4-tetrahydroquinolyl, naphthyridinyl, cinnolinyl, quinazolinyl, quinoxalinyl, 1,2,3,4-tetrahydroquinoxalinyl, phthalazinyl, 5,6,7,8-tetrahydro-[1,2,4]triazolo[4, 3-a]pyrazinyl, 4,5,6,7-tetrahydrothieno[3,2-c]pyridinyl, 5-oxo-6,7-dihydrothieno[3,2-d]pyrimidinyl, thieno[2,3-d]pyrimidinyl, thieno[3,2-d]pyrimidinyl, isoxazolo[4,5-c]pyridinyl, isoxazolo[4,5-c]pyrimidinyl, isoxazolo[4,5-d]pyrimidinyl, pyrazolo[1,5-a]pyridinyl, pyrazolo[1,5-a]pyrimidinyl, imidazo[1,2-a]pyridinyl, 1H-pyrrolo[3,2-b]pyridinyl, 1H-pyrrolo[2,3-b]pyridinyl, pyrrolo[2,1-b]thiazolyl, imidazo[2,1-b]thiazolyl, 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidinyl, or 6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidinyl, which may be substituted by one or more (e.g., 1-10) groups independently selected from halogen, amino, hydroxy, thiol, cyano, oxo, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkynyl and C 2-6 Substitution of alkenyl groups by substituents; azetidinyl, oxetanyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, oxazolidinyl, thiazolidinyl, piperidinyl, piperazinyl, tetrahydropyridinyl, dihydroxypiperidinyl, difluoropiperidinyl, morpholinyl, thiomorpholinyl, azepanyl, azocanyl, dioxanyl, azepanyl, azocanyl, diazepanyl, Cycloheptyl (e.g., 1,4-diazacycloheptyl, 4,5-diazacycloheptyl, 1,3-diazacycloheptyl), diazacyclooctanyl, bridged heterocyclic groups (e.g., 6- to 20-membered bridged heterocyclic groups, such as 6-azabicyclo[3.1.1]heptyl, 2,5-diazabicyclo[2.2.1]heptyl, 3,6-diazabicyclo[3.1.1]heptyl, 3-azabicyclo[3 .2.1]octyl, 3,8-diazabicyclo[3.2.1]octyl, 3,8-diazabicyclo[3.2.1]octyl, 2,5-diazabicyclo[2.2.2]octyl and quinuclidine), and azaspirocyclyl (e.g., a 5- to 20-membered azaspirocyclyl, such as 2,6-diazaspiro[3.3]heptyl, 2,7-diazaspiro[3.5]nonyl, 2,8-diazaspiro[4.5]decyl, 3,9-diazaspiro[5.5]undecyl, 3-azaspiro[5.5]undecyl and 7-azaspiro[3.5]nonyl), or octahydropyrrolo[3,4-c]pyrrolyl, which is optionally substituted with one or more (e.g., 1-10) substituents each independently selected from the group consisting of halogen, amino, hydroxy, thiol, cyano, oxo, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkynyl, C 2-6 alkenyl, tert-butyloxycarbonyl, and optionally substituted by one or more (e.g. 1-5) selected from halogen, C 1-6 Alkyl and C 1-6 Alkoxy substituents substituted C 5-15 aryl; Cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, cyclooctyl, decahydronaphthyl, octahydropentalenyl, octahydro-1H-indenyl, spirocycloalkyl (e.g., C5-C 20 Spirocyclic groups such as spiro[3.3]heptanyl, spiro[2.5]octanyl, spiro[3.5]nonanyl, spiro[3.5]nonenyl, spiro[4.4]nonanyl, spiro[4.5]decanyl, spiro[4.5]decenyl, spiro[5.5]undecyl), p-menthanyl, m-menthanyl, and bridged cycloalkyl groups (e.g., C6-C 20 Bridged ring groups, such as adamantyl, noradamantyl, bornyl, norbornyl, bicyclo[2.2.1]heptanyl, 2-oxobicyclo[ 2.2.1]heptyl or bicyclo[2.2.1]heptenyl), which is optionally substituted by one or more (e.g., 1-10) substituents each independently selected from the group consisting of halogen, amino, hydroxy, mercapto, cyano, oxo, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkynyl, C 2-6 alkenyl, tert-butyloxycarbonyl, and optionally substituted by one or more (e.g. 1-5) selected from halogen, C 1-6 Alkyl and C 1-6 Alkoxy substituents substituted C 5-15 aryl; and NR3R4, wherein R3 and R4 each independently represent: H； C 1-3 alkyl; or Cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, cyclooctyl, decahydronaphthyl, octahydropentalenyl, octahydro-1H-indenyl, spirocycloalkyl (e.g., C5-C 20 spirocyclic groups, such as spiro[3.3]heptanyl, spiro[2.5]octanyl, spiro[3.5]nonanyl, spiro[3.5]nonenyl, spiro[4.4]nonanyl, spiro[4.5]decanyl, spiro[4.5]decenyl, spiro[5.5]undecyl), p-menthanyl, m-menthanyl, or bridged cycloalkyl groups (e.g., C6-C 20 Bridged ring groups, such as adamantyl, noradamantyl, bornyl, norbornyl, bicyclo[2.2.1]heptanyl, 2-oxobicyclo[ 2.2.1]heptyl or bicyclo[2.2.1]heptenyl), which is optionally substituted by one or more (e.g., 1-10) substituents each independently selected from the group consisting of halogen, amino, hydroxy, mercapto, cyano, oxo, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkynyl, C 2-6 alkenyl, tert-butyloxycarbonyl, and optionally substituted by one or more (e.g. 1-5) selected from halogen, C 1-6 Alkyl and C 1-6 Alkoxy substituents substituted C 5-15 Aryl.

13. A compound of formula (I') according to any one of claims 9 to 12, or a salt, enantiomer, stereoisomer, solvate or polymorph thereof, wherein (i)R w Indicates H or (ii)R e Indicates a bond, C(O)O, The symbol # indicates that R f connection points; (iii)R f express: Methyl, isopropyl, tert-butyl, 14. The compound of formula (I') according to claim 9, or a salt, enantiomer, stereoisomer, solvate or polymorph thereof, which is selected from the compounds in Table 2.

15. A compound of formula (I') or a salt, enantiomer, stereoisomer, solvate or polymorph thereof as claimed in any one of claims 9 to 14, which is a hydrohalide salt (including hydrochloride, hydrobromide), sulfate, citrate / citrate, maleate, lactate, lactobionate, L-tartrate, fumarate, L-malate, L-lactate, α-ketoglutarate, hippurate, D-glucuronate, D-gluconate, α-D-glucoheptonate, glycolate, mucate, L-ascorbate, orotate, picrate, glycinate, alanine, arginine, cinnamate, laurate, pamoate, sebacate, benzenesulfonate, methanesulfonate, ethanesulfonate, edisylate, formate, acetate, 2-hydroxy-1,2-dextrose, ... , 2-dichloroacetate, pivalate, propionate, valerate, palmitate, triphenylacetate, 2-ethyl-succinate, iodate, nicotinate, L-pyroglutamate, L-proline, ferulate, 2-hydroxyethanesulfonate, nitrate, gentisate, cholate, salicylate, terephthalate, glutarate, adipate, stearate, oleate, undecenoate, camphorate, camphorsulfonate, dodecylsulfonate, phosphate, thiocyanate, dihydrogenphosphate, pyrophosphate, metaphosphate, oxalate, carbonate, malonate, benzoate, mandelate, succinate, pyruvate, p-chlorobenzenesulfonate, 1,5-naphthalenedisulfonate, 3-hydroxy-2-naphthoate, 1-hydroxy-2-naphthoate, 2-naphthalenesulfonate, trifluoroacetate, glycolate, or p-toluenesulfonate.

16. A pharmaceutical composition comprising: A compound of formula (I) or a pharmaceutically acceptable salt thereof as claimed in any one of claims 1 to 8, and at least one pharmaceutically acceptable carrier or excipient; or A compound of formula (I') or a pharmaceutically acceptable salt thereof according to any one of claims 9 to 15, and at least one pharmaceutically acceptable carrier or excipient; and optionally a second therapeutic agent, such as an anticancer agent.

17. A compound of formula (I), a compound of formula (I') or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 15, for use in preventing or treating a disease or condition associated with cereblon protein.

18. The compound of formula (I), the compound of formula (I') or a pharmaceutically acceptable salt thereof according to claim 17, wherein the disease or condition associated with cereblon protein is selected from the group consisting of: tumors, infectious diseases, inflammatory diseases, autoimmune diseases, anemia, hemorrhagic shock, transplant rejection, multiple organ dysfunction syndrome (MODS), sarcoidosis, adult respiratory distress syndrome, cardiovascular disease, Richter syndrome (RS), acute liver failure or diabetes.

19. The compound of formula (I), formula (I') or a pharmaceutically acceptable salt thereof according to claim 17, wherein the disease or condition associated with cereblon protein is selected from the group consisting of: myeloma, including multiple myeloma, plasma cell myeloma, smoldering myeloma, smoldering multiple myeloma; myelofibrosis; bone marrow disease; myelodysplastic syndrome (MDS); previously treated myelodysplastic syndrome; transplant-related cancer; neutropenia; leukemia, including acute myeloid leukemia; Leukemia (AML), chronic myeloid leukemia (CML), chronic myeloid leukemia, acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), B-cell chronic lymphocytic leukemia, anemia associated with leukemia, acute B-cell leukemia, T-cell leukemia, acute T-lymphocytic leukemia, lymphoma cell leukemia, monocytic leukemia, myelomonocytic leukemia; lymphomas, including diffuse large B-cell lymphoma, non-Hodgkin lymphoma, Hodgkin lymphoma, anaplastic lymphoma , anaplastic large cell lymphoma, CD20-positive lymphoma, mantle cell lymphoma, follicular lymphoma (FL), Burkitt's lymphoma; marginal zone lymphoma (MZL); primary lymphoma, B-cell lymphoma, relapsed B-cell non-Hodgkin's lymphoma, relapsed diffuse large B-cell lymphoma, relapsed mediastinal (thymic) large B-cell lymphoma, primary mediastinal (thymic) large B-cell lymphoma, relapsed transformed non-Hodgkin's lymphoma, refractory B-cell non-Hodgkin's lymphoma, refractory diffuse large B-cell lymphoma Diffuse large B-cell lymphoma, refractory primary mediastinal (thymic) large B-cell lymphoma, refractory transformed non-Hodgkin's lymphoma; thyroid cancer; melanoma; lung cancer, including adenocarcinoma, squamous cell carcinoma, non-small cell lung cancer, and small cell lung cancer; inflammatory myofibroblastic tumor; colorectal cancer; intestinal cancer; glioma; astrocytoblastoma; ovarian cancer; bronchogenic carcinoma; prostate cancer; breast cancer, including triple-negative breast cancer, incidental breast cancer, and patients with Cowden's disease; pancreatic cancer; central nervous system cancers; neuroblastoma; glioma; Peripheral neuroepithelial tumor; extramedullary plasmacytoma; plasmacytoma; gastric cancer; gastrointestinal stromal tumor; esophageal cancer; colorectal adenocarcinoma; esophageal squamous cell carcinoma; liver cancer; renal cell carcinoma; bladder cancer; endometrial cancer; uterine cancer; head and neck cancer; brain cancer; oral cancer; sarcomas, including rhabdomyosarcoma, various adipose tumors, Ewing sarcoma / primitive neuroectodermal tumors (Ewing / PNETs), and leiomyosarcoma; urothelial carcinoma; basal cell carcinoma; oral squamous cell carcinoma; bile duct cancer; Bone cancer; cervical cancer; skin cancer; Richter syndrome (RS); sepsis syndrome; autoimmune diseases, including rheumatoid arthritis, autoimmune encephalomyelitis, ankylosing spondylitis, psoriasis, psoriatic arthritis, systemic lupus erythematosus, multiple sclerosis, recurrent oral ulcers, Kawasaki disease, polymyositis / dermatomyositis, Sjögren's syndrome, atopic dermatitis, hidradenitis suppurativa, gout, type 1 diabetes, urticaria, inflammatory bowel disease (including Crohn's disease and ulcerative colitis); keratoconjunctivitis sicca; inflammatory diseases, including Crohn's disease and ulcerative colitis, pneumonia, osteoarthritis, synovitis, systemic inflammatory response syndrome, airway inflammation, bronchitis; cerebral malaria diseases; infectious diseases, including viral pneumonia, AIDS, COVID-19 novel coronavirus infection, Gram-negative bacterial infection, Gram-positive bacterial infection, tuberculosis, etc.; septic shock; tuberculosis; bacterial meningitis; chronic obstructive pulmonary disease; asthma; hemorrhagic shock; organ (including kidney, heart, lung) or tissue transplant rejection; diabetes; sarcoidosis; adult respiratory distress syndrome; anemia; pediatric aplastic anemia; cardiovascular disease (such as coronary heart disease, congestive heart failure, myocardial infarction, atherosclerosis); multiple organ failure caused by cachexia and septic shock; or acute liver failure.

20. Use of a compound of formula (I), a compound of formula (I') or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 15, or a pharmaceutical composition according to claim 15, for preparing a medicament for preventing or treating a disease or condition associated with cereblon protein.

21. A method for treating or preventing a disease or condition associated with cereblon protein in a subject, comprising administering to the subject a therapeutically effective amount of a compound of formula (I), a compound of formula (I') or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 15, or a pharmaceutical composition according to claim 16.

22. The use according to claim 20 or the method according to claim 21, wherein the disease or disorder associated with the cereblon protein is selected from the group consisting of: tumors, infectious diseases, inflammatory diseases, autoimmune diseases, anemia, hemorrhagic shock, transplant rejection, multiple organ dysfunction syndrome (MODS), sarcoidosis, adult respiratory distress syndrome, cardiovascular disease, Richter syndrome (RS), acute liver failure or diabetes.

23. The use of claim 20 or the method of claim 21, wherein the disease or condition associated with the cereblon protein is selected from the group consisting of: myeloma, including multiple myeloma, plasma cell myeloma, smoldering myeloma, smoldering multiple myeloma; myelofibrosis; bone marrow disease; myelodysplastic syndrome (MDS); previously treated myelodysplastic syndrome; transplant-related cancer; neutropenia; leukemia, including acute myeloid leukemia (AML), Chronic myeloid leukemia (CML), chronic myeloid leukemia, acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), B-cell chronic lymphocytic leukemia, anemia associated with leukemia, acute B-cell leukemia, T-cell leukemia, acute T-lymphocytic leukemia, lymphoma cell leukemia, monocytic leukemia, myelomonocytic leukemia; lymphomas, including diffuse large B-cell lymphoma, non-Hodgkin's lymphoma, Hodgkin's lymphoma, anaplastic lymphoma, anaplastic large B-cell lymphoma, CD20-positive lymphoma, mantle cell lymphoma, follicular lymphoma (FL), Burkitt's lymphoma; marginal zone lymphoma (MZL); primary lymphoma, B-cell lymphoma, relapsed B-cell non-Hodgkin's lymphoma, relapsed diffuse large B-cell lymphoma, relapsed mediastinal (thymic) large B-cell lymphoma, primary mediastinal (thymic) large B-cell lymphoma, relapsed transformed non-Hodgkin's lymphoma, refractory B-cell non-Hodgkin's lymphoma, refractory diffuse large B-cell lymphoma Large B-cell lymphoma, refractory primary mediastinal (thymic) large B-cell lymphoma, refractory transformed non-Hodgkin's lymphoma; thyroid cancer; melanoma; lung cancer, including adenocarcinoma, squamous cell carcinoma, non-small cell lung cancer, and small cell lung cancer; inflammatory myofibroblastic tumor; colorectal cancer; intestinal cancer; glioma; astrocytoblastoma; ovarian cancer; bronchogenic carcinoma; prostate cancer; breast cancer, including triple-negative breast cancer, incidental breast cancer, and patients with Cowden's disease; pancreatic cancer; central nervous system cancers; neuroblastoma; glioma; Peripheral neuroepithelial tumor; extramedullary plasmacytoma; plasmacytoma; gastric cancer; gastrointestinal stromal tumor; esophageal cancer; colorectal adenocarcinoma; esophageal squamous cell carcinoma; liver cancer; renal cell carcinoma; bladder cancer; endometrial cancer; uterine cancer; head and neck cancer; brain cancer; oral cancer; sarcomas, including rhabdomyosarcoma, various adipose tumors, Ewing sarcoma / primitive neuroectodermal tumors (Ewing / PNETs), and leiomyosarcoma; urothelial carcinoma; basal cell carcinoma; oral squamous cell carcinoma; bile duct cancer; Bone cancer; cervical cancer; skin cancer; Richter syndrome (RS); sepsis syndrome; autoimmune diseases, including rheumatoid arthritis, autoimmune encephalomyelitis, ankylosing spondylitis, psoriasis, psoriatic arthritis, systemic lupus erythematosus, multiple sclerosis, recurrent oral ulcers, Kawasaki disease, polymyositis / dermatomyositis, Sjögren's syndrome, atopic dermatitis, hidradenitis suppurativa, gout, type 1 diabetes, urticaria, inflammatory bowel disease (including Crohn's disease and ulcerative colitis); keratoconjunctivitis sicca; inflammatory diseases, including Crohn's disease and ulcerative colitis, pneumonia, osteoarthritis, synovitis, systemic inflammatory response syndrome, airway inflammation, bronchitis; cerebral malaria diseases; infectious diseases, including viral pneumonia, AIDS, COVID-19 novel coronavirus infection, Gram-negative bacterial infection, Gram-positive bacterial infection, tuberculosis, etc.; septic shock; tuberculosis; bacterial meningitis; chronic obstructive pulmonary disease; asthma; hemorrhagic shock; organ (including kidney, heart, lung) or tissue transplant rejection; diabetes; sarcoidosis; adult respiratory distress syndrome; anemia; pediatric aplastic anemia; cardiovascular disease (such as coronary heart disease, congestive heart failure, myocardial infarction, atherosclerosis); multiple organ failure caused by cachexia and septic shock; or acute liver failure.

24. A method for preparing the compound of formula (I) according to claim 1, comprising using a compound of formula (M1) and a compound of formula (M2) as starting materials to prepare the compound of formula (I): where R a1 、R a2 、R a3 、R a4 、(R a5 ) m , Z, R, Ring B, Ring C, (R d2 ) n2 、(R d3 ) n3 , and m1 as defined in claim 1; and R w3 Indicates CHO, COOH or where R c2 As defined in claim 1, wherein the group LE represents Cl, Br, I, OMs, OTs, or ONs; Where (1)-R w1 -R w2 express And R represents or (2)-R w1 -R w2 express And R represents or (3)-R w1 -R w2 represents -NH-NH2, and R represents -NH-NH-; or (4)-R w1 -R w2 express And R represents where R w 、Ring A1、(R d1 ) n1 , Ring A2 and (R d4 ) n4 As defined in claim 1; When R w3 When it represents CHO, R c3 and R c4 means H; or When R w3 When it represents COOH, R c3 and R c4 together to form a carbonyl group; or When R w3 express When R c3 Represents H, and R c4 It is R c2 .

25. The method of claim 24, wherein (1) When R w3 When CHO is represented, the compound of formula (M1) and the compound of formula (M2) undergo a reductive amination reaction to prepare a compound of formula (I), wherein R c3 and R c4 Indicates H; (2) When R w3 When the compound of formula (M1) and the compound of formula (M2) undergo amide condensation reaction to prepare the compound of formula (I), wherein R c3 and R c4 together to form a carbonyl group; or (3) When R w3 express When the compound of formula (M1) and the compound of formula (M2) undergo amine alkylation reaction to prepare the compound of formula (I), wherein R c3 Represents H, and R c4 It is R c2 .

26. The method of claim 24, wherein When -R w1 -R w2 express When the compound of formula (M1) is prepared by reacting the compound of formula (M3) with the compound of formula (M4) as starting materials, Y represents F or Br; W1 represents H, and W2 represents an amino protecting group; or W1 represents an amino protecting group, and W2 represents H.

Images